{"PMC7463198": [["In 2019, heads of state pledged to strengthen efforts to address noncommunicable diseases and mental health as part of universal health coverage.", [["noncommunicable diseases", "DISEASE", 65, 89], ["noncommunicable diseases", "PROBLEM", 65, 89], ["universal health coverage", "TREATMENT", 119, 144]]], ["They committed to progressively cover 1 billion additional people within four years with essential health services, as well as quality, safe, effective and affordable essential medicines and other health products.1 The coronavirus disease 2019 (COVID-19) pandemic has slowed these efforts and highlighted the vulnerability of people living with noncommunicable diseases and mental, neurological and substance use disorders,2 referred to as mental health conditions.", [["coronavirus disease", "DISEASE", 219, 238], ["COVID-19", "CHEMICAL", 245, 253], ["noncommunicable diseases", "DISEASE", 345, 369], ["neurological and substance use disorders", "DISEASE", 382, 422], ["people", "ORGANISM", 59, 65], ["coronavirus", "ORGANISM", 219, 230], ["COVID-19", "ORGANISM", 245, 253], ["people", "ORGANISM", 326, 332], ["people", "SPECIES", 59, 65], ["people", "SPECIES", 326, 332], ["coronavirus disease 2019 (COVID-19", "SPECIES", 219, 253], ["affordable essential medicines", "TREATMENT", 156, 186], ["The coronavirus disease", "PROBLEM", 215, 238], ["COVID", "TEST", 245, 250], ["pandemic", "PROBLEM", 255, 263], ["noncommunicable diseases", "PROBLEM", 345, 369], ["mental, neurological and substance use disorders", "PROBLEM", 374, 422], ["coronavirus disease", "OBSERVATION", 219, 238]]]], "582c4b768935aad5653177e4175a341cc1f8e593": [["lymphocytic leukemia (CLL) diagnosed with symptomatic COVID-19.", [["lymphocytic leukemia", "ANATOMY", 0, 20], ["CLL", "ANATOMY", 22, 25], ["lymphocytic leukemia", "DISEASE", 0, 20], ["CLL", "DISEASE", 22, 25], ["lymphocytic leukemia", "CANCER", 0, 20], ["CLL", "CANCER", 22, 25], ["lymphocytic leukemia", "PROBLEM", 0, 20], ["CLL", "PROBLEM", 22, 25], ["symptomatic COVID", "TEST", 42, 59], ["CLL", "OBSERVATION", 22, 25], ["symptomatic", "OBSERVATION_MODIFIER", 42, 53]]], ["The course of the disease was mild, and no patient required admission in an intensive care unit.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["the disease", "PROBLEM", 14, 25], ["disease", "OBSERVATION", 18, 25], ["mild", "OBSERVATION_MODIFIER", 30, 34]]], ["The authors speculate that the CLL-related immunodeficiency might be beneficial in the outcome of the COVID-19 and deserved further investigation.", [["CLL", "ANATOMY", 31, 34], ["CLL", "DISEASE", 31, 34], ["immunodeficiency", "DISEASE", 43, 59], ["CLL", "CANCER", 31, 34], ["immunodeficiency", "ORGANISM", 43, 59], ["the CLL", "PROBLEM", 27, 34], ["immunodeficiency", "PROBLEM", 43, 59], ["the COVID", "TEST", 98, 107], ["further investigation", "TEST", 124, 145], ["CLL", "OBSERVATION", 31, 34]]]], "087ab994411f8da32654985b1ee2a7f3b9f3626f": [["IntroductionAfter the first cases were identified in Wuhan (China) in December 2019, the novel coronavirus SARS-CoV-2 has caused a pandemic of respiratory illness named COVID-19.", [["respiratory", "ANATOMY", 143, 154], ["coronavirus", "DISEASE", 95, 106], ["SARS-CoV-2", "CHEMICAL", 107, 117], ["respiratory illness", "DISEASE", 143, 162], ["coronavirus SARS-CoV-2", "ORGANISM", 95, 117], ["the novel coronavirus SARS", "PROBLEM", 85, 111], ["respiratory illness", "PROBLEM", 143, 162], ["respiratory illness", "OBSERVATION", 143, 162]]], ["1 To date, more than 20 million cases have been reported worldwide, including more than 750,000 deaths.", [["deaths", "DISEASE", 96, 102]]], ["2 Typical COVID-19 patients present with fever, myalgia, fatigue, and dry cough.", [["fever", "DISEASE", 41, 46], ["myalgia", "DISEASE", 48, 55], ["fatigue", "DISEASE", 57, 64], ["dry cough", "DISEASE", 70, 79], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["fever", "PROBLEM", 41, 46], ["myalgia", "PROBLEM", 48, 55], ["fatigue", "PROBLEM", 57, 64], ["dry cough", "PROBLEM", 70, 79], ["fever", "OBSERVATION", 41, 46], ["myalgia", "OBSERVATION", 48, 55], ["dry", "OBSERVATION_MODIFIER", 70, 73], ["cough", "OBSERVATION", 74, 79]]], ["3, 4 Severe cases progress to severe dyspnoea and hypoxemia within one week after the onset of symptoms.", [["dyspnoea", "DISEASE", 37, 45], ["hypoxemia", "DISEASE", 50, 59], ["severe dyspnoea", "PROBLEM", 30, 45], ["hypoxemia", "PROBLEM", 50, 59], ["symptoms", "PROBLEM", 95, 103], ["Severe", "OBSERVATION_MODIFIER", 5, 11], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["dyspnoea", "OBSERVATION", 37, 45], ["hypoxemia", "OBSERVATION", 50, 59]]], ["[3] [4] [5] In hospitalized COVID-19 patients, the prevalence of hypoxemic respiratory failure is around 20%, and more than 25% of them may require intensive care treatment.", [["respiratory", "ANATOMY", 75, 86], ["hypoxemic respiratory failure", "DISEASE", 65, 94], ["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["COVID", "TEST", 28, 33], ["hypoxemic respiratory failure", "PROBLEM", 65, 94], ["intensive care treatment", "TREATMENT", 148, 172], ["hypoxemic", "OBSERVATION_MODIFIER", 65, 74], ["respiratory failure", "OBSERVATION", 75, 94]]], ["6 The increasing number of COVID-19 cases has challenged healthcare systems worldwide.", [["COVID", "TEST", 27, 32], ["increasing", "OBSERVATION_MODIFIER", 6, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["In this context of overwhelming demand for medical assessment and triage in emergency departments (EDs), early warning scores (EWS) may be useful.", [["medical assessment", "TEST", 43, 61]]], ["EWS are physiological scoring systems based on a rapid and quantitative assessment of changes in vital signs, 7 and were initially developed to identify and track hospitalised patients at risk of deterioration outside critical care areas in order to ensure early stabilisation and transfer to intensive care unit (ICU) when appropriate, and to prevent avoidable cardiac arrests.", [["cardiac", "ANATOMY", 362, 369], ["cardiac arrests", "DISEASE", 362, 377], ["patients", "ORGANISM", 176, 184], ["cardiac", "ORGAN", 362, 369], ["EWS", "PROTEIN", 0, 3], ["patients", "SPECIES", 176, 184], ["quantitative assessment", "TEST", 59, 82], ["vital signs", "TEST", 97, 108], ["avoidable cardiac arrests", "PROBLEM", 352, 377], ["stabilisation", "OBSERVATION", 263, 276], ["cardiac", "ANATOMY", 362, 369], ["arrests", "OBSERVATION", 370, 377]]], ["8, 9 However, these scores have also subsequently been investigated as a tool to predict critical illness in ED patients, 10 and some, as the Rapid Emergency Medicine Score (REMS), 11 have specifically been developed for this purpose.IntroductionIn studies performed on the general ED population, the National Early Warning Score (NEWS) 12 was the most accurate in predicting both in-hospital mortality and ICU admission.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["10 A recent document from the Swiss Society of Intensive Care Medicine 13 suggested using a score greater than 6 of a modified version of NEWS (hereafter referred as to NEWS-C) for deciding admission to ICU of COVID-19 patients.", [["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 219, 227]]], ["14 However, this recommendation is based on previous evidence on non-COVID-19 patients, 15, 16 and it has not been validated so far.", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["non-COVID", "TEST", 65, 74]]], ["At present, it is not clear which EWS is the most accurate for triaging COVID-19 patients in the ED.IntroductionThe aim of the present study was to compare the ability of EWS assessed on ED arrival to identify adult COVID-19 patients at risk for ICU admission or death within seven days.", [["death", "DISEASE", 263, 268], ["EWS", "CANCER", 34, 37], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 225, 233], ["triaging COVID", "TEST", 63, 77], ["the present study", "TEST", 123, 140], ["death", "PROBLEM", 263, 268], ["not", "UNCERTAINTY", 18, 21], ["clear", "OBSERVATION", 22, 27]]], ["The EWS assessed in this study J o u r n a l P r e -p r o o f included Modified EWS (MEWS), 17 NEWS, NEWS2, 18 NEWS-C, Quick Sepsis Related Organ Failure Assessment (qSOFA), 19 and REMS.", [["Sepsis", "DISEASE", 125, 131], ["EWS", "PROTEIN", 4, 7], ["The EWS", "TEST", 0, 7], ["this study", "TEST", 20, 30], ["NEWS2", "TEST", 101, 106], ["Quick Sepsis Related Organ Failure", "PROBLEM", 119, 153], ["Sepsis", "OBSERVATION", 125, 131], ["Organ", "ANATOMY", 140, 145], ["Failure", "OBSERVATION", 146, 153]]], ["Moreover, in order to measure the added value of EWS to the conventional ED triage process, we also compared the accuracy of EWS with that of the Regional Triage System for Infectious Diseases in use in our hospital for COVID-19 patients.Study design and settingThis is a retrospective observational study (clinicaltrials.gov NCT04371562) conducted in the ED of the Fondazione Policlinico Universitario Agostino Gemelli, in Rome.", [["Infectious Diseases", "DISEASE", 173, 192], ["patients", "ORGANISM", 229, 237], ["EWS", "PROTEIN", 49, 52], ["patients", "SPECIES", 229, 237], ["a retrospective observational study", "TEST", 270, 305], ["Infectious", "OBSERVATION", 173, 183]]], ["Policlinico Gemelli is the largest teaching hospital in Rome and a referral centre for COVID-19 in central Italy.", [["COVID", "TEST", 87, 92], ["largest", "OBSERVATION_MODIFIER", 27, 34]]], ["The Regional Triage System for Infectious Diseases in our ED is based on a protocol issued by the Health Service of Lazio Region, where our hospital is located.", [["Infectious Diseases", "DISEASE", 31, 50], ["Infectious", "OBSERVATION", 31, 41]]], ["The protocol, summarised on ESM Tables 1a-b, follows an ABCDE scheme (airway, breathing, circulation, disability, exposure) with additional variables such as age, blood glucose level, plus additional symptoms and signs.", [["airway", "ANATOMY", 70, 76], ["blood", "ANATOMY", 163, 168], ["disability", "DISEASE", 102, 112], ["glucose", "CHEMICAL", 169, 176], ["glucose", "CHEMICAL", 169, 176], ["airway", "MULTI-TISSUE_STRUCTURE", 70, 76], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["glucose", "SIMPLE_CHEMICAL", 169, 176], ["The protocol", "TREATMENT", 0, 12], ["blood glucose level", "TEST", 163, 182], ["additional symptoms", "PROBLEM", 189, 208], ["airway", "ANATOMY", 70, 76]]], ["The triage system assigns a priority value from 1 to 5, in descending order of severity.", [["descending", "ANATOMY_MODIFIER", 59, 69]]], ["Triage is performed by a nurse certified in a full time 7-day course followed by a 6-month supervised training.Study design and settingThe criteria for ICU admission of COVID-19 patients in our hospital during the study period included circulatory shock requiring vasopressors and the need for positive pressure respiratory support, including non-invasive ventilation.", [["circulatory", "ANATOMY", 236, 247], ["circulatory shock", "DISEASE", 236, 253], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["Study design", "TEST", 111, 123], ["COVID", "TEST", 169, 174], ["the study", "TEST", 210, 219], ["circulatory shock", "PROBLEM", 236, 253], ["vasopressors", "TREATMENT", 264, 276], ["positive pressure respiratory support", "TREATMENT", 294, 331], ["non-invasive ventilation", "TREATMENT", 343, 367], ["circulatory shock", "OBSERVATION", 236, 253], ["respiratory support", "OBSERVATION", 312, 331]]], ["High-flow oxygen treatment is provided in general wards.", [["oxygen", "CHEMICAL", 10, 16], ["oxygen", "CHEMICAL", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["High-flow oxygen treatment", "TREATMENT", 0, 26], ["flow oxygen treatment", "OBSERVATION", 5, 26]]], ["At present, no EWS is in use in our hospital.Study design and settingJ o u r n a l P r e -p r o o fEligibility criteriaFrom March 1 to April 15, 2020 we included all adult (>18y) patients assessed in our ED for suspected COVID-19 whose diagnosis was confirmed with real-time reverse-transcriptase-polymerase-chain-reaction assay of nasal and pharyngeal swab specimens.", [["nasal", "ANATOMY", 332, 337], ["pharyngeal swab specimens", "ANATOMY", 342, 367], ["EWS", "CANCER", 15, 18], ["patients", "ORGANISM", 179, 187], ["nasal", "ORGANISM_SUBDIVISION", 332, 337], ["pharyngeal swab specimens", "CANCER", 342, 367], ["EWS", "DNA", 15, 18], ["reverse-transcriptase", "PROTEIN", 275, 296], ["patients", "SPECIES", 179, 187], ["Study design", "TEST", 45, 57], ["nasal and pharyngeal swab specimens", "TEST", 332, 367], ["no", "UNCERTAINTY", 12, 14], ["EWS", "OBSERVATION", 15, 18], ["nasal", "ANATOMY", 332, 337], ["pharyngeal", "ANATOMY", 342, 352]]], ["Testing for COVID-19 was conducted according to the World Health Organization (WHO) interim guidance.", [["COVID-19", "DNA", 12, 20], ["Testing", "TEST", 0, 7], ["COVID", "TEST", 12, 17]]], ["20 We excluded pregnant women and patients who were on circulatory shock and positive pressure support on arrival to ED.", [["circulatory shock", "DISEASE", 55, 72], ["women", "ORGANISM", 24, 29], ["patients", "ORGANISM", 34, 42], ["women", "SPECIES", 24, 29], ["patients", "SPECIES", 34, 42], ["circulatory shock", "TREATMENT", 55, 72], ["positive pressure support", "TREATMENT", 77, 102], ["pressure support", "OBSERVATION", 86, 102]]], ["Patients with a do-not-resuscitate/do-not-intubate (DNR/DNI) order in place were also excluded..Data collection and measurementsTwo authors blinded to patients' outcome retrieved clinical information from the electronic medical records (EMR) of the ED database.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 151, 159], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 151, 159], ["a do-not-resuscitate", "TREATMENT", 14, 34], ["Data collection", "TEST", 96, 111], ["measurements", "TEST", 116, 128]]], ["Extracted data included age, sex, clinical history and presentation, temperature, heart rate (HR), respiratory rate (RR), blood pressure (BP), Glasgow Coma Scale (GCS) score, oxygen therapy, and peripheral oxygen saturation (SpO2).", [["heart", "ANATOMY", 82, 87], ["blood", "ANATOMY", 122, 127], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "CHEMICAL", 206, 212], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "CHEMICAL", 206, 212], ["heart", "ORGAN", 82, 87], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["oxygen", "SIMPLE_CHEMICAL", 206, 212], ["temperature", "TEST", 69, 80], ["heart rate", "TEST", 82, 92], ["HR", "TEST", 94, 96], ["respiratory rate", "TEST", 99, 115], ["RR", "TEST", 117, 119], ["blood pressure", "TEST", 122, 136], ["BP", "TEST", 138, 140], ["Glasgow Coma Scale", "TEST", 143, 161], ["GCS", "TEST", 163, 166], ["oxygen therapy", "TREATMENT", 175, 189], ["peripheral oxygen saturation", "TEST", 195, 223], ["SpO2", "TEST", 225, 229], ["heart", "ANATOMY", 82, 87], ["oxygen therapy", "OBSERVATION", 175, 189], ["peripheral", "ANATOMY_MODIFIER", 195, 205], ["oxygen saturation", "OBSERVATION", 206, 223]]], ["All clinical signs, including SpO2, were measured upon ED arrival.", [["All clinical signs", "TEST", 0, 18], ["SpO2", "TEST", 30, 34]]], ["For NEWS2 calculation, patients were considered at risk of type 2 respiratory failure (T2RF) if they had a confirmed history of chronic obstructive pulmonary disease.OutcomesThe primary study outcomes were death and ICU admission within seven days from ED arrival.", [["respiratory", "ANATOMY", 66, 77], ["pulmonary", "ANATOMY", 148, 157], ["type 2 respiratory failure", "DISEASE", 59, 85], ["T2RF", "DISEASE", 87, 91], ["chronic obstructive pulmonary disease", "DISEASE", 128, 165], ["death", "DISEASE", 206, 211], ["patients", "ORGANISM", 23, 31], ["pulmonary", "ORGAN", 148, 157], ["patients", "SPECIES", 23, 31], ["NEWS2 calculation", "TEST", 4, 21], ["type 2 respiratory failure", "PROBLEM", 59, 85], ["chronic obstructive pulmonary disease", "PROBLEM", 128, 165], ["respiratory", "ANATOMY", 66, 77], ["failure", "OBSERVATION", 78, 85], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["obstructive", "OBSERVATION_MODIFIER", 136, 147], ["pulmonary", "ANATOMY", 148, 157], ["disease", "OBSERVATION", 158, 165]]], ["Secondary outcomes were death and ICU admission within 48h from ED arrival.", [["death", "DISEASE", 24, 29]]], ["Receiver operating characteristic (ROC) curve analysis was used to estimate the performance of the evaluated scores in predicting the study outcomes.", [["curve analysis", "TEST", 40, 54]]], ["For each score threshold value, the following was calculated: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), and negative likelihood ratio (-LR).", [["each score threshold value", "TEST", 4, 30], ["PPV", "TEST", 115, 118], ["NPV", "TEST", 148, 151]]], ["The Youden index was used to estimate the optimal thresholds for sensitivity and specificity.", [["The Youden index", "TEST", 0, 16], ["sensitivity", "TEST", 65, 76], ["specificity", "TEST", 81, 92]]], ["The comparison between the areas under the ROC curve (AUROCs) was made according to the DeLong method.", [["the ROC curve", "TEST", 39, 52]]], ["21 A p value \u2264 0.05 was regarded as significant.OutcomesTo check the robustness of our analysis we imputed data in patients with less than three missing parameters using a multiple imputation approach 22 .", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["A p value \u2264", "TEST", 3, 14], ["our analysis", "TEST", 83, 95], ["a multiple imputation approach", "TREATMENT", 170, 200]]], ["The results of imputation were added to the original study cohort with the complete dataset of vital parameters and EWS were recalculated.", [["EWS", "PROTEIN", 116, 119], ["imputation", "TREATMENT", 15, 25], ["the original study", "TEST", 40, 58], ["vital parameters", "TEST", 95, 111]]], ["The resulting AUROCs were compared to the AUROC obtained in the study population by using the z-statistics (2 sided).", [["the AUROC", "TEST", 38, 47]]], ["Further data on imputation are available in Appendix 1.Ethical approvalThis study has been approved by the local Ethics Committee (authorization #001705520) and has been performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments.", [["Further data", "TEST", 0, 12], ["imputation", "TREATMENT", 16, 26], ["Ethical approval", "TREATMENT", 55, 71], ["This study", "TEST", 71, 81], ["Appendix", "ANATOMY", 44, 52]]], ["All patients gave their informed consent for clinical data analysis.Characteristics of the study subjectsDuring the study period, 3955 patients were seen in the ED, of whom 1801 were evaluated for suspect COVID-19 and 512 were found positive to the COVID-19 test.", [["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 135, 143], ["clinical data analysis", "TEST", 45, 67], ["the study", "TEST", 87, 96], ["COVID", "TEST", 205, 210], ["the COVID", "TEST", 245, 254]]], ["Of these, 336 had sufficient data on EMR for calculating EWS.", [["EWS", "PROTEIN", 57, 60], ["EMR", "TEST", 37, 40], ["calculating EWS", "TEST", 45, 60]]], ["Two patients with a DNR/DNI order in place were excluded, leaving 334 patients for final analysis (Figure 1 ).", [["DNR", "CHEMICAL", 20, 23], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 70, 78], ["a DNR/DNI", "TREATMENT", 18, 27], ["final analysis", "TEST", 83, 97]]], ["Patients' median [IQR] age was 66 [54 -78] years (range 20 -98 years) and 215 (64.4%) were male ( Table 1) .Characteristics of the study subjectsThirty-eight (11%) COVID-19 patients were discharged from ED and quarantined.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 173, 181], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 173, 181], ["the study", "TEST", 127, 136]]], ["These patients were contacted daily to assess their clinical condition.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["The remaining 296 patients were admitted to hospital, of whom 56 (17% of the total) were admitted to ICU.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Fifty patients were admitted to ICU within 48 hours, while the remaining six patients were admitted on days 3-7 after ED arrival.", [["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 77, 85]]], ["Patients who needed ICU admission were older, had lower SpO2 and higher respiratory rate on ED arrival, and more frequently reported a history of hypertension, obesity, and chronic heart failure or coronary artery disease (Table 1) .Characteristics of the study subjectsOverall, 26 patients (7.8%) deceased within seven days after ED arrival, among whom 11 (3.3%) deceased by 48 hours.", [["heart", "ANATOMY", 181, 186], ["coronary artery", "ANATOMY", 198, 213], ["hypertension", "DISEASE", 146, 158], ["obesity", "DISEASE", 160, 167], ["chronic heart failure", "DISEASE", 173, 194], ["coronary artery disease", "DISEASE", 198, 221], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 181, 186], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 198, 213], ["patients", "ORGANISM", 282, 290], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 282, 290], ["lower SpO2", "PROBLEM", 50, 60], ["higher respiratory rate", "PROBLEM", 65, 88], ["hypertension", "PROBLEM", 146, 158], ["obesity", "PROBLEM", 160, 167], ["chronic heart failure", "PROBLEM", 173, 194], ["coronary artery disease", "PROBLEM", 198, 221], ["the study", "TEST", 252, 261], ["respiratory rate", "OBSERVATION", 72, 88], ["hypertension", "OBSERVATION", 146, 158], ["obesity", "OBSERVATION", 160, 167], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["heart", "ANATOMY", 181, 186], ["failure", "OBSERVATION", 187, 194], ["coronary artery", "ANATOMY", 198, 213], ["disease", "OBSERVATION", 214, 221]]], ["These patients were significantly older, had a higher respiratory rate, and a lower SpO2 on ED arrival.", [["respiratory", "ANATOMY", 54, 65], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["a higher respiratory rate", "PROBLEM", 45, 70], ["a lower SpO2", "PROBLEM", 76, 88], ["respiratory rate", "OBSERVATION", 54, 70]]], ["As for ICU admission, in patients who died a history of hypertension and chronic heart failure or coronary artery disease was more commonly reported ( Table 1) .", [["heart", "ANATOMY", 81, 86], ["coronary artery", "ANATOMY", 98, 113], ["hypertension", "DISEASE", 56, 68], ["heart failure", "DISEASE", 81, 94], ["coronary artery disease", "DISEASE", 98, 121], ["patients", "ORGANISM", 25, 33], ["heart", "ORGAN", 81, 86], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 98, 113], ["patients", "SPECIES", 25, 33], ["hypertension", "PROBLEM", 56, 68], ["chronic heart failure", "PROBLEM", 73, 94], ["coronary artery disease", "PROBLEM", 98, 121], ["hypertension", "OBSERVATION", 56, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["heart", "ANATOMY", 81, 86], ["failure", "OBSERVATION", 87, 94], ["coronary artery", "ANATOMY", 98, 113], ["disease", "OBSERVATION", 114, 121]]], ["Among all EWS, MEWS and qSOFA showed the lowest overall accuracy.", [["EWS", "CANCER", 10, 13], ["EWS", "DNA", 10, 13], ["MEWS", "DNA", 15, 19], ["qSOFA", "DNA", 24, 29], ["MEWS", "TEST", 15, 19], ["qSOFA", "TEST", 24, 29]]], ["Their AUROCs were significantly lower than that of the triage system of our hospital, except for prediction of death at 48h for qSOFA ( Table 3) .Accuracy of warning scoresESM figures 1 and 2 include the ROC curves for prediction of ICU admission and death, respectively, along with a statistical comparison of the AUROCs of the scores included in the study.Accuracy of warning scoresAmong the 176 patients excluded because of missing parameters, 78 (44.3%) had less than three missing parameters and were eligible for imputation.", [["death", "DISEASE", 111, 116], ["death", "DISEASE", 251, 256], ["patients", "ORGANISM", 398, 406], ["patients", "SPECIES", 398, 406], ["death", "PROBLEM", 111, 116], ["warning scoresESM figures", "TEST", 158, 183], ["the ROC curves", "TEST", 200, 214], ["the study", "TEST", 348, 357], ["warning scores", "TEST", 370, 384], ["imputation", "PROBLEM", 519, 529]]], ["Their available parameters are shown in Appendix 1, Table A1 .Accuracy of warning scoresAmong these 78 patients, six deaths (7.7%) and nine ICU admissions (11.5%) occurred within 7 days.Accuracy of warning scoresThe EWS AUROCs in the extended population including 78 patients with imputed vital parameters (total 412 patients) were not significantly different from those of the 334 patients with complete original data.", [["deaths", "DISEASE", 117, 123], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 317, 325], ["patients", "ORGANISM", 382, 390], ["EWS AUROCs", "DNA", 216, 226], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 317, 325], ["patients", "SPECIES", 382, 390], ["warning scores", "TEST", 74, 88], ["warning scores", "TEST", 198, 212], ["The EWS AUROCs", "TEST", 212, 226], ["imputed vital parameters", "TEST", 281, 305], ["complete original data", "TEST", 396, 418], ["Appendix", "ANATOMY", 40, 48], ["significantly different", "OBSERVATION_MODIFIER", 336, 359]]], ["(Appendix 1, Tables A2 and A3).DiscussionOur study showed that in COVID-19 patients NEWS and REMS assessed on arrival at the emergency department were the most accurate scores for predicting the risk of ICU admission and death, respectively, both at 48h and at 7 days.", [["death", "DISEASE", 221, 226], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["DiscussionOur study", "TEST", 31, 50]]], ["Moreover, the accuracy of these scores was comparable with that of the comprehensive triage score used in our department.DiscussionJ o u r n a l P r e -p r o o f NEWS is among the most accurate tools for predicting patient deterioration outside ICU.", [["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 215, 222]]], ["10 In a comparative study including 198,755 observation sets collected from 35,585 consecutive acute medical admissions in UK, 23 NEWS was more strongly associated with ICU admission or death compared to 33 other scoring systems (not including REMS).", [["death", "DISEASE", 186, 191], ["a comparative study", "TEST", 6, 25], ["observation sets", "TEST", 44, 60], ["death", "PROBLEM", 186, 191], ["acute", "OBSERVATION_MODIFIER", 95, 100]]], ["Moreover, in the specific setting of acute care patients admitted for suspected infection in ED or hospital wards, NEWS has proven to be more accurate for predicting death or ICU transfer than other tools that were purposely designed to assess infected patients, such as qSOFA and systemic inflammatory response syndrome (SIRS) criteria.", [["infection", "DISEASE", 80, 89], ["death", "DISEASE", 166, 171], ["systemic inflammatory response syndrome", "DISEASE", 281, 320], ["SIRS", "DISEASE", 322, 326], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 253, 261], ["infection", "PROBLEM", 80, 89], ["predicting death", "PROBLEM", 155, 171], ["other tools", "TEST", 193, 204], ["qSOFA", "TEST", 271, 276], ["systemic inflammatory response syndrome", "PROBLEM", 281, 320], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["infection", "OBSERVATION", 80, 89], ["inflammatory response syndrome", "OBSERVATION", 290, 320]]], ["24 In 2017, NEWS has been updated to NEWS2 by adding a new SpO2 scoring scale for patients with type 2 respiratory failure (T2RF), 25 even if the added value of this modification in improving discrimination of adverse outcomes in patients with documented T2RF has not been demonstrated yet.", [["respiratory", "ANATOMY", 103, 114], ["type 2 respiratory failure", "DISEASE", 96, 122], ["T2RF", "DISEASE", 124, 128], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 230, 238], ["NEWS2", "DNA", 37, 42], ["T2RF", "PROTEIN", 255, 259], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 230, 238], ["a new SpO2 scoring scale", "TEST", 53, 77], ["type 2 respiratory failure", "PROBLEM", 96, 122], ["this modification", "TREATMENT", 161, 178], ["documented T2RF", "PROBLEM", 244, 259], ["respiratory", "ANATOMY", 103, 114], ["failure", "OBSERVATION", 115, 122]]], ["26 NEWS2 is recommended by the Royal College of Physicians for use in COVID-19 patients.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["27 In our study, NEWS2 did not perform better than NEWS in predicting ICU admission or death.", [["death", "DISEASE", 87, 92], ["our study", "TEST", 6, 15], ["death", "PROBLEM", 87, 92]]], ["However, the prevalence of T2RF patients in our population was very low (19/334 patients; 5.7%) .", [["T2RF", "DISEASE", 27, 31], ["T2RF", "ORGANISM", 27, 31], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 80, 88], ["low", "OBSERVATION_MODIFIER", 68, 71]]], ["This is in accordance with data from other studies showing that hypercapnia is uncommon in COVID-19 patients, even in those admitted to ICU, 28 while hypoxia from early pulmonary involvement is the most common presentation feature.", [["pulmonary", "ANATOMY", 169, 178], ["hypercapnia", "DISEASE", 64, 75], ["hypoxia", "DISEASE", 150, 157], ["patients", "ORGANISM", 100, 108], ["pulmonary", "ORGAN", 169, 178], ["patients", "SPECIES", 100, 108], ["other studies", "TEST", 37, 50], ["hypercapnia", "PROBLEM", 64, 75], ["hypoxia", "PROBLEM", 150, 157], ["early pulmonary involvement", "PROBLEM", 163, 190], ["hypercapnia", "OBSERVATION", 64, 75], ["pulmonary", "ANATOMY", 169, 178], ["involvement", "OBSERVATION", 179, 190], ["most common", "OBSERVATION_MODIFIER", 198, 209]]], ["4, 29 NEWS-C, another modified version of NEWS, has recently been suggested for assessment of COVID-19 patients.", [["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["assessment", "TEST", 80, 90], ["COVID", "TEST", 94, 99]]], ["14 Age \u226565 years was added to NEWS-C as an independent risk factor based on recent reports in patients with influenza or other non-COVID infectious diseases.", [["influenza", "DISEASE", 108, 117], ["infectious diseases", "DISEASE", 137, 156], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["an independent risk factor", "PROBLEM", 40, 66], ["influenza", "PROBLEM", 108, 117], ["other non-COVID infectious diseases", "PROBLEM", 121, 156], ["infectious", "OBSERVATION", 137, 147]]], ["15, 16 Indeed, older age is associated with increased mortality in COVID-19 patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["increased mortality", "PROBLEM", 44, 63], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["mortality", "OBSERVATION", 54, 63]]], ["30 However, NEWS-C did not perform better than NEWS in predicting ICU admission or mortality in our study.", [["our study", "TEST", 96, 105]]], ["In fact, the median age of survivors vs. non-survivors was 64 years vs. 79.5 years in our COVID-19 population, as compared with 51 vs.68 years respectively in a recent report from J o u r n a l P r e -p r o o f China.", [["our COVID", "TEST", 86, 95]]], ["30 These data may reflect differences in demographics (median population age is 34.4 years in China vs. 42.5 years in Europe and 47.3 years in Italy 31 ) and in policies for ICU admission and triage.", [["may reflect", "UNCERTAINTY", 14, 25]]], ["Among the scoring systems we evaluated, REMS was the only one specifically developed to predict mortality in ED patients.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120]]], ["11, 32 The qSOFA has been proposed as a prompt to consider possible sepsis outside the ICU.", [["qSOFA", "CHEMICAL", 11, 16], ["sepsis", "DISEASE", 68, 74], ["sepsis", "PROBLEM", 68, 74]]], ["Criteria to calculate qSOFA include altered mental status (GCS<15), tachypnoea (RR \u226522), and hypotension (systolic BP\u2264100).", [["GCS", "DISEASE", 59, 62], ["tachypnoea", "DISEASE", 68, 78], ["hypotension", "DISEASE", 93, 104], ["qSOFA", "TEST", 22, 27], ["altered mental status", "PROBLEM", 36, 57], ["GCS", "TEST", 59, 62], ["tachypnoea", "PROBLEM", 68, 78], ["RR", "TEST", 80, 82], ["hypotension", "PROBLEM", 93, 104], ["systolic BP", "TEST", 106, 117], ["hypotension", "OBSERVATION", 93, 104]]], ["In the original validation study, a qSOFA score of 2 or higher was associated with a significantly increased risk of hospital mortality.", [["the original validation study", "TEST", 3, 32], ["a qSOFA score", "TEST", 34, 47]]], ["19 However, the accuracy of qSOFA was low in our study, confirming results from previous studies conducted in non-COVID potentially septic patients.", [["septic", "DISEASE", 132, 138], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["qSOFA", "TEST", 28, 33], ["our study", "TEST", 45, 54], ["previous studies", "TEST", 80, 96], ["septic", "OBSERVATION", 132, 138]]], ["24, 33, 34 Notably, most patients in our cohort did not have any of the three qSOFA criteria, and none of them had a qSOFA score of 2 or higher.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["a qSOFA score", "TEST", 115, 128]]], ["Among the three qSOFA criteria, the prevalence of hypotension and altered mental status on ED admission in our patient population was particularly low (6.6% and 3.3%; data not shown).", [["hypotension", "DISEASE", 50, 61], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["hypotension", "PROBLEM", 50, 61], ["altered mental status", "PROBLEM", 66, 87], ["hypotension", "OBSERVATION", 50, 61], ["altered", "OBSERVATION_MODIFIER", 66, 73]]], ["This is in line with recent reports showing that extrapulmonary organ dysfunction occurs later in the clinical course of COVID-19.", [["extrapulmonary organ", "ANATOMY", 49, 69], ["extrapulmonary organ dysfunction", "DISEASE", 49, 81], ["COVID-19", "CHEMICAL", 121, 129], ["organ", "ORGAN", 64, 69], ["extrapulmonary organ dysfunction", "PROBLEM", 49, 81], ["COVID", "TEST", 121, 126], ["extrapulmonary organ", "ANATOMY", 49, 69], ["dysfunction", "OBSERVATION", 70, 81]]], ["35 When compared with other scoring systems, including our institutional triage score, NEWS and REMS had the highest sensitivity and NPV for adverse outcomes.", [["our institutional triage score", "TEST", 55, 85], ["NPV", "TEST", 133, 136], ["adverse outcomes", "PROBLEM", 141, 157]]], ["In other words, they performed particularly well in identifying COVID-19 patients who did not require ICU admission or were at low risk of death, respectively.DiscussionWhen triaging patients in ED, having a high NPV (i.e., a low rate of false negative predictions) for adverse outcomes is paramount in order to avoid inappropriately admitting a patient at risk of deterioration to a non-critical care area.", [["death", "DISEASE", 139, 144], ["patients", "ORGANISM", 73, 81], ["patients", "ORGANISM", 183, 191], ["patient", "ORGANISM", 346, 353], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 183, 191], ["patient", "SPECIES", 346, 353], ["a high NPV", "PROBLEM", 206, 216], ["adverse outcomes", "PROBLEM", 270, 286], ["a non-critical care area", "TREATMENT", 382, 406]]], ["However, because of the relatively low incidence of adverse outcomes in our population, all the EWS we evaluated had a low PPV (i.e., a low rate of true positive predictions), which implies a risk of overtriage when these scores are used to decide admission to a critical care area.", [["a low PPV", "PROBLEM", 117, 126], ["low", "OBSERVATION_MODIFIER", 35, 38]]], ["Although J o u r n a l P r e -p r o o f consensus suggests that overtriage is generally preferable to undertriage, 36 this may not be the case when meeting the demands of healthcare resources is difficult.", [["a l P r e -p r o o f consensus", "TEST", 19, 49]]], ["The prognostic indications from physiological scores should be interpreted within a more comprehensive clinical approach including patient's comorbidities, functional status, and preferences.DiscussionIn our study we assessed EWS only once, on patient arrival to the ED.", [["patient", "ORGANISM", 131, 138], ["patient", "ORGANISM", 244, 251], ["patient", "SPECIES", 131, 138], ["patient", "SPECIES", 244, 251], ["patient's comorbidities", "PROBLEM", 131, 154], ["our study", "TEST", 204, 213]]], ["Since EWS have been designed as track-and-trigger systems to detect deterioration of vital signs over time, their sequential measurement in COVID-19 patients admitted to non-monitored wards may represent the logical continuation of their use in ED.", [["EWS", "CANCER", 6, 9], ["patients", "ORGANISM", 149, 157], ["EWS", "PROTEIN", 6, 9], ["patients", "SPECIES", 149, 157], ["vital signs", "TEST", 85, 96], ["their sequential measurement", "TEST", 108, 136], ["COVID", "TEST", 140, 145]]], ["The value of EWS in this context deserves further investigation.DiscussionSome limitations of our study should be acknowledged.", [["EWS", "CANCER", 13, 16], ["EWS", "PROTEIN", 13, 16], ["further investigation", "TEST", 42, 63], ["our study", "TEST", 94, 103]]], ["First, this was a single-centre study conducted on a relatively small population, and its confirmation on a larger, multicentre cohort is warranted.", [["a single-centre study", "TEST", 16, 37], ["its confirmation", "TEST", 86, 102], ["small", "OBSERVATION_MODIFIER", 64, 69], ["population", "OBSERVATION", 70, 80], ["larger", "OBSERVATION_MODIFIER", 108, 114]]], ["Secondly, the EWS were retrospectively calculated from data recorded on the patients' EMR that were not specifically collected for this purpose.", [["EWS", "CANCER", 14, 17], ["patients", "ORGANISM", 76, 84], ["EWS", "DNA", 14, 17], ["patients", "SPECIES", 76, 84]]], ["This resulted in missing data necessitating imputation.", [["imputation", "TREATMENT", 44, 54]]], ["Thirdly, ICU admission is an institution-dependent outcome, which may limit the generalizability of our results.DiscussionIn summary, our study showed that in patients with confirmed COVID-19 assessed on ED arrival, REMS and NEWS were the most accurate indices for predicting in-hospital death and ICU admission within seven days, respectively.", [["death", "DISEASE", 288, 293], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["our study", "TEST", 134, 143], ["COVID", "TEST", 183, 188]]], ["Due to their high NPV, these indices could be particularly useful for identifying patients who are at lower risk of poor outcome and can be admitted to a non-monitored ward.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["their high NPV", "PROBLEM", 7, 21]]], ["This supports their use as an adjunct to the process of triage and disposition of COVID-19 patients in the ED.DiscussionProspective multicentre cohort studies are needed to provide an external validation of our results.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["DiscussionProspective multicentre cohort studies", "TEST", 110, 158], ["an external validation", "TEST", 181, 203]]]], "9ec6c6bf7df458d5d550fbbc6c554102b0468b1f": [["I. IntroductionThe unaffected central nervous system (CNS) is an immunologically sequestered organ.", [["central nervous system", "ANATOMY", 30, 52], ["CNS", "ANATOMY", 54, 57], ["organ", "ANATOMY", 93, 98], ["central nervous system", "ANATOMICAL_SYSTEM", 30, 52], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["organ", "ORGAN", 93, 98], ["central", "ANATOMY_MODIFIER", 30, 37], ["nervous system", "ANATOMY", 38, 52], ["CNS", "ANATOMY", 54, 57]]], ["This is evidenced by low expression of MHC antigens on very few meningeal and perivascular cells, the lack of immunostimulatory dendritic ceils, absence of draining lymphatic vessels and a tight blood-brain barrier that prevents extensive lymphoid cell traffic (Wekerle et al., 1986; .", [["meningeal", "ANATOMY", 64, 73], ["perivascular cells", "ANATOMY", 78, 96], ["dendritic ceils", "ANATOMY", 128, 143], ["lymphatic vessels", "ANATOMY", 165, 182], ["blood", "ANATOMY", 195, 200], ["brain", "ANATOMY", 201, 206], ["lymphoid cell", "ANATOMY", 239, 252], ["MHC antigens", "GENE_OR_GENE_PRODUCT", 39, 51], ["meningeal", "CELL", 64, 73], ["perivascular cells", "CELL", 78, 96], ["dendritic ceils", "CELL", 128, 143], ["lymphatic vessels", "MULTI-TISSUE_STRUCTURE", 165, 182], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["brain barrier", "TISSUE", 201, 214], ["lymphoid cell", "CELL", 239, 252], ["MHC antigens", "PROTEIN", 39, 51], ["meningeal and perivascular cells", "CELL_TYPE", 64, 96], ["low expression of MHC antigens", "PROBLEM", 21, 51], ["very few meningeal and perivascular cells", "PROBLEM", 55, 96], ["immunostimulatory dendritic ceils", "PROBLEM", 110, 143], ["draining lymphatic vessels", "PROBLEM", 156, 182], ["a tight blood-brain barrier", "TREATMENT", 187, 214], ["low expression", "OBSERVATION_MODIFIER", 21, 35], ["MHC antigens", "OBSERVATION", 39, 51], ["very", "OBSERVATION_MODIFIER", 55, 59], ["few", "OBSERVATION_MODIFIER", 60, 63], ["meningeal", "ANATOMY", 64, 73], ["perivascular cells", "ANATOMY", 78, 96], ["immunostimulatory dendritic ceils", "OBSERVATION", 110, 143], ["draining", "ANATOMY_MODIFIER", 156, 164], ["lymphatic vessels", "ANATOMY", 165, 182], ["brain", "ANATOMY", 201, 206], ["extensive", "OBSERVATION_MODIFIER", 229, 238], ["lymphoid cell traffic", "OBSERVATION", 239, 260]]], ["The immunologically privileged state is rapidly changed when the CNS becomes a target for viral infections.", [["CNS", "ANATOMY", 65, 68], ["viral infections", "DISEASE", 90, 106], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["viral infections", "PROBLEM", 90, 106]]], ["Inflammatory infiltrates in the CNS tissue clearly indicate the engagement of the immune system, but to date neither the afferent nor the efferent arm of a CNS-localised virus-specific immune response are completely understood.", [["CNS tissue", "ANATOMY", 32, 42], ["immune system", "ANATOMY", 82, 95], ["afferent", "ANATOMY", 121, 129], ["efferent arm", "ANATOMY", 138, 150], ["CNS", "ANATOMY", 156, 159], ["CNS tissue", "TISSUE", 32, 42], ["immune system", "ANATOMICAL_SYSTEM", 82, 95], ["CNS", "ANATOMICAL_SYSTEM", 156, 159], ["Inflammatory infiltrates in the CNS tissue", "PROBLEM", 0, 42], ["a CNS-localised virus", "PROBLEM", 154, 175], ["infiltrates", "OBSERVATION", 13, 24], ["CNS tissue", "ANATOMY", 32, 42], ["efferent", "ANATOMY_MODIFIER", 138, 146], ["arm", "ANATOMY", 147, 150], ["CNS", "ANATOMY", 156, 159]]], ["In particular, the upregulation of MHC class II antigens in the inflamed virus-infected CNS raises many questions with respect to infiltrating CD4 \u00f7 T lymphocytes.", [["CNS", "ANATOMY", 88, 91], ["infiltrating CD4 \u00f7 T lymphocytes", "ANATOMY", 130, 162], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 35, 56], ["inflamed virus", "ORGANISM", 64, 78], ["CNS", "ANATOMICAL_SYSTEM", 88, 91], ["CD4", "GENE_OR_GENE_PRODUCT", 143, 146], ["MHC class II antigens", "PROTEIN", 35, 56], ["infiltrating CD4 \u00f7 T lymphocytes", "CELL_TYPE", 130, 162], ["the inflamed virus", "PROBLEM", 60, 78], ["inflamed", "OBSERVATION_MODIFIER", 64, 72], ["virus", "OBSERVATION", 73, 78], ["lymphocytes", "ANATOMY", 151, 162]]], ["It has been shown in vitro that expression of MHC class II antigens can be induced by y-interferon on CNS-resident glia cells (Wong et al., 1985) .", [["CNS-resident glia cells", "ANATOMY", 102, 125], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 46, 67], ["y-interferon", "GENE_OR_GENE_PRODUCT", 86, 98], ["CNS-resident glia cells", "CELL", 102, 125], ["MHC class II antigens", "PROTEIN", 46, 67], ["y-interferon", "PROTEIN", 86, 98], ["CNS-resident glia cells", "CELL_TYPE", 102, 125]]], ["Microglia cells have been identified as the major cell type expressing class II antigens in the CNS (Matsumoto et al., 1986; Hayes et al., 1987) and perivascular microglia cells can function as antigen-presenting cells for CD4 \u00f7 T lymphocytes (Hickey and Kimura, 1988) .", [["Microglia cells", "ANATOMY", 0, 15], ["cell", "ANATOMY", 50, 54], ["CNS", "ANATOMY", 96, 99], ["perivascular microglia cells", "ANATOMY", 149, 177], ["antigen-presenting cells", "ANATOMY", 194, 218], ["CD4 \u00f7 T lymphocytes", "ANATOMY", 223, 242], ["Microglia cells", "CELL", 0, 15], ["cell type", "CELL", 50, 59], ["class II antigens", "GENE_OR_GENE_PRODUCT", 71, 88], ["CNS", "ANATOMICAL_SYSTEM", 96, 99], ["perivascular microglia cells", "CELL", 149, 177], ["cells", "CELL", 213, 218], ["CD4", "GENE_OR_GENE_PRODUCT", 223, 226], ["Microglia cells", "CELL_TYPE", 0, 15], ["class II antigens", "PROTEIN", 71, 88], ["perivascular microglia cells", "CELL_TYPE", 149, 177], ["antigen-presenting cells", "CELL_TYPE", 194, 218], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 223, 242], ["Microglia cells", "TEST", 0, 15], ["perivascular microglia cells", "TEST", 149, 177], ["antigen", "TEST", 194, 201], ["CD4", "TEST", 223, 226], ["lymphocytes", "TEST", 231, 242], ["CNS", "ANATOMY", 96, 99], ["perivascular", "ANATOMY", 149, 161], ["microglia cells", "OBSERVATION", 162, 177]]], ["Hence, microglia cells might support expansion and differentiation of immunoregulatory important CD4 \u00f7 T lymphocytes inside the CNS.I. IntroductionA suitable animal model to study these questions in vivo is the intracerebral infection of rats with the murine coronavirus strain JHM (JHMV).", [["microglia cells", "ANATOMY", 7, 22], ["CD4 \u00f7 T lymphocytes", "ANATOMY", 97, 116], ["CNS", "ANATOMY", 128, 131], ["intracerebral", "ANATOMY", 211, 224], ["intracerebral infection", "DISEASE", 211, 234], ["microglia cells", "CELL", 7, 22], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 211, 224], ["rats", "ORGANISM", 238, 242], ["murine coronavirus strain JHM", "ORGANISM", 252, 281], ["JHMV", "CANCER", 283, 287], ["microglia cells", "CELL_TYPE", 7, 22], ["immunoregulatory important CD4 \u00f7 T lymphocytes", "CELL_TYPE", 70, 116], ["rats", "SPECIES", 238, 242], ["murine", "SPECIES", 252, 258], ["murine coronavirus", "SPECIES", 252, 270], ["JHMV", "SPECIES", 283, 287], ["microglia cells", "PROBLEM", 7, 22], ["expansion", "PROBLEM", 37, 46], ["the intracerebral infection of rats", "PROBLEM", 207, 242], ["the murine coronavirus strain JHM", "PROBLEM", 248, 281], ["microglia cells", "OBSERVATION", 7, 22], ["CNS", "ANATOMY", 128, 131], ["intracerebral", "ANATOMY", 211, 224], ["infection", "OBSERVATION", 225, 234]]], ["Whereas in 3-week-old BN rats the infection remains subclinical, LEW rats infected at the same age die either from an acute encephalitis within 5-6 days or suffer from a subacute monophasic disease, characterised by ataxic gait, hind leg paresis or tetraplegia.", [["hind leg", "ANATOMY", 229, 237], ["infection", "DISEASE", 34, 43], ["encephalitis", "DISEASE", 124, 136], ["ataxic gait", "DISEASE", 216, 227], ["paresis", "DISEASE", 238, 245], ["tetraplegia", "DISEASE", 249, 260], ["BN rats", "ORGANISM", 22, 29], ["LEW rats", "ORGANISM", 65, 73], ["hind leg", "ORGANISM_SUBDIVISION", 229, 237], ["rats", "SPECIES", 25, 29], ["rats", "SPECIES", 69, 73], ["the infection", "PROBLEM", 30, 43], ["an acute encephalitis", "PROBLEM", 115, 136], ["a subacute monophasic disease", "PROBLEM", 168, 197], ["ataxic gait", "PROBLEM", 216, 227], ["hind leg paresis", "PROBLEM", 229, 245], ["tetraplegia", "PROBLEM", 249, 260], ["infection", "OBSERVATION", 34, 43], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["encephalitis", "OBSERVATION", 124, 136], ["subacute", "OBSERVATION_MODIFIER", 170, 178], ["monophasic", "OBSERVATION_MODIFIER", 179, 189], ["disease", "OBSERVATION", 190, 197], ["leg", "ANATOMY", 234, 237], ["paresis", "OBSERVATION", 238, 245], ["tetraplegia", "OBSERVATION", 249, 260]]], ["The neurological disease in LEW rats is accompanied by a strong inflammatory response, dominated by CD4 +, a//3 T cell antigen receptor (TCR) + T lymphocytes, CD8 +, a//3 TCR + T lymphocytes and ED 1 + macrophages, all of which home to virus-infected areas in the CNS (D6rries et al., 1991) .", [["neurological", "ANATOMY", 4, 16], ["CD4 +, a//3 T cell antigen receptor (TCR) + T lymphocytes", "ANATOMY", 100, 157], ["CD8 +, a//3 TCR + T lymphocytes", "ANATOMY", 159, 190], ["ED 1 + macrophages", "ANATOMY", 195, 213], ["CNS", "ANATOMY", 264, 267], ["neurological disease", "DISEASE", 4, 24], ["LEW rats", "ORGANISM", 28, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 100, 103], ["3 T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 110, 135], ["TCR", "GENE_OR_GENE_PRODUCT", 137, 140], ["CD8", "GENE_OR_GENE_PRODUCT", 159, 162], ["TCR", "GENE_OR_GENE_PRODUCT", 171, 174], ["CNS", "ANATOMICAL_SYSTEM", 264, 267], ["CD4", "PROTEIN", 100, 103], ["T cell antigen receptor (TCR) + T lymphocytes", "CELL_TYPE", 112, 157], ["CD8", "PROTEIN", 159, 162], ["TCR", "PROTEIN", 171, 174], ["T lymphocytes", "CELL_TYPE", 177, 190], ["ED 1 + macrophages", "CELL_TYPE", 195, 213], ["rats", "SPECIES", 32, 36], ["The neurological disease", "PROBLEM", 0, 24], ["a strong inflammatory response", "PROBLEM", 55, 85], ["CD4", "TEST", 100, 103], ["TCR", "TEST", 137, 140], ["T lymphocytes", "TEST", 144, 157], ["CD8", "TEST", 159, 162], ["lymphocytes", "TEST", 179, 190], ["macrophages", "PROBLEM", 202, 213], ["neurological disease", "OBSERVATION", 4, 24], ["strong", "OBSERVATION_MODIFIER", 57, 63], ["inflammatory", "OBSERVATION", 64, 76], ["lymphocytes", "ANATOMY", 146, 157], ["lymphocytes", "ANATOMY", 179, 190], ["macrophages", "ANATOMY", 202, 213], ["infected", "OBSERVATION", 242, 250], ["CNS", "ANATOMY", 264, 267]]], ["Healthy BN rats recruit similar lymphocyte subsets into the CNS but usually fewer than in LEW rats (D6rries et al., 1991) .", [["lymphocyte", "ANATOMY", 32, 42], ["CNS", "ANATOMY", 60, 63], ["BN rats", "ORGANISM", 8, 15], ["lymphocyte", "CELL", 32, 42], ["CNS", "ANATOMICAL_SYSTEM", 60, 63], ["LEW rats", "ORGANISM", 90, 98], ["lymphocyte subsets", "CELL_TYPE", 32, 50], ["rats", "SPECIES", 11, 15], ["rats", "SPECIES", 94, 98], ["similar lymphocyte subsets", "OBSERVATION", 24, 50], ["CNS", "ANATOMY", 60, 63]]], ["Concomitant with the increase of lymphoid cells in the brain parenchyma of JHMV-infected rats, MHC class II antigen expression is upregulated on CNS-resident microglia cells and peripheral MHC class II + cells pass the blood-brain barrier .", [["lymphoid cells", "ANATOMY", 33, 47], ["brain parenchyma", "ANATOMY", 55, 71], ["CNS-resident microglia cells", "ANATOMY", 145, 173], ["peripheral MHC class II + cells", "ANATOMY", 178, 209], ["blood-brain barrier", "ANATOMY", 219, 238], ["lymphoid cells", "CELL", 33, 47], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 55, 71], ["JHMV", "GENE_OR_GENE_PRODUCT", 75, 79], ["rats", "ORGANISM", 89, 93], ["MHC class II antigen", "GENE_OR_GENE_PRODUCT", 95, 115], ["CNS-resident microglia cells", "CELL", 145, 173], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 225, 238], ["lymphoid cells", "CELL_TYPE", 33, 47], ["MHC class II antigen", "PROTEIN", 95, 115], ["CNS-resident microglia cells", "CELL_TYPE", 145, 173], ["peripheral MHC class II + cells", "CELL_TYPE", 178, 209], ["rats", "SPECIES", 89, 93], ["lymphoid cells", "PROBLEM", 33, 47], ["infected rats", "PROBLEM", 80, 93], ["microglia cells", "TEST", 158, 173], ["the blood", "TEST", 215, 224], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["lymphoid cells", "OBSERVATION", 33, 47], ["brain", "ANATOMY", 55, 60], ["parenchyma", "ANATOMY_MODIFIER", 61, 71], ["infected", "OBSERVATION_MODIFIER", 80, 88], ["brain", "ANATOMY", 225, 230]]], ["In this context, presence of viral antigens might allow antigen-driven proliferation of CD4 + T lymphocytes resulting in intracerebral increase of this lymphocyte subset.", [["CD4 + T lymphocytes", "ANATOMY", 88, 107], ["intracerebral", "ANATOMY", 121, 134], ["lymphocyte", "ANATOMY", 152, 162], ["CD4", "GENE_OR_GENE_PRODUCT", 88, 91], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 134], ["lymphocyte", "CELL", 152, 162], ["viral antigens", "PROTEIN", 29, 43], ["CD4", "PROTEIN", 88, 91], ["T lymphocytes", "CELL_TYPE", 94, 107], ["lymphocyte subset", "CELL_TYPE", 152, 169], ["viral antigens", "PROBLEM", 29, 43], ["antigen", "TEST", 56, 63], ["CD4 + T lymphocytes", "PROBLEM", 88, 107], ["intracerebral increase", "PROBLEM", 121, 143], ["this lymphocyte subset", "PROBLEM", 147, 169], ["viral", "OBSERVATION", 29, 34], ["intracerebral", "OBSERVATION_MODIFIER", 121, 134], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["lymphocyte subset", "OBSERVATION", 152, 169]]], ["We addressed this question by examination of T lymphocytes from the CNS and CLNs of JHMV-infected BN and LEW rats at different times post infection.", [["T lymphocytes", "ANATOMY", 45, 58], ["CNS", "ANATOMY", 68, 71], ["CLNs", "ANATOMY", 76, 80], ["BN", "ANATOMY", 98, 100], ["infection", "DISEASE", 138, 147], ["T lymphocytes", "CELL", 45, 58], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["CLNs", "CELL", 76, 80], ["JHMV", "CELL", 84, 88], ["BN", "CELL", 98, 100], ["LEW rats", "ORGANISM", 105, 113], ["T lymphocytes", "CELL_TYPE", 45, 58], ["rats", "SPECIES", 109, 113], ["JHMV", "SPECIES", 84, 88], ["LEW", "SPECIES", 105, 108], ["examination", "TEST", 30, 41], ["T lymphocytes", "PROBLEM", 45, 58], ["JHMV", "PROBLEM", 84, 88], ["infected BN", "PROBLEM", 89, 100], ["infection", "PROBLEM", 138, 147], ["CNS", "ANATOMY", 68, 71], ["infected", "OBSERVATION", 89, 97], ["infection", "OBSERVATION", 138, 147]]], ["Here, we demonstrate that T lymphocytes from CLNs but not from CNS of JHMV-infected BN and LEW rats proliferate ex vivo and can be stimulated to proliferate by JHMV-antigens in vitro.", [["T lymphocytes", "ANATOMY", 26, 39], ["CLNs", "ANATOMY", 45, 49], ["CNS", "ANATOMY", 63, 66], ["BN", "ANATOMY", 84, 86], ["T lymphocytes", "CELL", 26, 39], ["CLNs", "CELL", 45, 49], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["JHMV", "GENE_OR_GENE_PRODUCT", 70, 74], ["BN", "CELL", 84, 86], ["LEW rats", "ORGANISM", 91, 99], ["JHMV-antigens", "GENE_OR_GENE_PRODUCT", 160, 173], ["T lymphocytes", "CELL_TYPE", 26, 39], ["CLNs", "CELL_TYPE", 45, 49], ["JHMV", "PROTEIN", 160, 164], ["rats", "SPECIES", 95, 99], ["JHMV", "SPECIES", 70, 74], ["LEW", "SPECIES", 91, 94], ["T lymphocytes from CLNs", "PROBLEM", 26, 49], ["infected BN", "PROBLEM", 75, 86], ["infected", "OBSERVATION", 75, 83]]], ["This suggests that priming and clonal expansion of virus-specific T lymphocytes during JHMV-induced encephalitis occur in CLNs and that increase of this lymphocyte population in the brain parenchyma reflects accumulation rather than local expansion of virus-specific T lymphocyte clones.VirusJHM virus for infection of animals was propagated as described earlier .", [["T lymphocytes", "ANATOMY", 66, 79], ["CLNs", "ANATOMY", 122, 126], ["lymphocyte", "ANATOMY", 153, 163], ["brain parenchyma", "ANATOMY", 182, 198], ["T lymphocyte clones", "ANATOMY", 267, 286], ["JHMV", "CHEMICAL", 87, 91], ["encephalitis", "DISEASE", 100, 112], ["infection", "DISEASE", 306, 315], ["clonal", "CELL", 31, 37], ["T lymphocytes", "CELL", 66, 79], ["JHMV", "GENE_OR_GENE_PRODUCT", 87, 91], ["CLNs", "CANCER", 122, 126], ["lymphocyte", "CELL", 153, 163], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 182, 198], ["T lymphocyte clones", "CELL", 267, 286], ["VirusJHM virus", "ORGANISM", 287, 301], ["animals", "ORGANISM", 319, 326], ["T lymphocytes", "CELL_TYPE", 66, 79], ["CLNs", "CELL_TYPE", 122, 126], ["lymphocyte population", "CELL_TYPE", 153, 174], ["virus-specific T lymphocyte clones", "CELL_LINE", 252, 286], ["VirusJHM virus", "SPECIES", 287, 301], ["clonal expansion of virus", "PROBLEM", 31, 56], ["specific T lymphocytes", "PROBLEM", 57, 79], ["JHMV", "TEST", 87, 91], ["encephalitis", "PROBLEM", 100, 112], ["this lymphocyte population in the brain parenchyma", "PROBLEM", 148, 198], ["local expansion of virus", "PROBLEM", 233, 257], ["specific T lymphocyte clones", "PROBLEM", 258, 286], ["VirusJHM virus", "PROBLEM", 287, 301], ["infection of animals", "PROBLEM", 306, 326], ["clonal", "OBSERVATION_MODIFIER", 31, 37], ["expansion", "OBSERVATION_MODIFIER", 38, 47], ["virus", "OBSERVATION", 51, 56], ["encephalitis", "OBSERVATION", 100, 112], ["increase", "OBSERVATION_MODIFIER", 136, 144], ["lymphocyte population", "OBSERVATION", 153, 174], ["brain", "ANATOMY", 182, 187], ["parenchyma", "ANATOMY_MODIFIER", 188, 198], ["accumulation", "OBSERVATION_MODIFIER", 208, 220], ["virus", "OBSERVATION", 252, 257], ["lymphocyte clones", "OBSERVATION", 269, 286], ["infection", "OBSERVATION", 306, 315]]], ["Virus particles used as antigen for stimulation of T lymphocytes were purified according to Wege et al. (1978) .", [["T lymphocytes", "ANATOMY", 51, 64], ["Virus", "ORGANISM", 0, 5], ["T lymphocytes", "CELL", 51, 64], ["T lymphocytes", "CELL_TYPE", 51, 64], ["Virus particles", "TREATMENT", 0, 15], ["stimulation of T lymphocytes", "TREATMENT", 36, 64]]], ["Purified viral particles were denatured for 30 min at 100\u00b0C before addition to the rat lymphocyte cultures.", [["lymphocyte cultures", "ANATOMY", 87, 106], ["C", "GENE_OR_GENE_PRODUCT", 58, 59], ["rat", "ORGANISM", 83, 86], ["lymphocyte cultures", "CELL", 87, 106], ["rat lymphocyte cultures", "CELL_LINE", 83, 106], ["rat", "SPECIES", 83, 86], ["Purified viral particles", "PROBLEM", 0, 24], ["the rat lymphocyte cultures", "TEST", 79, 106], ["viral particles", "OBSERVATION", 9, 24]]], ["The same virus batch was used throughout all assays for antigen-specific proliferation.", [["antigen", "GENE_OR_GENE_PRODUCT", 56, 63], ["The same virus batch", "TREATMENT", 0, 20], ["antigen", "TEST", 56, 63], ["specific proliferation", "OBSERVATION", 64, 86]]], ["The stimulating capacity of this virus batch on T lymphocyte proliferation was verified on a JHMV-specific rat T cell line by [3H]thymidine incorporation (data not shown).AnimalsLEW and BN rats were obtained from the Zentralinstitut fiir Versuchstierzucht, Hannover, Germany.", [["T lymphocyte", "ANATOMY", 48, 60], ["T cell line", "ANATOMY", 111, 122], ["[3H]thymidine", "CHEMICAL", 126, 139], ["[3H]thymidine", "CHEMICAL", 126, 139], ["T lymphocyte", "CELL", 48, 60], ["rat", "ORGANISM", 107, 110], ["T cell line", "CELL", 111, 122], ["[3H]thymidine", "SIMPLE_CHEMICAL", 126, 139], ["BN rats", "ORGANISM", 186, 193], ["T lymphocyte", "CELL_TYPE", 48, 60], ["JHMV-specific rat T cell line", "CELL_LINE", 93, 122], ["rat", "SPECIES", 107, 110], ["rats", "SPECIES", 189, 193], ["JHMV", "SPECIES", 93, 97], ["The stimulating capacity", "PROBLEM", 0, 24], ["this virus batch", "TREATMENT", 28, 44], ["T lymphocyte proliferation", "PROBLEM", 48, 74], ["a JHMV", "TEST", 91, 97], ["3H]thymidine incorporation", "TREATMENT", 127, 153], ["lymphocyte proliferation", "OBSERVATION", 50, 74]]], ["They were JHMV seronegative and kept under SPF conditions until inoculation with virus.", [["JHMV", "SPECIES", 10, 14], ["JHMV seronegative", "PROBLEM", 10, 27], ["virus", "PROBLEM", 81, 86]]], ["At the age of 3 weeks, the animals were intracerebrally infected with 80 /xl of JHM virus containing 1.0 x 10 3 plaque-forming units.", [["plaque", "ANATOMY", 112, 118], ["animals", "ORGANISM", 27, 34], ["JHM virus", "ORGANISM", 80, 89], ["JHM virus", "SPECIES", 80, 89], ["intracerebrally infected", "PROBLEM", 40, 64], ["JHM virus", "PROBLEM", 80, 89]]], ["Their clinical state was recorded daily using the following score (D6rries et al., 1991) : (0) no overt disease; (1) uncommon social behaviour, such as separation from other rats in the cage; (2) paresis of 1 or 2 legs; (3) paresis of more than 2 legs; (4) paralysis and (5) moribund.Monoclonal antibodiesTo stain lymphocytes for flow-cytometric analysis the following monoclonal antibodies (mAbs) were used: W3/25 specific for the rat CD4 (Williams et al., 1977) , OX22 specific for the rat CD45RC (Spickett et al., 1983) , OX39 specific for the rat IL-2 receptor (IL-2R) (Paterson et al., 1987) , R73 specific for the a//3 chains of the rat TCR (Hiinig et al., 1989) and as a negative control 4B4 specific for the 13 chain of the human VLA4 (CD29) (Morimoto et al., 1985) .Isolation of lymphocytes from the CNS and cervical lymph nodesInflammatory lymphocytes were isolated from the brain according to a procedure published by our laboratory earlier .", [["legs", "ANATOMY", 214, 218], ["legs", "ANATOMY", 247, 251], ["lymphocytes", "ANATOMY", 314, 325], ["lymphocytes", "ANATOMY", 788, 799], ["CNS", "ANATOMY", 809, 812], ["cervical lymph nodes", "ANATOMY", 817, 837], ["lymphocytes", "ANATOMY", 850, 861], ["brain", "ANATOMY", 885, 890], ["paresis", "DISEASE", 196, 203], ["paresis", "DISEASE", 224, 231], ["paralysis", "DISEASE", 257, 266], ["TCR", "CHEMICAL", 643, 646], ["rats", "ORGANISM", 174, 178], ["legs", "ORGANISM_SUBDIVISION", 214, 218], ["legs", "ORGANISM_SUBDIVISION", 247, 251], ["lymphocytes", "CELL", 314, 325], ["W3/25", "ORGANISM", 409, 414], ["rat", "ORGANISM", 432, 435], ["CD4", "GENE_OR_GENE_PRODUCT", 436, 439], ["OX22", "GENE_OR_GENE_PRODUCT", 466, 470], ["rat", "ORGANISM", 488, 491], ["CD45RC", "GENE_OR_GENE_PRODUCT", 492, 498], ["OX39", "GENE_OR_GENE_PRODUCT", 525, 529], ["rat", "ORGANISM", 547, 550], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 551, 564], ["IL-2R", "GENE_OR_GENE_PRODUCT", 566, 571], ["rat", "ORGANISM", 639, 642], ["TCR", "GENE_OR_GENE_PRODUCT", 643, 646], ["human", "ORGANISM", 732, 737], ["VLA4", "GENE_OR_GENE_PRODUCT", 738, 742], ["CD29", "GENE_OR_GENE_PRODUCT", 744, 748], ["lymphocytes", "CELL", 788, 799], ["CNS", "CELL", 809, 812], ["cervical lymph nodesInflammatory lymphocytes", "CELL", 817, 861], ["brain", "ORGAN", 885, 890], ["Monoclonal antibodies", "PROTEIN", 284, 305], ["stain lymphocytes", "CELL_TYPE", 308, 325], ["monoclonal antibodies", "PROTEIN", 369, 390], ["mAbs", "PROTEIN", 392, 396], ["rat CD4", "PROTEIN", 432, 439], ["rat CD45RC", "PROTEIN", 488, 498], ["rat TCR", "PROTEIN", 639, 646], ["4B4", "PROTEIN", 695, 698], ["13 chain", "PROTEIN", 716, 724], ["human VLA4", "PROTEIN", 732, 742], ["CD29", "PROTEIN", 744, 748], ["lymphocytes", "CELL_TYPE", 788, 799], ["Inflammatory lymphocytes", "CELL_TYPE", 837, 861], ["rats", "SPECIES", 174, 178], ["rat", "SPECIES", 432, 435], ["rat", "SPECIES", 488, 491], ["rat", "SPECIES", 547, 550], ["rat", "SPECIES", 639, 642], ["human", "SPECIES", 732, 737], ["rat", "SPECIES", 488, 491], ["rat", "SPECIES", 639, 642], ["human", "SPECIES", 732, 737], ["overt disease", "PROBLEM", 98, 111], ["paresis", "PROBLEM", 196, 203], ["paresis", "PROBLEM", 224, 231], ["paralysis", "PROBLEM", 257, 266], ["Monoclonal antibodies", "TEST", 284, 305], ["stain lymphocytes", "TEST", 308, 325], ["flow", "TEST", 330, 334], ["cytometric analysis", "TEST", 335, 354], ["monoclonal antibodies", "TEST", 369, 390], ["the rat IL", "TEST", 543, 553], ["lymphocytes", "PROBLEM", 788, 799], ["the CNS", "TEST", 805, 812], ["cervical lymph nodesInflammatory lymphocytes", "PROBLEM", 817, 861], ["a procedure", "TREATMENT", 904, 915], ["disease", "OBSERVATION", 104, 111], ["cage", "ANATOMY", 186, 190], ["legs", "ANATOMY", 214, 218], ["legs", "ANATOMY", 247, 251], ["paralysis", "OBSERVATION", 257, 266], ["lymphocytes", "OBSERVATION", 788, 799], ["CNS", "ANATOMY", 809, 812], ["cervical", "ANATOMY", 817, 825], ["lymph nodes", "OBSERVATION", 826, 837], ["Inflammatory lymphocytes", "OBSERVATION", 837, 861], ["brain", "ANATOMY", 885, 890]]], ["Briefly, the killed animal was perfused with PBS.", [["animal", "ORGANISM", 20, 26]]], ["The CNS was removed and lymphoid cells were recovered by mechanical disruption and enzymatic digestion of the CNS followed by Percoll step gradient centrifugation.", [["CNS", "ANATOMY", 4, 7], ["lymphoid cells", "ANATOMY", 24, 38], ["CNS", "ANATOMY", 110, 113], ["CNS", "ANATOMICAL_SYSTEM", 4, 7], ["lymphoid cells", "CELL", 24, 38], ["lymphoid cells", "CELL_TYPE", 24, 38], ["lymphoid cells", "PROBLEM", 24, 38], ["mechanical disruption", "PROBLEM", 57, 78], ["enzymatic digestion of the CNS", "PROBLEM", 83, 113], ["Percoll step gradient centrifugation", "TREATMENT", 126, 162], ["CNS", "ANATOMY", 4, 7], ["lymphoid cells", "OBSERVATION", 24, 38], ["mechanical disruption", "OBSERVATION", 57, 78], ["enzymatic digestion", "OBSERVATION", 83, 102], ["CNS", "ANATOMY", 110, 113], ["gradient centrifugation", "OBSERVATION", 139, 162]]], ["Lymphocytes were collected from interfaces of the appropriate density and sedimented in Hank's buffer (170 x g, 10 min, 4\u00b0C).Isolation of lymphocytes from the CNS and cervical lymph nodesCLNs were taken from the killed animal and minced through a steel sieve in Hank's buffer.", [["Lymphocytes", "ANATOMY", 0, 11], ["lymphocytes", "ANATOMY", 138, 149], ["CNS", "ANATOMY", 159, 162], ["cervical lymph nodesCLNs", "ANATOMY", 167, 191], ["Lymphocytes", "CELL", 0, 11], ["lymphocytes", "CELL", 138, 149], ["CNS", "ANATOMICAL_SYSTEM", 159, 162], ["cervical lymph nodesCLNs", "MULTI-TISSUE_STRUCTURE", 167, 191], ["Lymphocytes", "CELL_TYPE", 0, 11], ["lymphocytes", "CELL_TYPE", 138, 149], ["Lymphocytes", "TEST", 0, 11], ["lymphocytes", "PROBLEM", 138, 149], ["the CNS and cervical lymph nodesCLNs", "PROBLEM", 155, 191], ["a steel sieve in Hank's buffer", "TREATMENT", 245, 275], ["appropriate", "OBSERVATION_MODIFIER", 50, 61], ["density", "OBSERVATION", 62, 69], ["sedimented", "OBSERVATION_MODIFIER", 74, 84], ["lymphocytes", "OBSERVATION", 138, 149], ["CNS", "ANATOMY", 159, 162], ["cervical", "ANATOMY", 167, 175], ["lymph nodesCLNs", "OBSERVATION", 176, 191]]], ["Connective tissue fragments were allowed to settle for 10 min at 4\u00b0C and lymphocytes were sedimented from the supernatant (170 x g, 10 min, 4\u00b0C).Quantitation and phenotypic characterisation of isolated CNS lymphocytesCNS isolated lymphocytes were quantitated and phenotypically characterised by two-color immunofluorescence and four-parameter (forward/side scatter, red/green fluorescence) flow cytometry as described earlier (D6rries et al., 1991) .", [["Connective tissue fragments", "ANATOMY", 0, 27], ["lymphocytes", "ANATOMY", 73, 84], ["supernatant", "ANATOMY", 110, 121], ["CNS lymphocytesCNS", "ANATOMY", 202, 220], ["lymphocytes", "ANATOMY", 230, 241], ["Connective tissue fragments", "TISSUE", 0, 27], ["C", "CELL", 67, 68], ["lymphocytes", "CELL", 73, 84], ["CNS lymphocytesCNS isolated lymphocytes", "CELL", 202, 241], ["lymphocytes", "CELL_TYPE", 73, 84], ["CNS lymphocytesCNS isolated lymphocytes", "CELL_TYPE", 202, 241], ["Connective tissue fragments", "PROBLEM", 0, 27], ["C and lymphocytes", "PROBLEM", 67, 84], ["Quantitation", "TEST", 145, 157], ["phenotypic characterisation", "TEST", 162, 189], ["isolated CNS lymphocytesCNS isolated lymphocytes", "PROBLEM", 193, 241], ["color immunofluorescence", "TEST", 299, 323], ["forward/side scatter", "TEST", 344, 364], ["red/green fluorescence", "TEST", 366, 388], ["flow cytometry", "TEST", 390, 404], ["tissue", "ANATOMY", 11, 17], ["fragments", "OBSERVATION", 18, 27], ["lymphocytes", "ANATOMY", 73, 84], ["sedimented", "OBSERVATION_MODIFIER", 90, 100], ["isolated", "OBSERVATION_MODIFIER", 193, 201], ["CNS", "ANATOMY", 202, 205]]], ["Briefly, lymphocytes were stained indirectly using a primary mouse mAb and a phycoerythrin (PE)-labelled secondary goat anti-mouse IgG, followed by another primary mouse mAb labelled with FITC.Quantitation and phenotypic characterisation of isolated CNS lymphocytesFlow-cytometric analysis was done on a FACScan (Becton-Dickinson, Heidelberg, Germany).", [["lymphocytes", "ANATOMY", 9, 20], ["CNS lymphocytes", "ANATOMY", 250, 265], ["PE", "CHEMICAL", 92, 94], ["FITC", "CHEMICAL", 188, 192], ["lymphocytes", "CELL", 9, 20], ["mouse", "ORGANISM", 61, 66], ["phycoerythrin", "GENE_OR_GENE_PRODUCT", 77, 90], ["PE", "SIMPLE_CHEMICAL", 92, 94], ["goat", "ORGANISM", 115, 119], ["mouse", "ORGANISM", 164, 169], ["FITC", "GENE_OR_GENE_PRODUCT", 188, 192], ["CNS lymphocytes", "CELL", 250, 265], ["lymphocytes", "CELL_TYPE", 9, 20], ["primary mouse mAb", "PROTEIN", 53, 70], ["phycoerythrin (PE)-labelled secondary goat anti-mouse IgG", "PROTEIN", 77, 134], ["primary mouse mAb", "PROTEIN", 156, 173], ["FITC", "PROTEIN", 188, 192], ["CNS lymphocytes", "CELL_TYPE", 250, 265], ["mouse", "SPECIES", 61, 66], ["goat", "SPECIES", 115, 119], ["anti-mouse", "SPECIES", 120, 130], ["mouse", "SPECIES", 164, 169], ["mouse", "SPECIES", 61, 66], ["goat", "SPECIES", 115, 119], ["mouse", "SPECIES", 164, 169], ["lymphocytes", "PROBLEM", 9, 20], ["a primary mouse mAb", "TREATMENT", 51, 70], ["a phycoerythrin (PE", "TREATMENT", 75, 94], ["labelled secondary goat anti-mouse IgG", "TREATMENT", 96, 134], ["Quantitation", "TEST", 193, 205], ["phenotypic characterisation", "TEST", 210, 237], ["isolated CNS lymphocytes", "PROBLEM", 241, 265], ["cytometric analysis", "TEST", 270, 289], ["a FACScan", "TEST", 302, 311], ["lymphocytes", "ANATOMY", 9, 20], ["PE", "OBSERVATION", 92, 94], ["isolated", "OBSERVATION_MODIFIER", 241, 249], ["CNS lymphocytesFlow", "OBSERVATION", 250, 269]]], ["Collected data were processed by a Hewlett Packard 6000 computer and the Consort 32/Lysis II software package.Quantitation and phenotypic characterisation of isolated CNS lymphocytesThe number of CD4 +, a//3 TCR + cells per CNS was calculated by multiplying the percentage of positive cells by the total number of lymphocytes recovered from the CNS of individual animals.Determination of T lymphocyte proliferationLymphocytes were isolated each day post infection from the CNS of three animals and pooled in RPMI 1640 medium supplemented with 3% rat serum.", [["CNS lymphocytes", "ANATOMY", 167, 182], ["CD4 +, a//3 TCR + cells", "ANATOMY", 196, 219], ["CNS", "ANATOMY", 224, 227], ["cells", "ANATOMY", 285, 290], ["lymphocytes", "ANATOMY", 314, 325], ["CNS", "ANATOMY", 345, 348], ["T lymphocyte", "ANATOMY", 388, 400], ["CNS", "ANATOMY", 473, 476], ["serum", "ANATOMY", 550, 555], ["CNS lymphocytes", "CELL", 167, 182], ["CD4", "GENE_OR_GENE_PRODUCT", 196, 199], ["TCR", "GENE_OR_GENE_PRODUCT", 208, 211], ["cells", "CELL", 285, 290], ["lymphocytes", "CELL", 314, 325], ["CNS", "ANATOMICAL_SYSTEM", 345, 348], ["T lymphocyte proliferationLymphocytes", "CELL", 388, 425], ["CNS", "ANATOMICAL_SYSTEM", 473, 476], ["rat", "ORGANISM", 546, 549], ["serum", "ORGANISM_SUBSTANCE", 550, 555], ["CNS lymphocytes", "CELL_TYPE", 167, 182], ["CD4", "PROTEIN", 196, 199], ["TCR", "PROTEIN", 208, 211], ["positive cells", "CELL_TYPE", 276, 290], ["lymphocytes", "CELL_TYPE", 314, 325], ["T lymphocyte proliferationLymphocytes", "CELL_TYPE", 388, 425], ["rat", "SPECIES", 546, 549], ["rat", "SPECIES", 546, 549], ["Quantitation", "TEST", 110, 122], ["phenotypic characterisation", "TEST", 127, 154], ["isolated CNS lymphocytes", "PROBLEM", 158, 182], ["CD4", "TEST", 196, 199], ["positive cells", "PROBLEM", 276, 290], ["T lymphocyte proliferationLymphocytes", "PROBLEM", 388, 425], ["infection", "PROBLEM", 454, 463], ["isolated CNS lymphocytes", "OBSERVATION", 158, 182], ["CNS", "ANATOMY", 224, 227], ["positive cells", "OBSERVATION", 276, 290], ["lymphocytes", "OBSERVATION", 314, 325], ["lymphocyte proliferationLymphocytes", "OBSERVATION", 390, 425], ["infection", "OBSERVATION", 454, 463]]], ["In order to recover a comparable proportion of CD4 \u00f7 T lymphocytes at different days post infection, isolated lymphoid cells were passaged through a nylon wool column.", [["CD4 \u00f7 T lymphocytes", "ANATOMY", 47, 66], ["lymphoid cells", "ANATOMY", 110, 124], ["infection", "DISEASE", 90, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["lymphoid cells", "CELL", 110, 124], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 47, 66], ["isolated lymphoid cells", "CELL_TYPE", 101, 124], ["CD4 \u00f7 T lymphocytes", "PROBLEM", 47, 66], ["infection", "PROBLEM", 90, 99], ["isolated lymphoid cells", "TREATMENT", 101, 124], ["a nylon wool column", "TREATMENT", 147, 166], ["CD4", "OBSERVATION", 47, 50], ["infection", "OBSERVATION", 90, 99], ["lymphoid cells", "OBSERVATION", 110, 124], ["nylon wool column", "OBSERVATION", 149, 166]]], ["A 10-ml syringe was loaded with 0.6 g of nylon wool (Type 200L, Du Pont, Boston, MA) and equilibrated with 10 ml of RPMI 1640 (5% FCS).", [["A 10-ml syringe", "TREATMENT", 0, 15], ["RPMI", "TREATMENT", 116, 120]]], ["After closing the outlet of the syringe, 3 ml of RPMI 1640 (5% FCS) were added followed by a pre-incubation for 1 h at 37\u00b0C (5% CO2).", [["RPMI 1640", "CHEMICAL", 49, 58], ["CO2", "CHEMICAL", 128, 131], ["CO2", "CHEMICAL", 128, 131], ["CO2", "SIMPLE_CHEMICAL", 128, 131], ["RPMI", "TREATMENT", 49, 53]]], ["Subsequently, 1 \u00d7 107 isolated lymphocytes in 3 ml RPMI 1640 (5% FCS) were added to the column followed by another incubation of 1 h at 37\u00b0C (5% CO2).", [["lymphocytes", "ANATOMY", 31, 42], ["CO2", "CHEMICAL", 145, 148], ["CO2", "CHEMICAL", 145, 148], ["lymphocytes", "CELL", 31, 42], ["CO2", "SIMPLE_CHEMICAL", 145, 148], ["lymphocytes", "CELL_TYPE", 31, 42]]], ["Non-adherent T lymphocytes were eluted from the column with 40 ml of RPMI 1640 (5% FCS).", [["T lymphocytes", "ANATOMY", 13, 26], ["T lymphocytes", "CELL", 13, 26], ["Non-adherent T lymphocytes", "CELL_TYPE", 0, 26], ["Non-adherent T lymphocytes", "TEST", 0, 26], ["T lymphocytes", "OBSERVATION", 13, 26]]], ["Subsequently, they were collected by low-speed centrifugation (170 \u00d7 g, 4\u00b0C, 10 rain) and resuspended in RPMI 1640 supplemented with 3% rat serum.", [["serum", "ANATOMY", 140, 145], ["rat", "ORGANISM", 136, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["rat", "SPECIES", 136, 139], ["rat", "SPECIES", 136, 139]]], ["Dependent on cell recovery they were seeded at least in duplicates but usually in triplicates or quadruplicates into the wells of a microtiter plate (100/zl/well).", [["cell", "ANATOMY", 13, 17], ["cell", "CELL", 13, 17], ["a microtiter plate", "TREATMENT", 130, 148], ["cell recovery", "OBSERVATION", 13, 26]]], ["Cell densities varied between 1 x 106/ml and 1 x 107/ml.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell densities", "PROBLEM", 0, 14], ["densities", "OBSERVATION", 5, 14]]], ["The actual amount is stated in the context of experiments described in Results.", [["amount", "OBSERVATION_MODIFIER", 11, 17]]], ["Ex vivo proliferation of T lymphocytes was assessed after 48 h of culture at 37\u00b0C (5% CO2), by adding 14.8 kBq of [3H]thymidine (specific activity 1.59 TBq/mMol) per well for another 24 h.", [["T lymphocytes", "ANATOMY", 25, 38], ["CO2", "CHEMICAL", 86, 89], ["[3H]thymidine", "CHEMICAL", 114, 127], ["CO2", "CHEMICAL", 86, 89], ["[3H]thymidine", "CHEMICAL", 114, 127], ["T lymphocytes", "CELL", 25, 38], ["CO2", "SIMPLE_CHEMICAL", 86, 89], ["[3H]thymidine", "SIMPLE_CHEMICAL", 114, 127], ["T lymphocytes", "CELL_TYPE", 25, 38], ["T lymphocytes", "PROBLEM", 25, 38], ["culture", "TEST", 66, 73], ["thymidine", "TREATMENT", 118, 127], ["proliferation", "OBSERVATION_MODIFIER", 8, 21]]], ["Incorporated radioactivity was determined by harvesting the lymphocytes on glass fiber filters, lysing of cells by hypotonic wash and subsequent count of radioactive decays in a B-plate counter.", [["lymphocytes", "ANATOMY", 60, 71], ["cells", "ANATOMY", 106, 111], ["lymphocytes", "CELL", 60, 71], ["cells", "CELL", 106, 111], ["lymphocytes", "CELL_TYPE", 60, 71], ["glass fiber filters", "TREATMENT", 75, 94], ["lysing of cells", "TREATMENT", 96, 111], ["hypotonic wash", "TREATMENT", 115, 129], ["radioactive decays", "TREATMENT", 154, 172], ["a B-plate counter", "TREATMENT", 176, 193], ["radioactivity", "OBSERVATION", 13, 26], ["lymphocytes", "ANATOMY", 60, 71], ["hypotonic wash", "OBSERVATION", 115, 129], ["radioactive decays", "OBSERVATION", 154, 172]]], ["Mean values were calculated and plotted versus the time post infection.", [["infection", "DISEASE", 61, 70], ["Mean values", "TEST", 0, 11], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["The same assay protocol was used to determine antigen-or mitogen-inducible proliferation.", [["mitogen", "PROTEIN", 57, 64], ["The same assay protocol", "TEST", 0, 23], ["antigen", "TEST", 46, 53], ["mitogen-inducible proliferation", "PROBLEM", 57, 88], ["inducible proliferation", "OBSERVATION", 65, 88]]], ["JHMV-antigens (20 /xg/ml), control antigen (keyhole limpet hemocyanine (KLH), 20/zg/ml) or concanavalin A (2 /xg/ml) were added immediately after taking the cells into culture.", [["cells", "ANATOMY", 157, 162], ["concanavalin A", "CHEMICAL", 91, 105], ["JHMV-antigens", "GENE_OR_GENE_PRODUCT", 0, 13], ["concanavalin A", "SIMPLE_CHEMICAL", 91, 105], ["cells", "CELL", 157, 162], ["JHMV", "PROTEIN", 0, 4], ["antigens", "PROTEIN", 5, 13], ["control antigen", "PROTEIN", 27, 42], ["keyhole limpet hemocyanine", "PROTEIN", 44, 70], ["KLH", "PROTEIN", 72, 75], ["JHMV", "SPECIES", 0, 4], ["JHMV", "TEST", 0, 4], ["antigens", "TEST", 5, 13], ["control antigen (keyhole limpet hemocyanine (KLH)", "TREATMENT", 27, 76], ["concanavalin A", "TREATMENT", 91, 105], ["culture", "TEST", 168, 175]]], ["After 48 h of incubation, cells were radioactively labelled and further processed as described above.Determination of T lymphocyte proliferationCLN cells were processed in an identical way, except that they were not passaged through nylon wool.Course of the infection and dynamics of the inflammatory T lymphocyte responseThe mean clinical score of infected LEW and BN rats during the first 3 weeks post infection is shown in Schwender et al., 1991) , clinical signs of the infection started to develop in LEW rats at day 6 post infection and reached a maximum at 11 days post infection (dpi).", [["cells", "ANATOMY", 26, 31], ["T lymphocyte proliferationCLN cells", "ANATOMY", 118, 153], ["inflammatory T lymphocyte", "ANATOMY", 288, 313], ["infection", "DISEASE", 258, 267], ["infection", "DISEASE", 404, 413], ["infection", "DISEASE", 474, 483], ["infection", "DISEASE", 529, 538], ["infection", "DISEASE", 577, 586], ["cells", "CELL", 26, 31], ["T lymphocyte proliferationCLN cells", "CELL", 118, 153], ["T lymphocyte", "CELL", 301, 313], ["LEW", "ORGANISM", 358, 361], ["BN rats", "ORGANISM", 366, 373], ["LEW rats", "ORGANISM", 506, 514], ["T lymphocyte proliferationCLN cells", "CELL_TYPE", 118, 153], ["rats", "SPECIES", 369, 373], ["rats", "SPECIES", 510, 514], ["LEW", "SPECIES", 506, 509], ["incubation", "TREATMENT", 14, 24], ["cells", "TREATMENT", 26, 31], ["T lymphocyte proliferationCLN cells", "PROBLEM", 118, 153], ["the infection", "PROBLEM", 254, 267], ["the inflammatory T lymphocyte response", "PROBLEM", 284, 322], ["infected LEW", "PROBLEM", 349, 361], ["infection", "PROBLEM", 404, 413], ["the infection", "PROBLEM", 470, 483], ["infection", "PROBLEM", 529, 538], ["infection", "PROBLEM", 577, 586], ["lymphocyte proliferationCLN", "OBSERVATION", 120, 147], ["infection", "OBSERVATION", 258, 267], ["inflammatory", "OBSERVATION_MODIFIER", 288, 300], ["lymphocyte response", "OBSERVATION", 303, 322], ["infected", "OBSERVATION", 349, 357], ["infection", "OBSERVATION", 404, 413], ["infection", "OBSERVATION", 474, 483], ["infection", "OBSERVATION", 529, 538], ["infection", "OBSERVATION", 577, 586]]], ["Thereafter, animals started to recover from disease.", [["disease", "PROBLEM", 44, 51], ["disease", "OBSERVATION", 44, 51]]], ["The infection remained subclinical in BN rats.Course of the infection and dynamics of the inflammatory T lymphocyte responseContribution of CD4 \u00f7, all3 TCR \u00f7 T lymphocytes to the inflammation was determined by 2-color immunofluorescence and flow cytometry using the pooled leukocyte fraction from the CNS of three animals every 2nd day post infection.", [["T lymphocyte", "ANATOMY", 103, 115], ["CD4 \u00f7, all3 TCR \u00f7 T lymphocytes", "ANATOMY", 140, 171], ["leukocyte", "ANATOMY", 273, 282], ["CNS", "ANATOMY", 301, 304], ["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 60, 69], ["inflammation", "DISEASE", 179, 191], ["infection", "DISEASE", 341, 350], ["BN rats", "ORGANISM", 38, 45], ["T lymphocyte", "CELL", 103, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 140, 143], ["all3 TCR", "GENE_OR_GENE_PRODUCT", 147, 155], ["leukocyte", "CELL", 273, 282], ["CNS", "ANATOMICAL_SYSTEM", 301, 304], ["CD4", "PROTEIN", 140, 143], ["all3 TCR \u00f7 T lymphocytes", "CELL_TYPE", 147, 171], ["rats", "SPECIES", 41, 45], ["The infection", "PROBLEM", 0, 13], ["the infection", "PROBLEM", 56, 69], ["the inflammatory T lymphocyte responseContribution", "PROBLEM", 86, 136], ["CD4", "TEST", 140, 143], ["T lymphocytes", "PROBLEM", 158, 171], ["the inflammation", "PROBLEM", 175, 191], ["color immunofluorescence", "TEST", 212, 236], ["flow cytometry", "TEST", 241, 255], ["the pooled leukocyte fraction", "TEST", 262, 291], ["infection", "PROBLEM", 341, 350], ["infection", "OBSERVATION", 4, 13], ["subclinical", "OBSERVATION_MODIFIER", 23, 34], ["infection", "OBSERVATION", 60, 69], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["lymphocyte", "OBSERVATION", 105, 115], ["inflammation", "OBSERVATION", 179, 191], ["flow cytometry", "OBSERVATION", 241, 255], ["leukocyte fraction", "OBSERVATION", 273, 291], ["infection", "OBSERVATION", 341, 350]]], ["In agreement with our earlier findings (D6rries et al., 1991) , the amount of CD4 \u00f7, all3 TCR \u00f7 T lymphocytes started to increase in the CNS of both rat strains at day 6 post infection ( Fig. 2) .", [["CD4 \u00f7", "ANATOMY", 78, 83], ["all3 TCR \u00f7 T lymphocytes", "ANATOMY", 85, 109], ["CNS", "ANATOMY", 137, 140], ["strains", "ANATOMY", 153, 160], ["infection", "DISEASE", 175, 184], ["CD4", "GENE_OR_GENE_PRODUCT", 78, 81], ["all3 TCR", "GENE_OR_GENE_PRODUCT", 85, 93], ["CNS", "ANATOMICAL_SYSTEM", 137, 140], ["rat", "ORGANISM", 149, 152], ["CD4", "PROTEIN", 78, 81], ["TCR", "PROTEIN", 90, 93], ["T lymphocytes", "CELL_TYPE", 96, 109], ["rat", "SPECIES", 149, 152], ["rat", "SPECIES", 149, 152], ["CD4", "TEST", 78, 81], ["T lymphocytes", "PROBLEM", 96, 109], ["infection", "PROBLEM", 175, 184], ["increase", "OBSERVATION_MODIFIER", 121, 129], ["CNS", "ANATOMY", 137, 140], ["infection", "OBSERVATION", 175, 184]]], ["Initially, LEW rats recruited CD4 \u00f7 T cells more rapid and to a higher extent compared to BN rats.", [["CD4 \u00f7 T cells", "ANATOMY", 30, 43], ["LEW rats", "ORGANISM", 11, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 30, 33], ["BN rats", "ORGANISM", 90, 97], ["CD4 \u00f7 T cells", "CELL_TYPE", 30, 43], ["rats", "SPECIES", 15, 19], ["rats", "SPECIES", 93, 97], ["higher extent", "OBSERVATION_MODIFIER", 64, 77]]], ["The increase paralleled the sharp onset of clinical symptomatology in LEW rats (Phenotypic characterisation of CD4 + T lymphocytes from the CNSCD4 + T lymphocytes infiltrating the CNS were examined for their composition with respect to naive and primed memory cells, respectively.", [["CD4 + T lymphocytes", "ANATOMY", 111, 130], ["CNSCD4 + T lymphocytes", "ANATOMY", 140, 162], ["CNS", "ANATOMY", 180, 183], ["memory cells", "ANATOMY", 253, 265], ["LEW rats", "ORGANISM", 70, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 111, 114], ["CNSCD4", "GENE_OR_GENE_PRODUCT", 140, 146], ["CNS", "ANATOMICAL_SYSTEM", 180, 183], ["memory cells", "CELL", 253, 265], ["CD4", "PROTEIN", 111, 114], ["T lymphocytes", "CELL_TYPE", 117, 130], ["CNSCD4", "PROTEIN", 140, 146], ["T lymphocytes", "CELL_TYPE", 149, 162], ["naive and primed memory cells", "CELL_TYPE", 236, 265], ["rats", "SPECIES", 74, 78], ["clinical symptomatology", "PROBLEM", 43, 66], ["LEW rats", "TEST", 70, 78], ["Phenotypic characterisation", "TEST", 80, 107], ["CD4", "TEST", 111, 114], ["T lymphocytes", "PROBLEM", 117, 130], ["the CNSCD4", "TEST", 136, 146], ["T lymphocytes infiltrating the CNS", "PROBLEM", 149, 183], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["sharp", "OBSERVATION_MODIFIER", 28, 33], ["CNS", "ANATOMY", 180, 183]]], ["Fig. 2 demonstrates that the majority of CNS-infiltrating CD4 \u00f7 lymphocytes consisted of antigen-primed cells by virtue of absence of the CD45RC molecule.", [["CNS-infiltrating CD4 \u00f7 lymphocytes", "ANATOMY", 41, 75], ["cells", "ANATOMY", 104, 109], ["CNS-infiltrating CD4 \u00f7 lymphocytes", "CELL", 41, 75], ["antigen", "GENE_OR_GENE_PRODUCT", 89, 96], ["cells", "CELL", 104, 109], ["CD45RC", "GENE_OR_GENE_PRODUCT", 138, 144], ["CNS-infiltrating CD4 \u00f7 lymphocytes", "CELL_TYPE", 41, 75], ["antigen-primed cells", "CELL_TYPE", 89, 109], ["CD45RC molecule", "PROTEIN", 138, 153], ["lymphocytes", "TEST", 64, 75], ["antigen", "TEST", 89, 96], ["the CD45RC molecule", "PROBLEM", 134, 153], ["CNS", "ANATOMY", 41, 44], ["infiltrating", "OBSERVATION", 45, 57]]], ["Early post infection (2 dpi), roughly 40% of detectable CD4 \u00f7 T lymphocytes were naive (CD45RC \u00f7) whereas with proceeding infection this population contributed less than 4% to the recoverable CD4 + subset of T lymphocytes.", [["CD4 \u00f7 T lymphocytes", "ANATOMY", 56, 75], ["CD45RC \u00f7", "ANATOMY", 88, 96], ["CD4 + subset", "ANATOMY", 192, 204], ["T lymphocytes", "ANATOMY", 208, 221], ["infection", "DISEASE", 11, 20], ["infection", "DISEASE", 122, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD45RC", "GENE_OR_GENE_PRODUCT", 88, 94], ["CD4", "GENE_OR_GENE_PRODUCT", 192, 195], ["T lymphocytes", "CELL", 208, 221], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 56, 75], ["CD4", "PROTEIN", 192, 195], ["T lymphocytes", "CELL_TYPE", 208, 221], ["Early post infection", "PROBLEM", 0, 20], ["detectable CD4 \u00f7 T lymphocytes", "PROBLEM", 45, 75], ["proceeding infection", "PROBLEM", 111, 131], ["infection", "OBSERVATION", 11, 20], ["infection", "OBSERVATION", 122, 131], ["T lymphocytes", "OBSERVATION", 208, 221]]], ["This holds true for healthy BN rats as well as for diseased Lewis rats.", [["BN rats", "ORGANISM", 28, 35], ["rats", "ORGANISM", 66, 70], ["rats", "SPECIES", 31, 35], ["rats", "SPECIES", 66, 70]]], ["Interestingly, double staining of CNS iso- lated leukocytes for CD4 and IL-2R disclosed a very low proportion of such cells amongst the inflammatory infiltrate (Fig. 2) .", [["CNS iso- lated leukocytes", "ANATOMY", 34, 59], ["cells", "ANATOMY", 118, 123], ["inflammatory infiltrate", "ANATOMY", 136, 159], ["leukocytes", "CELL", 49, 59], ["CD4", "GENE_OR_GENE_PRODUCT", 64, 67], ["IL-2R", "GENE_OR_GENE_PRODUCT", 72, 77], ["cells", "CELL", 118, 123], ["CNS iso- lated leukocytes", "CELL_TYPE", 34, 59], ["CD4", "PROTEIN", 64, 67], ["IL-2R", "PROTEIN", 72, 77], ["CNS iso", "TEST", 34, 41], ["CD4", "TEST", 64, 67], ["IL", "TEST", 72, 74], ["such cells", "PROBLEM", 113, 123], ["the inflammatory infiltrate", "PROBLEM", 132, 159], ["CNS", "ANATOMY", 34, 37], ["very", "OBSERVATION_MODIFIER", 90, 94], ["low proportion", "OBSERVATION_MODIFIER", 95, 109], ["such cells", "OBSERVATION", 113, 123], ["inflammatory", "OBSERVATION_MODIFIER", 136, 148], ["infiltrate", "OBSERVATION", 149, 159], ["Fig", "OBSERVATION_MODIFIER", 161, 164]]], ["Between 20 and 3% of infiltrating leukocytes were of the CD4 +, IL-2R + phenotype at 6 dpi and 18 dpi, respectively.", [["infiltrating leukocytes", "ANATOMY", 21, 44], ["CD4 +", "ANATOMY", 57, 62], ["leukocytes", "CELL", 34, 44], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["IL-2R", "GENE_OR_GENE_PRODUCT", 64, 69], ["infiltrating leukocytes", "CELL_TYPE", 21, 44], ["CD4", "PROTEIN", 57, 60], ["infiltrating leukocytes", "TEST", 21, 44], ["the CD4", "TEST", 53, 60], ["IL", "TEST", 64, 66], ["phenotype", "PROBLEM", 72, 81], ["infiltrating leukocytes", "OBSERVATION", 21, 44]]], ["This result predicted that only a minority of CNS-infiltrating CD4 + cells were in a state to respond to IL-2 by proliferation.", [["CNS-infiltrating CD4 + cells", "ANATOMY", 46, 74], ["CNS-infiltrating CD4 + cells", "CELL", 46, 74], ["IL-2", "GENE_OR_GENE_PRODUCT", 105, 109], ["CNS-infiltrating CD4 + cells", "CELL_TYPE", 46, 74], ["IL", "PROTEIN", 105, 107], ["infiltrating CD4 + cells", "PROBLEM", 50, 74], ["IL", "TREATMENT", 105, 107], ["CNS", "ANATOMY", 46, 49], ["infiltrating", "OBSERVATION_MODIFIER", 50, 62], ["CD4 + cells", "OBSERVATION", 63, 74]]], ["Thus, we enriched T lymphocytes from CNS-isolated leukocytes and assayed them for proliferation.Enrichment of T lymphocytes from CNS-&olated leukocytesFrom previous experiments, the contribution of T lymphocytes to the CNS-extractable leukocyte fraction varies considerably in the course of the infection.", [["T lymphocytes", "ANATOMY", 18, 31], ["CNS", "ANATOMY", 37, 40], ["leukocytes", "ANATOMY", 50, 60], ["T lymphocytes", "ANATOMY", 110, 123], ["CNS-&olated leukocytes", "ANATOMY", 129, 151], ["T lymphocytes", "ANATOMY", 198, 211], ["CNS", "ANATOMY", 219, 222], ["leukocyte", "ANATOMY", 235, 244], ["infection", "DISEASE", 295, 304], ["T lymphocytes", "CELL", 18, 31], ["CNS-isolated leukocytes", "CELL", 37, 60], ["T lymphocytes", "CELL", 110, 123], ["CNS-&olated leukocytes", "CELL", 129, 151], ["T lymphocytes", "CELL", 198, 211], ["CNS", "ANATOMICAL_SYSTEM", 219, 222], ["leukocyte", "CELL", 235, 244], ["T lymphocytes", "CELL_TYPE", 18, 31], ["CNS-isolated leukocytes", "CELL_TYPE", 37, 60], ["T lymphocytes", "CELL_TYPE", 110, 123], ["CNS-&olated leukocytes", "CELL_TYPE", 129, 151], ["T lymphocytes", "CELL_TYPE", 198, 211], ["isolated leukocytes", "PROBLEM", 41, 60], ["proliferation", "PROBLEM", 82, 95], ["T lymphocytes", "PROBLEM", 110, 123], ["&olated leukocytes", "PROBLEM", 133, 151], ["T lymphocytes", "PROBLEM", 198, 211], ["the CNS", "TEST", 215, 222], ["extractable leukocyte fraction", "PROBLEM", 223, 253], ["the infection", "PROBLEM", 291, 304], ["leukocytes", "ANATOMY", 50, 60], ["T lymphocytes", "OBSERVATION", 110, 123], ["CNS", "ANATOMY", 129, 132], ["T lymphocytes", "OBSERVATION", 198, 211], ["CNS", "ANATOMY", 219, 222], ["extractable leukocyte fraction", "OBSERVATION", 223, 253], ["infection", "OBSERVATION", 295, 304]]], ["Especially, early post infection or in the uninfected CNS the vast majority of CNS extracted cells expressing the leukocyte common antigen (LCA) are mieroglia cells .", [["CNS", "ANATOMY", 54, 57], ["CNS", "ANATOMY", 79, 82], ["cells", "ANATOMY", 93, 98], ["leukocyte", "ANATOMY", 114, 123], ["mieroglia cells", "ANATOMY", 149, 164], ["infection", "DISEASE", 23, 32], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["cells", "CELL", 93, 98], ["leukocyte common antigen", "GENE_OR_GENE_PRODUCT", 114, 138], ["mieroglia cells", "CELL", 149, 164], ["CNS extracted cells", "CELL_TYPE", 79, 98], ["leukocyte common antigen", "PROTEIN", 114, 138], ["LCA", "PROTEIN", 140, 143], ["mieroglia cells", "CELL_TYPE", 149, 164], ["infection", "PROBLEM", 23, 32], ["mieroglia cells", "PROBLEM", 149, 164], ["early", "OBSERVATION_MODIFIER", 12, 17], ["post", "OBSERVATION_MODIFIER", 18, 22], ["infection", "OBSERVATION", 23, 32], ["CNS", "ANATOMY", 54, 57], ["CNS", "ANATOMY", 79, 82], ["leukocyte", "OBSERVATION_MODIFIER", 114, 123], ["LCA", "OBSERVATION_MODIFIER", 140, 143], ["mieroglia cells", "OBSERVATION", 149, 164]]], ["To allow comparison of data from proliferation assays at different times post infection we enriched T lymphocytes from the CNS by nylon-wool passage of isolated cells.", [["T lymphocytes", "ANATOMY", 100, 113], ["CNS", "ANATOMY", 123, 126], ["cells", "ANATOMY", 161, 166], ["T lymphocytes", "CELL", 100, 113], ["CNS", "ANATOMICAL_SYSTEM", 123, 126], ["cells", "CELL", 161, 166], ["T lymphocytes", "CELL_TYPE", 100, 113], ["isolated cells", "CELL_TYPE", 152, 166], ["proliferation assays", "TEST", 33, 53], ["infection", "PROBLEM", 78, 87], ["isolated cells", "PROBLEM", 152, 166], ["infection", "OBSERVATION", 78, 87], ["CNS", "ANATOMY", 123, 126], ["isolated cells", "OBSERVATION", 152, 166]]], ["Fig. 3 shows a representative example of T lymphocyte enrichment at 14 dpi.", [["T lymphocyte", "ANATOMY", 41, 53], ["T lymphocyte", "CELL", 41, 53], ["T lymphocyte", "CELL_TYPE", 41, 53], ["T lymphocyte enrichment", "TREATMENT", 41, 64], ["lymphocyte enrichment", "OBSERVATION", 43, 64]]], ["Cells were extracted from the CNS of a JHMV-infected LEW rat and FACS analysed for rat CD4 and rat ce//3 TCR.", [["Cells", "ANATOMY", 0, 5], ["CNS", "ANATOMY", 30, 33], ["Cells", "CELL", 0, 5], ["CNS", "ANATOMICAL_SYSTEM", 30, 33], ["JHMV", "GENE_OR_GENE_PRODUCT", 39, 43], ["LEW rat", "ORGANISM", 53, 60], ["FACS", "CELL", 65, 69], ["rat", "ORGANISM", 83, 86], ["CD4", "GENE_OR_GENE_PRODUCT", 87, 90], ["rat", "ORGANISM", 95, 98], ["TCR", "GENE_OR_GENE_PRODUCT", 105, 108], ["rat CD4", "PROTEIN", 83, 90], ["TCR", "PROTEIN", 105, 108], ["rat", "SPECIES", 57, 60], ["rat", "SPECIES", 83, 86], ["rat", "SPECIES", 95, 98], ["JHMV", "SPECIES", 39, 43], ["rat", "SPECIES", 57, 60], ["rat", "SPECIES", 83, 86], ["a JHMV", "TEST", 37, 43], ["FACS", "TEST", 65, 69], ["rat CD4", "TEST", 83, 90], ["rat ce", "TEST", 95, 101]]], ["Approximately 20% of the cells expressed a//3 TCR (quadrants upper left and upper right).", [["cells", "ANATOMY", 25, 30], ["left", "ANATOMY", 67, 71], ["cells", "CELL", 25, 30], ["TCR", "GENE_OR_GENE_PRODUCT", 46, 49], ["TCR", "PROTEIN", 46, 49], ["quadrants", "ANATOMY_MODIFIER", 51, 60], ["upper", "ANATOMY_MODIFIER", 61, 66], ["left", "ANATOMY_MODIFIER", 67, 71], ["upper", "ANATOMY_MODIFIER", 76, 81], ["right", "ANATOMY_MODIFIER", 82, 87]]], ["The majority of cells lacked CD4 and a//3 TCR and represent mostly microglia and very few B lymphocytes .", [["cells", "ANATOMY", 16, 21], ["microglia", "ANATOMY", 67, 76], ["B lymphocytes", "ANATOMY", 90, 103], ["cells", "CELL", 16, 21], ["CD4", "GENE_OR_GENE_PRODUCT", 29, 32], ["TCR", "GENE_OR_GENE_PRODUCT", 42, 45], ["microglia", "CELL", 67, 76], ["B lymphocytes", "CELL", 90, 103], ["CD4", "PROTEIN", 29, 32], ["TCR", "PROTEIN", 42, 45], ["microglia", "CELL_TYPE", 67, 76], ["B lymphocytes", "CELL_TYPE", 90, 103], ["CD4", "TEST", 29, 32], ["a//3 TCR", "TEST", 37, 45], ["mostly microglia", "PROBLEM", 60, 76], ["CD4", "OBSERVATION", 29, 32], ["mostly", "OBSERVATION_MODIFIER", 60, 66], ["microglia", "OBSERVATION", 67, 76], ["very", "OBSERVATION_MODIFIER", 81, 85], ["few", "OBSERVATION_MODIFIER", 86, 89], ["lymphocytes", "OBSERVATION", 92, 103]]], ["Within this fraction, however, a small percentage exhibited a low expression of CD4.", [["CD4", "GENE_OR_GENE_PRODUCT", 80, 83], ["CD4", "PROTEIN", 80, 83], ["a small percentage", "PROBLEM", 31, 49], ["a low expression of CD4", "PROBLEM", 60, 83], ["small", "OBSERVATION_MODIFIER", 33, 38], ["percentage", "OBSERVATION_MODIFIER", 39, 49], ["low expression", "OBSERVATION_MODIFIER", 62, 76]]], ["As we have shown earlier, these cells are activated microglia cells .", [["cells", "ANATOMY", 32, 37], ["microglia cells", "ANATOMY", 52, 67], ["cells", "CELL", 32, 37], ["microglia cells", "CELL", 52, 67], ["microglia cells", "CELL_TYPE", 52, 67], ["activated microglia cells", "PROBLEM", 42, 67], ["microglia cells", "OBSERVATION", 52, 67]]], ["After Passage through a nylon wool column, there was a significant increase (to approx.", [["a nylon wool column", "TREATMENT", 22, 41], ["a significant increase", "PROBLEM", 53, 75], ["nylon wool column", "OBSERVATION", 24, 41], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75]]], ["60%) in the ce/~ TCR-expressing T lymphocyte fraction (lower panel).", [["T lymphocyte", "ANATOMY", 32, 44], ["TCR", "CHEMICAL", 17, 20], ["TCR", "GENE_OR_GENE_PRODUCT", 17, 20], ["T lymphocyte", "CELL", 32, 44], ["TCR", "PROTEIN", 17, 20], ["expressing T lymphocyte fraction", "CELL_TYPE", 21, 53], ["the ce", "TEST", 8, 14]]], ["Moreover, the CD41\u00b0W-expressing population was removed from the TCR-fraction without affecting the CD4/CD8 ratio of the TCR + fraction, suggesting that activated microglia cells are nylon wool-adherent. fluorescence CD4 (log I 0) Fig. 3 .", [["microglia cells", "ANATOMY", 162, 177], ["TCR", "CHEMICAL", 64, 67], ["TCR", "CHEMICAL", 120, 123], ["CD41\u00b0W", "GENE_OR_GENE_PRODUCT", 14, 20], ["TCR", "GENE_OR_GENE_PRODUCT", 64, 67], ["CD4", "GENE_OR_GENE_PRODUCT", 99, 102], ["CD8", "GENE_OR_GENE_PRODUCT", 103, 106], ["TCR", "GENE_OR_GENE_PRODUCT", 120, 123], ["microglia cells", "CELL", 162, 177], ["CD41", "PROTEIN", 14, 18], ["TCR", "PROTEIN", 64, 67], ["CD4", "PROTEIN", 99, 102], ["CD8", "PROTEIN", 103, 106], ["TCR", "PROTEIN", 120, 123], ["activated microglia cells", "CELL_TYPE", 152, 177], ["CD4", "PROTEIN", 216, 219], ["the CD41", "TEST", 10, 18], ["the CD4", "TEST", 95, 102], ["activated microglia cells", "PROBLEM", 152, 177], ["fluorescence CD4", "TEST", 203, 219], ["microglia cells", "OBSERVATION", 162, 177]]], ["Enrichment of T lymphocytes from CNS-isolated lymphocytes.", [["T lymphocytes", "ANATOMY", 14, 27], ["CNS-isolated lymphocytes", "ANATOMY", 33, 57], ["T lymphocytes", "CELL", 14, 27], ["CNS-isolated lymphocytes", "CELL", 33, 57], ["T lymphocytes", "CELL_TYPE", 14, 27], ["CNS-isolated lymphocytes", "CELL_TYPE", 33, 57], ["Enrichment of T lymphocytes", "TEST", 0, 27], ["isolated lymphocytes", "PROBLEM", 37, 57], ["T lymphocytes", "OBSERVATION", 14, 27], ["CNS", "ANATOMY", 33, 36], ["isolated lymphocytes", "OBSERVATION", 37, 57]]], ["Leukocytes isolated from the CNS of a JHM-infected Lewis rat at 14 dpi were double-labelled by mAbs with specificity for CD4 and a/13 TCR and subjected to flow cytometry either before (upper panel) or after nylon wool passage (lower panel).", [["Leukocytes", "ANATOMY", 0, 10], ["CNS", "ANATOMY", 29, 32], ["Leukocytes", "CELL", 0, 10], ["CNS", "ANATOMICAL_SYSTEM", 29, 32], ["JHM", "GENE_OR_GENE_PRODUCT", 38, 41], ["Lewis rat", "ORGANISM", 51, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 121, 124], ["TCR", "GENE_OR_GENE_PRODUCT", 134, 137], ["Leukocytes", "CELL_TYPE", 0, 10], ["mAbs", "PROTEIN", 95, 99], ["CD4", "PROTEIN", 121, 124], ["TCR", "PROTEIN", 134, 137], ["rat", "SPECIES", 57, 60], ["Leukocytes", "TEST", 0, 10], ["a JHM", "PROBLEM", 36, 41], ["specificity", "TEST", 105, 116], ["CD4", "TEST", 121, 124], ["a/13 TCR", "TEST", 129, 137], ["flow cytometry", "TEST", 155, 169], ["nylon wool passage", "TREATMENT", 207, 225], ["infected", "OBSERVATION_MODIFIER", 42, 50], ["Lewis", "OBSERVATION_MODIFIER", 51, 56]]], ["Numbers in quadrants refer to the percentage of cells with respect to the total number.", [["cells", "ANATOMY", 48, 53], ["cells", "CELL", 48, 53], ["quadrants", "ANATOMY_MODIFIER", 11, 20]]], ["Total events were gated for lymphocytes by criteria of forward and side scatter.Proliferation of T lymphocytes from CNSEnriched T lymphocyte fractions were prepared every dpi and assayed for proliferation (0.1 \u00d7 107 cells/ml) by incorporation of [3H]thymidine between 48 and 72 h of culture in RPMI medium without addition of growth factors, mitogens or viral antigens.", [["lymphocytes", "ANATOMY", 28, 39], ["T lymphocytes", "ANATOMY", 97, 110], ["CNSEnriched T lymphocyte fractions", "ANATOMY", 116, 150], ["cells", "ANATOMY", 216, 221], ["[3H]thymidine", "CHEMICAL", 246, 259], ["[3H]thymidine", "CHEMICAL", 246, 259], ["lymphocytes", "CELL", 28, 39], ["T lymphocytes", "CELL", 97, 110], ["CNSEnriched T lymphocyte", "CELL", 116, 140], ["[3H]thymidine", "SIMPLE_CHEMICAL", 246, 259], ["lymphocytes", "CELL_TYPE", 28, 39], ["T lymphocytes", "CELL_TYPE", 97, 110], ["growth factors", "PROTEIN", 326, 340], ["mitogens", "PROTEIN", 342, 350], ["viral antigens", "PROTEIN", 354, 368], ["Total events", "PROBLEM", 0, 12], ["lymphocytes", "PROBLEM", 28, 39], ["Proliferation of T lymphocytes", "PROBLEM", 80, 110], ["CNSEnriched T lymphocyte fractions", "TREATMENT", 116, 150], ["proliferation", "TEST", 191, 204], ["thymidine", "TEST", 250, 259], ["culture in RPMI medium", "TEST", 283, 305], ["growth factors", "PROBLEM", 326, 340], ["mitogens", "PROBLEM", 342, 350], ["viral antigens", "PROBLEM", 354, 368], ["T lymphocytes", "OBSERVATION", 97, 110]]], ["As a reference, lymphocytes from the CNS of uninfected rats were included in this assay.", [["lymphocytes", "ANATOMY", 16, 27], ["CNS", "ANATOMY", 37, 40], ["lymphocytes", "CELL", 16, 27], ["CNS", "ANATOMICAL_SYSTEM", 37, 40], ["rats", "ORGANISM", 55, 59], ["lymphocytes", "CELL_TYPE", 16, 27], ["rats", "SPECIES", 55, 59], ["this assay", "TEST", 77, 87]]], ["For BN but not for LEW rats a slightly increased rate of proliferation above that of lymphocytes from uninfected animals was only observed 15 dpi (Fig. 4) .", [["lymphocytes", "ANATOMY", 85, 96], ["LEW rats", "ORGANISM", 19, 27], ["lymphocytes", "CELL", 85, 96], ["lymphocytes", "CELL_TYPE", 85, 96], ["rats", "SPECIES", 23, 27], ["LEW", "SPECIES", 19, 22], ["BN", "PROBLEM", 4, 6], ["LEW rats", "PROBLEM", 19, 27], ["a slightly increased rate of proliferation", "PROBLEM", 28, 70], ["lymphocytes", "PROBLEM", 85, 96], ["slightly", "OBSERVATION_MODIFIER", 30, 38], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["If the amount of recoverable T lymphocytes permitted, five times more cells were assayed for proliferation at distinct times post infection.", [["T lymphocytes", "ANATOMY", 29, 42], ["cells", "ANATOMY", 70, 75], ["infection", "DISEASE", 130, 139], ["T lymphocytes", "CELL", 29, 42], ["cells", "CELL", 70, 75], ["recoverable T lymphocytes", "CELL_TYPE", 17, 42], ["recoverable T lymphocytes", "PROBLEM", 17, 42], ["proliferation", "PROBLEM", 93, 106], ["infection", "PROBLEM", 130, 139], ["amount", "OBSERVATION_MODIFIER", 7, 13], ["lymphocytes", "OBSERVATION", 31, 42], ["infection", "OBSERVATION", 130, 139]]], ["However, no increase of [3H]thymidine incorporation was detectable (Fig. 5) .Proliferation of T lymphocytes from CNSThis result in combination with the high percentage of CNS-extracted T lymphocytes expressing the phenotype CD4 \u00f7, CD45RC-, CD25-suggested that the invading cells must have been expanded outside the CNS before they crossed the blood-brain barrier.", [["T lymphocytes", "ANATOMY", 94, 107], ["CNSThis", "ANATOMY", 113, 120], ["CNS", "ANATOMY", 171, 174], ["T lymphocytes", "ANATOMY", 185, 198], ["cells", "ANATOMY", 273, 278], ["CNS", "ANATOMY", 315, 318], ["blood-brain barrier", "ANATOMY", 343, 362], ["[3H]thymidine", "CHEMICAL", 24, 37], ["[3H]thymidine", "CHEMICAL", 24, 37], ["[3H]thymidine", "SIMPLE_CHEMICAL", 24, 37], ["T lymphocytes", "CELL", 94, 107], ["CNSThis", "CELL", 113, 120], ["CNS", "ANATOMICAL_SYSTEM", 171, 174], ["T lymphocytes", "CELL", 185, 198], ["CD4", "GENE_OR_GENE_PRODUCT", 224, 227], ["CD45RC", "GENE_OR_GENE_PRODUCT", 231, 237], ["CD25", "GENE_OR_GENE_PRODUCT", 240, 244], ["cells", "CELL", 273, 278], ["CNS", "ANATOMICAL_SYSTEM", 315, 318], ["blood-", "MULTI-TISSUE_STRUCTURE", 343, 349], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 349, 362], ["T lymphocytes", "CELL_TYPE", 94, 107], ["T lymphocytes", "CELL_TYPE", 185, 198], ["CD4", "PROTEIN", 224, 227], ["CD45RC", "PROTEIN", 231, 237], ["CD25", "PROTEIN", 240, 244], ["invading cells", "CELL_TYPE", 264, 278], ["increase of [3H]thymidine incorporation", "PROBLEM", 12, 51], ["Proliferation of T lymphocytes", "PROBLEM", 77, 107], ["CNSThis result", "TEST", 113, 127], ["the phenotype CD4", "TEST", 210, 227], ["CD45RC", "TEST", 231, 237], ["CD25", "TEST", 240, 244], ["the invading cells", "PROBLEM", 260, 278], ["no", "UNCERTAINTY", 9, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["T lymphocytes", "OBSERVATION", 94, 107], ["CNS", "ANATOMY", 171, 174], ["invading cells", "OBSERVATION", 264, 278], ["brain", "ANATOMY", 349, 354]]], ["On the assumption that at least some of CD4 + T lymphocytes that had passed the blood-brain barrier were virus-specific, a proliferative recall response could be expected after a challenge with viral antigens in vitro.", [["CD4 + T lymphocytes", "ANATOMY", 40, 59], ["blood-brain barrier", "ANATOMY", 80, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 86, 99], ["CD4", "PROTEIN", 40, 43], ["T lymphocytes", "CELL_TYPE", 46, 59], ["viral antigens", "PROTEIN", 194, 208], ["CD4 + T lymphocytes", "PROBLEM", 40, 59], ["the blood", "TEST", 76, 85], ["virus", "PROBLEM", 105, 110], ["viral antigens in vitro", "TREATMENT", 194, 217], ["brain", "ANATOMY", 86, 91]]], ["Consequently, CNS-isolated T lymphocytes were cultured in the presence of inactivated JHM virus.", [["CNS", "ANATOMY", 14, 17], ["T lymphocytes", "ANATOMY", 27, 40], ["CNS-isolated T lymphocytes", "CELL", 14, 40], ["JHM virus", "ORGANISM", 86, 95], ["CNS-isolated T lymphocytes", "CELL_TYPE", 14, 40], ["JHM virus", "SPECIES", 86, 95], ["isolated T lymphocytes", "PROBLEM", 18, 40], ["inactivated JHM virus", "PROBLEM", 74, 95], ["CNS", "ANATOMY", 14, 17], ["JHM virus", "OBSERVATION", 86, 95]]], ["Stimulation of cell proliferation was monitored by the addition of [3H]thymidine between 48 and 72 h of culture.", [["cell", "ANATOMY", 15, 19], ["[3H]thymidine", "CHEMICAL", 67, 80], ["[3H]thymidine", "CHEMICAL", 67, 80], ["cell", "CELL", 15, 19], ["[3H]thymidine", "SIMPLE_CHEMICAL", 67, 80], ["thymidine", "TREATMENT", 71, 80], ["culture", "TEST", 104, 111], ["cell proliferation", "OBSERVATION", 15, 33]]], ["Surprisingly, neither T cells from BN nor from LEW brain disclosed a proliferative JHMV-specific response (Fig. 4) .", [["T cells", "ANATOMY", 22, 29], ["BN", "ANATOMY", 35, 37], ["brain", "ANATOMY", 51, 56], ["T cells", "CELL", 22, 29], ["BN", "CELL", 35, 37], ["LEW", "ORGANISM", 47, 50], ["brain", "ORGAN", 51, 56], ["JHMV", "CANCER", 83, 87], ["T cells", "CELL_TYPE", 22, 29], ["LEW", "SPECIES", 47, 50], ["LEW brain", "TEST", 47, 56], ["a proliferative JHMV", "TEST", 67, 87], ["brain", "ANATOMY", 51, 56]]], ["This failure to respond to a recall antigen could neither be overcome by adding irradiated feeder cells from syngeneic rats (data not shown) nor by increasing the cell density per well (Fig. 5) .", [["feeder cells", "ANATOMY", 91, 103], ["cell", "ANATOMY", 163, 167], ["feeder cells", "CELL", 91, 103], ["syngeneic rats", "ORGANISM", 109, 123], ["cell", "CELL", 163, 167], ["irradiated feeder cells", "CELL_LINE", 80, 103], ["rats", "SPECIES", 119, 123], ["This failure", "PROBLEM", 0, 12], ["irradiated feeder cells", "TREATMENT", 80, 103], ["syngeneic rats", "TREATMENT", 109, 123], ["cell density", "OBSERVATION", 163, 175]]], ["Since the brain-isolated T lymphocytes did also not respond to the T cell mitogen Con A (Fig. 4) , it was assumed that the majority of primed infiltrating T lymphocytes was insensitive to further stimulation within the brain parenchyma.Proliferation of T lymphocytes from CLNsSince cervical lymph nodes are known to drain the head area (Harling-Berg et al., 1989; Doherty et al., 1990; Cserr and Knopf, 1992) , it seemed possible that prior to the infiltration in the CNS, sensitisation and expansion of virus-specific T lymphocytes had occurred in these lymphoid organs.", [["brain", "ANATOMY", 10, 15], ["T lymphocytes", "ANATOMY", 25, 38], ["T cell", "ANATOMY", 67, 73], ["infiltrating T lymphocytes", "ANATOMY", 142, 168], ["brain parenchyma", "ANATOMY", 219, 235], ["T lymphocytes", "ANATOMY", 253, 266], ["cervical lymph nodes", "ANATOMY", 282, 302], ["head area", "ANATOMY", 326, 335], ["CNS", "ANATOMY", 468, 471], ["T lymphocytes", "ANATOMY", 519, 532], ["lymphoid organs", "ANATOMY", 555, 570], ["brain", "ORGAN", 10, 15], ["T lymphocytes", "CELL", 25, 38], ["T cell", "CELL", 67, 73], ["Con A", "GENE_OR_GENE_PRODUCT", 82, 87], ["T lymphocytes", "CELL", 155, 168], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 219, 235], ["T lymphocytes", "CELL", 253, 266], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 282, 302], ["head area", "MULTI-TISSUE_STRUCTURE", 326, 335], ["CNS", "ANATOMICAL_SYSTEM", 468, 471], ["T lymphocytes", "CELL", 519, 532], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 555, 570], ["T lymphocytes", "CELL_TYPE", 25, 38], ["primed infiltrating T lymphocytes", "CELL_LINE", 135, 168], ["T lymphocytes", "CELL_TYPE", 253, 266], ["T lymphocytes", "CELL_TYPE", 519, 532], ["isolated T lymphocytes", "PROBLEM", 16, 38], ["primed infiltrating T lymphocytes", "PROBLEM", 135, 168], ["Proliferation of T lymphocytes", "PROBLEM", 236, 266], ["CLNsSince cervical lymph nodes", "PROBLEM", 272, 302], ["the infiltration", "PROBLEM", 444, 460], ["the CNS", "PROBLEM", 464, 471], ["sensitisation", "PROBLEM", 473, 486], ["expansion of virus", "PROBLEM", 491, 509], ["specific T lymphocytes", "PROBLEM", 510, 532], ["brain", "ANATOMY", 10, 15], ["T lymphocytes", "OBSERVATION", 25, 38], ["infiltrating", "OBSERVATION", 142, 154], ["brain", "ANATOMY", 219, 224], ["parenchyma", "ANATOMY_MODIFIER", 225, 235], ["T lymphocytes", "OBSERVATION", 253, 266], ["cervical", "ANATOMY", 282, 290], ["lymph nodes", "OBSERVATION", 291, 302], ["head", "ANATOMY", 326, 330], ["area", "ANATOMY_MODIFIER", 331, 335], ["infiltration", "OBSERVATION", 448, 460], ["CNS", "ANATOMY", 468, 471], ["virus", "OBSERVATION", 504, 509], ["lymphoid organs", "ANATOMY", 555, 570]]], ["Therefore, we assayed CLN lymphocytes taken from the same animals as for isolation of lymphocytes from the CNS.", [["CLN lymphocytes", "ANATOMY", 22, 37], ["lymphocytes", "ANATOMY", 86, 97], ["CNS", "ANATOMY", 107, 110], ["CLN lymphocytes", "CELL", 22, 37], ["lymphocytes", "CELL", 86, 97], ["CNS", "ANATOMICAL_SYSTEM", 107, 110], ["CLN lymphocytes", "CELL_TYPE", 22, 37], ["lymphocytes", "CELL_TYPE", 86, 97], ["CLN lymphocytes", "TEST", 22, 37], ["lymphocytes", "PROBLEM", 86, 97], ["lymphocytes", "OBSERVATION", 86, 97], ["CNS", "ANATOMY", 107, 110]]], ["In contrast to brain-extracted lymphocytes, a clear dose-response curve was detected when the proliferation signal was examined in relation to the seeded cell density, giving the best signal at 1.0 X 107 cells/ml (Fig. 5 ).", [["brain", "ANATOMY", 15, 20], ["lymphocytes", "ANATOMY", 31, 42], ["cell", "ANATOMY", 154, 158], ["cells", "ANATOMY", 204, 209], ["brain", "ORGAN", 15, 20], ["lymphocytes", "CELL", 31, 42], ["cell", "CELL", 154, 158], ["lymphocytes", "CELL_TYPE", 31, 42], ["a clear dose-response curve", "TEST", 44, 71], ["the proliferation signal", "TEST", 90, 114], ["brain", "ANATOMY", 15, 20], ["lymphocytes", "ANATOMY", 31, 42], ["seeded cell density", "OBSERVATION", 147, 166]]], ["This result reflects the fact that in lymphoid tissue the majority of cells consists of naive recirculating cells, whereas in tissue primed and activated lymphoid cells are preferentially accumulated.", [["lymphoid tissue", "ANATOMY", 38, 53], ["cells", "ANATOMY", 70, 75], ["cells", "ANATOMY", 108, 113], ["tissue", "ANATOMY", 126, 132], ["lymphoid cells", "ANATOMY", 154, 168], ["lymphoid tissue", "TISSUE", 38, 53], ["cells", "CELL", 70, 75], ["cells", "CELL", 108, 113], ["tissue", "TISSUE", 126, 132], ["lymphoid cells", "CELL", 154, 168], ["naive recirculating cells", "CELL_TYPE", 88, 113], ["activated lymphoid cells", "CELL_TYPE", 144, 168], ["naive recirculating cells", "PROBLEM", 88, 113], ["activated lymphoid cells", "PROBLEM", 144, 168], ["lymphoid tissue", "OBSERVATION", 38, 53], ["majority", "OBSERVATION_MODIFIER", 58, 66], ["naive recirculating cells", "OBSERVATION", 88, 113], ["lymphoid cells", "OBSERVATION", 154, 168]]], ["Thus, it needs much more lymphocytes from second/~ry lymphoid tissue to obtain an amount of primed and activated cells comparable to tissue-infiltrating leukocytes.Proliferation of T lymphocytes from CLNsCompared to uninfected rats, assays of CLN lymphocytes at a density of 1.0 x 107/ml without further stimulation revealed proliferation at day 4 in BN and at 12 dpi in LEW rats ex vivo (Fig. 6) .", [["lymphocytes", "ANATOMY", 25, 36], ["~ry lymphoid tissue", "ANATOMY", 49, 68], ["cells", "ANATOMY", 113, 118], ["tissue-infiltrating leukocytes", "ANATOMY", 133, 163], ["T lymphocytes", "ANATOMY", 181, 194], ["CLN lymphocytes", "ANATOMY", 243, 258], ["BN", "ANATOMY", 351, 353], ["lymphocytes", "CELL", 25, 36], ["~ry lymphoid tissue", "TISSUE", 49, 68], ["cells", "CELL", 113, 118], ["tissue-infiltrating leukocytes", "CELL", 133, 163], ["T lymphocytes", "CELL", 181, 194], ["CLNsCompared", "CELL", 200, 212], ["rats", "ORGANISM", 227, 231], ["CLN lymphocytes", "CELL", 243, 258], ["LEW rats", "ORGANISM", 371, 379], ["lymphocytes", "CELL_TYPE", 25, 36], ["activated cells", "CELL_TYPE", 103, 118], ["tissue-infiltrating leukocytes", "CELL_TYPE", 133, 163], ["T lymphocytes", "CELL_TYPE", 181, 194], ["CLN lymphocytes", "CELL_TYPE", 243, 258], ["rats", "SPECIES", 227, 231], ["rats", "SPECIES", 375, 379], ["LEW", "SPECIES", 371, 374], ["second/~ry lymphoid tissue", "TREATMENT", 42, 68], ["activated cells", "PROBLEM", 103, 118], ["infiltrating leukocytes", "PROBLEM", 140, 163], ["Proliferation of T lymphocytes", "PROBLEM", 164, 194], ["uninfected rats", "PROBLEM", 216, 231], ["CLN lymphocytes", "PROBLEM", 243, 258], ["further stimulation", "TEST", 296, 315], ["proliferation", "PROBLEM", 325, 338], ["infiltrating leukocytes", "OBSERVATION", 140, 163], ["T lymphocytes", "OBSERVATION", 181, 194], ["CLN lymphocytes", "OBSERVATION", 243, 258], ["proliferation", "OBSERVATION", 325, 338]]], ["Most remarkable, LEW rats revealed a later but stronger proliferation compared to BN rats.", [["LEW rats", "ORGANISM", 17, 25], ["BN rats", "ORGANISM", 82, 89], ["rats", "SPECIES", 21, 25], ["rats", "SPECIES", 85, 89], ["LEW rats", "TEST", 17, 25], ["stronger proliferation", "PROBLEM", 47, 69]]], ["The highest [3H]thymidine incorporation rates in LEW rats were detected at a time when the neurological disease was already fully developed (Fig. 6, upper panel; and Fig. 1) .", [["neurological", "ANATOMY", 91, 103], ["[3H]thymidine", "CHEMICAL", 12, 25], ["neurological disease", "DISEASE", 91, 111], ["[3H]thymidine", "CHEMICAL", 12, 25], ["[3H]thymidine", "SIMPLE_CHEMICAL", 12, 25], ["LEW rats", "ORGANISM", 49, 57], ["rats", "SPECIES", 53, 57], ["thymidine incorporation rates", "TEST", 16, 45], ["LEW rats", "TEST", 49, 57], ["the neurological disease", "PROBLEM", 87, 111], ["Fig.", "TEST", 141, 145], ["upper panel", "TEST", 149, 160]]], ["In contrast, the maximal response of BN rats was seen shortly before the first clinical signs of the infection were detectable in LEW rats (Fig. 6, lower panel; and Fig. 1 ).", [["infection", "DISEASE", 101, 110], ["BN rats", "ORGANISM", 37, 44], ["LEW rats", "ORGANISM", 130, 138], ["rats", "SPECIES", 40, 44], ["rats", "SPECIES", 134, 138], ["LEW", "SPECIES", 130, 133], ["the infection", "PROBLEM", 97, 110], ["lower panel", "TEST", 148, 159], ["infection", "OBSERVATION", 101, 110]]], ["These findings suggest that BN rats probably reacted earlier to the viral challenge compared to LEW rats.", [["BN rats", "ORGANISM", 28, 35], ["LEW rats", "ORGANISM", 96, 104], ["rats", "SPECIES", 31, 35], ["rats", "SPECIES", 100, 104], ["LEW", "SPECIES", 96, 99], ["the viral challenge", "TEST", 64, 83]]], ["To verify this assumption, CLN cells were stimulated by the same viral antigen batch used for T lymphocytes extracted from the CNS.", [["CLN cells", "ANATOMY", 27, 36], ["T lymphocytes", "ANATOMY", 94, 107], ["CNS", "ANATOMY", 127, 130], ["CLN cells", "CELL", 27, 36], ["T lymphocytes", "CELL", 94, 107], ["CNS", "ANATOMICAL_SYSTEM", 127, 130], ["CLN cells", "CELL_LINE", 27, 36], ["T lymphocytes", "CELL_TYPE", 94, 107], ["CLN cells", "PROBLEM", 27, 36], ["the same viral antigen batch", "TEST", 56, 84], ["T lymphocytes", "PROBLEM", 94, 107], ["CNS", "ANATOMY", 127, 130]]], ["The results of this assay in Fig. 6 support our hypothesis.", [["this assay", "TEST", 15, 25]]], ["CLN cells from BN rats could be stimulated to strong virusspecific proliferation already at day 5 post infection.", [["CLN cells", "ANATOMY", 0, 9], ["virusspecific", "ANATOMY", 53, 66], ["infection", "DISEASE", 103, 112], ["CLN cells", "CELL", 0, 9], ["BN rats", "ORGANISM", 15, 22], ["CLN cells", "CELL_TYPE", 0, 9], ["rats", "SPECIES", 18, 22], ["strong virusspecific proliferation", "PROBLEM", 46, 80], ["infection", "PROBLEM", 103, 112], ["infection", "OBSERVATION", 103, 112]]], ["At this time the response of CLN lymphocytes from LEW rats was significantly lower.", [["CLN lymphocytes", "ANATOMY", 29, 44], ["CLN lymphocytes", "CELL", 29, 44], ["LEW rats", "ORGANISM", 50, 58], ["CLN lymphocytes", "CELL_TYPE", 29, 44], ["rats", "SPECIES", 54, 58], ["CLN lymphocytes", "TEST", 29, 44], ["LEW rats", "TEST", 50, 58], ["CLN lymphocytes", "OBSERVATION", 29, 44], ["significantly", "OBSERVATION_MODIFIER", 63, 76], ["lower", "OBSERVATION_MODIFIER", 77, 82]]], ["It took 6-7 additional days until CLN cells responded in these rats as detectable in BN rats.", [["CLN cells", "ANATOMY", 34, 43], ["CLN cells", "CELL", 34, 43], ["rats", "ORGANISM", 63, 67], ["BN rats", "ORGANISM", 85, 92], ["CLN cells", "CELL_TYPE", 34, 43], ["rats", "SPECIES", 63, 67], ["rats", "SPECIES", 88, 92], ["CLN cells", "PROBLEM", 34, 43]]], ["Nevertheless, in contrast to CLN cells from BN rats, enhancement of proliferation above the level observed in ex vivo assayed CLN cells was only marginal after restimulation with JHMV.", [["CLN cells", "ANATOMY", 29, 38], ["CLN cells", "ANATOMY", 126, 135], ["CLN cells", "CELL", 29, 38], ["BN rats", "ORGANISM", 44, 51], ["CLN cells", "CELL", 126, 135], ["CLN cells", "CELL_TYPE", 29, 38], ["CLN cells", "CELL_LINE", 126, 135], ["rats", "SPECIES", 47, 51], ["enhancement of proliferation", "PROBLEM", 53, 81], ["JHMV", "TREATMENT", 179, 183], ["proliferation", "OBSERVATION", 68, 81], ["CLN cells", "OBSERVATION", 126, 135], ["marginal", "OBSERVATION_MODIFIER", 145, 153]]], ["Moreover, lymphocytes from BN rats revealed a second peak of JHMV- specific proliferation concomitantly with the observed increase of [3H]thymidine incorporation in LEW rats.", [["lymphocytes", "ANATOMY", 10, 21], ["[3H]thymidine", "CHEMICAL", 134, 147], ["[3H]thymidine", "CHEMICAL", 134, 147], ["lymphocytes", "CELL", 10, 21], ["BN rats", "ORGANISM", 27, 34], ["JHMV", "SIMPLE_CHEMICAL", 61, 65], ["[3H]thymidine", "SIMPLE_CHEMICAL", 134, 147], ["LEW rats", "ORGANISM", 165, 173], ["lymphocytes", "CELL_TYPE", 10, 21], ["rats", "SPECIES", 30, 34], ["rats", "SPECIES", 169, 173], ["lymphocytes", "TEST", 10, 21], ["BN rats", "TEST", 27, 34], ["a second peak of JHMV", "PROBLEM", 44, 65], ["specific proliferation", "PROBLEM", 67, 89], ["thymidine incorporation", "TREATMENT", 138, 161], ["specific proliferation", "OBSERVATION", 67, 89], ["increase", "OBSERVATION_MODIFIER", 122, 130]]], ["This indicates that in JHMV-infected LEW rats the proliferative response of CLN cells is vigorous, but slower and less specific compared to BN rats.DiscussionUpregulation of MHC class II antigens on ramified microglia cells in the inflamed virus-infected CNS and a phenotype of resting microglia reminiscent of dendritic cells is indicative of a potential immunoregulatory role of this CNS-resident cell (Lowe et al., 1989; Weinstein et al., 1990; Griffin et al., 1992) .", [["CLN cells", "ANATOMY", 76, 85], ["microglia cells", "ANATOMY", 208, 223], ["CNS", "ANATOMY", 255, 258], ["microglia", "ANATOMY", 286, 295], ["dendritic cells", "ANATOMY", 311, 326], ["CNS", "ANATOMY", 386, 389], ["cell", "ANATOMY", 399, 403], ["JHMV", "ORGANISM", 23, 27], ["LEW rats", "ORGANISM", 37, 45], ["CLN cells", "CELL", 76, 85], ["BN rats", "ORGANISM", 140, 147], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 174, 195], ["ramified microglia cells", "CELL", 199, 223], ["CNS", "ANATOMICAL_SYSTEM", 255, 258], ["microglia", "CELL", 286, 295], ["dendritic cells", "CELL", 311, 326], ["CNS-resident cell", "CELL", 386, 403], ["CLN cells", "CELL_TYPE", 76, 85], ["MHC class II antigens", "PROTEIN", 174, 195], ["ramified microglia cells", "CELL_TYPE", 199, 223], ["resting microglia", "CELL_TYPE", 278, 295], ["dendritic cells", "CELL_TYPE", 311, 326], ["rats", "SPECIES", 41, 45], ["rats", "SPECIES", 143, 147], ["JHMV", "SPECIES", 23, 27], ["LEW", "SPECIES", 37, 40], ["JHMV", "TEST", 23, 27], ["CLN cells", "PROBLEM", 76, 85], ["ramified microglia cells", "PROBLEM", 199, 223], ["the inflamed virus", "PROBLEM", 227, 245], ["infected CNS", "PROBLEM", 246, 258], ["dendritic cells", "PROBLEM", 311, 326], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["proliferative", "OBSERVATION_MODIFIER", 50, 63], ["response", "OBSERVATION_MODIFIER", 64, 72], ["CLN cells", "OBSERVATION", 76, 85], ["vigorous", "OBSERVATION_MODIFIER", 89, 97], ["slower", "OBSERVATION_MODIFIER", 103, 109], ["microglia cells", "OBSERVATION", 208, 223], ["inflamed virus", "ANATOMY", 231, 245], ["infected", "OBSERVATION_MODIFIER", 246, 254], ["CNS", "ANATOMY", 255, 258], ["resting microglia", "OBSERVATION", 278, 295], ["dendritic cells", "OBSERVATION", 311, 326], ["indicative of", "UNCERTAINTY", 330, 343]]], ["This is strongly supported by studies that demonstrate the capacity of microglia cells to induce a proliferative response of antigen-specific CD4 + T lymphocytes in vitro (Frei et al., 1987; Matsumoto et al., 1992; Williams et al., 1992) .", [["microglia cells", "ANATOMY", 71, 86], ["CD4 + T lymphocytes", "ANATOMY", 142, 161], ["microglia cells", "CELL", 71, 86], ["antigen", "GENE_OR_GENE_PRODUCT", 125, 132], ["CD4", "GENE_OR_GENE_PRODUCT", 142, 145], ["microglia cells", "CELL_TYPE", 71, 86], ["CD4 + T lymphocytes", "CELL_TYPE", 142, 161], ["the capacity of microglia cells", "PROBLEM", 55, 86], ["antigen", "TEST", 125, 132]]], ["However, the data presented here do not corroborate a stimulating influence of activated microglia on proliferation of brain-infiltrating T lymphocytes in vivo.", [["microglia", "ANATOMY", 89, 98], ["brain-infiltrating T lymphocytes", "ANATOMY", 119, 151], ["microglia", "CELL", 89, 98], ["brain-infiltrating T lymphocytes", "CELL", 119, 151], ["activated microglia", "CELL_TYPE", 79, 98], ["brain-infiltrating T lymphocytes", "CELL_TYPE", 119, 151], ["activated microglia on proliferation of brain", "PROBLEM", 79, 124], ["infiltrating T lymphocytes", "PROBLEM", 125, 151], ["brain", "ANATOMY", 119, 124], ["infiltrating T lymphocytes", "OBSERVATION", 125, 151]]], ["We have previously documented upregulation of MHC class II antigens on brain-resident microglia cells of rats infected intracerebrally with the murine coronavirus strain JHM (Sedgwick and D~Srries, 1991; as well as presence of JHM virus antigen in the CNS for at least 3 weeks post infection .", [["brain-resident microglia cells", "ANATOMY", 71, 101], ["CNS", "ANATOMY", 252, 255], ["infection", "DISEASE", 282, 291], ["MHC class II antigens", "GENE_OR_GENE_PRODUCT", 46, 67], ["brain-resident microglia cells", "CELL", 71, 101], ["rats", "ORGANISM", 105, 109], ["murine", "ORGANISM", 144, 150], ["coronavirus strain JHM", "ORGANISM", 151, 173], ["JHM virus antigen", "GENE_OR_GENE_PRODUCT", 227, 244], ["CNS", "ANATOMICAL_SYSTEM", 252, 255], ["MHC class II antigens", "PROTEIN", 46, 67], ["brain-resident microglia cells", "CELL_TYPE", 71, 101], ["JHM virus antigen", "PROTEIN", 227, 244], ["rats", "SPECIES", 105, 109], ["murine", "SPECIES", 144, 150], ["coronavirus", "SPECIES", 151, 162], ["murine coronavirus", "SPECIES", 144, 162], ["JHM virus", "SPECIES", 227, 236], ["the murine coronavirus strain JHM", "PROBLEM", 140, 173], ["JHM virus antigen", "PROBLEM", 227, 244], ["infection", "PROBLEM", 282, 291], ["brain", "ANATOMY", 71, 76], ["JHM virus", "OBSERVATION", 227, 236], ["CNS", "ANATOMY", 252, 255], ["infection", "OBSERVATION", 282, 291]]], ["Additionally, as shown in this paper, CD4 + T cells infiltrating into the CNS of these animals are of primed or memory phenotype by virtue of a low expression of CD45RC.", [["CD4 + T cells", "ANATOMY", 38, 51], ["CNS", "ANATOMY", 74, 77], ["CD4", "GENE_OR_GENE_PRODUCT", 38, 41], ["CNS", "ANATOMICAL_SYSTEM", 74, 77], ["CD45RC", "GENE_OR_GENE_PRODUCT", 162, 168], ["CD4", "PROTEIN", 38, 41], ["T cells", "CELL_TYPE", 44, 51], ["CD45RC", "PROTEIN", 162, 168], ["T cells", "PROBLEM", 44, 51], ["a low expression of CD45RC", "PROBLEM", 142, 168], ["CNS", "ANATOMY", 74, 77], ["low expression", "OBSERVATION_MODIFIER", 144, 158]]], ["Nevertheless, we were unable to demonstrate a proliferative response of CNS-isolated T lymphocytes ex vivo.", [["CNS", "ANATOMY", 72, 75], ["T lymphocytes", "ANATOMY", 85, 98], ["CNS-isolated T lymphocytes", "CELL", 72, 98], ["CNS-isolated T lymphocytes", "CELL_TYPE", 72, 98], ["CNS", "ANATOMY", 72, 75], ["lymphocytes", "OBSERVATION", 87, 98]]], ["Concurring with this result is the fact that after a week post infection less than 5% of CNS-recoverable CD4 + T cells expressed the IL-2R.", [["CNS", "ANATOMY", 89, 92], ["CD4 + T cells", "ANATOMY", 105, 118], ["infection", "DISEASE", 63, 72], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["CD4", "GENE_OR_GENE_PRODUCT", 105, 108], ["IL-2R", "GENE_OR_GENE_PRODUCT", 133, 138], ["CD4 + T cells", "CELL_TYPE", 105, 118], ["IL-2R", "PROTEIN", 133, 138], ["infection", "PROBLEM", 63, 72], ["CNS", "TEST", 89, 92]]], ["Both low expression of CD45RC and IL-2R are not confined to CD4 \u00f7 T lymphocytes from virus-infected rat brain.", [["CD4 \u00f7 T lymphocytes", "ANATOMY", 60, 79], ["brain", "ANATOMY", 104, 109], ["CD45RC", "GENE_OR_GENE_PRODUCT", 23, 29], ["IL-2R", "GENE_OR_GENE_PRODUCT", 34, 39], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["rat", "ORGANISM", 100, 103], ["brain", "ORGAN", 104, 109], ["CD45RC", "PROTEIN", 23, 29], ["IL-2R", "PROTEIN", 34, 39], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 60, 79], ["rat", "SPECIES", 100, 103], ["rat", "SPECIES", 100, 103], ["IL-2R", "TREATMENT", 34, 39], ["CD4", "TEST", 60, 63], ["virus", "PROBLEM", 85, 90], ["infected rat brain", "PROBLEM", 91, 109], ["low expression", "OBSERVATION_MODIFIER", 5, 19], ["infected", "OBSERVATION", 91, 99], ["brain", "ANATOMY", 104, 109]]], ["As shown by McCombe et al. (1992) , the majority of T lymphocytes that can be detected in spinal cord of rats suffering from experimental allergic encephalomyelitis (EAE) is of the same phenotype.", [["T lymphocytes", "ANATOMY", 52, 65], ["spinal cord", "ANATOMY", 90, 101], ["allergic encephalomyelitis", "DISEASE", 138, 164], ["EAE", "DISEASE", 166, 169], ["T lymphocytes", "CELL", 52, 65], ["spinal cord", "ORGAN", 90, 101], ["rats", "ORGANISM", 105, 109], ["T lymphocytes", "CELL_TYPE", 52, 65], ["rats", "SPECIES", 105, 109], ["T lymphocytes", "PROBLEM", 52, 65], ["experimental allergic encephalomyelitis", "PROBLEM", 125, 164], ["the same phenotype", "PROBLEM", 177, 195], ["spinal cord", "ANATOMY", 90, 101], ["experimental", "OBSERVATION_MODIFIER", 125, 137], ["allergic encephalomyelitis", "OBSERVATION", 138, 164]]], ["This suggests that the CD4 + T lymphocyte population infiltrating the brain in the course of acute inflammatory CNS disorders is generally dominated by primed and already differentiated cells.DiscussionOn the other hand, infiltrating CD4 \u00f7 T lymphocytes usually home to virus-infected areas of the brain (D/Srries et al., 1991) , making it very likely that they are indeed virus-specific.", [["CD4 + T lymphocyte", "ANATOMY", 23, 41], ["brain", "ANATOMY", 70, 75], ["CNS", "ANATOMY", 112, 115], ["cells", "ANATOMY", 186, 191], ["hand", "ANATOMY", 215, 219], ["infiltrating CD4 \u00f7 T lymphocytes", "ANATOMY", 221, 253], ["brain", "ANATOMY", 298, 303], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["brain", "ORGAN", 70, 75], ["CNS", "ANATOMICAL_SYSTEM", 112, 115], ["cells", "CELL", 186, 191], ["CD4", "GENE_OR_GENE_PRODUCT", 234, 237], ["brain", "ORGAN", 298, 303], ["CD4", "PROTEIN", 23, 26], ["differentiated cells", "CELL_TYPE", 171, 191], ["infiltrating CD4 \u00f7 T lymphocytes", "CELL_TYPE", 221, 253], ["the CD4", "TEST", 19, 26], ["T lymphocyte population infiltrating the brain", "PROBLEM", 29, 75], ["acute inflammatory CNS disorders", "PROBLEM", 93, 125], ["infiltrating CD4 \u00f7 T lymphocytes", "PROBLEM", 221, 253], ["indeed virus", "PROBLEM", 366, 378], ["lymphocyte population", "OBSERVATION", 31, 52], ["brain", "ANATOMY", 70, 75], ["course", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["inflammatory", "OBSERVATION", 99, 111], ["differentiated cells", "OBSERVATION", 171, 191], ["hand", "ANATOMY", 215, 219], ["infiltrating", "OBSERVATION", 221, 233], ["infected", "OBSERVATION", 276, 284], ["brain", "ANATOMY", 298, 303], ["virus", "OBSERVATION", 373, 378]]], ["In this context, our failure to restimulate these cells in vitro with viral antigens was surprising.", [["cells", "ANATOMY", 50, 55], ["cells", "CELL", 50, 55], ["viral antigens", "PROTEIN", 70, 84], ["our failure", "PROBLEM", 17, 28], ["these cells", "PROBLEM", 44, 55], ["viral antigens", "PROBLEM", 70, 84], ["failure", "OBSERVATION", 21, 28]]], ["For an explanation of this phenomenon at least two aspects have to be discussed: (i) Viability of cells could be impaired by the extraction procedure.", [["cells", "ANATOMY", 98, 103], ["cells", "CELL", 98, 103], ["this phenomenon", "PROBLEM", 22, 37], ["the extraction procedure", "TREATMENT", 125, 149]]], ["Beside the fact that we recover roughly 80% of viable cells from a Percoll gradient when we mix viable spleen cells into the CNS extraction procedure (unpublished observation), cell counts for proliferation assays are expressed as viable cells by Trypan blue exclusion immediately before stimulation experiments.", [["cells", "ANATOMY", 54, 59], ["spleen cells", "ANATOMY", 103, 115], ["CNS", "ANATOMY", 125, 128], ["cell", "ANATOMY", 177, 181], ["cells", "ANATOMY", 238, 243], ["Trypan blue", "CHEMICAL", 247, 258], ["Trypan blue", "CHEMICAL", 247, 258], ["cells", "CELL", 54, 59], ["spleen cells", "CELL", 103, 115], ["CNS", "ANATOMICAL_SYSTEM", 125, 128], ["cell", "CELL", 177, 181], ["cells", "CELL", 238, 243], ["Trypan blue", "SIMPLE_CHEMICAL", 247, 258], ["spleen cells", "CELL_TYPE", 103, 115], ["a Percoll gradient", "TREATMENT", 65, 83], ["the CNS extraction procedure", "TREATMENT", 121, 149], ["unpublished observation", "TEST", 151, 174], ["cell counts", "TEST", 177, 188], ["proliferation assays", "TEST", 193, 213], ["Trypan blue exclusion", "TREATMENT", 247, 268], ["spleen", "ANATOMY", 103, 109], ["CNS", "ANATOMY", 125, 128]]], ["Nevertheless, in view of recent data from the EAE rat model (Schmied et al., 1993) we cannot rule out that a certain percentage of cells is apoptotic.", [["cells", "ANATOMY", 131, 136], ["EAE", "DISEASE", 46, 49], ["rat", "ORGANISM", 50, 53], ["cells", "CELL", 131, 136], ["rat", "SPECIES", 50, 53], ["apoptotic", "PROBLEM", 140, 149]]], ["Indeed, we have observed in preliminary experiments by FACS analysis, that up to 40% of CNS extracted cells can show DNA fragmentation without being necessarily recognised as dying cell by Trypan blue exclusion (unpublished observation).", [["CNS", "ANATOMY", 88, 91], ["cells", "ANATOMY", 102, 107], ["cell", "ANATOMY", 181, 185], ["Trypan blue", "CHEMICAL", 189, 200], ["Trypan blue", "CHEMICAL", 189, 200], ["cells", "CELL", 102, 107], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["cell", "CELL", 181, 185], ["Trypan blue", "SIMPLE_CHEMICAL", 189, 200], ["CNS extracted cells", "CELL_TYPE", 88, 107], ["dying cell", "CELL_TYPE", 175, 185], ["FACS analysis", "TEST", 55, 68], ["CNS extracted cells", "PROBLEM", 88, 107], ["DNA fragmentation", "PROBLEM", 117, 134]]], ["In any case, 60% of living cells should be enough cells to give a proliferative response. (ii) As hypothesised by Cross et al. (1991) , only a minority of CNS-infiltrating T cells may be antigen-specific in au-toimmune EAE.", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 50, 55], ["CNS-infiltrating T cells", "ANATOMY", 155, 179], ["EAE", "DISEASE", 219, 222], ["cells", "CELL", 27, 32], ["cells", "CELL", 50, 55], ["CNS-infiltrating T cells", "CELL", 155, 179], ["CNS-infiltrating T cells", "CELL_TYPE", 155, 179], ["living cells", "TREATMENT", 20, 32], ["infiltrating T cells", "PROBLEM", 159, 179], ["antigen", "TEST", 187, 194], ["CNS", "ANATOMY", 155, 158], ["infiltrating", "OBSERVATION", 159, 171]]], ["Although we cannot exclude the possibility that this could also be the case in virus-induced encephalomyelitis, absence of a dose-response relationship between amount of CNS-extracted T cells and virus-specific proliferation argues against it.", [["CNS", "ANATOMY", 170, 173], ["T cells", "ANATOMY", 184, 191], ["encephalomyelitis", "DISEASE", 93, 110], ["CNS", "ANATOMICAL_SYSTEM", 170, 173], ["T cells", "CELL", 184, 191], ["T cells", "CELL_TYPE", 184, 191], ["virus", "PROBLEM", 79, 84], ["encephalomyelitis", "PROBLEM", 93, 110], ["CNS-extracted T cells", "PROBLEM", 170, 191], ["virus", "PROBLEM", 196, 201], ["encephalomyelitis", "OBSERVATION", 93, 110], ["CNS", "ANATOMY", 170, 173]]], ["Since attempts to induce proliferation by ConA were also unsuccessful, we believe indeed that the majority of CD4 \u00f7 T lymphocytes entering the virus-infected brain is unresponsive to further proliferation signals that probably could be given by MHC class II expressing brain-resident cells.DiscussionApparently conflicting data have been published recently by Williamson (1992) , who reported a proliferative response of leukocytes from the CNS of JHMVinfected mice after in vitro stimulation with viral antigen or ConA.", [["CD4 \u00f7 T lymphocytes", "ANATOMY", 110, 129], ["brain", "ANATOMY", 158, 163], ["brain-resident cells", "ANATOMY", 269, 289], ["leukocytes", "ANATOMY", 421, 431], ["CNS", "ANATOMY", 441, 444], ["ConA", "GENE_OR_GENE_PRODUCT", 42, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 110, 113], ["brain", "ORGAN", 158, 163], ["MHC class II", "GENE_OR_GENE_PRODUCT", 245, 257], ["brain-resident cells", "CELL", 269, 289], ["leukocytes", "CELL", 421, 431], ["CNS", "ANATOMICAL_SYSTEM", 441, 444], ["mice", "ORGANISM", 461, 465], ["ConA", "GENE_OR_GENE_PRODUCT", 515, 519], ["ConA", "PROTEIN", 42, 46], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 110, 129], ["MHC class II expressing brain-resident cells", "CELL_TYPE", 245, 289], ["leukocytes", "CELL_TYPE", 421, 431], ["viral antigen", "PROTEIN", 498, 511], ["ConA", "PROTEIN", 515, 519], ["mice", "SPECIES", 461, 465], ["mice", "SPECIES", 461, 465], ["CD4 \u00f7 T lymphocytes", "PROBLEM", 110, 129], ["the virus", "PROBLEM", 139, 148], ["infected brain", "PROBLEM", 149, 163], ["further proliferation signals", "PROBLEM", 183, 212], ["leukocytes", "PROBLEM", 421, 431], ["JHMVinfected mice", "TREATMENT", 448, 465], ["vitro stimulation", "TREATMENT", 475, 492], ["viral antigen", "PROBLEM", 498, 511], ["ConA", "PROBLEM", 515, 519], ["infected", "OBSERVATION", 149, 157], ["brain", "ANATOMY", 158, 163], ["brain", "ANATOMY", 269, 274], ["leukocytes", "OBSERVATION", 421, 431]]], ["However, careful evaluation of these investigations reveals that CNS-extracted leukocytes were assayed only on a single day post infection (day 5) and that compared to unstimulated cells the inducible proliferative response was marginal (2-fold enhancement).", [["CNS", "ANATOMY", 65, 68], ["leukocytes", "ANATOMY", 79, 89], ["cells", "ANATOMY", 181, 186], ["infection", "DISEASE", 129, 138], ["leukocytes", "CELL", 79, 89], ["cells", "CELL", 181, 186], ["leukocytes", "CELL_TYPE", 79, 89], ["unstimulated cells", "CELL_TYPE", 168, 186], ["careful evaluation", "TEST", 9, 27], ["these investigations", "TEST", 31, 51], ["extracted leukocytes", "PROBLEM", 69, 89], ["infection", "PROBLEM", 129, 138], ["unstimulated cells", "TEST", 168, 186], ["marginal (2-fold enhancement", "PROBLEM", 228, 256], ["infection", "OBSERVATION", 129, 138], ["inducible", "OBSERVATION_MODIFIER", 191, 200], ["proliferative", "OBSERVATION_MODIFIER", 201, 214], ["response", "OBSERVATION_MODIFIER", 215, 223], ["marginal", "OBSERVATION_MODIFIER", 228, 236]]], ["In this context, it is most remarkable that we also observed a slight (2-fold) enhancement of virus-inducible proliferation in CNS-extracted leukocytes of LEW and BN rats 4 dpi (Fig. 4) .", [["CNS", "ANATOMY", 127, 130], ["leukocytes", "ANATOMY", 141, 151], ["leukocytes", "CELL", 141, 151], ["LEW", "CELL", 155, 158], ["BN rats", "ORGANISM", 163, 170], ["CNS-extracted leukocytes", "CELL_TYPE", 127, 151], ["rats", "SPECIES", 166, 170], ["a slight (2-fold) enhancement of virus", "PROBLEM", 61, 99], ["inducible proliferation", "PROBLEM", 100, 123], ["slight", "OBSERVATION_MODIFIER", 63, 69], ["inducible proliferation", "OBSERVATION", 100, 123], ["CNS", "ANATOMY", 127, 130]]], ["However, this very low and statistically doubtful induction of proliferation is the only exemption from the rule of proliferative unresponsiveness within 14 dpi.", [["proliferative unresponsiveness", "PROBLEM", 116, 146], ["proliferation", "OBSERVATION", 63, 76], ["proliferative", "OBSERVATION_MODIFIER", 116, 129], ["unresponsiveness", "OBSERVATION", 130, 146]]], ["Probably, a transient increased permissiveness of the blood-brain barrier as observed by us in rats early post intracerebral JHMV infection (D6rries et al., 1986 ) opens a small window allowing a few activated but not fully differentiated T cells to gain access to the brain parenchyma, where they can be detected for a very limited time as a small T cell population reactive to proliferation-inducing signals.DiscussionThe assumption that the majority of CNS-extractable T cells is refractory to further antigen or mitogeninducible proliferation is supported by findings in other animal models.", [["blood-brain barrier", "ANATOMY", 54, 73], ["intracerebral", "ANATOMY", 111, 124], ["T cells", "ANATOMY", 239, 246], ["brain parenchyma", "ANATOMY", 269, 285], ["T cell", "ANATOMY", 349, 355], ["CNS-extractable T cells", "ANATOMY", 456, 479], ["intracerebral JHMV infection", "DISEASE", 111, 139], ["blood-brain barrier", "TISSUE", 54, 73], ["rats", "ORGANISM", 95, 99], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["JHMV", "ORGANISM", 125, 129], ["T cells", "CELL", 239, 246], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 269, 285], ["T cell", "CELL", 349, 355], ["CNS-extractable T cells", "CELL", 456, 479], ["mitogeninducible", "SIMPLE_CHEMICAL", 516, 532], ["T cells", "CELL_TYPE", 239, 246], ["T cell population", "CELL_TYPE", 349, 366], ["CNS-extractable T cells", "CELL_TYPE", 456, 479], ["rats", "SPECIES", 95, 99], ["JHMV", "SPECIES", 125, 129], ["a transient increased permissiveness", "PROBLEM", 10, 46], ["the blood-brain barrier", "PROBLEM", 50, 73], ["intracerebral JHMV infection", "PROBLEM", 111, 139], ["a small window", "PROBLEM", 170, 184], ["a small T cell population", "PROBLEM", 341, 366], ["extractable T cells", "PROBLEM", 460, 479], ["further antigen", "PROBLEM", 497, 512], ["mitogeninducible proliferation", "PROBLEM", 516, 546], ["transient", "OBSERVATION_MODIFIER", 12, 21], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["permissiveness", "OBSERVATION_MODIFIER", 32, 46], ["brain", "ANATOMY", 60, 65], ["intracerebral JHMV", "ANATOMY", 111, 129], ["infection", "OBSERVATION", 130, 139], ["brain", "ANATOMY", 269, 274], ["parenchyma", "ANATOMY_MODIFIER", 275, 285], ["small", "OBSERVATION_MODIFIER", 343, 348], ["CNS", "ANATOMY", 456, 459], ["proliferation", "OBSERVATION", 533, 546]]], ["Nelson et al. (1990) reported low proliferative activity of CD4 \u00f7 T lymphocytes isolated from lungs, and Ohmori et al. (1992) used the bromodeoxyuridine labelling technique to demonstrate in situ that the majority of T lymphocytes in the CNS of LEW rats suffering from EAE do not proliferate.", [["CD4 \u00f7 T lymphocytes", "ANATOMY", 60, 79], ["lungs", "ANATOMY", 94, 99], ["T lymphocytes", "ANATOMY", 217, 230], ["CNS", "ANATOMY", 238, 241], ["bromodeoxyuridine", "CHEMICAL", 135, 152], ["EAE", "DISEASE", 269, 272], ["bromodeoxyuridine", "CHEMICAL", 135, 152], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["lungs", "ORGAN", 94, 99], ["bromodeoxyuridine", "SIMPLE_CHEMICAL", 135, 152], ["T lymphocytes", "CELL", 217, 230], ["CNS", "ANATOMICAL_SYSTEM", 238, 241], ["LEW rats", "ORGANISM", 245, 253], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 60, 79], ["T lymphocytes", "CELL_TYPE", 217, 230], ["rats", "SPECIES", 249, 253], ["low proliferative activity", "PROBLEM", 30, 56], ["the bromodeoxyuridine labelling technique", "TREATMENT", 131, 172], ["EAE", "PROBLEM", 269, 272], ["low proliferative", "OBSERVATION_MODIFIER", 30, 47], ["lungs", "ANATOMY", 94, 99], ["CNS", "ANATOMY", 238, 241]]], ["Moreover, proliferating T lymphocytes that were transferred from EAE animals to healthy syngeneic hosts stopped proliferation after entry into the CNS.", [["T lymphocytes", "ANATOMY", 24, 37], ["CNS", "ANATOMY", 147, 150], ["EAE", "DISEASE", 65, 68], ["T lymphocytes", "CELL", 24, 37], ["syngeneic hosts", "ORGANISM", 88, 103], ["CNS", "ANATOMICAL_SYSTEM", 147, 150], ["proliferating T lymphocytes", "CELL_TYPE", 10, 37], ["proliferating T lymphocytes", "PROBLEM", 10, 37], ["healthy syngeneic hosts", "TREATMENT", 80, 103], ["proliferating T lymphocytes", "OBSERVATION", 10, 37], ["CNS", "ANATOMY", 147, 150]]], ["Recent in vitro data from Matsumoto et al. (1992) suggest that astrocytes probably exhibit inhibitory functions on T lymphocyte proliferation, comparable to alveolar macrophages that probably suppress a proliferative response of non-recirculating T lymphocytes in the lung (Holt, 1986) .DiscussionIn line with these observations, our data add more support to the idea that inside a target organ of lymphoid infiltration priming and expansion of CD4 \u00f7 T lymphocytes is rare.", [["astrocytes", "ANATOMY", 63, 73], ["T lymphocyte", "ANATOMY", 115, 127], ["alveolar macrophages", "ANATOMY", 157, 177], ["T lymphocytes", "ANATOMY", 247, 260], ["lung", "ANATOMY", 268, 272], ["organ", "ANATOMY", 389, 394], ["lymphoid", "ANATOMY", 398, 406], ["CD4 \u00f7 T lymphocytes", "ANATOMY", 445, 464], ["astrocytes", "CELL", 63, 73], ["T lymphocyte", "CELL", 115, 127], ["alveolar macrophages", "CELL", 157, 177], ["T lymphocytes", "CELL", 247, 260], ["lung", "ORGAN", 268, 272], ["organ", "ORGAN", 389, 394], ["lymphoid", "CELL", 398, 406], ["CD4", "GENE_OR_GENE_PRODUCT", 445, 448], ["astrocytes", "CELL_TYPE", 63, 73], ["T lymphocyte", "CELL_TYPE", 115, 127], ["alveolar macrophages", "CELL_TYPE", 157, 177], ["non-recirculating T lymphocytes", "CELL_TYPE", 229, 260], ["CD4 \u00f7 T lymphocytes", "CELL_TYPE", 445, 464], ["astrocytes", "PROBLEM", 63, 73], ["inhibitory functions", "PROBLEM", 91, 111], ["T lymphocyte proliferation", "PROBLEM", 115, 141], ["alveolar macrophages", "PROBLEM", 157, 177], ["non-recirculating T lymphocytes in the lung", "PROBLEM", 229, 272], ["lymphoid infiltration", "PROBLEM", 398, 419], ["CD4", "TEST", 445, 448], ["lymphocyte proliferation", "OBSERVATION", 117, 141], ["alveolar macrophages", "OBSERVATION", 157, 177], ["proliferative", "OBSERVATION_MODIFIER", 203, 216], ["response", "OBSERVATION_MODIFIER", 217, 225], ["non-recirculating T lymphocytes", "OBSERVATION", 229, 260], ["lung", "ANATOMY", 268, 272], ["lymphoid infiltration", "OBSERVATION", 398, 419], ["expansion", "OBSERVATION_MODIFIER", 432, 441]]], ["Under these circumstances the absence of a lymphoid drainage system in the CNS raises the question for the peripheral sites that will allow priming and expansion of CD4 + T lymphocytes that subsequently will enter the CNS.", [["lymphoid", "ANATOMY", 43, 51], ["CNS", "ANATOMY", 75, 78], ["peripheral sites", "ANATOMY", 107, 123], ["CD4 + T lymphocytes", "ANATOMY", 165, 184], ["CNS", "ANATOMY", 218, 221], ["lymphoid", "PATHOLOGICAL_FORMATION", 43, 51], ["CNS", "ANATOMICAL_SYSTEM", 75, 78], ["peripheral sites", "MULTI-TISSUE_STRUCTURE", 107, 123], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["CNS", "ANATOMICAL_SYSTEM", 218, 221], ["CD4", "PROTEIN", 165, 168], ["T lymphocytes", "CELL_TYPE", 171, 184], ["a lymphoid drainage system", "TREATMENT", 41, 67], ["the peripheral sites", "PROBLEM", 103, 123], ["CD4 + T lymphocytes", "PROBLEM", 165, 184], ["lymphoid drainage", "OBSERVATION", 43, 60], ["CNS", "ANATOMY", 75, 78], ["CNS", "ANATOMY", 218, 221]]], ["Data published by Harling-Berg et al. (1989) , Doherty et al. (1990) and Cserr and Knopf (1992) show that CLNs are the most important secondary lymphoid organ collecting antigens applied to the brain.", [["CLNs", "ANATOMY", 106, 110], ["lymphoid organ", "ANATOMY", 144, 158], ["brain", "ANATOMY", 194, 199], ["CLNs", "CANCER", 106, 110], ["lymphoid organ", "TISSUE", 144, 158], ["brain", "ORGAN", 194, 199], ["antigens", "PROTEIN", 170, 178], ["secondary lymphoid organ", "OBSERVATION", 134, 158], ["brain", "ANATOMY", 194, 199]]], ["Most likely, these antigens will leak with cerebrospinal fluid through the cribriform plate where olfactorial nerves cross the bloodbrain barrier and leave the base of the skull to penetrate the mucosa of the nose.", [["cerebrospinal fluid", "ANATOMY", 43, 62], ["cribriform plate", "ANATOMY", 75, 91], ["olfactorial nerves", "ANATOMY", 98, 116], ["bloodbrain barrier", "ANATOMY", 127, 145], ["skull", "ANATOMY", 172, 177], ["mucosa", "ANATOMY", 195, 201], ["nose", "ANATOMY", 209, 213], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 43, 62], ["cribriform plate", "TISSUE", 75, 91], ["olfactorial nerves", "MULTI-TISSUE_STRUCTURE", 98, 116], ["bloodbrain barrier", "TISSUE", 127, 145], ["skull", "ORGAN", 172, 177], ["mucosa", "MULTI-TISSUE_STRUCTURE", 195, 201], ["nose", "ORGAN", 209, 213], ["these antigens will leak", "PROBLEM", 13, 37], ["cerebrospinal fluid through the cribriform plate", "TEST", 43, 91], ["olfactorial nerves", "PROBLEM", 98, 116], ["the bloodbrain barrier", "TREATMENT", 123, 145], ["cerebrospinal fluid", "OBSERVATION", 43, 62], ["cribriform plate", "OBSERVATION", 75, 91], ["olfactorial nerves", "ANATOMY", 98, 116], ["base", "ANATOMY_MODIFIER", 160, 164], ["skull", "ANATOMY", 172, 177], ["mucosa", "ANATOMY", 195, 201], ["nose", "ANATOMY", 209, 213]]], ["From there lymphatic drainage will take antigens to CLNs where priming and differentiation of antigen-specific lymphocytes occur.", [["lymphatic", "ANATOMY", 11, 20], ["CLNs", "ANATOMY", 52, 56], ["lymphocytes", "ANATOMY", 111, 122], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 11, 20], ["antigen", "GENE_OR_GENE_PRODUCT", 94, 101], ["lymphocytes", "CELL", 111, 122], ["CLNs", "CELL_TYPE", 52, 56], ["lymphocytes", "CELL_TYPE", 111, 122], ["lymphatic drainage", "TREATMENT", 11, 29], ["antigen", "TEST", 94, 101], ["specific lymphocytes", "PROBLEM", 102, 122], ["lymphatic", "ANATOMY", 11, 20], ["drainage", "OBSERVATION", 21, 29], ["specific lymphocytes", "OBSERVATION", 102, 122]]], ["Our data from CLNs of JHMV-infected rats are consistent with this hypothesis.", [["CLNs", "ANATOMY", 14, 18], ["CLNs", "CANCER", 14, 18], ["JHMV", "GENE_OR_GENE_PRODUCT", 22, 26], ["rats", "ORGANISM", 36, 40], ["rats", "SPECIES", 36, 40], ["Our data", "TEST", 0, 8], ["JHMV", "TEST", 22, 26], ["infected rats", "PROBLEM", 27, 40], ["this hypothesis", "PROBLEM", 61, 76], ["infected", "OBSERVATION", 27, 35], ["consistent with", "UNCERTAINTY", 45, 60]]], ["T lymphocytes extracted from CLNs of animals that were taken to isolate lymphocytes from the CNS do proliferate ex vivo and can be stimulated to JHMV-specific proliferation in vitro.", [["T lymphocytes", "ANATOMY", 0, 13], ["CLNs", "ANATOMY", 29, 33], ["lymphocytes", "ANATOMY", 72, 83], ["CNS", "ANATOMY", 93, 96], ["T lymphocytes", "CELL", 0, 13], ["CLNs", "CANCER", 29, 33], ["animals", "ORGANISM", 37, 44], ["lymphocytes", "CELL", 72, 83], ["CNS", "ANATOMICAL_SYSTEM", 93, 96], ["JHMV", "CELL", 145, 149], ["T lymphocytes", "CELL_TYPE", 0, 13], ["CLNs", "CELL_TYPE", 29, 33], ["lymphocytes", "CELL_TYPE", 72, 83], ["JHMV", "SPECIES", 145, 149], ["T lymphocytes", "PROBLEM", 0, 13], ["JHMV", "TEST", 145, 149], ["lymphocytes", "OBSERVATION", 2, 13], ["CNS", "ANATOMY", 93, 96], ["proliferation", "OBSERVATION", 159, 172]]], ["Since the dynamics of this CLN response reveal distinct maxima that precede onset as well as recovery from neurological disease, it seems very likely that the clinical course of the infection is closely related to the sensitisation event.", [["neurological", "ANATOMY", 107, 119], ["neurological disease", "DISEASE", 107, 127], ["infection", "DISEASE", 182, 191], ["CLN", "CANCER", 27, 30], ["neurological disease", "PROBLEM", 107, 127], ["the infection", "PROBLEM", 178, 191], ["the sensitisation event", "PROBLEM", 214, 237], ["distinct", "OBSERVATION_MODIFIER", 47, 55], ["maxima", "OBSERVATION_MODIFIER", 56, 62], ["neurological disease", "OBSERVATION", 107, 127], ["seems very likely", "UNCERTAINTY", 132, 149], ["infection", "OBSERVATION", 182, 191]]], ["These relationships are further substantiated by differences between LEW and BN rats with respect to the JHMV-specific in vitro response of CLN lymphocytes.", [["CLN lymphocytes", "ANATOMY", 140, 155], ["LEW", "ORGANISM", 69, 72], ["BN rats", "ORGANISM", 77, 84], ["JHMV", "CANCER", 105, 109], ["CLN lymphocytes", "CELL", 140, 155], ["CLN lymphocytes", "CELL_TYPE", 140, 155], ["rats", "SPECIES", 80, 84], ["the JHMV", "TEST", 101, 109], ["CLN lymphocytes", "PROBLEM", 140, 155], ["CLN lymphocytes", "OBSERVATION", 140, 155]]], ["Whereas in BN rats a strong proliferative response can be provoked by viral antigens early post infection, in LEW rats at the same time only minor virus-specific proliferation was inducible in vitro.", [["infection", "DISEASE", 96, 105], ["BN rats", "ORGANISM", 11, 18], ["LEW rats", "ORGANISM", 110, 118], ["viral antigens", "PROTEIN", 70, 84], ["rats", "SPECIES", 14, 18], ["rats", "SPECIES", 114, 118], ["LEW", "SPECIES", 110, 113], ["viral antigens", "PROBLEM", 70, 84], ["infection", "PROBLEM", 96, 105], ["minor virus", "PROBLEM", 141, 152], ["specific proliferation", "PROBLEM", 153, 175], ["infection", "OBSERVATION", 96, 105], ["minor", "OBSERVATION_MODIFIER", 141, 146], ["virus", "OBSERVATION", 147, 152], ["proliferation", "OBSERVATION", 162, 175]]], ["It is of note, however, that minor in vitro induction of virus-specific proliferation in CLN cells from LEW rats is not due to a general incapability of these cells to proliferate.", [["CLN cells", "ANATOMY", 89, 98], ["cells", "ANATOMY", 159, 164], ["CLN cells", "CELL", 89, 98], ["LEW rats", "ORGANISM", 104, 112], ["cells", "CELL", 159, 164], ["CLN cells", "CELL_TYPE", 89, 98], ["rats", "SPECIES", 108, 112], ["virus", "PROBLEM", 57, 62], ["specific proliferation in CLN cells", "PROBLEM", 63, 98], ["a general incapability of these cells", "PROBLEM", 127, 164], ["CLN cells", "OBSERVATION", 89, 98]]], ["It seems rather the strong ex vivo proliferation of CLN cells from JHMV-infected LEW rats that prevents further enhancement of proliferation by exposure to viral antigens.", [["CLN cells", "ANATOMY", 52, 61], ["CLN cells", "CELL", 52, 61], ["JHMV-infected LEW rats", "ORGANISM", 67, 89], ["CLN cells", "CELL_TYPE", 52, 61], ["viral antigens", "PROTEIN", 156, 170], ["rats", "SPECIES", 85, 89], ["LEW", "SPECIES", 81, 84], ["CLN cells", "PROBLEM", 52, 61], ["JHMV", "TEST", 67, 71], ["infected LEW rats", "TREATMENT", 72, 89], ["proliferation", "PROBLEM", 127, 140], ["viral antigens", "PROBLEM", 156, 170], ["proliferation", "OBSERVATION_MODIFIER", 35, 48], ["CLN cells", "OBSERVATION", 52, 61], ["infected", "OBSERVATION_MODIFIER", 72, 80], ["LEW rats", "OBSERVATION_MODIFIER", 81, 89], ["enhancement", "OBSERVATION_MODIFIER", 112, 123], ["proliferation", "OBSERVATION_MODIFIER", 127, 140]]], ["Thus, it is likely that in contrast to BN rats the T cell compartment of LEW rats responds less specific with a long-lasting broad polyclonal proliferation to the viral challenge.DiscussionAs we have reported previously (D6rries et al., 1991) in infected but healthy BN rats, viral spread in the CNS is limited to few and small periventricular sites.", [["T cell compartment", "ANATOMY", 51, 69], ["CNS", "ANATOMY", 296, 299], ["periventricular sites", "ANATOMY", 328, 349], ["BN rats", "ORGANISM", 39, 46], ["T cell", "CELL", 51, 57], ["LEW rats", "ORGANISM", 73, 81], ["BN rats", "ORGANISM", 267, 274], ["CNS", "ANATOMICAL_SYSTEM", 296, 299], ["periventricular sites", "MULTI-TISSUE_STRUCTURE", 328, 349], ["rats", "SPECIES", 42, 46], ["rats", "SPECIES", 77, 81], ["rats", "SPECIES", 270, 274], ["a long-lasting broad polyclonal proliferation", "PROBLEM", 110, 155], ["the viral challenge", "TREATMENT", 159, 178], ["viral spread in the CNS", "PROBLEM", 276, 299], ["small periventricular sites", "PROBLEM", 322, 349], ["is likely", "UNCERTAINTY", 9, 18], ["polyclonal proliferation", "OBSERVATION", 131, 155], ["viral challenge", "OBSERVATION", 163, 178], ["viral spread", "OBSERVATION", 276, 288], ["CNS", "ANATOMY", 296, 299], ["small", "OBSERVATION_MODIFIER", 322, 327], ["periventricular sites", "OBSERVATION", 328, 349]]], ["In contrast, large virus-infected areas spread through the CNS of LEW rats, including brain stem, cerebellum and spinal cord.", [["CNS", "ANATOMY", 59, 62], ["brain stem", "ANATOMY", 86, 96], ["cerebellum", "ANATOMY", 98, 108], ["spinal cord", "ANATOMY", 113, 124], ["large virus", "ORGANISM", 13, 24], ["CNS", "ANATOMICAL_SYSTEM", 59, 62], ["LEW rats", "ORGANISM", 66, 74], ["brain stem", "TISSUE", 86, 96], ["cerebellum", "ORGAN", 98, 108], ["spinal cord", "ORGAN", 113, 124], ["rats", "SPECIES", 70, 74], ["LEW", "SPECIES", 66, 69], ["large virus", "PROBLEM", 13, 24], ["brain stem, cerebellum and spinal cord", "PROBLEM", 86, 124], ["large", "OBSERVATION_MODIFIER", 13, 18], ["virus", "OBSERVATION", 19, 24], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["CNS", "ANATOMY", 59, 62], ["LEW rats", "OBSERVATION", 66, 74], ["brain stem", "ANATOMY", 86, 96], ["cerebellum", "ANATOMY", 98, 108], ["spinal cord", "ANATOMY", 113, 124]]], ["Most likely, restricted viral spread in the BN rat is associated with the humoral immune response because virus-specific antibody-secreting plasma cells rapidly increase in the brain parenchyma post infection, whereas LEW rats show a considerable delay in the appearance of such cells in the CNS .", [["plasma cells", "ANATOMY", 140, 152], ["brain parenchyma", "ANATOMY", 177, 193], ["cells", "ANATOMY", 279, 284], ["CNS", "ANATOMY", 292, 295], ["infection", "DISEASE", 199, 208], ["BN rat", "ORGANISM", 44, 50], ["antibody", "GENE_OR_GENE_PRODUCT", 121, 129], ["plasma cells", "CELL", 140, 152], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 177, 193], ["LEW rats", "ORGANISM", 218, 226], ["cells", "CELL", 279, 284], ["CNS", "ANATOMICAL_SYSTEM", 292, 295], ["secreting plasma cells", "CELL_TYPE", 130, 152], ["rat", "SPECIES", 47, 50], ["rats", "SPECIES", 222, 226], ["rat", "SPECIES", 47, 50], ["restricted viral spread", "PROBLEM", 13, 36], ["the humoral immune response", "TEST", 70, 97], ["virus", "TEST", 106, 111], ["specific antibody", "TEST", 112, 129], ["secreting plasma cells", "PROBLEM", 130, 152], ["infection", "PROBLEM", 199, 208], ["LEW rats", "TEST", 218, 226], ["a considerable delay", "PROBLEM", 232, 252], ["such cells in the CNS", "PROBLEM", 274, 295], ["restricted", "OBSERVATION_MODIFIER", 13, 23], ["viral spread", "OBSERVATION", 24, 36], ["secreting plasma cells", "OBSERVATION", 130, 152], ["increase", "OBSERVATION_MODIFIER", 161, 169], ["brain", "ANATOMY", 177, 182], ["parenchyma", "ANATOMY_MODIFIER", 183, 193], ["infection", "OBSERVATION", 199, 208], ["considerable", "OBSERVATION_MODIFIER", 234, 246], ["delay", "OBSERVATION_MODIFIER", 247, 252], ["such cells", "OBSERVATION", 274, 284], ["CNS", "ANATOMY", 292, 295]]], ["Additionally, more of these plasma cells can be recovered from the infected BN brain and their capacity to secrete virus-specific antibodies as determined on a single-cell basis is much higher compared to LEW rats.", [["plasma cells", "ANATOMY", 28, 40], ["BN brain", "ANATOMY", 76, 84], ["cell", "ANATOMY", 167, 171], ["plasma cells", "CELL", 28, 40], ["BN", "ORGANISM", 76, 78], ["brain", "ORGAN", 79, 84], ["cell", "CELL", 167, 171], ["LEW rats", "ORGANISM", 205, 213], ["plasma cells", "CELL_TYPE", 28, 40], ["virus-specific antibodies", "PROTEIN", 115, 140], ["rats", "SPECIES", 209, 213], ["these plasma cells", "PROBLEM", 22, 40], ["the infected BN brain", "PROBLEM", 63, 84], ["secrete virus", "PROBLEM", 107, 120], ["a single-cell basis", "TEST", 158, 177], ["plasma cells", "OBSERVATION", 28, 40], ["infected", "OBSERVATION", 67, 75], ["brain", "ANATOMY", 79, 84], ["secrete virus", "OBSERVATION", 107, 120]]], ["These differences result in a rapid accumulation of virus-specific neutralising antibodies in the cerebrospinal fluid of BN rats .", [["cerebrospinal fluid", "ANATOMY", 98, 117], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 98, 117], ["BN rats", "ORGANISM", 121, 128], ["neutralising antibodies", "PROTEIN", 67, 90], ["rats", "SPECIES", 124, 128], ["a rapid accumulation of virus", "PROBLEM", 28, 57], ["specific neutralising antibodies", "PROBLEM", 58, 90], ["the cerebrospinal fluid", "TEST", 94, 117], ["rapid", "OBSERVATION_MODIFIER", 30, 35], ["accumulation", "OBSERVATION_MODIFIER", 36, 48], ["virus", "OBSERVATION", 52, 57], ["neutralising antibodies", "OBSERVATION", 67, 90], ["cerebrospinal", "ANATOMY", 98, 111], ["fluid", "OBSERVATION", 112, 117]]], ["Differentiation of B lymphocytes into antibody-secreting plasma cells is highly dependent on the help from interleukins provided by T lymphocytes expressing the CD4, a//3 T cell antigen receptor (a//3 TCR) phenotype.", [["B lymphocytes", "ANATOMY", 19, 32], ["plasma cells", "ANATOMY", 57, 69], ["T lymphocytes", "ANATOMY", 132, 145], ["B lymphocytes", "CELL", 19, 32], ["antibody", "GENE_OR_GENE_PRODUCT", 38, 46], ["plasma cells", "CELL", 57, 69], ["interleukins", "GENE_OR_GENE_PRODUCT", 107, 119], ["T lymphocytes", "CELL", 132, 145], ["CD4", "GENE_OR_GENE_PRODUCT", 161, 164], ["T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 171, 194], ["TCR", "GENE_OR_GENE_PRODUCT", 201, 204], ["B lymphocytes", "CELL_TYPE", 19, 32], ["antibody-secreting plasma cells", "CELL_TYPE", 38, 69], ["interleukins", "PROTEIN", 107, 119], ["T lymphocytes", "CELL_TYPE", 132, 145], ["CD4", "PROTEIN", 161, 164], ["T cell antigen receptor", "PROTEIN", 171, 194], ["TCR", "PROTEIN", 201, 204], ["Differentiation of B lymphocytes into antibody", "TEST", 0, 46], ["secreting plasma cells", "PROBLEM", 47, 69], ["interleukins", "TEST", 107, 119], ["T lymphocytes", "TEST", 132, 145], ["the CD4", "TEST", 157, 164], ["phenotype", "PROBLEM", 206, 215], ["B lymphocytes", "OBSERVATION", 19, 32], ["highly dependent", "OBSERVATION_MODIFIER", 73, 89]]], ["Hence, the observed differences between BN and LEW rats with respect to kinetics, magnitude and quality of virus-specific antibody responses in the CNS could possibly be explained by the more rapid and specific sensitisation of the CD4 +, a//3 TCR + T lymphocyte fraction in CLNs of BN rats.", [["CNS", "ANATOMY", 148, 151], ["CD4 +, a//3 TCR + T lymphocyte", "ANATOMY", 232, 262], ["CLNs", "ANATOMY", 275, 279], ["LEW rats", "ORGANISM", 47, 55], ["CNS", "ANATOMICAL_SYSTEM", 148, 151], ["CD4", "GENE_OR_GENE_PRODUCT", 232, 235], ["TCR", "GENE_OR_GENE_PRODUCT", 244, 247], ["CLNs", "PATHOLOGICAL_FORMATION", 275, 279], ["BN rats", "ORGANISM", 283, 290], ["CD4", "PROTEIN", 232, 235], ["TCR", "PROTEIN", 244, 247], ["CLNs", "CELL_TYPE", 275, 279], ["rats", "SPECIES", 51, 55], ["rats", "SPECIES", 286, 290], ["BN and LEW rats", "TREATMENT", 40, 55], ["virus", "PROBLEM", 107, 112], ["specific antibody responses", "TEST", 113, 140], ["the CD4", "TEST", 228, 235], ["lymphocyte fraction", "OBSERVATION", 252, 271]]], ["However, since there is no simple quantitative relationship between local virus-specific antibody response and CNS-invading CD4 +, a//3 TCR + T lymphocytes, this hypothesis remains to be clarified on a qualitative basis.DiscussionIn conclusion, CLNs are an important site of T lymphocyte priming and expansion during virus-induced encephalitis.", [["CNS", "ANATOMY", 111, 114], ["CD4 +, a//3 TCR + T lymphocytes", "ANATOMY", 124, 155], ["CLNs", "ANATOMY", 245, 249], ["T lymphocyte", "ANATOMY", 275, 287], ["encephalitis", "DISEASE", 331, 343], ["CNS", "ANATOMICAL_SYSTEM", 111, 114], ["CD4", "GENE_OR_GENE_PRODUCT", 124, 127], ["TCR", "GENE_OR_GENE_PRODUCT", 136, 139], ["CLNs", "CANCER", 245, 249], ["T lymphocyte", "CELL", 275, 287], ["CD4", "PROTEIN", 124, 127], ["TCR", "PROTEIN", 136, 139], ["T lymphocytes", "CELL_TYPE", 142, 155], ["simple quantitative relationship between local virus", "PROBLEM", 27, 79], ["specific antibody response", "TEST", 80, 106], ["CNS", "TEST", 111, 114], ["invading CD4", "TEST", 115, 127], ["T lymphocyte priming", "TREATMENT", 275, 295], ["expansion during virus", "PROBLEM", 300, 322], ["encephalitis", "PROBLEM", 331, 343], ["no", "UNCERTAINTY", 24, 26], ["encephalitis", "OBSERVATION", 331, 343]]], ["Speed and intensity of T cell sensitisation in these organs are most likely of major importance for the clinical outcome of the infection.", [["T cell", "ANATOMY", 23, 29], ["organs", "ANATOMY", 53, 59], ["infection", "DISEASE", 128, 137], ["T cell", "CELL", 23, 29], ["organs", "ORGAN", 53, 59], ["T cell sensitisation", "PROBLEM", 23, 43], ["the infection", "PROBLEM", 124, 137], ["T cell sensitisation", "OBSERVATION", 23, 43], ["organs", "ANATOMY", 53, 59], ["most likely", "UNCERTAINTY", 64, 75], ["infection", "OBSERVATION", 128, 137]]], ["Primed T lymphocytes enter the CNS and acquire a state of unresponsiveness to antigen-or mitogen-induced proliferation by a yet unknown regulatory event.", [["T lymphocytes", "ANATOMY", 7, 20], ["CNS", "ANATOMY", 31, 34], ["T lymphocytes", "CELL", 7, 20], ["CNS", "ANATOMICAL_SYSTEM", 31, 34], ["antigen", "GENE_OR_GENE_PRODUCT", 78, 85], ["Primed T lymphocytes", "CELL_TYPE", 0, 20], ["mitogen", "PROTEIN", 89, 96], ["unresponsiveness", "PROBLEM", 58, 74], ["antigen", "TEST", 78, 85], ["mitogen-induced proliferation", "PROBLEM", 89, 118], ["CNS", "ANATOMY", 31, 34]]], ["Of course, this silent state with respect to proliferation does not necessarily exclude secretion of cytokines by these cells.", [["cells", "ANATOMY", 120, 125], ["cells", "CELL", 120, 125], ["cytokines", "PROTEIN", 101, 110], ["secretion of cytokines", "PROBLEM", 88, 110]]], ["Preliminary, so far unpublished investigations of cytokine-specific mRNA expression performed in our laboratory by RT PCR on CNS extracted leukocytes revealed a strong interferon-y response in the CNS of both LEW and BN rats.", [["CNS", "ANATOMY", 125, 128], ["leukocytes", "ANATOMY", 139, 149], ["CNS", "ANATOMY", 197, 200], ["leukocytes", "CELL", 139, 149], ["interferon-y", "GENE_OR_GENE_PRODUCT", 168, 180], ["CNS", "ANATOMICAL_SYSTEM", 197, 200], ["LEW", "ORGANISM", 209, 212], ["BN rats", "ORGANISM", 217, 224], ["cytokine", "PROTEIN", 50, 58], ["leukocytes", "CELL_TYPE", 139, 149], ["interferon", "PROTEIN", 168, 178], ["rats", "SPECIES", 220, 224], ["cytokine", "TEST", 50, 58], ["RT PCR", "TEST", 115, 121], ["CNS extracted leukocytes", "TEST", 125, 149]]], ["Thus, future examinations of functional properties of CNS-infiltrating CD4 + T cells especially with respect to interleukin secretion and to consequences of their possible interaction with upregulated MHC class II molecules on CNS-resident cells will further elucidate their important role as effector cells in virus-induced demyelinating encephalomyelitis.", [["CNS-infiltrating CD4 + T cells", "ANATOMY", 54, 84], ["CNS-resident cells", "ANATOMY", 227, 245], ["effector cells", "ANATOMY", 293, 307], ["demyelinating encephalomyelitis", "DISEASE", 325, 356], ["CNS-infiltrating CD4 + T cells", "CELL", 54, 84], ["interleukin", "GENE_OR_GENE_PRODUCT", 112, 123], ["CNS-resident cells", "CELL", 227, 245], ["cells", "CELL", 302, 307], ["CNS-infiltrating CD4 + T cells", "CELL_TYPE", 54, 84], ["interleukin", "PROTEIN", 112, 123], ["MHC class II molecules", "PROTEIN", 201, 223], ["CNS-resident cells", "CELL_TYPE", 227, 245], ["effector cells", "CELL_TYPE", 293, 307], ["future examinations", "TEST", 6, 25], ["CNS", "TEST", 54, 57], ["infiltrating CD4 + T cells", "PROBLEM", 58, 84], ["interleukin secretion", "PROBLEM", 112, 133], ["effector cells in virus", "PROBLEM", 293, 316], ["demyelinating encephalomyelitis", "PROBLEM", 325, 356], ["CNS", "ANATOMY", 54, 57], ["demyelinating encephalomyelitis", "OBSERVATION", 325, 356]]]], "26d4e19371510c820a20cff9f1cc446f3597d66a": [["INTRODUCTIONA novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was recently identified as the pathogen that causes the potentially life-threatening disease called coronavirus disease 2019 , which has rapidly spread across the world.", [["coronavirus", "DISEASE", 20, 31], ["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["coronavirus disease", "DISEASE", 195, 214], ["coronavirus", "ORGANISM", 20, 31], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 33, 80], ["SARS-CoV-2", "ORGANISM", 82, 92], ["coronavirus", "ORGANISM", 195, 206], ["coronavirus", "SPECIES", 20, 31], ["severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV-2", "SPECIES", 82, 92], ["novel coronavirus", "PROBLEM", 14, 31], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 33, 78], ["SARS-CoV", "TEST", 82, 90], ["the pathogen", "PROBLEM", 122, 134], ["threatening disease", "PROBLEM", 168, 187], ["coronavirus disease", "PROBLEM", 195, 214], ["coronavirus", "OBSERVATION", 20, 31], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome coronavirus", "OBSERVATION", 46, 78], ["coronavirus disease", "OBSERVATION", 195, 214]]], ["Currently there are no vaccines or therapeutics approved to prevent SARS-CoV-2 infection or to treat COVID-19.INTRODUCTIONRecently remdesivir, the prodrug of an adenosine nucleotide analog, originally developed for the treatment of Ebola virus infections, has demonstrated potent in vitro activity against SARS-CoV-2 (Wang et al., 2020) and has shown sufficient promise in the treatment of COVID-19 patients (Beigel et al., 2020) such that the FDA has granted Emergency Use Authorization to this nucleotide prodrug.", [["SARS-CoV-2 infection", "DISEASE", 68, 88], ["COVID-19.INTRODUCTIONRecently remdesivir", "CHEMICAL", 101, 141], ["adenosine nucleotide", "CHEMICAL", 161, 181], ["Ebola virus infections", "DISEASE", 232, 254], ["nucleotide", "CHEMICAL", 496, 506], ["remdesivir", "CHEMICAL", 131, 141], ["adenosine nucleotide", "CHEMICAL", 161, 181], ["nucleotide", "CHEMICAL", 496, 506], ["SARS-CoV-2", "ORGANISM", 68, 78], ["COVID-19.INTRODUCTIONRecently remdesivir", "SIMPLE_CHEMICAL", 101, 141], ["adenosine nucleotide", "SIMPLE_CHEMICAL", 161, 181], ["Ebola virus", "ORGANISM", 232, 243], ["SARS-CoV-2", "ORGANISM", 306, 316], ["patients", "ORGANISM", 399, 407], ["Ebola virus", "SPECIES", 232, 243], ["patients", "SPECIES", 399, 407], ["SARS-CoV-2", "SPECIES", 68, 78], ["Ebola virus", "SPECIES", 232, 243], ["SARS-CoV", "SPECIES", 306, 314], ["vaccines", "TREATMENT", 23, 31], ["therapeutics", "TREATMENT", 35, 47], ["SARS", "PROBLEM", 68, 72], ["CoV", "PROBLEM", 73, 76], ["2 infection", "PROBLEM", 77, 88], ["COVID", "TEST", 101, 106], ["remdesivir", "TREATMENT", 131, 141], ["an adenosine nucleotide analog", "TREATMENT", 158, 188], ["Ebola virus infections", "PROBLEM", 232, 254], ["SARS", "PROBLEM", 306, 310], ["COVID", "TEST", 390, 395], ["this nucleotide prodrug", "TREATMENT", 491, 514], ["no", "UNCERTAINTY", 20, 22], ["Ebola virus", "OBSERVATION", 232, 243], ["potent", "OBSERVATION_MODIFIER", 273, 279]]], ["The limited oral bioavailability of remdesivir (Eastman et al., 2020) , however, requires that it be administered via intravenous infusion, thus limiting its use to hospitalized patients.", [["oral", "ANATOMY", 12, 16], ["intravenous", "ANATOMY", 118, 129], ["remdesivir", "CHEMICAL", 36, 46], ["remdesivir", "CHEMICAL", 36, 46], ["oral", "ORGANISM_SUBDIVISION", 12, 16], ["remdesivir", "SIMPLE_CHEMICAL", 36, 46], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 129], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["intravenous infusion", "TREATMENT", 118, 138]]], ["COVID-19 is an acute viral infection for which antiviral therapeutics will be most effective within the first stage of the infection when viral load is at its maximum, with rapid viral replication initially in nasal, throat and pulmonary cells (Mason, 2020) .", [["nasal", "ANATOMY", 210, 215], ["throat", "ANATOMY", 217, 223], ["pulmonary cells", "ANATOMY", 228, 243], ["COVID-19", "CHEMICAL", 0, 8], ["viral infection", "DISEASE", 21, 36], ["infection", "DISEASE", 123, 132], ["nasal", "ORGANISM_SUBDIVISION", 210, 215], ["pulmonary cells", "CELL", 228, 243], ["pulmonary cells", "CELL_TYPE", 228, 243], ["COVID", "TEST", 0, 5], ["an acute viral infection", "PROBLEM", 12, 36], ["antiviral therapeutics", "TREATMENT", 47, 69], ["the infection", "PROBLEM", 119, 132], ["viral load", "PROBLEM", 138, 148], ["rapid viral replication", "PROBLEM", 173, 196], ["nasal, throat and pulmonary cells", "PROBLEM", 210, 243], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["viral", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 123, 132], ["viral replication", "OBSERVATION", 179, 196], ["nasal", "ANATOMY", 210, 215], ["throat", "ANATOMY", 217, 223], ["pulmonary cells", "ANATOMY", 228, 243]]], ["Only the availability of a potent, safe, oral antiviral administered to SARS-CoV-2 infected individuals in their early stage of disease will avert clinical illness and mitigate the COVID-19 pandemic.INTRODUCTIONAT-527, an oral double prodrug of a guanosine nucleotide analog, has demonstrated potent in vitro activity against clinical isolates of hepatitis C virus (HCV) by inhibiting the RNA-dependent RNA polymerase (RdRp) .", [["oral", "ANATOMY", 41, 45], ["oral", "ANATOMY", 222, 226], ["SARS-CoV-2 infected", "DISEASE", 72, 91], ["INTRODUCTIONAT-527", "CHEMICAL", 199, 217], ["guanosine nucleotide", "CHEMICAL", 247, 267], ["hepatitis C", "DISEASE", 347, 358], ["INTRODUCTIONAT-527", "CHEMICAL", 199, 217], ["guanosine nucleotide", "CHEMICAL", 247, 267], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["SARS-CoV-2", "ORGANISM", 72, 82], ["individuals", "ORGANISM", 92, 103], ["INTRODUCTIONAT-527", "SIMPLE_CHEMICAL", 199, 217], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["guanosine nucleotide", "SIMPLE_CHEMICAL", 247, 267], ["hepatitis C virus", "ORGANISM", 347, 364], ["HCV", "ORGANISM", 366, 369], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 389, 417], ["RNA-dependent RNA polymerase", "PROTEIN", 389, 417], ["RdRp", "PROTEIN", 419, 423], ["CoV-2", "SPECIES", 77, 82], ["hepatitis C virus", "SPECIES", 347, 364], ["SARS-CoV", "SPECIES", 72, 80], ["hepatitis C virus", "SPECIES", 347, 364], ["HCV", "SPECIES", 366, 369], ["oral antiviral", "TREATMENT", 41, 55], ["disease", "PROBLEM", 128, 135], ["clinical illness", "PROBLEM", 147, 163], ["the COVID", "TEST", 177, 186], ["pandemic", "PROBLEM", 190, 198], ["an oral double prodrug", "TREATMENT", 219, 241], ["a guanosine nucleotide analog", "TREATMENT", 245, 274], ["hepatitis C virus (HCV)", "PROBLEM", 347, 370], ["early stage", "OBSERVATION_MODIFIER", 113, 124], ["disease", "OBSERVATION", 128, 135], ["hepatitis", "OBSERVATION", 347, 356]]], ["Supported by a comprehensive preclinical toxicology and safety pharmacology package, AT-527 has recently been evaluated in a Phase 1B study (Berliba et al., 2019) and a Phase 2 clinical trial (Mungar, et al. 2020 ).", [["AT-527", "CHEMICAL", 85, 91], ["AT-527", "CHEMICAL", 85, 91], ["AT-527", "SIMPLE_CHEMICAL", 85, 91], ["a Phase 1B study", "TEST", 123, 139]]], ["In the latter study, AT-527 was safe and well-tolerated for up to 12 weeks in HCV-infected subjects and achieved a high rate of efficacy.", [["AT-527", "CHEMICAL", 21, 27], ["HCV-infected", "DISEASE", 78, 90], ["AT-527", "CHEMICAL", 21, 27], ["AT-527", "SIMPLE_CHEMICAL", 21, 27], ["HCV", "ORGANISM", 78, 81], ["subjects", "ORGANISM", 91, 99], ["HCV", "SPECIES", 78, 81], ["the latter study", "TEST", 3, 19], ["HCV", "PROBLEM", 78, 81], ["infected", "OBSERVATION", 82, 90]]], ["Amid the SARS-CoV-2 pandemic, the activity of AT-511, the free base of AT-527, was tested in vitro against several human coronaviruses, including SARS-CoV-2.RESULTSIn an initial screening, BHK-21 cells acutely infected with a seasonal human alpha coronavirus, HCoV-229E, were exposed to serial dilutions of AT-511.", [["BHK-21 cells", "ANATOMY", 189, 201], ["SARS", "DISEASE", 9, 13], ["AT-511", "CHEMICAL", 46, 52], ["AT-527", "CHEMICAL", 71, 77], ["HCoV-229E", "CHEMICAL", 260, 269], ["AT-511", "CHEMICAL", 307, 313], ["AT-511", "CHEMICAL", 46, 52], ["AT-527", "CHEMICAL", 71, 77], ["AT-511", "CHEMICAL", 307, 313], ["SARS-CoV-2", "ORGANISM", 9, 19], ["AT-511", "SIMPLE_CHEMICAL", 46, 52], ["AT-527", "SIMPLE_CHEMICAL", 71, 77], ["human", "ORGANISM", 115, 120], ["SARS-CoV-2", "ORGANISM", 146, 156], ["BHK-21 cells", "CELL", 189, 201], ["human", "ORGANISM", 235, 240], ["alpha coronavirus", "ORGANISM", 241, 258], ["HCoV-229E", "CELL", 260, 269], ["AT-511", "SIMPLE_CHEMICAL", 307, 313], ["BHK-21 cells", "CELL_LINE", 189, 201], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 235, 240], ["coronavirus", "SPECIES", 247, 258], ["human coronaviruses", "SPECIES", 115, 134], ["SARS-CoV", "SPECIES", 146, 154], ["BHK-21", "SPECIES", 189, 195], ["human alpha coronavirus", "SPECIES", 235, 258], ["HCoV-229E", "SPECIES", 260, 269], ["the SARS", "TEST", 5, 13], ["CoV", "TEST", 14, 17], ["pandemic", "PROBLEM", 20, 28], ["several human coronaviruses", "PROBLEM", 107, 134], ["SARS", "TEST", 146, 150], ["CoV", "TEST", 151, 154], ["an initial screening", "TEST", 167, 187], ["BHK", "TEST", 189, 192], ["acutely infected", "PROBLEM", 202, 218], ["a seasonal human alpha coronavirus", "PROBLEM", 224, 258], ["HCoV", "TEST", 260, 264], ["serial dilutions", "TEST", 287, 303], ["SARS", "OBSERVATION", 9, 13], ["coronaviruses", "OBSERVATION", 121, 134], ["infected", "OBSERVATION", 210, 218], ["alpha coronavirus", "OBSERVATION", 241, 258]]], ["After a 3-day incubation, the effective concentration of AT-511 required to achieve 50% inhibition (EC50) of the virus-induced cytopathic effect (CPE) from two independent experiments averaged 1.8 \u00b5M (Table 1 ).", [["AT-511", "CHEMICAL", 57, 63], ["AT-511", "CHEMICAL", 57, 63], ["AT-511", "SIMPLE_CHEMICAL", 57, 63], ["the virus", "PROBLEM", 109, 118], ["cytopathic effect (CPE", "PROBLEM", 127, 149], ["cytopathic", "OBSERVATION_MODIFIER", 127, 137]]], ["In contrast, the 2'fluoro-2'-methyl uridine nucleotide prodrug sofosbuvir did not inhibit HCoV-229E replication at concentrations as high as 100 \u00b5M.", [["HCoV-229E", "ANATOMY", 90, 99], ["2'fluoro-2'-methyl uridine", "CHEMICAL", 17, 43], ["nucleotide", "CHEMICAL", 44, 54], ["sofosbuvir", "CHEMICAL", 63, 73], ["HCoV-229E", "CHEMICAL", 90, 99], ["2'fluoro-2'-methyl uridine nucleotide", "CHEMICAL", 17, 54], ["sofosbuvir", "CHEMICAL", 63, 73], ["2'fluoro-2'-methyl uridine nucleotide prodrug", "SIMPLE_CHEMICAL", 17, 62], ["sofosbuvir", "SIMPLE_CHEMICAL", 63, 73], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 90, 99], ["HCoV-229E", "SPECIES", 90, 99], ["the 2'fluoro", "TREATMENT", 13, 25], ["methyl uridine nucleotide prodrug sofosbuvir", "TREATMENT", 29, 73], ["HCoV", "TEST", 90, 94]]], ["No toxicity was detected from either drug.RESULTSThe in vitro potency of AT-511 against HCoV-229E, HCoV-OC43 (another seasonal human coronavirus strain), MERS-CoV and SARS-CoV was then evaluated in Huh-7 cell-based assays.", [["HCoV-229E", "ANATOMY", 88, 97], ["HCoV-OC43", "ANATOMY", 99, 108], ["Huh-7 cell", "ANATOMY", 198, 208], ["toxicity", "DISEASE", 3, 11], ["AT-511", "CHEMICAL", 73, 79], ["HCoV-229E", "CHEMICAL", 88, 97], ["AT-511", "CHEMICAL", 73, 79], ["AT-511", "SIMPLE_CHEMICAL", 73, 79], ["HCoV-229E", "CELL", 88, 97], ["HCoV-OC43", "CELL", 99, 108], ["human", "ORGANISM", 127, 132], ["coronavirus strain", "ORGANISM", 133, 151], ["MERS-CoV", "ORGANISM", 154, 162], ["SARS-CoV", "ORGANISM", 167, 175], ["Huh-7 cell", "CELL", 198, 208], ["human", "SPECIES", 127, 132], ["coronavirus", "SPECIES", 133, 144], ["HCoV-229E", "SPECIES", 88, 97], ["HCoV", "SPECIES", 99, 103], ["human coronavirus", "SPECIES", 127, 144], ["MERS-CoV", "SPECIES", 154, 162], ["SARS-CoV", "SPECIES", 167, 175], ["toxicity", "PROBLEM", 3, 11], ["HCoV", "TEST", 88, 92], ["HCoV", "TEST", 99, 103], ["OC43", "PROBLEM", 104, 108], ["another seasonal human coronavirus strain", "PROBLEM", 110, 151], ["MERS-CoV", "PROBLEM", 154, 162], ["SARS", "PROBLEM", 167, 171], ["CoV", "PROBLEM", 172, 175], ["Huh", "TEST", 198, 201], ["toxicity", "OBSERVATION", 3, 11]]], ["This human hepatocarcinoma cell line was selected based on its ability to activate AT-511 intracellularly to its triphosphate metabolite, unlike MRC-5 cells in which AT-511 lacked activity against HCoV-229E (EC50 >100 \u00b5M; Good et al., 2020) .", [["hepatocarcinoma cell line", "ANATOMY", 11, 36], ["MRC-5 cells", "ANATOMY", 145, 156], ["hepatocarcinoma", "DISEASE", 11, 26], ["AT-511", "CHEMICAL", 83, 89], ["triphosphate", "CHEMICAL", 113, 125], ["AT-511", "CHEMICAL", 166, 172], ["HCoV-229E", "CHEMICAL", 197, 206], ["AT-511", "CHEMICAL", 83, 89], ["triphosphate", "CHEMICAL", 113, 125], ["human", "ORGANISM", 5, 10], ["hepatocarcinoma cell line", "CELL", 11, 36], ["AT-511", "GENE_OR_GENE_PRODUCT", 83, 89], ["triphosphate", "SIMPLE_CHEMICAL", 113, 125], ["MRC-5 cells", "CELL", 145, 156], ["HCoV-229E", "CELL", 197, 206], ["human hepatocarcinoma cell line", "CELL_LINE", 5, 36], ["MRC-5 cells", "CELL_LINE", 145, 156], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["HCoV-229E", "SPECIES", 197, 206], ["This human hepatocarcinoma cell line", "TREATMENT", 0, 36], ["its triphosphate metabolite", "TEST", 109, 136], ["MRC", "TEST", 145, 148], ["HCoV", "TEST", 197, 201], ["EC50", "TEST", 208, 212], ["hepatocarcinoma cell line", "OBSERVATION", 11, 36]]], ["Antiviral activity was assessed by two different methods after exposure of Huh-7 cells to virus and serial dilutions of test compound by determining 1) the EC50 for virus-induced CPE by neutral red dye staining after a 5-day (229E and OC43) or 7-day (MERS and SARS) incubation and 2) the effective concentration required to reduce secretion of infectious virus into the culture medium by 90% (EC90) after a 3-day incubation using a standard endpoint dilution CCID50 assay to determine virus yield reduction (VYR).", [["Huh-7 cells", "ANATOMY", 75, 86], ["Huh-7 cells", "CELL", 75, 86], ["Huh-7 cells", "CELL_LINE", 75, 86], ["Huh-7", "SPECIES", 75, 80], ["Antiviral activity", "TREATMENT", 0, 18], ["Huh-7 cells", "TREATMENT", 75, 86], ["virus", "TREATMENT", 90, 95], ["serial dilutions of test compound", "TEST", 100, 133], ["the EC50", "TEST", 152, 160], ["virus", "PROBLEM", 165, 170], ["CPE", "PROBLEM", 179, 182], ["neutral red dye staining", "PROBLEM", 186, 210], ["OC43", "TEST", 235, 239], ["the effective concentration", "TREATMENT", 284, 311], ["secretion of infectious virus", "PROBLEM", 331, 360], ["the culture", "TEST", 366, 377], ["a standard endpoint dilution CCID50 assay", "TREATMENT", 430, 471], ["infectious", "OBSERVATION", 344, 354]]], ["Half-maximal cytotoxicity (CC50) was measured by neutral red staining of compound-treated duplicates in the absence of virus.", [["neutral red staining of compound", "PROBLEM", 49, 81], ["virus", "PROBLEM", 119, 124], ["virus", "OBSERVATION", 119, 124]]], ["Although a robust VYR endpoint was obtained in Huh-7 cells infected with HCoV-OC43 or SARS-CoV, CPE was not observed and EC50 values using neutral red staining were not obtained with these viruses.", [["Huh-7 cells", "ANATOMY", 47, 58], ["VYR", "CANCER", 18, 21], ["Huh-7 cells", "CELL", 47, 58], ["HCoV-OC43", "CELL", 73, 82], ["SARS-CoV", "ORGANISM", 86, 94], ["CPE", "ORGANISM", 96, 99], ["Huh-7 cells", "CELL_LINE", 47, 58], ["Huh-7", "SPECIES", 47, 52], ["HCoV", "SPECIES", 73, 77], ["SARS-CoV", "SPECIES", 86, 94], ["a robust VYR endpoint", "TEST", 9, 30], ["Huh", "TEST", 47, 50], ["HCoV", "TEST", 73, 77], ["OC43", "PROBLEM", 78, 82], ["SARS", "PROBLEM", 86, 90], ["CPE", "TEST", 96, 99], ["EC50 values", "TEST", 121, 132], ["neutral red staining", "TEST", 139, 159], ["these viruses", "PROBLEM", 183, 196], ["viruses", "OBSERVATION", 189, 196]]], ["Individual determinations of EC90 values for AT-511 against HCoV-229E, HCoV-OC43 and SARS-CoV ranged from 0.34 to 1.2 \u00b5M, whereas the value against MERS-CoV averaged 37 \u00b5M (Table 1) .", [["AT-511", "CHEMICAL", 45, 51], ["HCoV-229E", "CHEMICAL", 60, 69], ["SARS", "DISEASE", 85, 89], ["AT-511", "SIMPLE_CHEMICAL", 45, 51], ["HCoV-229E", "ORGANISM", 60, 69], ["HCoV-OC43", "ORGANISM", 71, 80], ["SARS-CoV", "ORGANISM", 85, 93], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 148, 156], ["HCoV-229E", "SPECIES", 60, 69], ["SARS-CoV", "SPECIES", 85, 93], ["MERS-CoV", "SPECIES", 148, 156], ["Individual determinations", "TEST", 0, 25], ["EC90 values", "TEST", 29, 40], ["HCoV", "TEST", 60, 64], ["HCoV", "TEST", 71, 75], ["OC43", "TEST", 76, 80], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["the value", "TEST", 130, 139], ["MERS", "TEST", 148, 152], ["CoV", "TEST", 153, 156]]], ["No cytotoxicity was detected with AT-511 up to 86 \u00b5M, the highest concentration tested.RESULTSChloroquine and hydroxychloroquine appeared to be quite potent against HCoV-229E and HCoV-OC43 based on their EC90 values of <0.05 \u00b5M obtained using VYR measurements (Table 1 ).", [["AT-511", "CHEMICAL", 34, 40], ["RESULTSChloroquine", "CHEMICAL", 87, 105], ["hydroxychloroquine", "CHEMICAL", 110, 128], ["AT-511", "CHEMICAL", 34, 40], ["RESULTSChloroquine", "CHEMICAL", 87, 105], ["hydroxychloroquine", "CHEMICAL", 110, 128], ["AT-511", "SIMPLE_CHEMICAL", 34, 40], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 110, 128], ["HCoV-229E", "CELL", 165, 174], ["HCoV-OC43", "CELL", 179, 188], ["HCoV-229E", "SPECIES", 165, 174], ["cytotoxicity", "PROBLEM", 3, 15], ["RESULTSChloroquine", "TREATMENT", 87, 105], ["hydroxychloroquine", "TREATMENT", 110, 128], ["HCoV", "TEST", 165, 169], ["HCoV", "TEST", 179, 183], ["their EC90 values", "TEST", 198, 215], ["VYR measurements", "TEST", 243, 259], ["cytotoxicity", "OBSERVATION", 3, 15]]], ["The respective EC50 values for these two drugs (8.1 and 7.4 \u00b5M), obtained using the neutral red assay, were substantially higher and only 2.6-to 3.6-fold less than the corresponding CC50 values, indicating considerably lower potencies and poor selectivity indices.", [["CC50", "SIMPLE_CHEMICAL", 182, 186], ["The respective EC50 values", "TEST", 0, 26], ["these two drugs", "TEST", 31, 46], ["the neutral red assay", "TEST", 80, 101], ["the corresponding CC50 values", "TEST", 164, 193], ["considerably lower potencies", "PROBLEM", 206, 234], ["poor selectivity indices", "PROBLEM", 239, 263], ["higher", "OBSERVATION_MODIFIER", 122, 128], ["considerably", "OBSERVATION_MODIFIER", 206, 218], ["lower potencies", "OBSERVATION_MODIFIER", 219, 234], ["poor selectivity", "OBSERVATION", 239, 255]]], ["These differences illustrate an inherent error in assessing antiviral activities of cytotoxic compounds using only measurements of VYR.", [["VYR", "SIMPLE_CHEMICAL", 131, 134], ["VYR", "PROTEIN", 131, 134], ["an inherent error", "PROBLEM", 29, 46], ["cytotoxic compounds", "PROBLEM", 84, 103], ["inherent error", "OBSERVATION", 32, 46], ["antiviral activities", "OBSERVATION", 60, 80], ["cytotoxic compounds", "OBSERVATION", 84, 103]]], ["When cells are poisoned by toxic drugs and are progressing toward death, their ability to support viral replication and propagation in addition to their own health likely is greatly diminished.", [["cells", "ANATOMY", 5, 10], ["death", "DISEASE", 66, 71], ["cells", "CELL", 5, 10], ["viral replication", "TREATMENT", 98, 115], ["greatly diminished", "PROBLEM", 174, 192], ["greatly", "OBSERVATION_MODIFIER", 174, 181], ["diminished", "OBSERVATION", 182, 192]]], ["At the point when cell death is detected by staining, viral yield reduction measurements likely reflect a combination of antiviral activity and cytotoxicity, thus overestimating antiviral potencies.RESULTSIn contrast to a recent publication (Wang et al., 2020) , Huh-7 cells were not permissive for replication of SARS-CoV-2.", [["cell", "ANATOMY", 18, 22], ["Huh-7 cells", "ANATOMY", 263, 274], ["death", "DISEASE", 23, 28], ["SARS", "DISEASE", 314, 318], ["cell", "CELL", 18, 22], ["Huh-7 cells", "CELL", 263, 274], ["SARS-CoV-2", "ORGANISM", 314, 324], ["Huh-7 cells", "CELL_LINE", 263, 274], ["SARS-CoV", "SPECIES", 314, 322], ["cell death", "PROBLEM", 18, 28], ["viral yield reduction measurements", "TEST", 54, 88], ["antiviral activity", "PROBLEM", 121, 139], ["cytotoxicity", "PROBLEM", 144, 156], ["overestimating antiviral potencies", "PROBLEM", 163, 197], ["Huh", "TEST", 263, 266], ["SARS", "TEST", 314, 318], ["CoV", "TEST", 319, 322], ["antiviral activity", "OBSERVATION", 121, 139], ["antiviral potencies", "OBSERVATION", 178, 197]]], ["An assay was developed using normal human airway epithelial (HAE) cells, a highly relevant in vitro model of the lung, which has been established as a more representative system than cell lines for SARS-CoV-2 replication (Jonsdottir and Dijkman, 2016) .", [["airway epithelial (HAE) cells", "ANATOMY", 42, 71], ["lung", "ANATOMY", 113, 117], ["cell lines", "ANATOMY", 183, 193], ["HAE", "DISEASE", 61, 64], ["human", "ORGANISM", 36, 41], ["airway epithelial (HAE) cells", "CELL", 42, 71], ["lung", "ORGAN", 113, 117], ["cell lines", "CELL", 183, 193], ["CoV-2", "ORGANISM", 203, 208], ["normal human airway epithelial (HAE) cells", "CELL_TYPE", 29, 71], ["cell lines", "CELL_LINE", 183, 193], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["SARS-CoV", "SPECIES", 198, 206], ["An assay", "TEST", 0, 8], ["cell lines", "TREATMENT", 183, 193], ["SARS", "PROBLEM", 198, 202], ["CoV", "TEST", 203, 206], ["airway epithelial", "ANATOMY", 42, 59], ["lung", "ANATOMY", 113, 117]]], ["These primary cells form polarized monolayers, the apical side of which is exposed to air and produces a mucin layer, consistent with the physiology of the human airways (Sheahan et al., 2020) .", [["primary cells", "ANATOMY", 6, 19], ["monolayers", "ANATOMY", 35, 45], ["mucin layer", "ANATOMY", 105, 116], ["airways", "ANATOMY", 162, 169], ["cells", "CELL", 14, 19], ["monolayers", "CELL", 35, 45], ["mucin", "GENE_OR_GENE_PRODUCT", 105, 110], ["human", "ORGANISM", 156, 161], ["airways", "MULTI-TISSUE_STRUCTURE", 162, 169], ["primary cells", "CELL_TYPE", 6, 19], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 156, 161], ["a mucin layer", "PROBLEM", 103, 116], ["primary cells", "OBSERVATION", 6, 19], ["polarized", "OBSERVATION_MODIFIER", 25, 34], ["monolayers", "OBSERVATION_MODIFIER", 35, 45], ["apical", "ANATOMY_MODIFIER", 51, 57], ["air", "OBSERVATION", 86, 89], ["mucin layer", "OBSERVATION", 105, 116], ["consistent with", "UNCERTAINTY", 118, 133], ["human airways", "ANATOMY", 156, 169]]], ["Average EC90 and CC50 values for AT-511 against SARS-CoV-2 from two separate HAE assays (0.5 and >86 \u00b5M, respectively) were in the same range as those obtained for HCoV-OC43 and SARS-CoV (Table 1 ).RESULTSIn the second HAE assay, the activity of AT-511 was tested in parallel with N 4 -hydroxycytidine (the nucleoside formed from the mutagenic oral prodrug EIDD-2801) with recently reported in vitro and in vivo activity against SARS-CoV-2 (Sheahan et al., 2020) .", [["oral", "ANATOMY", 344, 348], ["AT-511", "CHEMICAL", 33, 39], ["HAE", "DISEASE", 77, 80], ["HAE", "DISEASE", 219, 222], ["AT-511", "CHEMICAL", 246, 252], ["N 4 -hydroxycytidine", "CHEMICAL", 281, 301], ["nucleoside", "CHEMICAL", 307, 317], ["EIDD-2801", "CHEMICAL", 357, 366], ["AT-511", "CHEMICAL", 246, 252], ["N 4 -hydroxycytidine", "CHEMICAL", 281, 301], ["nucleoside", "CHEMICAL", 307, 317], ["EIDD-2801", "CHEMICAL", 357, 366], ["AT-511", "SIMPLE_CHEMICAL", 33, 39], ["SARS-CoV-2", "ORGANISM", 48, 58], ["HCoV-OC43", "SIMPLE_CHEMICAL", 164, 173], ["SARS-CoV", "ORGANISM", 178, 186], ["AT-511", "SIMPLE_CHEMICAL", 246, 252], ["N 4 -hydroxycytidine", "SIMPLE_CHEMICAL", 281, 301], ["nucleoside", "SIMPLE_CHEMICAL", 307, 317], ["oral", "ORGANISM_SUBDIVISION", 344, 348], ["EIDD-2801", "SIMPLE_CHEMICAL", 357, 366], ["SARS-CoV-2", "ORGANISM", 429, 439], ["SARS-CoV", "SPECIES", 48, 56], ["HCoV-OC43", "SPECIES", 164, 173], ["SARS-CoV", "SPECIES", 178, 186], ["SARS-CoV", "SPECIES", 429, 437], ["Average EC90", "TEST", 0, 12], ["CC50 values", "TEST", 17, 28], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["two separate HAE assays", "TEST", 64, 87], ["HCoV", "TEST", 164, 168], ["OC43", "TEST", 169, 173], ["SARS", "TEST", 178, 182], ["the second HAE assay", "TEST", 208, 228], ["hydroxycytidine", "TREATMENT", 286, 301], ["the nucleoside", "TREATMENT", 303, 317], ["SARS", "PROBLEM", 429, 433]]], ["The potency of N 4hydroxycytidine against SARS-CoV-2 (EC90 = 3.9 \u00b5M) was 8 times less than that of AT-511 in the same experiment.DISCUSSIONThe 30-fold difference of AT-511 activity between MERS-CoV and other CoVs is puzzling.", [["N 4hydroxycytidine", "CHEMICAL", 15, 33], ["SARS", "DISEASE", 42, 46], ["AT-511", "CHEMICAL", 99, 105], ["AT-511", "CHEMICAL", 165, 171], ["N 4hydroxycytidine", "CHEMICAL", 15, 33], ["AT-511", "CHEMICAL", 99, 105], ["N 4hydroxycytidine", "SIMPLE_CHEMICAL", 15, 33], ["SARS-CoV-2", "ORGANISM", 42, 52], ["AT-511", "SIMPLE_CHEMICAL", 99, 105], ["AT-511", "GENE_OR_GENE_PRODUCT", 165, 171], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["CoVs", "CANCER", 208, 212], ["SARS-CoV", "SPECIES", 42, 50], ["MERS-CoV", "SPECIES", 189, 197], ["N 4hydroxycytidine", "TREATMENT", 15, 33], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["EC90", "TEST", 54, 58], ["CoV", "PROBLEM", 194, 197]]], ["Nucleotide and nucleotide analogue selection is achieved at the CoV RdRp active site, the nsp12 gene product activated by its processivity co-factors nsp7 and nsp8 (Subissi et al., 2014) .", [["Nucleotide", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 15, 25], ["Nucleotide", "CHEMICAL", 0, 10], ["nucleotide", "CHEMICAL", 15, 25], ["nsp12", "GENE_OR_GENE_PRODUCT", 90, 95], ["nsp7", "GENE_OR_GENE_PRODUCT", 150, 154], ["nsp8", "GENE_OR_GENE_PRODUCT", 159, 163], ["CoV RdRp active site", "DNA", 64, 84], ["nsp12 gene product", "PROTEIN", 90, 108], ["processivity co-factors", "PROTEIN", 126, 149], ["nsp7", "PROTEIN", 150, 154], ["nsp8", "PROTEIN", 159, 163], ["Nucleotide", "TREATMENT", 0, 10], ["nucleotide analogue selection", "TREATMENT", 15, 44], ["CoV RdRp", "OBSERVATION", 64, 72], ["active site", "OBSERVATION", 73, 84]]], ["Conserved amino acid motifs A and C are involved in phosphodiester bond formation, whereas motifs F and B participate in nucleotide channeling and binding at the active site, respectively.", [["amino acid", "CHEMICAL", 10, 20], ["nucleotide", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 10, 20], ["phosphodiester", "CHEMICAL", 52, 66], ["nucleotide", "CHEMICAL", 121, 131], ["amino acid", "AMINO_ACID", 10, 20], ["C", "AMINO_ACID", 34, 35], ["phosphodiester bond", "SIMPLE_CHEMICAL", 52, 71], ["B", "GENE_OR_GENE_PRODUCT", 104, 105], ["nucleotide", "SIMPLE_CHEMICAL", 121, 131], ["Conserved amino acid motifs", "PROBLEM", 0, 27], ["phosphodiester bond formation", "TREATMENT", 52, 81]]], ["No significant structural differences are apparent between MERS-CoV and other CoVs in these essential motifs.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["CoVs", "GENE_OR_GENE_PRODUCT", 78, 82], ["CoVs", "DNA", 78, 82], ["MERS-CoV", "SPECIES", 59, 67], ["significant structural differences", "PROBLEM", 3, 37], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["structural differences", "OBSERVATION", 15, 37]]], ["With a similar ribose modification between AT-511 and sofosbuvir, it is unlikely that the selective lack of activity of sofosbuvir would be due to excision by the CoV exonuclease carried by nsp14 (Ferron et al., 2018) .", [["ribose", "CHEMICAL", 15, 21], ["AT-511", "CHEMICAL", 43, 49], ["sofosbuvir", "CHEMICAL", 54, 64], ["sofosbuvir", "CHEMICAL", 120, 130], ["ribose", "CHEMICAL", 15, 21], ["AT-511", "CHEMICAL", 43, 49], ["sofosbuvir", "CHEMICAL", 54, 64], ["sofosbuvir", "CHEMICAL", 120, 130], ["ribose", "SIMPLE_CHEMICAL", 15, 21], ["AT-511", "SIMPLE_CHEMICAL", 43, 49], ["sofosbuvir", "SIMPLE_CHEMICAL", 54, 64], ["sofosbuvir", "SIMPLE_CHEMICAL", 120, 130], ["CoV", "GENE_OR_GENE_PRODUCT", 163, 166], ["nsp14", "GENE_OR_GENE_PRODUCT", 190, 195], ["CoV exonuclease", "PROTEIN", 163, 178], ["nsp14", "PROTEIN", 190, 195], ["a similar ribose modification", "TREATMENT", 5, 34], ["sofosbuvir", "TREATMENT", 54, 64], ["sofosbuvir", "TREATMENT", 120, 130], ["excision", "TREATMENT", 147, 155], ["the CoV exonuclease", "TREATMENT", 159, 178], ["ribose modification", "OBSERVATION", 15, 34], ["is unlikely", "UNCERTAINTY", 69, 80]]], ["Rather, our results suggest that the triphosphate formed from AT-511 most likely targets another less conserved viral GTP-binding protein, whose inhibition would account for both the antiviral effect and the MERS-CoV differential sensitivity pattern.DISCUSSIONTo date, human safety and tolerability have been confirmed in more than 40 HCV-infected patients treated orally with once-daily administration of 550 mg of AT-527 for seven days and up to 12 weeks.", [["triphosphate", "CHEMICAL", 37, 49], ["AT-511", "CHEMICAL", 62, 68], ["GTP", "CHEMICAL", 118, 121], ["HCV-infected", "DISEASE", 335, 347], ["AT-527", "CHEMICAL", 416, 422], ["triphosphate", "CHEMICAL", 37, 49], ["AT-511", "CHEMICAL", 62, 68], ["AT-527", "CHEMICAL", 416, 422], ["triphosphate", "SIMPLE_CHEMICAL", 37, 49], ["AT-511", "SIMPLE_CHEMICAL", 62, 68], ["GTP", "SIMPLE_CHEMICAL", 118, 121], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 208, 216], ["human", "ORGANISM", 269, 274], ["HCV", "ORGANISM", 335, 338], ["patients", "ORGANISM", 348, 356], ["viral GTP-binding protein", "PROTEIN", 112, 137], ["human", "SPECIES", 269, 274], ["patients", "SPECIES", 348, 356], ["human", "SPECIES", 269, 274], ["HCV", "SPECIES", 335, 338], ["the triphosphate", "TEST", 33, 49], ["viral GTP-binding protein", "PROBLEM", 112, 137], ["the antiviral effect", "PROBLEM", 179, 199], ["the MERS", "TEST", 204, 212], ["antiviral effect", "OBSERVATION", 183, 199]]], ["Excellent pharmacokinetics (50-60% bioavailability and long intracellular half-life of the active metabolite) associated with a dosing regimen of a 1,100 mg loading dose, followed by 550 mg BID, should provide lung drug exposures consistently above its in vitro EC90 of 0.5 \u00b5M against SARS-CoV-2 replication and should lead to a very effective antiviral treatment.", [["intracellular", "ANATOMY", 60, 73], ["lung", "ANATOMY", 210, 214], ["SARS", "DISEASE", 285, 289], ["BID", "CHEMICAL", 190, 193], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 73], ["BID", "SIMPLE_CHEMICAL", 190, 193], ["lung", "ORGAN", 210, 214], ["CoV-2", "ORGANISM", 290, 295], ["SARS-CoV", "SPECIES", 285, 293], ["a dosing regimen", "TREATMENT", 126, 142], ["a 1,100 mg loading dose", "TREATMENT", 146, 169], ["lung drug exposures", "TREATMENT", 210, 229], ["SARS", "PROBLEM", 285, 289], ["CoV-2 replication", "TREATMENT", 290, 307], ["a very effective antiviral treatment", "TREATMENT", 327, 363], ["lung", "ANATOMY", 210, 214], ["drug", "OBSERVATION", 215, 219]]], ["A Phase 2 clinical trial is currently ongoing to evaluate the safety and efficacy of AT-527 in COVID-19 patients.", [["AT-527", "CHEMICAL", 85, 91], ["AT-527", "CHEMICAL", 85, 91], ["AT-527", "SIMPLE_CHEMICAL", 85, 91], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["Additionally, the differential activities AT-511 against MERS-CoV in comparison to the other CoVs tested and of AT-511 in comparison to sofosbuvir against HCoV-229E are being exploited to probe the unique mechanism of inhibition of the active guanosine triphosphate analog formed from AT-527.DECLARATION OF INTERESTSThe authors affiliated with Atea Pharmaceuticals, Inc. are employees of the company and own company stock.", [["AT-511", "CHEMICAL", 42, 48], ["AT-511", "CHEMICAL", 112, 118], ["sofosbuvir", "CHEMICAL", 136, 146], ["HCoV-229E", "CHEMICAL", 155, 164], ["guanosine triphosphate", "CHEMICAL", 243, 265], ["AT-527", "CHEMICAL", 285, 291], ["AT-511", "CHEMICAL", 112, 118], ["sofosbuvir", "CHEMICAL", 136, 146], ["HCoV-229E", "CHEMICAL", 155, 164], ["guanosine triphosphate", "CHEMICAL", 243, 265], ["AT-527", "CHEMICAL", 285, 291], ["AT-511", "GENE_OR_GENE_PRODUCT", 42, 48], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["CoVs", "CANCER", 93, 97], ["AT-511", "SIMPLE_CHEMICAL", 112, 118], ["sofosbuvir", "SIMPLE_CHEMICAL", 136, 146], ["HCoV-229E", "ORGANISM", 155, 164], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 243, 265], ["AT-527", "SIMPLE_CHEMICAL", 285, 291], ["MERS-CoV", "SPECIES", 57, 65], ["AT-511", "SPECIES", 112, 118], ["HCoV-229E", "SPECIES", 155, 164], ["the differential activities", "TEST", 14, 41], ["MERS", "PROBLEM", 57, 61], ["CoV", "PROBLEM", 62, 65], ["the other CoVs", "TEST", 83, 97], ["sofosbuvir", "TREATMENT", 136, 146], ["HCoV", "TEST", 155, 159], ["the active guanosine triphosphate analog", "TREATMENT", 232, 272]]], ["AT-511 and N 4 -hydroxycytidine were prepared for Atea Pharmaceuticals by Topharman Shanghai Co., Ltd., Shanghai, China and Oxeltis, Montpellier, France, respectively.", [["AT-511", "CHEMICAL", 0, 6], ["N 4 -hydroxycytidine", "CHEMICAL", 11, 31], ["AT-511", "CHEMICAL", 0, 6], ["N 4 -hydroxycytidine", "CHEMICAL", 11, 31], ["AT-511", "SIMPLE_CHEMICAL", 0, 6], ["N 4 -hydroxycytidine", "SIMPLE_CHEMICAL", 11, 31], ["hydroxycytidine", "TREATMENT", 16, 31]]], ["Chloroquine and hydroxychloroquine were purchased from Mason-Chem, Palo Alto, CA and sofosbuvir was purchased from Pharma Sys, Inc., Cary, NC.Antiviral assays in BHK-21 cells:Test compounds were dissolved in DMSO at 100 mM and then diluted in Minimum Essential Medium with Earle's salts (MEM-E) containing 1 mM sodium pyruvate and 25 \u00b5g/mL kanamycin, supplemented with 10% FBS (growth medium) to final concentrations of 100, 20, 4 and 0.8 \u00b5M (two 24-well replica plates each).", [["BHK-21 cells", "ANATOMY", 162, 174], ["FBS", "ANATOMY", 373, 376], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["sofosbuvir", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 208, 212], ["MEM-E", "CHEMICAL", 288, 293], ["sodium pyruvate", "CHEMICAL", 311, 326], ["kanamycin", "CHEMICAL", 340, 349], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["sofosbuvir", "CHEMICAL", 85, 95], ["DMSO", "CHEMICAL", 208, 212], ["MEM-E", "CHEMICAL", 288, 293], ["sodium pyruvate", "CHEMICAL", 311, 326], ["kanamycin", "CHEMICAL", 340, 349], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["sofosbuvir", "SIMPLE_CHEMICAL", 85, 95], ["BHK-21 cells", "CELL", 162, 174], ["DMSO", "SIMPLE_CHEMICAL", 208, 212], ["MEM-E", "SIMPLE_CHEMICAL", 288, 293], ["sodium pyruvate", "SIMPLE_CHEMICAL", 311, 326], ["kanamycin", "SIMPLE_CHEMICAL", 340, 349], ["FBS", "ORGANISM_SUBSTANCE", 373, 376], ["BHK-21 cells", "CELL_LINE", 162, 174], ["BHK-21", "SPECIES", 162, 168], ["Chloroquine", "TREATMENT", 0, 11], ["hydroxychloroquine", "TREATMENT", 16, 34], ["sofosbuvir", "TREATMENT", 85, 95], ["NC", "TREATMENT", 139, 141], ["Antiviral assays", "TEST", 142, 158], ["BHK", "TEST", 162, 165], ["Test compounds", "TEST", 175, 189], ["DMSO", "TREATMENT", 208, 212], ["Earle's salts (MEM-E)", "TREATMENT", 273, 294], ["1 mM sodium pyruvate", "TREATMENT", 306, 326], ["kanamycin", "TREATMENT", 340, 349]]], ["After BHK-21 cells were grown to confluency in 96-well plates, growth medium was replaced with fresh maintenance medium (growth medium with 1% inactivated FBS in place of 10% FBS) containing serially diluted test compound and HCoV-229E at a multiplicity of infection (MOI) of 0.01.", [["BHK-21 cells", "ANATOMY", 6, 18], ["FBS", "ANATOMY", 155, 158], ["FBS", "ANATOMY", 175, 178], ["HCoV-229E", "CHEMICAL", 226, 235], ["infection", "DISEASE", 257, 266], ["BHK-21 cells", "CELL", 6, 18], ["FBS", "ORGANISM_SUBSTANCE", 155, 158], ["FBS", "ORGANISM_SUBSTANCE", 175, 178], ["HCoV-229E", "SIMPLE_CHEMICAL", 226, 235], ["BHK-21 cells", "CELL_LINE", 6, 18], ["HCoV-229E", "SPECIES", 226, 235], ["BHK", "TEST", 6, 9], ["confluency", "TEST", 33, 43], ["fresh maintenance medium (growth medium", "TREATMENT", 95, 134], ["FBS", "TEST", 155, 158], ["FBS", "TEST", 175, 178], ["serially diluted test compound", "TEST", 191, 221], ["HCoV", "TEST", 226, 230], ["infection", "PROBLEM", 257, 266], ["21 cells", "OBSERVATION_MODIFIER", 10, 18], ["confluency", "OBSERVATION_MODIFIER", 33, 43], ["infection", "OBSERVATION", 257, 266]]], ["Uninfected cells in the presence of serially diluted compound were used to assess the cytotoxicity of compounds.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Uninfected cells", "PROBLEM", 0, 16], ["serially diluted compound", "TREATMENT", 36, 61], ["the cytotoxicity of compounds", "PROBLEM", 82, 111]]], ["After a 3-day incubation at 37\u00b0C in a humidified 5% CO2 atmosphere, cell viability was determined by the MTT method (Pauwels et al., 1988) .", [["cell", "ANATOMY", 68, 72], ["CO2", "CHEMICAL", 52, 55], ["CO2", "CHEMICAL", 52, 55], ["MTT", "CHEMICAL", 105, 108], ["CO2", "SIMPLE_CHEMICAL", 52, 55], ["cell", "CELL", 68, 72], ["a humidified 5% CO2 atmosphere", "TREATMENT", 36, 66], ["cell viability", "TEST", 68, 82], ["cell viability", "OBSERVATION", 68, 82]]], ["The effective concentration of test compound required to prevent virus-induced cytopathic effect (CPE) by 50% (EC50) and to cause 50% cell death in the absence of virus (CC50) were calculated by regression analysis.Antiviral assays in Huh-7 and RD cells:The antiviral activities of test compounds were evaluated against human coronaviruses alpha (229E), beta (OC43), MERS (EMC) and SARS (Urbani) using a neutral red assay to determine inhibition of virus-induced and compoundinduced CPE and using a virus yield reduction (VYR) assay as a second, independent determination of the inhibition of viral replication.Antiviral assays in Huh-7 and RD cells:Neutral red assay: Test compounds were dissolved in DMSO at a concentration of 10 mg/mL and serially diluted using eight half-log dilutions in test medium (Minimum Essential Medium supplemented with 5% FBS and 50 \u00b5g/mL gentamicin) so that the highest test concentration was 50 \u00b5g/mL.", [["cell", "ANATOMY", 134, 138], ["Huh-7", "ANATOMY", 235, 240], ["RD cells", "ANATOMY", 245, 253], ["Huh-7", "ANATOMY", 631, 636], ["RD cells", "ANATOMY", 641, 649], ["death", "DISEASE", 139, 144], ["SARS", "DISEASE", 382, 386], ["CPE", "CHEMICAL", 483, 486], ["DMSO", "CHEMICAL", 702, 706], ["gentamicin", "CHEMICAL", 869, 879], ["DMSO", "CHEMICAL", 702, 706], ["gentamicin", "CHEMICAL", 869, 879], ["cell", "CELL", 134, 138], ["Huh-7", "CELL", 235, 240], ["RD cells", "CELL", 245, 253], ["human", "ORGANISM", 320, 325], ["alpha (229E)", "GENE_OR_GENE_PRODUCT", 340, 352], ["beta (OC43)", "GENE_OR_GENE_PRODUCT", 354, 365], ["Huh-7", "CELL", 631, 636], ["RD cells", "CELL", 641, 649], ["DMSO", "SIMPLE_CHEMICAL", 702, 706], ["FBS", "ORGANISM_SUBSTANCE", 852, 855], ["gentamicin", "SIMPLE_CHEMICAL", 869, 879], ["Huh-7", "CELL_LINE", 235, 240], ["RD cells", "CELL_LINE", 245, 253], ["Huh-7", "CELL_LINE", 631, 636], ["RD cells", "CELL_LINE", 641, 649], ["human", "SPECIES", 320, 325], ["Huh-7", "SPECIES", 235, 240], ["human", "SPECIES", 320, 325], ["Huh-7", "SPECIES", 631, 636], ["test compound", "PROBLEM", 31, 44], ["virus", "PROBLEM", 65, 70], ["cytopathic effect", "PROBLEM", 79, 96], ["50% cell death", "PROBLEM", 130, 144], ["virus", "PROBLEM", 163, 168], ["regression analysis", "TEST", 195, 214], ["Antiviral assays", "TEST", 215, 231], ["Huh", "TEST", 235, 238], ["test compounds", "TEST", 282, 296], ["human coronaviruses alpha", "TEST", 320, 345], ["beta (OC43", "TREATMENT", 354, 364], ["SARS (Urbani)", "TREATMENT", 382, 395], ["a neutral red assay", "TEST", 402, 421], ["virus", "PROBLEM", 449, 454], ["compoundinduced CPE", "PROBLEM", 467, 486], ["a virus yield reduction", "TREATMENT", 497, 520], ["viral replication", "TREATMENT", 593, 610], ["Antiviral assays", "TEST", 611, 627], ["Huh", "TEST", 631, 634], ["Neutral red assay", "TEST", 650, 667], ["Test compounds", "TEST", 669, 683], ["DMSO", "TREATMENT", 702, 706], ["5% FBS", "TREATMENT", 849, 855], ["gentamicin", "TREATMENT", 869, 879], ["the highest test concentration", "TEST", 889, 919], ["cytopathic", "OBSERVATION_MODIFIER", 79, 89], ["cell death", "OBSERVATION", 134, 144], ["viral replication", "OBSERVATION", 593, 610]]], ["Each dilution was added to 5 wells of a 96-well plate with 80-100% confluent Huh-7 or RD cells (OC43 only).", [["Huh-7", "ANATOMY", 77, 82], ["RD cells", "ANATOMY", 86, 94], ["OC43", "ANATOMY", 96, 100], ["Huh-7", "CELL", 77, 82], ["RD cells", "CELL", 86, 94], ["OC43", "CELL", 96, 100], ["Huh-7", "CELL_LINE", 77, 82], ["RD cells", "CELL_LINE", 86, 94], ["OC43", "CELL_LINE", 96, 100], ["Each dilution", "TREATMENT", 0, 13], ["confluent Huh", "TEST", 67, 80], ["RD cells", "PROBLEM", 86, 94], ["OC43", "TEST", 96, 100]]], ["Three wells of each dilution were infected with virus, and two wells remained uninfected as toxicity controls.", [["toxicity", "DISEASE", 92, 100], ["each dilution", "TREATMENT", 15, 28], ["virus", "TREATMENT", 48, 53]]], ["Six untreated wells were infected as virus controls and six untreated wells were left uninfected to use as virus controls.", [["Six untreated wells", "PROBLEM", 0, 19], ["virus controls and six untreated wells", "TREATMENT", 37, 75], ["virus controls", "TREATMENT", 107, 121]]], ["Viruses were diluted to achieve MOIs of 0.003, 0.002, 0.001 and 0.03 CCID50 per cell for 229E, OC43, MERS and SARS, respectively.", [["cell", "ANATOMY", 80, 84], ["SARS", "DISEASE", 110, 114], ["Viruses", "ORGANISM", 0, 7], ["cell", "CELL", 80, 84], ["Viruses", "PROBLEM", 0, 7], ["MOIs", "TEST", 32, 36], ["OC43", "TEST", 95, 99], ["SARS", "PROBLEM", 110, 114]]], ["Plates were incubated at 37\u00b12\u00b0C in a humidified atmosphere containing 5% CO2.Antiviral assays in Huh-7 and RD cells:On day 5 (229E and OC43) or day 7 (MERS and SARS) post-infection, when untreated virus control wells reached maximum CPE, the plates were stained with neutral red dye for approximately 2 hours (\u00b115 minutes).", [["Huh-7", "ANATOMY", 97, 102], ["RD cells", "ANATOMY", 107, 115], ["CO2", "CHEMICAL", 73, 76], ["CO2", "CHEMICAL", 73, 76], ["C", "SIMPLE_CHEMICAL", 30, 31], ["CO2", "SIMPLE_CHEMICAL", 73, 76], ["Huh-7", "CELL", 97, 102], ["RD cells", "CELL", 107, 115], ["red dye", "SIMPLE_CHEMICAL", 275, 282], ["Huh-7", "CELL_LINE", 97, 102], ["RD cells", "CELL_LINE", 107, 115], ["Huh-7", "SPECIES", 97, 102], ["Plates", "TEST", 0, 6], ["a humidified atmosphere", "TREATMENT", 35, 58], ["5% CO2", "TREATMENT", 70, 76], ["Antiviral assays", "TEST", 77, 93], ["Huh", "TEST", 97, 100], ["RD cells", "TEST", 107, 115], ["OC43", "TEST", 135, 139], ["SARS", "PROBLEM", 160, 164], ["post-infection", "PROBLEM", 166, 180], ["untreated virus control wells", "PROBLEM", 187, 216], ["the plates", "TEST", 238, 248], ["neutral red dye", "TREATMENT", 267, 282]]], ["Supernatant dye was removed, wells were rinsed with PBS, and the incorporated dye was extracted in 50:50 Sorensen citrate buffer/ethanol for >30 minutes and the optical density was read on a spectrophotometer at 540 nm.", [["Supernatant", "ANATOMY", 0, 11], ["Sorensen citrate", "CHEMICAL", 105, 121], ["ethanol", "CHEMICAL", 129, 136], ["Sorensen citrate", "CHEMICAL", 105, 121], ["ethanol", "CHEMICAL", 129, 136], ["Sorensen", "SIMPLE_CHEMICAL", 105, 113], ["citrate", "SIMPLE_CHEMICAL", 114, 121], ["ethanol", "SIMPLE_CHEMICAL", 129, 136], ["Supernatant dye", "TREATMENT", 0, 15], ["PBS", "TREATMENT", 52, 55], ["the incorporated dye", "TREATMENT", 61, 81], ["Sorensen citrate buffer/ethanol", "TREATMENT", 105, 136], ["dye", "OBSERVATION", 12, 15]]], ["Optical densities were converted to percent of controls and the concentrations of test compound required to prevent virus-induced CPE by 50% (EC50) and to cause 50% cell death in the absence of virus (CC50) were calculated.Antiviral assays in Huh-7 and RD cells:Virus yield reduction assay: Vero 76 cells were seeded in 96-well plates and grown overnight (37\u00b0C) to confluence.", [["cell", "ANATOMY", 165, 169], ["Huh-7", "ANATOMY", 243, 248], ["RD cells", "ANATOMY", 253, 261], ["Vero 76 cells", "ANATOMY", 291, 304], ["CPE", "DISEASE", 130, 133], ["death", "DISEASE", 170, 175], ["cell", "CELL", 165, 169], ["Huh-7", "CELL", 243, 248], ["RD cells", "CELL", 253, 261], ["Virus", "ORGANISM", 262, 267], ["Vero 76 cells", "CELL", 291, 304], ["Huh-7", "CELL_LINE", 243, 248], ["RD cells", "CELL_LINE", 253, 261], ["Vero 76 cells", "CELL_LINE", 291, 304], ["Huh-7", "SPECIES", 243, 248], ["Optical densities", "PROBLEM", 0, 17], ["test compound", "TREATMENT", 82, 95], ["virus", "PROBLEM", 116, 121], ["CPE", "PROBLEM", 130, 133], ["EC50", "TEST", 142, 146], ["50% cell death", "PROBLEM", 161, 175], ["Antiviral assays", "TEST", 223, 239], ["Huh", "TEST", 243, 246], ["RD cells", "TEST", 253, 261], ["Virus yield reduction", "TREATMENT", 262, 283], ["Vero 76 cells", "TEST", 291, 304], ["densities", "OBSERVATION", 8, 17], ["cell death", "OBSERVATION", 165, 175]]], ["A sample of the supernatant fluid from each compound concentration was collected on day 3 post infection (3 wells pooled) and tested for virus titer using a standard endpoint dilution CCID50 assay and titer calculations using the Reed-Muench equation (1938) and the concentration of compound required to reduce virus yield by 90% (EC90) was determined by regression analysis.Antiviral assays in HAE cell preparations:The antiviral activities of test compounds were evaluated against SARS-CoV-2 (USA-WA1/2020) using made to order differentiated normal human bronchial epithelial (HAE) cells.Antiviral assays in HAE cell preparations:Cell Culture: HAE cells were grown on 6mm mesh disks and arrived in kits with either 12-or 24well transwell inserts.", [["supernatant fluid", "ANATOMY", 16, 33], ["HAE cell", "ANATOMY", 395, 403], ["bronchial epithelial (HAE) cells", "ANATOMY", 557, 589], ["HAE cell", "ANATOMY", 610, 618], ["Cell", "ANATOMY", 632, 636], ["HAE cells", "ANATOMY", 646, 655], ["HAE", "DISEASE", 395, 398], ["HAE", "DISEASE", 579, 582], ["HAE", "DISEASE", 610, 613], ["HAE cell", "CELL", 395, 403], ["SARS-CoV-2", "ORGANISM", 483, 493], ["USA", "ORGANISM", 495, 498], ["human", "ORGANISM", 551, 556], ["bronchial epithelial (HAE) cells", "CELL", 557, 589], ["HAE cell", "CELL", 610, 618], ["Cell Culture", "CELL", 632, 644], ["HAE cells", "CELL", 646, 655], ["normal human bronchial epithelial (HAE) cells", "CELL_TYPE", 544, 589], ["HAE cells", "CELL_LINE", 646, 655], ["human", "SPECIES", 551, 556], ["SARS-CoV-2 (USA-WA1/2020)", "SPECIES", 483, 508], ["human", "SPECIES", 551, 556], ["the supernatant fluid from each compound concentration", "TEST", 12, 66], ["infection", "PROBLEM", 95, 104], ["virus titer", "TEST", 137, 148], ["titer calculations", "TEST", 201, 219], ["the Reed-Muench equation", "TREATMENT", 226, 250], ["regression analysis", "TEST", 355, 374], ["Antiviral assays", "TEST", 375, 391], ["test compounds", "TEST", 445, 459], ["SARS", "PROBLEM", 483, 487], ["CoV", "TEST", 488, 491], ["Antiviral assays", "TEST", 590, 606], ["Cell Culture", "TEST", 632, 644], ["HAE cells", "PROBLEM", 646, 655], ["6mm mesh disks", "PROBLEM", 670, 684], ["24well transwell inserts", "TREATMENT", 723, 747], ["supernatant fluid", "OBSERVATION", 16, 33], ["infection", "OBSERVATION", 95, 104], ["normal", "OBSERVATION", 544, 550], ["bronchial epithelial", "ANATOMY", 557, 577], ["6mm", "OBSERVATION_MODIFIER", 670, 673], ["mesh disks", "OBSERVATION", 674, 684]]], ["During transportation the tissues were stabilized on a sheet of agarose, which was removed upon receipt.", [["tissues", "ANATOMY", 26, 33], ["tissues", "TISSUE", 26, 33], ["agarose", "SIMPLE_CHEMICAL", 64, 71], ["a sheet of agarose", "TREATMENT", 53, 71], ["tissues", "ANATOMY", 26, 33], ["stabilized", "OBSERVATION", 39, 49]]], ["One insert was estimated to consist of approximately 1.2 x 10 6 cells.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["1.2 x 10 6 cells", "OBSERVATION_MODIFIER", 53, 69]]], ["Kits of cell inserts (EpiAirway TM AIR-100 or AIR-112) originated from a single donor, # 9831, a 23-year old, healthy, non-smoking, Caucasian male.", [["cell", "ANATOMY", 8, 12], ["cell", "CELL", 8, 12], ["cell inserts", "TREATMENT", 8, 20], ["EpiAirway TM AIR", "TEST", 22, 38], ["cell inserts", "OBSERVATION", 8, 20]]], ["The cells form polarized monolayers, the apical side of which is exposed to air and creates a mucin layer.", [["cells", "ANATOMY", 4, 9], ["monolayers", "ANATOMY", 25, 35], ["cells", "CELL", 4, 9], ["monolayers", "CELL", 25, 35], ["mucin", "GENE_OR_GENE_PRODUCT", 94, 99], ["polarized", "OBSERVATION_MODIFIER", 15, 24], ["monolayers", "OBSERVATION_MODIFIER", 25, 35], ["apical", "ANATOMY_MODIFIER", 41, 47], ["air", "OBSERVATION", 76, 79], ["mucin layer", "OBSERVATION", 94, 105]]], ["Upon arrival, the cell transwell inserts were immediately transferred to individual wells of a 6-well plate according to the manufacturer's instructions, and 1 mL of MatTek's proprietary culture medium (AIR-100-MM) was added to the basolateral side, whereas the apical side was exposed to a humidified 5% CO2 environment.", [["cell", "ANATOMY", 18, 22], ["basolateral", "ANATOMY", 232, 243], ["apical", "ANATOMY", 262, 268], ["AIR-100-MM", "CHEMICAL", 203, 213], ["CO2", "CHEMICAL", 305, 308], ["CO2", "CHEMICAL", 305, 308], ["cell", "CELL", 18, 22], ["AIR-100-MM", "CELL", 203, 213], ["CO2", "SIMPLE_CHEMICAL", 305, 308], ["the cell transwell inserts", "TREATMENT", 14, 40], ["a 6-well plate", "TREATMENT", 93, 107], ["MatTek's proprietary culture", "TEST", 166, 194], ["AIR", "TEST", 203, 206], ["a humidified 5% CO2 environment", "TREATMENT", 289, 320], ["cell transwell", "OBSERVATION", 18, 32], ["apical", "ANATOMY_MODIFIER", 262, 268]]], ["Cells were cultured at 37\u00b0C in a humidified atmosphere containing 5% CO2 for one day before the start of the experiment.", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 69, 72], ["CO2", "CHEMICAL", 69, 72], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 69, 72], ["Cells", "TEST", 0, 5], ["a humidified atmosphere", "TREATMENT", 31, 54], ["5% CO2", "TREATMENT", 66, 72]]], ["After the 24-h equilibration period, the mucin layer, secreted from the apical side of the cells, was removed by washing with 400 \u00b5L pre-warmed 30 mM HEPES buffered saline solution 3X.", [["mucin layer", "ANATOMY", 41, 52], ["apical side", "ANATOMY", 72, 83], ["cells", "ANATOMY", 91, 96], ["HEPES", "CHEMICAL", 150, 155], ["mucin", "GENE_OR_GENE_PRODUCT", 41, 46], ["cells", "CELL", 91, 96], ["the mucin layer", "TREATMENT", 37, 52], ["mM HEPES buffered saline solution", "TREATMENT", 147, 180], ["layer", "OBSERVATION_MODIFIER", 47, 52], ["apical", "ANATOMY_MODIFIER", 72, 78], ["cells", "ANATOMY", 91, 96]]], ["Culture medium was replenished following the wash steps.Antiviral assays in HAE cell preparations:Viruses: Virus was diluted in AIR-100-MM medium before infection to yield a MOI when added to cultures of approximately 0.0015 CCID50 per cell.Antiviral assays in HAE cell preparations:Experimental design: Each compound treatment (120 \uf06dL) and virus (120 \uf06dL) was applied to the apical side, and the compound treatment (1 mL) was applied to the basal side.", [["HAE cell", "ANATOMY", 76, 84], ["cell", "ANATOMY", 236, 240], ["HAE cell", "ANATOMY", 261, 269], ["apical", "ANATOMY", 375, 381], ["HAE", "DISEASE", 76, 79], ["AIR-100-MM", "CHEMICAL", 128, 138], ["infection", "DISEASE", 153, 162], ["HAE", "DISEASE", 261, 264], ["HAE cell", "CELL", 76, 84], ["Virus", "ORGANISM", 107, 112], ["cell", "CELL", 236, 240], ["HAE cell", "CELL", 261, 269], ["Culture medium", "TEST", 0, 14], ["Antiviral assays", "TEST", 56, 72], ["Virus", "PROBLEM", 107, 112], ["infection", "PROBLEM", 153, 162], ["a MOI", "PROBLEM", 172, 177], ["cultures", "TEST", 192, 200], ["Antiviral assays", "TEST", 241, 257], ["Each compound treatment", "TREATMENT", 304, 327], ["virus (120 \uf06dL)", "TREATMENT", 341, 355], ["the compound treatment (1 mL)", "TREATMENT", 392, 421], ["Virus", "OBSERVATION", 107, 112], ["apical", "ANATOMY_MODIFIER", 375, 381], ["basal", "ANATOMY_MODIFIER", 441, 446]]], ["As a virus control, some of the cells were treated with cell culture medium only.", [["cells", "ANATOMY", 32, 37], ["cell", "ANATOMY", 56, 60], ["cells", "CELL", 32, 37], ["cell", "CELL", 56, 60], ["a virus control", "TREATMENT", 3, 18], ["the cells", "PROBLEM", 28, 37], ["cell culture medium", "TREATMENT", 56, 75], ["virus", "OBSERVATION", 5, 10]]], ["After a 2-h infection incubation, the apical medium was removed, and the basal medium was replaced with fresh compound or medium (1 mL).", [["apical medium", "ANATOMY", 38, 51], ["infection", "DISEASE", 12, 21], ["a 2-h infection incubation", "TREATMENT", 6, 32], ["apical", "ANATOMY_MODIFIER", 38, 44], ["medium", "OBSERVATION_MODIFIER", 45, 51], ["basal", "ANATOMY_MODIFIER", 73, 78]]], ["The cells were maintained at the air-liquid interface.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["cells", "OBSERVATION", 4, 9], ["air-liquid interface", "OBSERVATION", 33, 53]]], ["On day 5, cytotoxicity (CC50 values) in the uninfected, compound-treated inserts was estimated by visual inspection, and the basal medium was removed from all inserts and discarded.", [["cytotoxicity (CC50 values", "TEST", 10, 35], ["visual inspection", "TEST", 98, 115], ["the basal medium", "TREATMENT", 121, 137], ["basal", "ANATOMY_MODIFIER", 125, 130]]], ["Virus released into the apical compartment of the HAE cells was harvested by the addition of 400 \u00b5L of culture medium that was pre-warmed at 37\uf0b0C. The contents were incubated for 30 min, mixed well, collected, thoroughly vortexed and plated on Vero 76 cells for VYR titration.", [["apical compartment", "ANATOMY", 24, 42], ["HAE cells", "ANATOMY", 50, 59], ["Vero 76 cells", "ANATOMY", 244, 257], ["HAE", "DISEASE", 50, 53], ["Virus", "ORGANISM", 0, 5], ["apical compartment", "MULTI-TISSUE_STRUCTURE", 24, 42], ["HAE cells", "CELL", 50, 59], ["Vero 76 cells", "CELL", 244, 257], ["VYR", "SIMPLE_CHEMICAL", 262, 265], ["HAE cells", "CELL_LINE", 50, 59], ["Vero 76 cells", "CELL_LINE", 244, 257], ["Virus", "PROBLEM", 0, 5], ["culture medium", "TEST", 103, 117], ["VYR titration", "TREATMENT", 262, 275], ["apical", "ANATOMY_MODIFIER", 24, 30], ["compartment", "ANATOMY_MODIFIER", 31, 42], ["HAE cells", "OBSERVATION", 50, 59]]], ["Separate wells were used for virus control and duplicate wells were used for untreated cell controls.", [["cell", "ANATOMY", 87, 91], ["cell", "CELL", 87, 91], ["Separate wells", "TREATMENT", 0, 14], ["virus control", "TREATMENT", 29, 42], ["duplicate wells", "TREATMENT", 47, 62], ["untreated cell controls", "TREATMENT", 77, 100], ["cell controls", "OBSERVATION", 87, 100]]], ["Virus titers from each treated culture were determined as described above.", [["Virus", "ORGANISM", 0, 5], ["Virus titers", "PROBLEM", 0, 12], ["each treated culture", "TEST", 18, 38]]]], "386574d3fd6c5f3c9da01c12607eae8c53c04232": [["infections has been monitored worldwide, with a daily count of the number of deaths due to COVID-19.", [["infections", "DISEASE", 0, 10], ["deaths", "DISEASE", 77, 83], ["COVID-19", "CHEMICAL", 91, 99], ["infections", "PROBLEM", 0, 10], ["COVID", "TEST", 91, 96]]], ["Several measures have been undertaken in the societal and professional field, and the healthcare systems have been reorganized to limit the virus spread, and to cope with the surge of hospital admissions for COVID-19.", [["the virus spread", "PROBLEM", 136, 152], ["COVID", "TEST", 208, 213]]], ["Questions have been raised regarding the indirect effect of the pandemic, with uncertainties regarding the impact of delays in non-COVID diseases management, due to lockdown, postponement of non-urgent medical consultations and interventions, and decrease in screening.", [["non-COVID diseases management", "TREATMENT", 127, 156], ["non-urgent medical consultations", "TEST", 191, 223], ["interventions", "TREATMENT", 228, 241], ["screening", "TEST", 259, 268]]], ["Sudden cardiac death could have been impacted by all those changes, and is generally a good surrogate of public health.", [["cardiac", "ANATOMY", 7, 14], ["Sudden cardiac death", "DISEASE", 0, 20], ["Sudden cardiac death", "PROBLEM", 0, 20], ["cardiac", "ANATOMY", 7, 14], ["death", "OBSERVATION", 15, 20], ["impacted", "OBSERVATION_MODIFIER", 37, 45]]], ["In the current article, we review the impact of the COVID-19 pandemic on the epidemiology and outcome of sudden cardiac death.", [["cardiac", "ANATOMY", 112, 119], ["sudden cardiac death", "DISEASE", 105, 125], ["cardiac", "ORGAN", 112, 119], ["the COVID", "TEST", 48, 57], ["sudden cardiac death", "PROBLEM", 105, 125], ["cardiac", "ANATOMY", 112, 119], ["death", "OBSERVATION", 120, 125]]]], "55b415d3a2abcaab6fb75fe136345544a5b95dcf": [["IntroductionIn December 2019, a highly infectious and deadly respiratory virus infected humans for the first time; it was named coronavirus disease 2019 .", [["respiratory virus infected", "DISEASE", 61, 87], ["coronavirus disease", "DISEASE", 128, 147], ["humans", "ORGANISM", 88, 94], ["coronavirus", "ORGANISM", 128, 139], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["a highly infectious and deadly respiratory virus infected humans", "PROBLEM", 30, 94], ["coronavirus disease", "PROBLEM", 128, 147], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["infectious", "OBSERVATION", 39, 49], ["respiratory virus", "OBSERVATION", 61, 78], ["coronavirus disease", "OBSERVATION", 128, 147]]], ["COVID-19 proliferated faster than public health measures could contain it.", [["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5]]], ["Scientists have chased the origin of coronaviruses for more than a decade, and found them to be from bats residing in China's Yanzi and Shitou caves (Wang et al. 2018) .", [["coronaviruses", "ORGANISM", 37, 50], ["coronaviruses", "PROBLEM", 37, 50]]], ["Coronaviruses are viruses that are covered in small spikes of protein, which look like a crown (Sawicki and Sawicki 1986 ).", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Coronaviruses", "PROBLEM", 0, 13], ["viruses", "PROBLEM", 18, 25], ["small spikes of protein", "PROBLEM", 46, 69], ["viruses", "OBSERVATION", 18, 25], ["small", "OBSERVATION_MODIFIER", 46, 51], ["spikes", "OBSERVATION_MODIFIER", 52, 58]]], ["There are several coronaviruses; however, only seven have been found to be extremely hazardous to humans, the most popular being severe acute respiratory syndrome (SARS-COV), middle East respiratory syndrome (MERS-COV) (Wong et al. 2015; Cattivelli and Rusciano 2020; Gallardo et al. 2020; Lee 2020) , and currently COVID-19 (also known as SARS-COV-2).", [["acute respiratory syndrome", "DISEASE", 136, 162], ["SARS-COV", "DISEASE", 164, 172], ["middle East respiratory syndrome (MERS-COV", "DISEASE", 175, 217], ["coronaviruses", "ORGANISM", 18, 31], ["humans", "ORGANISM", 98, 104], ["COVID-19", "CELL", 316, 324], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104], ["several coronaviruses", "PROBLEM", 10, 31], ["severe acute respiratory syndrome", "PROBLEM", 129, 162], ["SARS-COV)", "PROBLEM", 164, 173], ["middle East respiratory syndrome", "PROBLEM", 175, 207], ["COVID", "TEST", 316, 321], ["several", "OBSERVATION_MODIFIER", 10, 17], ["coronaviruses", "OBSERVATION", 18, 31], ["hazardous", "OBSERVATION", 85, 94], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["respiratory syndrome", "OBSERVATION", 142, 162], ["middle", "ANATOMY_MODIFIER", 175, 181], ["respiratory syndrome", "OBSERVATION", 187, 207]]], ["The latter is more dangerous because it has both MERS-COV and SARS-COV characteristics.", [["SARS", "DISEASE", 62, 66], ["more dangerous", "OBSERVATION_MODIFIER", 14, 28], ["COV characteristics", "OBSERVATION_MODIFIER", 67, 86]]], ["Cold weather prevents the fragile COVID-19 casing from drying out, enabling the virus to live between hosts for longer (Banik et al. 2020) .", [["Cold weather", "PROBLEM", 0, 12], ["the fragile COVID", "PROBLEM", 22, 39], ["fragile", "OBSERVATION_MODIFIER", 26, 33]]], ["At the same time, sunlight UV exposure can affect the housing, which is disarming to the virus, although these seasonal variations are more important for known infections (Shirbandi et al. 2020) .", [["UV", "CHEMICAL", 27, 29], ["infections", "DISEASE", 160, 170], ["sunlight UV exposure", "TREATMENT", 18, 38], ["the virus", "PROBLEM", 85, 94], ["these seasonal variations", "PROBLEM", 105, 130], ["known infections", "PROBLEM", 154, 170], ["infections", "OBSERVATION", 160, 170]]], ["Not many are immune to a new virus, though; therefore, it has so many potential hosts that it does not need idle spreading conditions.", [["a new virus", "PROBLEM", 23, 34], ["new", "OBSERVATION_MODIFIER", 25, 28], ["virus", "OBSERVATION", 29, 34]]], ["For this reason, COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020.IntroductionTwo weeks after China announced its first COVID-19 case, Turkey reported its first coronavirus case.", [["coronavirus", "ORGANISM", 203, 214], ["COVID", "TEST", 17, 22]]], ["Turkey took immediate actions to combat the pandemic.", [["the pandemic", "PROBLEM", 40, 52]]], ["On January 10, 2020, a science council was established to study and manage COVID-19 cases.", [["COVID", "TEST", 75, 80]]], ["This was followed by passenger testing at significant entry points in the country, especially at the airports.", [["passenger testing", "TEST", 21, 38]]], ["On March 12, 2020, schools and universities were closed to reduce the wide spread of the virus.", [["the virus", "PROBLEM", 85, 94], ["virus", "OBSERVATION", 89, 94]]], ["Although drastic measures were enacted, the number of confirmed cases increased exponentially to over 163,000.", [["drastic measures", "TREATMENT", 9, 25], ["drastic", "OBSERVATION_MODIFIER", 9, 16], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["exponentially", "OBSERVATION_MODIFIER", 80, 93]]], ["By May 30, 2020, nearly 4500 deaths had been confirmed in Turkey due to COVID-19 (Johns Hopkins University 2020).", [["deaths", "DISEASE", 29, 35], ["COVID", "TEST", 72, 77]]], ["There is no doubt that the COVID-19 pandemic has halted the Turkish economy.", [["the COVID", "TEST", 23, 32], ["no doubt", "UNCERTAINTY", 9, 17]]], ["Istanbul, one of the most visited cities in the world, has empty streets like never before, affecting tourism, which contributed the U.S. $34.5 billion in revenue in 2019.IntroductionTo curb the economy from plummeting, the country announced a nearly U.S. $16 billion stimulus package.", [["billion stimulus package", "TREATMENT", 260, 284]]], ["Furthermore, Turkey announced credit payment delays, lowered domestic duties on domestic flights, and canceled the accommodation tax to bootstrap the tourism sector.", [["tax", "PROTEIN", 129, 132]]], ["All these actions depict the direct effect of the coronavirus on the economy.", [["coronavirus", "ORGANISM", 50, 61], ["the coronavirus", "PROBLEM", 46, 61], ["coronavirus", "OBSERVATION", 50, 61]]], ["However, little has been documented to show the impact of COVID-19 on other spheres that govern life in Turkey.", [["COVID", "TEST", 58, 63]]], ["In this study, the effect of COVID-19 on air quality, municipal wastewater, and hospital waste generation are discussed.", [["COVID-19", "CHEMICAL", 29, 37], ["COVID-19", "CHEMICAL", 29, 37], ["this study", "TEST", 3, 13], ["COVID", "TEST", 29, 34]]], ["The changes in air, waste, and water directly reflect the public health of a given community.", [["The changes in air, waste", "PROBLEM", 0, 25], ["air", "OBSERVATION", 15, 18]]], ["This study acts a foundation for future atmospheric and water modes to be constructed after the pandemic.MethodologyTo study the variations in the air quality index during the pandemic, 20 regions covering different parts of Turkey were analyzed: Adana, Amasya, Ankara, Antalya, Artvin-Hopa Bal\u0131kesir, Bolu, Burdur, Bursa, Edirne-Ke\u015fan Erzurum, Eski\u015fehir, I\u011fd\u0131r, \u0130stanbul-\u00dcmraniye, \u0130stanbul-Ka\u011f\u0131thane, \u0130stanbul-Esenyurt, Kayseri Kocaeli-Gebze, Kocaeli-Alikahya, Konya, Ordu, Rize, Sakarya, Samsun, Sivas, Tekirda\u011f-\u00c7erkezk\u00f6y, and Trabzon.", [["This study", "TEST", 0, 10], ["future atmospheric and water modes", "TREATMENT", 33, 67], ["the pandemic", "PROBLEM", 92, 104], ["Amasya", "TREATMENT", 254, 260], ["Artvin", "TEST", 279, 285], ["Bursa", "TEST", 316, 321], ["Edirne", "TEST", 323, 329], ["\u0130stanbul", "TEST", 363, 371], ["\u0130stanbul", "TEST", 382, 390], ["Ka\u011f\u0131thane", "TREATMENT", 391, 400], ["\u0130stanbul", "TEST", 402, 410], ["Tekirda\u011f", "TREATMENT", 505, 513], ["\u00c7erkezk\u00f6y", "TREATMENT", 514, 523], ["Trabzon", "TREATMENT", 529, 536], ["Bursa", "ANATOMY", 316, 321]]], ["The study covered a period from December 2019 to May 2020.", [["The study", "TEST", 0, 9]]], ["The study covered PM, a driver of air quality, and tropospheric ozone, a leading cause of smog.", [["ozone", "CHEMICAL", 64, 69], ["ozone", "CHEMICAL", 64, 69], ["The study", "TEST", 0, 9], ["tropospheric ozone", "TREATMENT", 51, 69], ["smog", "PROBLEM", 90, 94], ["tropospheric ozone", "OBSERVATION", 51, 69], ["smog", "OBSERVATION", 90, 94]]], ["For wastewater treatment plants, the study covered Sakarya and L\u00fcleburgaz regions.", [["wastewater treatment plants", "TREATMENT", 4, 31], ["the study", "TEST", 33, 42], ["L\u00fcleburgaz", "ANATOMY", 63, 73], ["regions", "ANATOMY_MODIFIER", 74, 81]]], ["Changes in the flowrate, chemical oxygen demand (COD), and total suspended solids (TSS) were studied.", [["oxygen", "CHEMICAL", 34, 40], ["COD", "CHEMICAL", 49, 52], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["COD", "SIMPLE_CHEMICAL", 49, 52], ["the flowrate", "TREATMENT", 11, 23], ["chemical oxygen demand", "TREATMENT", 25, 47], ["total suspended solids (TSS", "TREATMENT", 59, 86], ["flowrate", "OBSERVATION_MODIFIER", 15, 23], ["oxygen demand", "OBSERVATION", 34, 47]]], ["Hospital waste data were based on Sakarya hospitals-one of the more affected regions in Turkey during the pandemic.", [["Hospital waste data", "TEST", 0, 19]]], ["All air quality data were obtained from the online portal of the Ministry of Environment and Urban Planning, Turkey (http://havai zleme .gov.tr/).", [["All air quality data", "TEST", 0, 20], ["air quality", "OBSERVATION", 4, 15], ["portal", "ANATOMY", 51, 57]]], ["ArcGIS Version 10.3 was used to generate spatial maps; maps were generated using Osra's and Kajjumba's (2020) approach.Air qualityAir quality has become one of the benchmarks to determine public health.", [["ArcGIS Version", "TEST", 0, 14], ["maps", "TEST", 55, 59], ["Osra's", "TREATMENT", 81, 87], ["Kajjumba's", "TREATMENT", 92, 102]]], ["Air quality is determined through air pollution.", [["air pollution", "OBSERVATION", 34, 47]]], ["Air pollution is the introduction of chemicals that threaten life; when such chemicals are inhaled, the chances of getting lung diseases, heart diseases, and cancer increase.", [["lung", "ANATOMY", 123, 127], ["heart", "ANATOMY", 138, 143], ["cancer", "ANATOMY", 158, 164], ["lung diseases", "DISEASE", 123, 136], ["heart diseases", "DISEASE", 138, 152], ["cancer", "DISEASE", 158, 164], ["lung", "ORGAN", 123, 127], ["heart", "ORGAN", 138, 143], ["cancer", "CANCER", 158, 164], ["Air pollution", "PROBLEM", 0, 13], ["lung diseases", "PROBLEM", 123, 136], ["heart diseases", "PROBLEM", 138, 152], ["cancer", "PROBLEM", 158, 164], ["lung", "ANATOMY", 123, 127], ["diseases", "OBSERVATION", 128, 136], ["heart", "ANATOMY", 138, 143], ["diseases", "OBSERVATION", 144, 152], ["cancer", "OBSERVATION", 158, 164]]], ["In 1952, the Great Smog of London was responsible for 4000 to 12,000 deaths (Polivka 2018) .", [["deaths", "DISEASE", 69, 75], ["Great", "OBSERVATION_MODIFIER", 13, 18], ["Smog", "OBSERVATION", 19, 23]]], ["This led to the birth of air quality legislation in different parts of the world.", [["air quality", "OBSERVATION", 25, 36]]], ["Air pollution is responsible for over ten premature deaths every three hours in Turkey (Temiz Hava Hakk\u0131 2019).", [["deaths", "DISEASE", 52, 58], ["Air pollution", "PROBLEM", 0, 13], ["pollution", "OBSERVATION", 4, 13]]], ["The Turkish authority enacted legislation to reduce emissions from industries and transportation, give incentives for cleaner technologies, and reduce emissions from open burning.", [["cleaner technologies", "TREATMENT", 118, 138], ["open burning", "PROBLEM", 166, 178]]], ["Air pollution can occur naturally (through volcano eruptions and wildfires) or by anthropogenic activities.", [["eruptions", "DISEASE", 51, 60], ["wildfires", "DISEASE", 65, 74], ["Air pollution", "PROBLEM", 0, 13], ["anthropogenic activities", "OBSERVATION", 82, 106]]], ["The latter is the main driver of air pollution.", [["main", "OBSERVATION_MODIFIER", 18, 22], ["driver", "OBSERVATION", 23, 29], ["air pollution", "OBSERVATION", 33, 46]]], ["Primary air pollutants include volatile organics (VCs), carbon monoxide, nitrogen oxides (NO x ), sulfur dioxide, lead, and particulate matter (PM).", [["VCs", "CHEMICAL", 50, 53], ["carbon monoxide", "CHEMICAL", 56, 71], ["nitrogen oxides", "CHEMICAL", 73, 88], ["NO", "CHEMICAL", 90, 92], ["sulfur dioxide", "CHEMICAL", 98, 112], ["carbon monoxide", "CHEMICAL", 56, 71], ["nitrogen oxides", "CHEMICAL", 73, 88], ["NO", "CHEMICAL", 90, 92], ["sulfur dioxide", "CHEMICAL", 98, 112], ["volatile organics", "SIMPLE_CHEMICAL", 31, 48], ["VCs", "SIMPLE_CHEMICAL", 50, 53], ["carbon monoxide", "SIMPLE_CHEMICAL", 56, 71], ["nitrogen oxides", "SIMPLE_CHEMICAL", 73, 88], ["NO", "SIMPLE_CHEMICAL", 90, 92], ["sulfur dioxide", "SIMPLE_CHEMICAL", 98, 112], ["lead", "SIMPLE_CHEMICAL", 114, 118], ["particulate matter", "SIMPLE_CHEMICAL", 124, 142], ["PM", "SIMPLE_CHEMICAL", 144, 146], ["Primary air pollutants", "PROBLEM", 0, 22], ["volatile organics", "TREATMENT", 31, 48], ["carbon monoxide", "TREATMENT", 56, 71], ["nitrogen oxides", "TREATMENT", 73, 88], ["sulfur dioxide", "TREATMENT", 98, 112], ["air pollutants", "OBSERVATION", 8, 22], ["volatile organics", "OBSERVATION", 31, 48]]], ["Secondary pollutants include sulfuric acid and ozone (O 3 ), which cause acidic rain and smog, respectively.", [["sulfuric acid", "CHEMICAL", 29, 42], ["ozone", "CHEMICAL", 47, 52], ["O 3", "CHEMICAL", 54, 57], ["sulfuric acid", "CHEMICAL", 29, 42], ["ozone", "CHEMICAL", 47, 52], ["O 3", "CHEMICAL", 54, 57], ["sulfuric acid", "SIMPLE_CHEMICAL", 29, 42], ["ozone", "SIMPLE_CHEMICAL", 47, 52], ["Secondary pollutants", "PROBLEM", 0, 20], ["sulfuric acid", "TREATMENT", 29, 42], ["sulfuric acid", "OBSERVATION", 29, 42], ["acidic rain", "OBSERVATION", 73, 84]]], ["Although Turkey passed laws to reduce air pollution, air quality has been ebbing; Turkey is ranked 10th among the countries with the worst air quality (World Air Quality Index 2020).Air qualityOn the arrival of COVID-19, industries were closed and cars were banned from the roads.", [["COVID-19", "CHEMICAL", 211, 219], ["air pollution", "PROBLEM", 38, 51], ["COVID", "TEST", 211, 216], ["industries", "TREATMENT", 221, 231], ["air pollution", "OBSERVATION", 38, 51]]], ["It is hypothesized that the reduction of such activities led to improved air quality, saving over 7000 lives within 3 months of the country's lockdown.", [["reduction", "OBSERVATION_MODIFIER", 28, 37]]], ["In this study, the changes in PM 2.5 and ozone before and during lockdown are presented.", [["ozone", "CHEMICAL", 41, 46], ["ozone", "CHEMICAL", 41, 46], ["ozone", "SIMPLE_CHEMICAL", 41, 46], ["this study", "TEST", 3, 13]]], ["Ozone changes were tracked because they represent the production of precursors such as NO x and VCs.", [["Ozone", "CHEMICAL", 0, 5], ["NO", "CHEMICAL", 87, 89], ["Ozone", "CHEMICAL", 0, 5], ["NO", "CHEMICAL", 87, 89], ["VCs", "CHEMICAL", 96, 99], ["Ozone", "SIMPLE_CHEMICAL", 0, 5], ["NO x", "SIMPLE_CHEMICAL", 87, 91], ["VCs", "SIMPLE_CHEMICAL", 96, 99], ["Ozone changes", "PROBLEM", 0, 13]]], ["Additionally, the effect of ozone is easily seen through the formation of photochemical smog.", [["ozone", "CHEMICAL", 28, 33], ["ozone", "CHEMICAL", 28, 33], ["ozone", "SIMPLE_CHEMICAL", 28, 33], ["ozone", "OBSERVATION", 28, 33], ["photochemical smog", "OBSERVATION", 74, 92]]], ["Figure 1 depicts PM 2.5 and O 3 levels in Turkey in December 2019 (before COVID-19), April 2020 (during lockdown), and May 2020 (reopening of some businesses).", [["O 3", "CHEMICAL", 28, 31], ["COVID", "TEST", 74, 79]]], ["The average air quality index (AQI) based on these two parameters varied among provinces.Air qualityApart from Ankara, the capital city of Turkey, the PM levels in the central region were below 125.", [["The average air quality index", "TEST", 0, 29], ["the PM levels", "TEST", 147, 160], ["average", "OBSERVATION_MODIFIER", 4, 11], ["air", "OBSERVATION_MODIFIER", 12, 15], ["quality", "OBSERVATION_MODIFIER", 16, 23], ["capital", "OBSERVATION_MODIFIER", 123, 130], ["central", "ANATOMY_MODIFIER", 168, 175], ["region", "ANATOMY_MODIFIER", 176, 182]]], ["The central part of Turkey is sparsely populated and less industrialized compared to the rest of the country.", [["central", "ANATOMY_MODIFIER", 4, 11], ["Turkey", "OBSERVATION_MODIFIER", 20, 26], ["sparsely", "OBSERVATION_MODIFIER", 30, 38], ["populated", "OBSERVATION", 39, 48], ["less", "OBSERVATION_MODIFIER", 53, 57], ["industrialized", "OBSERVATION_MODIFIER", 58, 72]]], ["The coastal areas elicited higher PM levels because of industrialization.", [["coastal", "OBSERVATION_MODIFIER", 4, 11], ["areas", "OBSERVATION_MODIFIER", 12, 17]]], ["Erzurum province had the highest AQI levels; the region has over 81 active industrial plants that include mining, textile, agriculture, and chemical plants.", [["active", "OBSERVATION_MODIFIER", 68, 74], ["industrial plants", "OBSERVATION", 75, 92], ["chemical plants", "OBSERVATION", 140, 155]]], ["This makes the air quality in the area unhealthy for sensitive groups.", [["air quality", "OBSERVATION", 15, 26]]], ["During the lockdown, AQI improved across the entire country.", [["AQI", "PROBLEM", 21, 24], ["improved", "OBSERVATION_MODIFIER", 25, 33]]], ["Highly polluted regions like Erzurum registered an improvement in air quality.", [["Erzurum", "CHEMICAL", 29, 36], ["Highly polluted regions like Erzurum", "PROBLEM", 0, 36], ["polluted", "OBSERVATION", 7, 15], ["Erzurum", "OBSERVATION", 29, 36], ["improvement", "OBSERVATION_MODIFIER", 51, 62], ["air quality", "OBSERVATION", 66, 77]]], ["In December 2019, the average AQI was 171, while in April and May 2020, it was 66.7 and 68.5, respectively.", [["the average AQI", "TEST", 18, 33]]], ["The air quality improved by over 2.5 times.", [["air", "OBSERVATION_MODIFIER", 4, 7], ["quality", "OBSERVATION_MODIFIER", 8, 15], ["improved", "OBSERVATION_MODIFIER", 16, 24]]], ["The air quality dropped from an unhealthy to a moderate category.", [["The air quality", "TEST", 0, 15], ["air quality", "OBSERVATION", 4, 15], ["moderate", "OBSERVATION_MODIFIER", 47, 55], ["category", "OBSERVATION", 56, 64]]], ["Although PM 2.5 registered an improvement, ozone levels increased during the lockdown (Fig. 1) .Air qualityCountries like Brazil, India, and China, also registered increases in ozone levels during the lockdown (Dantas et al. 2020; Sharma et al. 2020) .", [["ozone", "CHEMICAL", 43, 48], ["ozone", "CHEMICAL", 177, 182], ["ozone", "CHEMICAL", 43, 48], ["ozone", "CHEMICAL", 177, 182], ["ozone", "SIMPLE_CHEMICAL", 43, 48], ["ozone", "SIMPLE_CHEMICAL", 177, 182], ["ozone levels", "TEST", 43, 55], ["ozone levels", "TEST", 177, 189], ["improvement", "OBSERVATION_MODIFIER", 30, 41], ["increases", "OBSERVATION_MODIFIER", 164, 173], ["ozone levels", "OBSERVATION", 177, 189]]], ["Some studies have attributed the rise in the ozone to a decrease in NO x (Dantas et al. 2020) .", [["ozone", "CHEMICAL", 45, 50], ["NO", "CHEMICAL", 68, 70], ["ozone", "CHEMICAL", 45, 50], ["NO", "CHEMICAL", 68, 70], ["ozone", "SIMPLE_CHEMICAL", 45, 50], ["NO", "SIMPLE_CHEMICAL", 68, 70], ["Some studies", "TEST", 0, 12], ["rise", "OBSERVATION_MODIFIER", 33, 37], ["decrease", "OBSERVATION_MODIFIER", 56, 64]]], ["However, the decrease in NO x should plummet ozone levels since NO x is a precursor of ozone.", [["NO", "CHEMICAL", 25, 27], ["ozone", "CHEMICAL", 45, 50], ["NO", "CHEMICAL", 64, 66], ["ozone", "CHEMICAL", 87, 92], ["NO", "CHEMICAL", 25, 27], ["ozone", "CHEMICAL", 45, 50], ["NO", "CHEMICAL", 64, 66], ["ozone", "CHEMICAL", 87, 92], ["NO", "SIMPLE_CHEMICAL", 25, 27], ["ozone", "SIMPLE_CHEMICAL", 45, 50], ["NO", "SIMPLE_CHEMICAL", 64, 66], ["ozone", "SIMPLE_CHEMICAL", 87, 92], ["plummet ozone levels", "TEST", 37, 57], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["NO", "UNCERTAINTY", 25, 27]]], ["Tropospheric ozone formation is facilitated by the presence of NO x , VCs, and sunlight, as shown in Eqs.Air quality(1)-(3).", [["ozone", "CHEMICAL", 13, 18], ["NO", "CHEMICAL", 63, 65], ["ozone", "CHEMICAL", 13, 18], ["NO", "CHEMICAL", 63, 65], ["VCs", "CHEMICAL", 70, 73], ["ozone", "SIMPLE_CHEMICAL", 13, 18], ["NO x", "SIMPLE_CHEMICAL", 63, 67], ["VCs", "SIMPLE_CHEMICAL", 70, 73], ["Tropospheric ozone formation", "PROBLEM", 0, 28], ["VCs", "TEST", 70, 73], ["ozone formation", "OBSERVATION", 13, 28]]], ["In the presence of sunlight, NO x splits, releasing an oxygen atom; this reaction is quickly reversed to form the parent compound, NO x .", [["NO", "CHEMICAL", 29, 31], ["oxygen", "CHEMICAL", 55, 61], ["NO", "CHEMICAL", 131, 133], ["NO", "CHEMICAL", 29, 31], ["oxygen", "CHEMICAL", 55, 61], ["NO", "CHEMICAL", 131, 133], ["NO", "SIMPLE_CHEMICAL", 29, 31], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["NO", "SIMPLE_CHEMICAL", 131, 133], ["releasing an oxygen atom", "PROBLEM", 42, 66], ["this reaction", "PROBLEM", 68, 81], ["NO", "UNCERTAINTY", 29, 31], ["x splits", "OBSERVATION_MODIFIER", 32, 40], ["oxygen atom", "OBSERVATION", 55, 66]]], ["However, the presence of VCs that can readily react with NO inhibit the backward reaction of NO and oxygen atoms (Finlayson-Pitts and Pitts 1993) .", [["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 93, 95], ["oxygen", "CHEMICAL", 100, 106], ["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 93, 95], ["oxygen", "CHEMICAL", 100, 106], ["VCs", "SIMPLE_CHEMICAL", 25, 28], ["NO", "SIMPLE_CHEMICAL", 57, 59], ["NO", "SIMPLE_CHEMICAL", 93, 95], ["oxygen atoms", "SIMPLE_CHEMICAL", 100, 112], ["oxygen atoms", "TREATMENT", 100, 112]]], ["The free oxygen atom can now promptly react with an oxygen molecule to form tropospheric ozone.", [["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 52, 58], ["ozone", "CHEMICAL", 89, 94], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 52, 58], ["ozone", "CHEMICAL", 89, 94], ["oxygen", "SIMPLE_CHEMICAL", 9, 15], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["ozone", "SIMPLE_CHEMICAL", 89, 94], ["The free oxygen atom", "TREATMENT", 0, 20], ["an oxygen molecule", "TREATMENT", 49, 67], ["free", "OBSERVATION_MODIFIER", 4, 8], ["oxygen atom", "OBSERVATION", 9, 20], ["tropospheric ozone", "OBSERVATION", 76, 94]]], ["Therefore, the increase in ozone levels cannot be attributed to NO x reduction, but rather to the decrease in PM levels.", [["ozone", "CHEMICAL", 27, 32], ["NO", "CHEMICAL", 64, 66], ["ozone", "CHEMICAL", 27, 32], ["NO", "CHEMICAL", 64, 66], ["ozone", "SIMPLE_CHEMICAL", 27, 32], ["NO", "SIMPLE_CHEMICAL", 64, 66], ["PM", "SIMPLE_CHEMICAL", 110, 112], ["the increase in ozone levels", "PROBLEM", 11, 39], ["the decrease in PM levels", "PROBLEM", 94, 119], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["ozone levels", "OBSERVATION", 27, 39], ["reduction", "OBSERVATION", 69, 78], ["decrease", "OBSERVATION_MODIFIER", 98, 106]]], ["When the PM levels attenuate, more sunlight can penetrate the Earth's troposphere, facilitating the breakdown of NO x to NO and oxygen molecules.", [["NO", "CHEMICAL", 113, 115], ["NO", "CHEMICAL", 121, 123], ["oxygen", "CHEMICAL", 128, 134], ["NO", "CHEMICAL", 113, 115], ["NO", "CHEMICAL", 121, 123], ["oxygen", "CHEMICAL", 128, 134], ["NO", "SIMPLE_CHEMICAL", 113, 115], ["NO", "SIMPLE_CHEMICAL", 121, 123], ["oxygen molecules", "SIMPLE_CHEMICAL", 128, 144], ["the breakdown", "PROBLEM", 96, 109], ["oxygen molecules", "PROBLEM", 128, 144], ["oxygen molecules", "OBSERVATION", 128, 144]]], ["The increase in ozone is further escalated by the end of the winter season, as the number of sunny hours increase in Spring.", [["ozone", "CHEMICAL", 16, 21], ["ozone", "CHEMICAL", 16, 21], ["ozone", "SIMPLE_CHEMICAL", 16, 21], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["ozone", "OBSERVATION_MODIFIER", 16, 21], ["escalated", "OBSERVATION_MODIFIER", 33, 42], ["increase", "OBSERVATION_MODIFIER", 105, 113]]], ["The increase in sunny hours facilitates the formation of NO, (1).", [["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 57, 59], ["NO", "SIMPLE_CHEMICAL", 57, 59], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["The ozone index in Turkey increased from 16.8 in December 2019, to 28.8 in April 2020, and to 29.7 by the end of May 2020.", [["ozone", "CHEMICAL", 4, 9], ["ozone", "CHEMICAL", 4, 9], ["ozone", "SIMPLE_CHEMICAL", 4, 9], ["The ozone index", "TEST", 0, 15], ["ozone", "OBSERVATION_MODIFIER", 4, 9], ["index", "OBSERVATION_MODIFIER", 10, 15], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["However, all of these increases are still categorized as good, based on the AQI.Municipal wastewater and wasteWater is a cardinal pillar of life; without it, life is impossible (Kajjumba et al. 2018 (Kajjumba et al. , 2019 .", [["Municipal wastewater", "TREATMENT", 80, 100], ["a cardinal pillar of life", "TREATMENT", 119, 144], ["increases", "OBSERVATION_MODIFIER", 22, 31], ["good", "OBSERVATION_MODIFIER", 57, 61]]], ["The survival duration of coronavirus ranges from 2 h to 9 days, depending on the prevailing conditions (World Health Organisation 2020).", [["coronavirus", "ORGANISM", 25, 36], ["coronavirus ranges", "TEST", 25, 43]]], ["There are fears that COVID-19 can be transmitted in the water when a sick person releases contaminated water/waste from their homes.", [["COVID-19", "CHEMICAL", 21, 29], ["person", "SPECIES", 74, 80]]], ["Australia was among the first the country to detect coronavirus in untreated wastewater (Ahmed et al. 2020) .", [["coronavirus", "DISEASE", 52, 63], ["coronavirus", "ORGANISM", 52, 63], ["coronavirus", "PROBLEM", 52, 63]]], ["This raises concern to communities-if coronavirus can escape from water treatment facilities, then coronavirus will be here to stay.", [["coronavirus", "DISEASE", 38, 49], ["coronavirus", "ORGANISM", 38, 49], ["coronavirus", "ORGANISM", 99, 110], ["coronavirus", "PROBLEM", 38, 49], ["water treatment facilities", "TREATMENT", 66, 92], ["coronavirus", "PROBLEM", 99, 110]]], ["Chorine, ultraviolet rays, and ozone are promising technologies to treat coronavirus in water.", [["Chorine", "CHEMICAL", 0, 7], ["ultraviolet rays", "CHEMICAL", 9, 25], ["ozone", "CHEMICAL", 31, 36], ["coronavirus", "DISEASE", 73, 84], ["Chorine", "CHEMICAL", 0, 7], ["ozone", "CHEMICAL", 31, 36], ["Chorine", "SIMPLE_CHEMICAL", 0, 7], ["ozone", "SIMPLE_CHEMICAL", 31, 36], ["coronavirus", "ORGANISM", 73, 84], ["Chorine", "TREATMENT", 0, 7], ["ultraviolet rays", "TREATMENT", 9, 25], ["ozone", "TREATMENT", 31, 36], ["coronavirus", "PROBLEM", 73, 84]]], ["However, all of these treatment techniques are effective in water with few suspended or dissolved solids (Ghernaout and Ghernaout 2020) .", [["these treatment techniques", "TREATMENT", 16, 42]]], ["Thus, if the virus finds a perfect hiding place, it can be released back into the environment.", [["the virus", "PROBLEM", 9, 18]]], ["In addition, if the virus finds an ideal host that is resistant to chlorination or ozonation (e.g., cryptosporidium, adenovirus, or giardia), then effluent water is expected to contain coronavirus.", [["cryptosporidium", "CHEMICAL", 100, 115], ["adenovirus", "ORGANISM", 117, 127], ["coronavirus", "ORGANISM", 185, 196], ["the virus", "PROBLEM", 16, 25], ["chlorination", "TREATMENT", 67, 79], ["ozonation", "TREATMENT", 83, 92], ["cryptosporidium", "PROBLEM", 100, 115], ["adenovirus", "PROBLEM", 117, 127], ["giardia", "PROBLEM", 132, 139], ["coronavirus", "PROBLEM", 185, 196], ["coronavirus", "OBSERVATION", 185, 196]]], ["In this study, the authors tracked the changes in wastewater treatment influent and effluent to detect any changes in chemical oxygen demand (COD) and total suspended solids (TSS) (Fig. 2) .Municipal wastewater and wasteSakarya, Turkey, is one of the regions that has registered the highest number of COVID-19 cases.", [["oxygen", "CHEMICAL", 127, 133], ["COD", "CHEMICAL", 142, 145], ["oxygen", "CHEMICAL", 127, 133], ["oxygen", "SIMPLE_CHEMICAL", 127, 133], ["COD", "SIMPLE_CHEMICAL", 142, 145], ["this study", "TEST", 3, 13], ["wastewater treatment", "TREATMENT", 50, 70], ["chemical oxygen demand", "TREATMENT", 118, 140], ["total suspended solids (TSS", "TREATMENT", 151, 178], ["COVID", "TEST", 301, 306], ["oxygen demand", "OBSERVATION", 127, 140], ["regions", "ANATOMY_MODIFIER", 251, 258]]], ["Changes in the influent and effluent quality in one of the region's wastewater treatment plants were compared to changes in the L\u00fcleburgaz wastewater treatment plant-an area that is less affected.", [["L\u00fcleburgaz", "CHEMICAL", 128, 138], ["Changes in the influent and effluent quality", "PROBLEM", 0, 44], ["wastewater treatment plants", "TREATMENT", 68, 95], ["the L\u00fcleburgaz wastewater treatment plant", "TREATMENT", 124, 165], ["influent", "OBSERVATION_MODIFIER", 15, 23], ["effluent", "OBSERVATION_MODIFIER", 28, 36], ["quality", "OBSERVATION_MODIFIER", 37, 44], ["less", "OBSERVATION_MODIFIER", 182, 186], ["affected", "OBSERVATION_MODIFIER", 187, 195]]], ["Figure 2 elicits the changes in flowrate, COD, and TSS for both plants.", [["COD", "CHEMICAL", 42, 45], ["COD", "CHEMICAL", 42, 45], ["flowrate", "SIMPLE_CHEMICAL", 32, 40], ["COD", "SIMPLE_CHEMICAL", 42, 45], ["the changes in flowrate", "PROBLEM", 17, 40], ["COD", "TREATMENT", 42, 45], ["TSS", "TREATMENT", 51, 54]]], ["Neither of the plants' flow rates changed during the coronavirus pandemic.", [["coronavirus pandemic", "DISEASE", 53, 73], ["the plants' flow rates", "TEST", 11, 33], ["the coronavirus pandemic", "PROBLEM", 49, 73], ["plants", "OBSERVATION", 15, 21]]], ["However, the L\u00fcleburgaz plant showed an increase in COD effluent during the lockdown.", [["COD", "CHEMICAL", 52, 55], ["COD", "CHEMICAL", 52, 55], ["COD", "SIMPLE_CHEMICAL", 52, 55], ["an increase in COD effluent", "PROBLEM", 37, 64], ["the lockdown", "TREATMENT", 72, 84], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["COD effluent", "OBSERVATION", 52, 64]]], ["Overall, there was no significant change in TSS or COD in either plant.", [["COD", "CHEMICAL", 51, 54], ["COD", "CHEMICAL", 51, 54], ["COD", "SIMPLE_CHEMICAL", 51, 54], ["TSS", "DNA", 44, 47], ["significant change", "PROBLEM", 22, 40], ["TSS", "PROBLEM", 44, 47], ["COD", "PROBLEM", 51, 54], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["change", "OBSERVATION", 34, 40], ["TSS", "OBSERVATION", 44, 47], ["COD", "OBSERVATION", 51, 54]]], ["Since there were no changes in the plants' influents and effluents, it should be expected that the wastewater treatment managed any coronavirus contaminated water effectively.", [["coronavirus", "DISEASE", 132, 143], ["coronavirus", "ORGANISM", 132, 143], ["the wastewater treatment", "TREATMENT", 95, 119], ["no", "UNCERTAINTY", 17, 19], ["changes", "OBSERVATION_MODIFIER", 20, 27]]], ["When the amount of medical waste generated in the same region was analyzed, the amount of waste generated only increased in April 2020; however, by May 2020, the generation had gone back to the normal trend.", [["medical waste", "TREATMENT", 19, 32], ["amount", "OBSERVATION_MODIFIER", 80, 86]]], ["Because of the COVID-19 outbreak, only emergency cases were administered to in the hospitals; therefore, there was no spike in waste generation.Municipal wastewater and waste(1)ConclusionThe post coronavirus economic crisis is evidence that Turkey is not ready for anything similar, let alone the combined set of climate impacted complications.", [["coronavirus", "ORGANISM", 196, 207], ["the COVID", "TEST", 11, 20], ["spike in waste generation", "PROBLEM", 118, 143], ["The post coronavirus economic crisis", "PROBLEM", 187, 223], ["climate impacted complications", "PROBLEM", 313, 343], ["waste generation", "OBSERVATION", 127, 143], ["impacted", "OBSERVATION_MODIFIER", 321, 329], ["complications", "OBSERVATION", 330, 343]]], ["PM 2.5 had a maximum reduction in most cities, although ozone increased.", [["ozone", "CHEMICAL", 56, 61], ["ozone", "CHEMICAL", 56, 61], ["ozone", "SIMPLE_CHEMICAL", 56, 61], ["a maximum reduction", "TREATMENT", 11, 30], ["maximum", "OBSERVATION_MODIFIER", 13, 20], ["reduction", "OBSERVATION_MODIFIER", 21, 30], ["most cities", "OBSERVATION_MODIFIER", 34, 45], ["ozone", "OBSERVATION_MODIFIER", 56, 61], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["The increase in ozone was due to a reduction in PM, which increased sunlight penetration, in-turn increasing the breakdown of NO x .", [["ozone", "CHEMICAL", 16, 21], ["NO", "CHEMICAL", 126, 128], ["ozone", "CHEMICAL", 16, 21], ["NO", "CHEMICAL", 126, 128], ["ozone", "SIMPLE_CHEMICAL", 16, 21], ["PM", "SIMPLE_CHEMICAL", 48, 50], ["NO", "SIMPLE_CHEMICAL", 126, 128], ["The increase in ozone", "PROBLEM", 0, 21], ["the breakdown", "PROBLEM", 109, 122], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["ozone", "OBSERVATION", 16, 21], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["sunlight penetration", "OBSERVATION", 68, 88], ["breakdown", "OBSERVATION_MODIFIER", 113, 122], ["NO", "UNCERTAINTY", 126, 128]]], ["Therefore, it is possible to design emission control strategies that can improve air quality.", [["emission control strategies", "TREATMENT", 36, 63]]], ["There were no significant changes in flowrate, TSS, or COD levels in wastewater treatment plants studied, demonstrating that the treatment plants were not affected by the current pandemic.", [["COD", "CHEMICAL", 55, 58], ["COD", "CHEMICAL", 55, 58], ["flowrate", "SIMPLE_CHEMICAL", 37, 45], ["COD", "SIMPLE_CHEMICAL", 55, 58], ["significant changes in flowrate", "PROBLEM", 14, 45], ["TSS", "TEST", 47, 50], ["COD levels", "PROBLEM", 55, 65], ["wastewater treatment plants", "TREATMENT", 69, 96], ["the treatment plants", "TREATMENT", 125, 145], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["changes", "OBSERVATION", 26, 33]]]], "0c2f275cf824d28a4955241173c6903a395540b3": [["raising equal concerns for embryo and fetal development (Colaco et al., 2020) .In males, ACE2 receptor sites have been reported in testicular tissue which then have the capability to harbour SARS-CoV-2 virus and eventual shedding into the semen and hence its implication in sexual transmission, early pregnancy or early in utero embryonic development.", [["embryo", "ANATOMY", 27, 33], ["fetal", "ANATOMY", 38, 43], ["testicular tissue", "ANATOMY", 131, 148], ["semen", "ANATOMY", 239, 244], ["embryonic", "ANATOMY", 329, 338], ["SARS", "DISEASE", 191, 195], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 27, 33], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 38, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["testicular tissue", "TISSUE", 131, 148], ["SARS-CoV-2 virus", "ORGANISM", 191, 207], ["semen", "ORGANISM_SUBSTANCE", 239, 244], ["utero", "ORGANISM_SUBDIVISION", 323, 328], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 329, 338], ["ACE2", "PROTEIN", 89, 93], ["CoV-2 virus", "SPECIES", 196, 207], ["SARS-CoV-2 virus", "SPECIES", 191, 207], ["embryo and fetal development", "PROBLEM", 27, 55], ["ACE2 receptor sites", "TREATMENT", 89, 108], ["harbour SARS", "PROBLEM", 183, 195], ["CoV", "TEST", 196, 199], ["2 virus", "PROBLEM", 200, 207], ["early pregnancy", "PROBLEM", 295, 310], ["testicular tissue", "ANATOMY", 131, 148]]], ["This paper concerns the available information on SARS-CoV-2 and the male factors.Infection and the effects on the male reproductive systemAs SARS-CoV-2 is a novel strain of virus, there is little information on the mechanism by which it seems to invade the respiratory system and relies on information from the previous SARS or influenza studies.", [["respiratory system", "ANATOMY", 257, 275], ["SARS", "DISEASE", 49, 53], ["Infection", "DISEASE", 81, 90], ["SARS", "DISEASE", 141, 145], ["SARS", "DISEASE", 320, 324], ["SARS-CoV-2", "ORGANISM", 141, 151], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV-2", "SPECIES", 141, 151], ["Infection", "PROBLEM", 81, 90], ["a novel strain of virus", "PROBLEM", 155, 178], ["influenza studies", "TEST", 328, 345], ["virus", "OBSERVATION", 173, 178], ["respiratory system", "ANATOMY", 257, 275]]], ["Therefore, SARS-CoV-2 viral RNA in a specimen cannot be directly interpreted as a potential for disease transmission and infection.", [["specimen", "ANATOMY", 37, 45], ["infection", "DISEASE", 121, 130], ["SARS-CoV-2", "ORGANISM", 11, 21], ["SARS-CoV-2 viral RNA", "RNA", 11, 31], ["SARS", "TEST", 11, 15], ["CoV", "TEST", 16, 19], ["2 viral RNA", "PROBLEM", 20, 31], ["disease transmission", "PROBLEM", 96, 116], ["infection", "PROBLEM", 121, 130], ["infection", "OBSERVATION", 121, 130]]], ["Furthermore, viral RNA can be detected long after the disappearance of the infectious virus.", [["viral RNA", "RNA", 13, 22], ["viral RNA", "PROBLEM", 13, 22], ["the infectious virus", "PROBLEM", 71, 91], ["viral RNA", "OBSERVATION", 13, 22], ["infectious virus", "OBSERVATION", 75, 91]]], ["In the most recent reports the viral load data is absent.", [["the viral load data", "TEST", 27, 46], ["viral load", "OBSERVATION", 31, 41]]], ["Viral culture to evaluate viral virulence and activity are so far absent in clinical practice because of the relatively long turn-around time and its low sensitivity for virus detection.", [["Viral culture", "TEST", 0, 13], ["viral virulence", "PROBLEM", 26, 41], ["virus detection", "TEST", 170, 185]]], ["The virus can be neutralised by the immune system by lysing their envelope or aggregating virus particles, thereby preventing subsequent infection.", [["immune system", "ANATOMY", 36, 49], ["infection", "DISEASE", 137, 146], ["immune system", "ANATOMICAL_SYSTEM", 36, 49], ["The virus", "PROBLEM", 0, 9], ["aggregating virus particles", "PROBLEM", 78, 105], ["subsequent infection", "PROBLEM", 126, 146], ["virus", "OBSERVATION", 4, 9], ["infection", "OBSERVATION", 137, 146]]], ["However, the nucleic acid remains and is degraded over time.", [["nucleic acid", "CHEMICAL", 13, 25], ["the nucleic acid", "TEST", 9, 25], ["nucleic acid", "OBSERVATION", 13, 25]]], ["The presence of nucleic acid in PCR alone cannot be used to define viral shedding or infection potential as experienced with other viral diseases such as SARS-CoV, Middle East respiratory syndrome (MERS) coronavirus, influenza virus, Ebola virus, Zika virus (Atkinson, 2020) .Infection and the effects on the male reproductive systemThe main SARS-Cov-2 entry into cells appears to be via the viral spike (S) protein attaching to the Angiotensin Converting Enzyme 2 (ACE2) and employing the cellular serine protease (TMPRSS2) (Hoffmann et al., 2020) .", [["cells", "ANATOMY", 364, 369], ["cellular", "ANATOMY", 490, 498], ["nucleic acid", "CHEMICAL", 16, 28], ["infection", "DISEASE", 85, 94], ["viral diseases", "DISEASE", 131, 145], ["SARS-CoV", "DISEASE", 154, 162], ["Middle East respiratory syndrome (MERS) coronavirus", "DISEASE", 164, 215], ["influenza virus", "DISEASE", 217, 232], ["Ebola virus", "DISEASE", 234, 245], ["Infection", "DISEASE", 276, 285], ["Angiotensin", "CHEMICAL", 433, 444], ["serine", "CHEMICAL", 499, 505], ["SARS-CoV", "ORGANISM", 154, 162], ["Middle East respiratory syndrome (MERS) coronavirus", "ORGANISM", 164, 215], ["influenza virus", "ORGANISM", 217, 232], ["Ebola virus", "ORGANISM", 234, 245], ["Zika virus", "ORGANISM", 247, 257], ["Cov-2", "GENE_OR_GENE_PRODUCT", 347, 352], ["cells", "CELL", 364, 369], ["Angiotensin Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 433, 464], ["ACE2", "GENE_OR_GENE_PRODUCT", 466, 470], ["cellular serine protease", "GENE_OR_GENE_PRODUCT", 490, 514], ["viral spike (S) protein", "PROTEIN", 392, 415], ["Angiotensin Converting Enzyme 2", "PROTEIN", 433, 464], ["ACE2", "PROTEIN", 466, 470], ["cellular serine protease", "PROTEIN", 490, 514], ["TMPRSS2", "PROTEIN", 516, 523], ["influenza virus", "SPECIES", 217, 232], ["Ebola virus", "SPECIES", 234, 245], ["Zika virus", "SPECIES", 247, 257], ["SARS-CoV", "SPECIES", 154, 162], ["Middle East respiratory syndrome (MERS) coronavirus", "SPECIES", 164, 215], ["Ebola virus", "SPECIES", 234, 245], ["Zika virus", "SPECIES", 247, 257], ["nucleic acid in PCR", "PROBLEM", 16, 35], ["viral shedding", "PROBLEM", 67, 81], ["infection", "PROBLEM", 85, 94], ["other viral diseases", "PROBLEM", 125, 145], ["SARS", "PROBLEM", 154, 158], ["CoV", "PROBLEM", 159, 162], ["Middle East respiratory syndrome", "PROBLEM", 164, 196], ["coronavirus", "PROBLEM", 204, 215], ["influenza virus", "PROBLEM", 217, 232], ["Ebola virus", "PROBLEM", 234, 245], ["Zika virus", "PROBLEM", 247, 257], ["Infection", "PROBLEM", 276, 285], ["The main SARS", "TEST", 333, 346], ["Cov", "TEST", 347, 350], ["the viral spike", "PROBLEM", 388, 403], ["the Angiotensin Converting Enzyme", "TEST", 429, 462], ["the cellular serine protease", "TREATMENT", 486, 514], ["nucleic acid", "OBSERVATION", 16, 28], ["infection", "OBSERVATION", 85, 94], ["Middle", "ANATOMY_MODIFIER", 164, 170], ["respiratory syndrome", "OBSERVATION", 176, 196], ["main", "OBSERVATION_MODIFIER", 337, 341], ["SARS", "OBSERVATION", 342, 346], ["appears to be", "UNCERTAINTY", 370, 383], ["viral spike", "OBSERVATION", 392, 403]]], ["Both ACE2 and TMPRSS2 are also present in the testis and therefore testicular infection and subsequent sexual transmission is gaining interest amongst scientists.", [["testis", "ANATOMY", 46, 52], ["testicular", "ANATOMY", 67, 77], ["testicular infection", "DISEASE", 67, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 14, 21], ["testis", "ORGAN", 46, 52], ["testicular", "ORGAN", 67, 77], ["ACE2", "PROTEIN", 5, 9], ["TMPRSS2", "PROTEIN", 14, 21], ["TMPRSS2", "TREATMENT", 14, 21], ["testicular infection", "PROBLEM", 67, 87], ["TMPRSS2", "OBSERVATION", 14, 21], ["testis", "ANATOMY", 46, 52], ["testicular", "ANATOMY", 67, 77], ["infection", "OBSERVATION", 78, 87]]], ["Studies analysing SARS-CoV-2 in seminal fluid or testicular biopsies have so far lacked appropriate controls and patients suffered from predominantly mild infections and tested several weeks after the infection, thereby increasing the complexity of result interpretation.", [["seminal fluid", "ANATOMY", 32, 45], ["testicular biopsies", "ANATOMY", 49, 68], ["infections", "DISEASE", 155, 165], ["infection", "DISEASE", 201, 210], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 28], ["seminal fluid", "ORGANISM_SUBSTANCE", 32, 45], ["testicular biopsies", "MULTI-TISSUE_STRUCTURE", 49, 68], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["SARS-CoV", "SPECIES", 18, 26], ["Studies", "TEST", 0, 7], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["seminal fluid", "TEST", 32, 45], ["testicular biopsies", "TEST", 49, 68], ["predominantly mild infections", "PROBLEM", 136, 165], ["the infection", "PROBLEM", 197, 210], ["seminal", "ANATOMY", 32, 39], ["fluid", "OBSERVATION", 40, 45], ["testicular", "ANATOMY", 49, 59], ["biopsies", "OBSERVATION", 60, 68], ["predominantly", "OBSERVATION_MODIFIER", 136, 149], ["mild", "OBSERVATION_MODIFIER", 150, 154], ["infections", "OBSERVATION", 155, 165], ["infection", "OBSERVATION", 201, 210]]], ["A study conducted in 34 men, 25-75 days after mainly mild initial SARS-Cov-2 infection, showed that there was an absence of virus using RT-PCR in the semen (Pan F et al., 2020) .", [["semen", "ANATOMY", 150, 155], ["SARS-Cov-2 infection", "DISEASE", 66, 86], ["men", "ORGANISM", 24, 27], ["semen", "ORGANISM_SUBSTANCE", 150, 155], ["men", "SPECIES", 24, 27], ["A study", "TEST", 0, 7], ["mainly mild initial SARS-Cov-2 infection", "PROBLEM", 46, 86], ["virus", "PROBLEM", 124, 129], ["RT-PCR", "TEST", 136, 142], ["mild", "OBSERVATION_MODIFIER", 53, 57], ["SARS", "OBSERVATION", 66, 70], ["infection", "OBSERVATION", 77, 86]]], ["This may be causally reassuring (Eisenberg ML., 2020) but such cases cannot be generalised to those suffering severe infections and also does not account for the limitations of PCR test interpretation described earlier.Infection and the effects on the male reproductive systemIn contrast, of 38 men providing semen samples, 23 men (60.5%) had clinically recovered, whilst 15 men (39.5%) were at the acute stage of infection.", [["semen samples", "ANATOMY", 309, 322], ["infections", "DISEASE", 117, 127], ["infection", "DISEASE", 414, 423], ["men", "ORGANISM", 295, 298], ["semen samples", "MULTI-TISSUE_STRUCTURE", 309, 322], ["men", "ORGANISM", 327, 330], ["men", "ORGANISM", 375, 378], ["men", "SPECIES", 295, 298], ["men", "SPECIES", 327, 330], ["men", "SPECIES", 375, 378], ["severe infections", "PROBLEM", 110, 127], ["PCR test interpretation", "TEST", 177, 200], ["Infection", "PROBLEM", 219, 228], ["semen samples", "TEST", 309, 322], ["infection", "PROBLEM", 414, 423], ["may be", "UNCERTAINTY", 5, 11], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["infections", "OBSERVATION", 117, 127], ["acute stage", "OBSERVATION_MODIFIER", 399, 410], ["infection", "OBSERVATION", 414, 423]]], ["SARS-CoV-2 in semen from 6 patients (15.8%) was positive, including 4 of 15 patients (26.7%) who were in the acute stage of infection.", [["semen", "ANATOMY", 14, 19], ["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 124, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["semen", "ORGANISM_SUBSTANCE", 14, 19], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["infection", "PROBLEM", 124, 133], ["acute stage", "OBSERVATION_MODIFIER", 109, 120], ["infection", "OBSERVATION", 124, 133]]], ["However, 2 men (8.7%) were recovering, which is particularly noteworthy .", [["men", "ORGANISM", 11, 14], ["men", "SPECIES", 11, 14]]], ["Other viruses such as Zika, HIV and CMV are found in semen and it is possible for viral shedding to occur, if the viral loads due to the severity of infection are high.", [["semen", "ANATOMY", 53, 58], ["infection", "DISEASE", 149, 158], ["Zika", "GENE_OR_GENE_PRODUCT", 22, 26], ["HIV", "ORGANISM", 28, 31], ["CMV", "ORGANISM", 36, 39], ["semen", "ORGANISM_SUBSTANCE", 53, 58], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["CMV", "SPECIES", 36, 39], ["Other viruses", "PROBLEM", 0, 13], ["Zika", "PROBLEM", 22, 26], ["HIV", "PROBLEM", 28, 31], ["CMV", "PROBLEM", 36, 39], ["viral shedding", "PROBLEM", 82, 96], ["the viral loads", "PROBLEM", 110, 125], ["the severity of infection", "PROBLEM", 133, 158], ["viruses", "OBSERVATION", 6, 13], ["CMV", "OBSERVATION", 36, 39], ["infection", "OBSERVATION", 149, 158]]], ["This is especially true if the bloodtestes/deferens/epididymis barriers are damaged due to systemic local inflammation.", [["bloodtestes/deferens", "ANATOMY", 31, 51], ["epididymis", "ANATOMY", 52, 62], ["inflammation", "DISEASE", 106, 118], ["deferens", "ORGAN", 43, 51], ["epididymis", "ORGAN", 52, 62], ["the bloodtestes/deferens/epididymis barriers", "PROBLEM", 27, 71], ["systemic local inflammation", "PROBLEM", 91, 118], ["deferens", "ANATOMY", 43, 51], ["epididymis", "ANATOMY", 52, 62], ["systemic", "OBSERVATION_MODIFIER", 91, 99], ["local", "OBSERVATION_MODIFIER", 100, 105], ["inflammation", "OBSERVATION", 106, 118]]], ["It is unlikely that SARS-CoV-2 could replicate in the male reproductive tract Considering SARS-CoV-2 infected male patients, is there a possibility that a virus with a size of 70-90 nm may breach the blood-testis barrier?", [["reproductive tract", "ANATOMY", 59, 77], ["blood", "ANATOMY", 200, 205], ["testis", "ANATOMY", 206, 212], ["SARS", "DISEASE", 20, 24], ["SARS-CoV-2 infected", "DISEASE", 90, 109], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["male reproductive tract", "ORGANISM_SUBDIVISION", 54, 77], ["SARS-CoV-2", "ORGANISM", 90, 100], ["patients", "ORGANISM", 115, 123], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["testis barrier", "MULTI-TISSUE_STRUCTURE", 206, 220], ["patients", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 90, 98], ["SARS", "PROBLEM", 20, 24], ["CoV", "TEST", 25, 28], ["SARS", "PROBLEM", 90, 94], ["a virus", "PROBLEM", 153, 160], ["a size", "TEST", 166, 172], ["the blood", "TEST", 196, 205], ["unlikely", "UNCERTAINTY", 6, 14], ["SARS", "OBSERVATION", 20, 24], ["virus", "OBSERVATION", 155, 160], ["testis", "ANATOMY", 206, 212]]], ["Furthermore, is the mechanism of filtering out SARS-CoV-2 so complex and efficient that ACE2 could be absorbing the entire SARS-CoV-2 viruses, in which case should we be analysing the alterations to the ACE-2 receptor sites instead?", [["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["SARS-CoV-2 viruses", "ORGANISM", 123, 141], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 203, 217], ["ACE2", "PROTEIN", 88, 92], ["ACE-2 receptor sites", "DNA", 203, 223], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["the entire SARS", "PROBLEM", 112, 127], ["the ACE-2 receptor sites", "TREATMENT", 199, 223]]], ["In particular, this applies to the testes, where immune privilege may protect the immunogenic germ cells from some systemic viral infections.", [["testes", "ANATOMY", 35, 41], ["germ cells", "ANATOMY", 94, 104], ["viral infections", "DISEASE", 124, 140], ["testes", "ORGAN", 35, 41], ["germ cells", "CELL", 94, 104], ["immunogenic germ cells", "CELL_TYPE", 82, 104], ["immune privilege", "TREATMENT", 49, 65], ["the immunogenic germ cells", "PROBLEM", 78, 104], ["some systemic viral infections", "PROBLEM", 110, 140], ["testes", "ANATOMY", 35, 41], ["immunogenic germ cells", "OBSERVATION", 82, 104], ["systemic", "OBSERVATION_MODIFIER", 115, 123], ["viral infections", "OBSERVATION", 124, 140]]], ["However, a number of viruses e.g. mumps, HIV, HHV8, Ebola, Zika are confirmed to have traversed the blood-testis barrier to elicit an immune response within the testicle (Salam et al., 2017; Zhao et al., 2014) .", [["blood", "ANATOMY", 100, 105], ["testis", "ANATOMY", 106, 112], ["testicle", "ANATOMY", 161, 169], ["mumps, HIV, HHV8, Ebola", "DISEASE", 34, 57], ["mumps", "ORGANISM", 34, 39], ["HIV", "ORGANISM", 41, 44], ["HHV8", "ORGANISM", 46, 50], ["Ebola", "ORGANISM", 52, 57], ["Zika", "GENE_OR_GENE_PRODUCT", 59, 63], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["testis barrier", "MULTI-TISSUE_STRUCTURE", 106, 120], ["testicle", "ORGAN", 161, 169], ["HIV", "SPECIES", 41, 44], ["HIV", "SPECIES", 41, 44], ["viruses", "PROBLEM", 21, 28], ["mumps", "PROBLEM", 34, 39], ["HIV", "PROBLEM", 41, 44], ["HHV8", "PROBLEM", 46, 50], ["Ebola", "PROBLEM", 52, 57], ["Zika", "PROBLEM", 59, 63], ["the blood-testis barrier", "TREATMENT", 96, 120], ["viruses", "OBSERVATION", 21, 28], ["testis", "ANATOMY", 106, 112], ["immune response", "OBSERVATION", 134, 149], ["testicle", "ANATOMY", 161, 169]]], ["In the case of mumps, men can develop orchitis which is associated with testicular atrophy and azoospermia (Philips J., 2006) .", [["testicular", "ANATOMY", 72, 82], ["mumps", "DISEASE", 15, 20], ["orchitis", "DISEASE", 38, 46], ["testicular atrophy", "DISEASE", 72, 90], ["azoospermia", "DISEASE", 95, 106], ["mumps", "ORGANISM", 15, 20], ["men", "ORGANISM", 22, 25], ["testicular", "ORGAN", 72, 82], ["men", "SPECIES", 22, 25], ["mumps", "PROBLEM", 15, 20], ["orchitis", "PROBLEM", 38, 46], ["testicular atrophy", "PROBLEM", 72, 90], ["azoospermia", "PROBLEM", 95, 106], ["orchitis", "OBSERVATION", 38, 46], ["associated with", "UNCERTAINTY", 56, 71], ["testicular", "ANATOMY", 72, 82], ["atrophy", "OBSERVATION", 83, 90], ["azoospermia", "OBSERVATION", 95, 106]]], ["There is also a report relating to SARS infection and orchitis (Xu et al. 2006) .", [["SARS infection", "DISEASE", 35, 49], ["orchitis", "DISEASE", 54, 62], ["SARS infection", "PROBLEM", 35, 49], ["orchitis", "PROBLEM", 54, 62], ["SARS", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49], ["orchitis", "OBSERVATION", 54, 62]]], ["However, the mere presence of viruses in a semen sample does not mean that the disease is sexually transmitted (Feldmann., 2018) .Cryopreservation and sperm donation in the SARS-CoV-2 eraOn a practical level, this may have an impact for cryopreserving semen for oncology patients and highlights the need to resume fertility services.", [["semen sample", "ANATOMY", 43, 55], ["sperm", "ANATOMY", 151, 156], ["semen", "ANATOMY", 252, 257], ["SARS", "DISEASE", 173, 177], ["sperm", "ORGANISM_SUBSTANCE", 151, 156], ["semen", "ORGANISM_SUBSTANCE", 252, 257], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 271, 279], ["SARS-CoV", "SPECIES", 173, 181], ["viruses", "PROBLEM", 30, 37], ["the disease", "PROBLEM", 75, 86], ["Cryopreservation", "TREATMENT", 130, 146], ["sperm donation", "TEST", 151, 165], ["the SARS", "TEST", 169, 177], ["CoV", "TEST", 178, 181], ["fertility services", "TREATMENT", 314, 332], ["viruses", "OBSERVATION", 30, 37], ["disease", "OBSERVATION", 79, 86]]], ["For men with older female partners, age dependent subfertility may become irreversible if clinics remain closed except for emergency oncology patients.", [["subfertility", "DISEASE", 50, 62], ["men", "ORGANISM", 4, 7], ["patients", "ORGANISM", 142, 150], ["men", "SPECIES", 4, 7], ["patients", "SPECIES", 142, 150], ["age dependent subfertility", "PROBLEM", 36, 62]]], ["Likewise, if ovarian stimulation and fertilization were to occur, freezing the resulting embryos and delaying embryo transfer may be another strategy.", [["ovarian", "ANATOMY", 13, 20], ["embryos", "ANATOMY", 89, 96], ["embryo", "ANATOMY", 110, 116], ["ovarian", "ORGAN", 13, 20], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 89, 96], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 110, 116], ["ovarian stimulation", "PROBLEM", 13, 32], ["fertilization", "TREATMENT", 37, 50], ["the resulting embryos", "PROBLEM", 75, 96], ["embryo transfer", "TREATMENT", 110, 125]]], ["The use of highly secure devices and segregated cryovessels is suggested while acknowledging the risks associated with couriering cryopreserved samples between clinics (Yakass and Woodward, 2020) .", [["cryovessels", "ANATOMY", 48, 59], ["samples", "ANATOMY", 144, 151], ["cryovessels", "DISEASE", 48, 59], ["highly secure devices", "TREATMENT", 11, 32]]], ["The general problem of recruiting sperm donors in light of the incubation for SAR-Cov-2 also raises uncertainties.", [["sperm", "ANATOMY", 34, 39], ["sperm", "ORGANISM", 34, 39], ["recruiting sperm donors", "TREATMENT", 23, 46], ["the incubation", "TREATMENT", 59, 73], ["SAR", "TEST", 78, 81]]], ["Currently the 2-week suspension from the end of symptoms is suggested for donors showing respiratory symptoms or those who have returned from high-risk areas, seems not to be based on any particular follow-up studies or latency period for SARS-Cov-2 (La Marca et al., 2020) .", [["respiratory", "ANATOMY", 89, 100], ["respiratory symptoms", "DISEASE", 89, 109], ["SARS", "DISEASE", 239, 243], ["donors", "ORGANISM", 74, 80], ["symptoms", "PROBLEM", 48, 56], ["respiratory symptoms", "PROBLEM", 89, 109], ["SARS", "PROBLEM", 239, 243], ["Cov", "TEST", 244, 247]]], ["No data exists on semen quality following a SARS-CoV-2 infection but it is likely the stress period will increase cortisol levels and depress sperm quality similar to the effects of febrile systemic illnesses (Chan et al., 2020) .", [["semen", "ANATOMY", 18, 23], ["sperm", "ANATOMY", 142, 147], ["SARS", "DISEASE", 44, 48], ["infection", "DISEASE", 55, 64], ["cortisol", "CHEMICAL", 114, 122], ["febrile systemic illnesses", "DISEASE", 182, 208], ["cortisol", "CHEMICAL", 114, 122], ["semen", "ORGANISM_SUBSTANCE", 18, 23], ["SARS-CoV-2", "ORGANISM", 44, 54], ["cortisol", "SIMPLE_CHEMICAL", 114, 122], ["sperm", "ORGANISM_SUBSTANCE", 142, 147], ["sperm", "CELL_TYPE", 142, 147], ["SARS-CoV-2", "SPECIES", 44, 54], ["a SARS-CoV-2 infection", "PROBLEM", 42, 64], ["the stress period", "PROBLEM", 82, 99], ["cortisol levels", "TEST", 114, 129], ["depress sperm quality", "PROBLEM", 134, 155], ["febrile systemic illnesses", "PROBLEM", 182, 208], ["infection", "OBSERVATION", 55, 64]]], ["It is important to establish under controlled experiments whether the testis could harbour SARS-Cov-2 and its dormancy period before drafting policies on reproductive health (Cardona-Maya., 2020), while risk managing patients and staff (Anifandis et al., 2020) .Implication of non-peer, reviewed reports on SARS-CoV-2 and male factor implicationAgainst this backdrop are the numerous publications concerning SARS-Cov-2 and reproductive health in non-peer reviewed MedRxiv platform (https://www.medrxiv.org/) which cautions readers about its use to guide clinical practice or health-related behaviours, while urging news media to refrain from reporting these.Implication of non-peer, reviewed reports on SARS-CoV-2 and male factor implicationThe non-peer reviewed papers suggest that there is no clinical evidence on whether SARS-CoV-2 infection can affect male gonadal function.", [["testis", "ANATOMY", 70, 76], ["gonadal", "ANATOMY", 861, 868], ["SARS", "DISEASE", 91, 95], ["SARS", "DISEASE", 408, 412], ["SARS", "DISEASE", 824, 828], ["infection", "DISEASE", 835, 844], ["testis", "ORGAN", 70, 76], ["Cov-2", "CELL", 96, 101], ["patients", "ORGANISM", 217, 225], ["SARS-CoV-2", "ORGANISM", 824, 834], ["gonadal", "ORGAN", 861, 868], ["patients", "SPECIES", 217, 225], ["SARS", "PROBLEM", 408, 412], ["SARS", "PROBLEM", 824, 828], ["CoV-2 infection", "PROBLEM", 829, 844], ["testis", "ANATOMY", 70, 76]]], ["In a study of 81 reproductive-aged men with SARS-CoV-2, the serum luteinizing hormone (LH) was significantly increased, but the ratio of testosterone (T) to LH and the ratio of follicle stimulating hormone (FSH) to LH were dramatically decreased .", [["serum", "ANATOMY", 60, 65], ["SARS", "DISEASE", 44, 48], ["testosterone", "CHEMICAL", 137, 149], ["testosterone", "CHEMICAL", 137, 149], ["men", "ORGANISM", 35, 38], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["luteinizing hormone", "GENE_OR_GENE_PRODUCT", 66, 85], ["LH", "GENE_OR_GENE_PRODUCT", 87, 89], ["testosterone (T)", "GENE_OR_GENE_PRODUCT", 137, 153], ["LH", "GENE_OR_GENE_PRODUCT", 157, 159], ["follicle stimulating hormone", "GENE_OR_GENE_PRODUCT", 177, 205], ["FSH", "GENE_OR_GENE_PRODUCT", 207, 210], ["LH", "GENE_OR_GENE_PRODUCT", 215, 217], ["men", "SPECIES", 35, 38], ["a study", "TEST", 3, 10], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["the serum luteinizing hormone", "TEST", 56, 85], ["LH", "TEST", 157, 159], ["follicle stimulating hormone", "PROBLEM", 177, 205], ["FSH", "TEST", 207, 210], ["LH", "TEST", 215, 217], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["dramatically", "OBSERVATION_MODIFIER", 223, 235], ["decreased", "OBSERVATION_MODIFIER", 236, 245]]], ["There were no semen parameters reported alongside this, whilst stress and corticosteroid therapy may also affect the hypothalamic-pituitary-gonadal axis separately.", [["semen", "ANATOMY", 14, 19], ["corticosteroid", "SIMPLE_CHEMICAL", 74, 88], ["pituitary", "ORGAN", 130, 139], ["gonadal axis", "MULTI-TISSUE_STRUCTURE", 140, 152], ["semen parameters", "TEST", 14, 30], ["corticosteroid therapy", "TREATMENT", 74, 96], ["no", "UNCERTAINTY", 11, 13], ["pituitary", "ANATOMY", 130, 139], ["gonadal axis", "ANATOMY", 140, 152]]], ["The question on whether SARS-CoV-2 can directly infect the testes or the male genital tract and be sexually transmitted from mildly infected males has been considered (Song C., 2020) .", [["testes", "ANATOMY", 59, 65], ["genital tract", "ANATOMY", 78, 91], ["SARS", "DISEASE", 24, 28], ["sexually transmitted from mildly infected", "DISEASE", 99, 140], ["SARS-CoV-2", "ORGANISM", 24, 34], ["testes", "ORGAN", 59, 65], ["genital tract", "ORGAN", 78, 91], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["mildly infected males", "PROBLEM", 125, 146], ["testes", "ANATOMY", 59, 65], ["genital tract", "ANATOMY", 78, 91], ["mildly", "OBSERVATION_MODIFIER", 125, 131], ["infected", "OBSERVATION", 132, 140]]], ["In this study, the RT-PCR result was negative in 11 semen and 1 testicular biopsy specimens from a deceased 67-year-old.", [["semen", "ANATOMY", 52, 57], ["testicular biopsy specimens", "ANATOMY", 64, 91], ["semen", "ORGANISM_SUBSTANCE", 52, 57], ["testicular biopsy specimens", "CANCER", 64, 91], ["this study", "TEST", 3, 13], ["the RT-PCR result", "TEST", 15, 32], ["1 testicular biopsy specimens", "TEST", 62, 91], ["RT", "ANATOMY", 19, 21], ["negative", "OBSERVATION", 37, 45], ["testicular", "ANATOMY", 64, 74], ["biopsy", "OBSERVATION", 75, 81]]], ["While they concluded that there is no evidence of sexual transmission of SARS-CoV-2 from males there is no data to allow this statement with the serious limitations of interpretation raised earlier.", [["SARS", "DISEASE", 73, 77], ["SARS-CoV-2", "ORGANISM", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["SARS", "PROBLEM", 73, 77], ["no evidence of", "UNCERTAINTY", 35, 49]]], ["For example, these studies should have included PCR results from respiratory tissues or ocular fluids in optimally infected cases most likely to show viral presence.", [["respiratory tissues", "ANATOMY", 65, 84], ["ocular fluids", "ANATOMY", 88, 101], ["respiratory tissues", "TISSUE", 65, 84], ["ocular fluids", "ORGANISM_SUBSTANCE", 88, 101], ["these studies", "TEST", 13, 26], ["PCR", "TEST", 48, 51], ["respiratory tissues", "PROBLEM", 65, 84], ["ocular fluids", "PROBLEM", 88, 101], ["optimally infected cases", "PROBLEM", 105, 129], ["viral presence", "PROBLEM", 150, 164], ["respiratory tissues", "ANATOMY", 65, 84], ["viral", "OBSERVATION", 150, 155]]], ["Also no SARS-CoV-2 was detected in expressed prostatic secretion (EPS) of 18 confirmed Covid-19 infected patients and 5 strongly suspected cases but absent semen analyses.", [["prostatic", "ANATOMY", 45, 54], ["semen", "ANATOMY", 156, 161], ["Covid-19 infected", "DISEASE", 87, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 8, 18], ["prostatic", "ORGAN", 45, 54], ["patients", "ORGANISM", 105, 113], ["semen", "ORGANISM_SUBSTANCE", 156, 161], ["patients", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 8, 16], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["EPS", "TEST", 66, 69], ["Covid", "TEST", 87, 92], ["absent semen analyses", "PROBLEM", 149, 170], ["no", "UNCERTAINTY", 5, 7], ["SARS", "OBSERVATION", 8, 12], ["prostatic", "ANATOMY", 45, 54]]], ["Furthermore, some papers take a leap into the unknown by analysing vaginal fluids from 35 female patients for SARS-CoV-2 as a mode of sexual transmission and where 42.9% of partners were subsequently infected, completely disregards the lack of social distancing (Cui et al., 2020) .", [["vaginal fluids", "ANATOMY", 67, 81], ["SARS", "DISEASE", 110, 114], ["vaginal fluids", "TISSUE", 67, 81], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["SARS-CoV", "SPECIES", 110, 118], ["SARS", "PROBLEM", 110, 114]]], ["All these studies lack adequate controls, quality of infected males well away from the infected period.", [["All these studies", "TEST", 0, 17], ["infected", "OBSERVATION", 87, 95]]], ["We have further highlighted the limitation of interpretation from the diagnostic tests.", [["the diagnostic tests", "TEST", 66, 86]]], ["Despite the warnings on using these data, it is the appearance in the media which seems impossible to correct.Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesStandard testing kits for the public have so far used non-validated procedures for antibodies of which there may be up to a 50% false negative rate (Blanchard S, 2020) .", [["tissues", "ANATOMY", 199, 206], ["patients", "ORGANISM", 173, 181], ["reproductive tissues", "TISSUE", 186, 206], ["antibodies", "PROTEIN", 289, 299], ["patients", "SPECIES", 173, 181], ["these data", "TEST", 30, 40], ["Diagnostic testing", "TEST", 110, 128], ["reproductive tissues", "PROBLEM", 186, 206], ["Standard testing kits", "TEST", 206, 227], ["non-validated procedures", "TREATMENT", 260, 284], ["antibodies", "TREATMENT", 289, 299]]], ["In hospital and research establishments testing of bodily fluids and tissues is expected to be more sensitive but these too have not been validated for diagnosis of SARS-CoV-2 infection.", [["bodily fluids", "ANATOMY", 51, 64], ["tissues", "ANATOMY", 69, 76], ["SARS-CoV-2 infection", "DISEASE", 165, 185], ["tissues", "TISSUE", 69, 76], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV-2", "SPECIES", 165, 175], ["research establishments testing of bodily fluids and tissues", "TEST", 16, 76], ["SARS", "PROBLEM", 165, 169], ["CoV", "PROBLEM", 170, 173], ["2 infection", "PROBLEM", 174, 185], ["SARS", "OBSERVATION", 165, 169], ["infection", "OBSERVATION", 176, 185]]], ["Caution therefore needs to be exercised in accepting the validity of a SARS-CoV-2 infection test (FDA1), while the predictive values of a positive (or negative) test result is dependent on the prevalence of antibody-positive individuals in a given population as well as the sensitivity and specificity of the test.", [["SARS", "DISEASE", 71, 75], ["infection", "DISEASE", 82, 91], ["CoV-2", "ORGANISM", 76, 81], ["SARS-CoV", "SPECIES", 71, 79], ["a SARS", "TEST", 69, 75], ["CoV-2 infection test", "TEST", 76, 96], ["the predictive values", "TEST", 111, 132], ["antibody", "TEST", 207, 215], ["positive individuals", "PROBLEM", 216, 236], ["the sensitivity", "TEST", 270, 285], ["the test", "TEST", 305, 313]]], ["In other words, the predictive value of a serological test may be higher where there is widespread infection.", [["infection", "DISEASE", 99, 108], ["a serological test", "TEST", 40, 58], ["widespread infection", "PROBLEM", 88, 108], ["widespread", "OBSERVATION_MODIFIER", 88, 98], ["infection", "OBSERVATION", 99, 108]]], ["To minimize false positive results, the serological tests must specifically be able to identify antibodies against SARS-CoV-2 and should not \"cross-react\" with other antigens or similar respiratory viruses (FDA2).", [["SARS", "DISEASE", 115, 119], ["SARS-CoV-2", "ORGANISM", 115, 125], ["similar respiratory viruses", "ORGANISM", 178, 205], ["FDA2", "GENE_OR_GENE_PRODUCT", 207, 211], ["antibodies", "PROTEIN", 96, 106], ["antigens", "PROTEIN", 166, 174], ["SARS-CoV", "SPECIES", 115, 123], ["false positive results", "PROBLEM", 12, 34], ["the serological tests", "TEST", 36, 57], ["antibodies", "TEST", 96, 106], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["similar respiratory viruses", "PROBLEM", 178, 205], ["respiratory viruses", "OBSERVATION", 186, 205]]], ["Different types of clinical specimens from infected SARS-CoV-2 individuals tested by RT-PCR have shown a high degree of respiratory tissue preference; broncho-alveolar lavage fluid (93%), sputum (72%), nasal swabs (63%), pharyngeal swabs (32%), faeces (29%), blood (1%) and urine (0%) .", [["specimens", "ANATOMY", 28, 37], ["respiratory tissue", "ANATOMY", 120, 138], ["broncho-alveolar lavage fluid", "ANATOMY", 151, 180], ["sputum", "ANATOMY", 188, 194], ["nasal swabs", "ANATOMY", 202, 213], ["pharyngeal swabs", "ANATOMY", 221, 237], ["faeces", "ANATOMY", 245, 251], ["blood", "ANATOMY", 259, 264], ["urine", "ANATOMY", 274, 279], ["SARS", "DISEASE", 52, 56], ["SARS-CoV-2", "ORGANISM", 52, 62], ["individuals", "ORGANISM", 63, 74], ["tissue", "TISSUE", 132, 138], ["broncho-alveolar lavage fluid", "ORGANISM_SUBSTANCE", 151, 180], ["sputum", "ORGANISM_SUBSTANCE", 188, 194], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 202, 213], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 221, 237], ["faeces", "ORGANISM_SUBSTANCE", 245, 251], ["blood", "ORGANISM_SUBSTANCE", 259, 264], ["urine", "ORGANISM_SUBSTANCE", 274, 279], ["CoV-2", "SPECIES", 57, 62], ["SARS-CoV", "SPECIES", 52, 60], ["clinical specimens", "TEST", 19, 37], ["infected SARS", "TEST", 43, 56], ["CoV", "TEST", 57, 60], ["RT", "TEST", 85, 87], ["PCR", "TEST", 88, 91], ["respiratory tissue preference", "PROBLEM", 120, 149], ["broncho", "TEST", 151, 158], ["alveolar lavage fluid", "TEST", 159, 180], ["sputum", "TEST", 188, 194], ["nasal swabs", "TEST", 202, 213], ["pharyngeal swabs", "TEST", 221, 237], ["faeces", "TEST", 245, 251], ["blood", "TEST", 259, 264], ["urine", "TEST", 274, 279], ["high degree", "OBSERVATION_MODIFIER", 105, 116], ["respiratory tissue", "OBSERVATION", 120, 138], ["alveolar", "ANATOMY", 159, 167], ["nasal", "ANATOMY", 202, 207], ["pharyngeal swabs", "ANATOMY", 221, 237]]], ["Controlled data on specificity and sensitivity of tissue specific tests with `spiking' are absent.", [["tissue", "ANATOMY", 50, 56], ["tissue", "TISSUE", 50, 56], ["specificity", "TEST", 19, 30], ["tissue specific tests", "TEST", 50, 71]]], ["This limited report provides a glimmer of hope for the blood transfusion sector but equally raises questions about offering diagnostic SARS-CoV-2 testing in blood samples against swab tests.Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesOverall, little confidence exists in the clinical application of serological antibody tests showing heterogeneous assay performance.", [["blood", "ANATOMY", 55, 60], ["blood samples", "ANATOMY", 157, 170], ["swab", "ANATOMY", 179, 183], ["tissues", "ANATOMY", 279, 286], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["CoV-2", "GENE_OR_GENE_PRODUCT", 140, 145], ["blood samples", "ORGANISM_SUBSTANCE", 157, 170], ["patients", "ORGANISM", 253, 261], ["reproductive tissues", "TISSUE", 266, 286], ["patients", "SPECIES", 253, 261], ["the blood transfusion sector", "TREATMENT", 51, 79], ["diagnostic SARS", "TEST", 124, 139], ["CoV", "TEST", 140, 143], ["blood samples", "TEST", 157, 170], ["swab tests", "TEST", 179, 189], ["Diagnostic testing", "TEST", 190, 208], ["reproductive tissues", "PROBLEM", 266, 286], ["serological antibody tests", "TEST", 351, 377], ["heterogeneous assay performance", "PROBLEM", 386, 417], ["heterogeneous", "OBSERVATION_MODIFIER", 386, 399]]], ["In SARS-CoV-2 RT-PCR-positive individuals, seropositivity showed time dependence and peaked at 81.8-100.0% in samples taken >20 days after the onset of symptoms.", [["samples", "ANATOMY", 110, 117], ["SARS-CoV-2", "ORGANISM", 3, 13], ["individuals", "ORGANISM", 30, 41], ["SARS-CoV-2 RT-PCR", "DNA", 3, 20], ["SARS-CoV", "SPECIES", 3, 11], ["SARS", "TEST", 3, 7], ["CoV", "TEST", 8, 11], ["PCR", "TEST", 17, 20], ["positive individuals", "PROBLEM", 21, 41], ["seropositivity", "TEST", 43, 57], ["time dependence", "PROBLEM", 65, 80], ["symptoms", "PROBLEM", 152, 160]]], ["Test specificity ranged from 84.3-100.0% in pre-COVID-19 specimens and IgM detection was more variable than IgG, with optimal detection when both IgM and IgG results were combined.", [["specimens", "ANATOMY", 57, 66], ["IgG", "GENE_OR_GENE_PRODUCT", 108, 111], ["IgM", "GENE_OR_GENE_PRODUCT", 146, 149], ["IgG", "GENE_OR_GENE_PRODUCT", 154, 157], ["IgM", "PROTEIN", 71, 74], ["IgG", "PROTEIN", 108, 111], ["IgM", "PROTEIN", 146, 149], ["IgG", "PROTEIN", 154, 157], ["Test specificity", "TEST", 0, 16], ["pre-COVID", "TEST", 44, 53], ["IgM detection", "TEST", 71, 84], ["IgG", "TEST", 108, 111], ["optimal detection", "TEST", 118, 135], ["IgM", "TEST", 146, 149], ["IgG", "TEST", 154, 157]]], ["Agreement between two ELISAs and ten lateral flow assays ranged from 75.8-94.8%.", [["two ELISAs", "TEST", 18, 28], ["ten lateral flow assays", "TEST", 33, 56]]], ["Improving serological tests will require evaluations of the full spectrum of SARS-CoV-2 infections, from asymptomatic individuals or mild infection to severe disease, and later convalescence (Whitman et al., 2020) .Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesIn contrast, RT-PCR which is used extensively in diagnostic virology and expected to give a precise result is lacking in several key aspects.", [["tissues", "ANATOMY", 304, 311], ["SARS", "DISEASE", 77, 81], ["infections", "DISEASE", 88, 98], ["infection", "DISEASE", 138, 147], ["SARS-CoV-2", "ORGANISM", 77, 87], ["patients", "ORGANISM", 278, 286], ["reproductive tissues", "TISSUE", 291, 311], ["patients", "SPECIES", 278, 286], ["SARS-CoV-2", "SPECIES", 77, 87], ["Improving serological tests", "TEST", 0, 27], ["evaluations", "TEST", 41, 52], ["SARS", "PROBLEM", 77, 81], ["CoV-2 infections", "PROBLEM", 82, 98], ["asymptomatic individuals", "PROBLEM", 105, 129], ["mild infection to severe disease", "PROBLEM", 133, 165], ["Diagnostic testing", "TEST", 215, 233], ["reproductive tissues", "PROBLEM", 291, 311], ["RT-PCR", "TEST", 324, 330], ["mild", "OBSERVATION_MODIFIER", 133, 137], ["infection", "OBSERVATION", 138, 147], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["disease", "OBSERVATION", 158, 165]]], ["The SARS-CoV-2 infection validation has been against previous 2002/03 SARS viral strains and aided by the use of synthetic nucleic acid technology (Corman et al., 2020) .", [["infection", "DISEASE", 15, 24], ["nucleic acid", "CHEMICAL", 123, 135], ["SARS-CoV-2", "ORGANISM", 4, 14], ["The SARS-CoV-2 infection validation", "PROBLEM", 0, 35], ["SARS viral strains", "PROBLEM", 70, 88], ["synthetic nucleic acid technology", "TREATMENT", 113, 146], ["infection", "OBSERVATION", 15, 24]]], ["Other SARS-CoV RNA has been used as a positive control.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["SARS-CoV RNA", "RNA", 6, 18], ["SARS-CoV", "SPECIES", 6, 14], ["Other SARS-CoV RNA", "PROBLEM", 0, 18], ["a positive control", "TREATMENT", 36, 54], ["CoV RNA", "OBSERVATION_MODIFIER", 11, 18]]], ["Whilst the molecular assay sensitivity for SARS-coronavirus (SARS-CoV) is too low for early stages of the infection, the sensitivity improves with the severity of infection to optimize the test .", [["SARS-coronavirus", "DISEASE", 43, 59], ["infection", "DISEASE", 106, 115], ["infection", "DISEASE", 163, 172], ["SARS-coronavirus", "ORGANISM", 43, 59], ["SARS-CoV", "ORGANISM", 61, 69], ["SARS-coronavirus", "SPECIES", 43, 59], ["SARS-CoV", "SPECIES", 61, 69], ["the molecular assay sensitivity", "TEST", 7, 38], ["SARS", "PROBLEM", 43, 47], ["coronavirus", "PROBLEM", 48, 59], ["the infection", "PROBLEM", 102, 115], ["the sensitivity", "TEST", 117, 132], ["infection", "PROBLEM", 163, 172], ["the test", "TEST", 185, 193], ["infection", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 163, 172]]], ["These types of tests normally take months rather than weeks to validate.", [["tests", "TEST", 15, 20]]], ["While work is in progress to improve the diagnostic tests, the limits of using the tests along with the sample type, fluid or tissue, sampling technique, severity of the infection and above all using appropriate controls need to be factored in the results.", [["fluid", "ANATOMY", 117, 122], ["tissue", "ANATOMY", 126, 132], ["infection", "DISEASE", 170, 179], ["tissue", "TISSUE", 126, 132], ["the diagnostic tests", "TEST", 37, 57], ["the tests", "TEST", 79, 88], ["sampling technique", "TEST", 134, 152], ["the infection", "PROBLEM", 166, 179], ["fluid", "OBSERVATION", 117, 122], ["infection", "OBSERVATION", 170, 179]]], ["RT-PCR swab kits which give a positive result does not necessarily mean that infection exists, as the virus is not known to be alive and active.", [["infection", "DISEASE", 77, 86], ["RT-PCR swab kits", "TEST", 0, 16], ["infection", "PROBLEM", 77, 86], ["the virus", "PROBLEM", 98, 107], ["infection", "OBSERVATION", 77, 86], ["active", "OBSERVATION_MODIFIER", 137, 143]]], ["RT PCR sensitivity in symptomatic patients is approximately 60-95% while good sampling collection and virus transfer is key to false negatives.Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesWhilst population testing targets preoccupies the political-public arena, little attention is paid to critically appraise the underlying inaccurate diagnostic science, highly commercialised without complete validation.", [["tissues", "ANATOMY", 232, 239], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 206, 214], ["reproductive tissues", "TISSUE", 219, 239], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 206, 214], ["RT PCR sensitivity", "TEST", 0, 18], ["Diagnostic testing", "TEST", 143, 161], ["reproductive tissues", "PROBLEM", 219, 239], ["symptomatic", "OBSERVATION_MODIFIER", 22, 33]]], ["This false reassurance constitutes a major risk factor to the public through free movement of virus releasing spreaders.", [["This false reassurance", "TREATMENT", 0, 22]]], ["Therefore, the best policy is to presume that all patients are infected and to use the best available infection prevention and PPE possible during this pandemic.", [["infection", "DISEASE", 102, 111], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["infected", "PROBLEM", 63, 71], ["infection prevention", "TREATMENT", 102, 122], ["PPE", "TREATMENT", 127, 130], ["this pandemic", "PROBLEM", 147, 160], ["infected", "OBSERVATION", 63, 71], ["infection", "OBSERVATION", 102, 111]]], ["The limitations of tests also cast doubt on the many publications coming through as to how to interpret a negative test result.", [["tests", "TEST", 19, 24]]], ["To understand the tests, the public needs to understand the underlying science.Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesThe design and validation for SARS-CoV-2 RT-PCR testing was framed close genetic relatedness to the 2003 SARS-CoV virus and aided by the use of synthetic nucleic acid technology (Corman et al., 2020) .", [["tissues", "ANATOMY", 168, 175], ["SARS-CoV virus", "DISEASE", 280, 294], ["nucleic acid", "CHEMICAL", 329, 341], ["patients", "ORGANISM", 142, 150], ["reproductive tissues", "TISSUE", 155, 175], ["SARS-CoV virus", "ORGANISM", 280, 294], ["patients", "SPECIES", 142, 150], ["CoV virus", "SPECIES", 285, 294], ["SARS-CoV", "SPECIES", 205, 213], ["SARS-CoV virus", "SPECIES", 280, 294], ["the tests", "TEST", 14, 23], ["Diagnostic testing", "TEST", 79, 97], ["reproductive tissues", "PROBLEM", 155, 175], ["validation", "TEST", 190, 200], ["SARS", "TEST", 205, 209], ["CoV", "TEST", 210, 213], ["PCR testing", "TEST", 219, 230], ["CoV virus", "TREATMENT", 285, 294], ["synthetic nucleic acid technology", "TREATMENT", 319, 352]]], ["This was further improved with the availability of the SARS-CoV-2 genome sequence and incorporating variant viruses from an animal reservoir to theoretically ensure broad sensitivity.", [["SARS-CoV-2 genome sequence", "DNA", 55, 81], ["SARS-CoV", "SPECIES", 55, 63], ["the SARS", "TEST", 51, 59], ["variant viruses", "PROBLEM", 100, 115], ["an animal reservoir", "TREATMENT", 121, 140], ["broad sensitivity", "PROBLEM", 165, 182]]], ["Sampling problems contribute to false negatives and multiple site sampling may improve the test sensitivity .", [["Sampling problems", "PROBLEM", 0, 17], ["false negatives", "PROBLEM", 32, 47], ["multiple site sampling", "PROBLEM", 52, 74], ["the test sensitivity", "TEST", 87, 107], ["false negatives", "OBSERVATION", 32, 47]]], ["The rapid introduction of new diagnostic tests and controls during this evaluation study may add to the uncertainty of measurements.", [["new diagnostic tests", "TEST", 26, 46], ["this evaluation study", "TEST", 67, 88]]], ["In non-pregnant patients falsenegative results ranged from 17-63% for SARS-CoV-2 RT-PCT (Kelly et al., 2020) .", [["SARS", "DISEASE", 70, 74], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78]]], ["There was no clear gold standard test available.", [["no", "UNCERTAINTY", 10, 12]]], ["Diagnostic test characteristics included sensitivity and specificity, while positive and negative predictive values of SARS-CoV-2 RT-PCR assays are difficult to determine.", [["SARS-CoV", "SPECIES", 119, 127], ["Diagnostic test characteristics", "TEST", 0, 31], ["sensitivity", "TEST", 41, 52], ["specificity", "TEST", 57, 68], ["SARS", "TEST", 119, 123], ["CoV", "TEST", 124, 127], ["RT-PCR assays", "TEST", 130, 143]]], ["SARS-CoV-2 RT-PCR false-negative testing has major clinical implications, especially in pregnant women and in men with suspicion of severe/critical SARS-CoV-2infection and for the research reports emerging.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2infection", "DISEASE", 148, 167], ["women", "ORGANISM", 97, 102], ["men", "ORGANISM", 110, 113], ["women", "SPECIES", 97, 102], ["men", "SPECIES", 110, 113], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["PCR false", "TEST", 14, 23], ["severe/critical SARS", "PROBLEM", 132, 152], ["2infection", "PROBLEM", 157, 167], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["SARS", "OBSERVATION", 148, 152]]], ["Two individuals, with a history of exposure to SARS-CoV-2-infected patients showed positive results on RT-PCR a day before onset , thereby suggesting infected individuals can be infectious before they become symptomatic.", [["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "ORGANISM", 47, 57], ["patients", "ORGANISM", 67, 75], ["individuals", "ORGANISM", 159, 170], ["CoV-", "SPECIES", 52, 56], ["patients", "SPECIES", 67, 75], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["RT-PCR", "TEST", 103, 109], ["infected individuals", "PROBLEM", 150, 170], ["symptomatic", "PROBLEM", 208, 219], ["suggesting", "UNCERTAINTY", 139, 149], ["infected", "OBSERVATION", 150, 158]]], ["Unlike the earlier SARS virus peaking at 10 days, the SARS-CoV-2 peaks at around 5-6 days after symptom onset.", [["SARS", "DISEASE", 19, 23], ["SARS", "DISEASE", 54, 58], ["SARS virus", "SPECIES", 19, 29], ["SARS-CoV", "SPECIES", 54, 62], ["the earlier SARS virus", "PROBLEM", 7, 29], ["the SARS", "TEST", 50, 58], ["CoV", "TEST", 59, 62], ["symptom onset", "PROBLEM", 96, 109]]], ["Sputum samples generally showed higher viral loads than throat swab samples, while in the same two patients viral RNA was not detected in urine or stool samples , raising the question whether severity of illness would alter detection at other sites and whether adequate viral spiking controls were performed to rule out sensitivity of testing for these sites.", [["Sputum samples", "ANATOMY", 0, 14], ["throat swab samples", "ANATOMY", 56, 75], ["urine", "ANATOMY", 138, 143], ["stool samples", "ANATOMY", 147, 160], ["illness", "DISEASE", 204, 211], ["Sputum samples", "ORGANISM_SUBSTANCE", 0, 14], ["throat swab samples", "ORGANISM_SUBSTANCE", 56, 75], ["patients", "ORGANISM", 99, 107], ["urine", "ORGANISM_SUBSTANCE", 138, 143], ["stool samples", "ORGANISM_SUBSTANCE", 147, 160], ["viral RNA", "RNA", 108, 117], ["patients", "SPECIES", 99, 107], ["Sputum samples", "TEST", 0, 14], ["higher viral loads", "PROBLEM", 32, 50], ["throat swab samples", "TEST", 56, 75], ["viral RNA", "TEST", 108, 117], ["urine or stool samples", "TEST", 138, 160], ["illness", "PROBLEM", 204, 211], ["adequate viral spiking controls", "PROBLEM", 261, 292], ["testing", "TEST", 335, 342], ["these sites", "PROBLEM", 347, 358], ["viral loads", "OBSERVATION", 39, 50], ["viral RNA", "OBSERVATION", 108, 117]]], ["Clearly as many as 3-5 repeat SARS-CoV2 RT-PCR testing may be required for a positive result .Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesThe WHO recommends two negative SARS-CoV-2 RNA PCR tests, at least 24 h apart, before discharge although this is not widely practiced (WHO, 2020) .", [["tissues", "ANATOMY", 183, 190], ["patients", "ORGANISM", 157, 165], ["reproductive tissues", "TISSUE", 170, 190], ["CoV2", "DNA", 35, 39], ["patients", "SPECIES", 157, 165], ["repeat SARS", "TEST", 23, 34], ["CoV2 RT", "TEST", 35, 42], ["PCR testing", "TEST", 43, 54], ["a positive result", "PROBLEM", 75, 92], ["Diagnostic testing", "TEST", 94, 112], ["reproductive tissues", "PROBLEM", 170, 190], ["CoV", "TEST", 227, 230], ["RNA PCR tests", "TEST", 233, 246]]], ["Prolonged presence of SARS-CoV-2 RNA may suggest the potential for viral replication to occur.", [["SARS", "DISEASE", 22, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["SARS-CoV-2 RNA", "RNA", 22, 36], ["SARS", "PROBLEM", 22, 26], ["CoV-2 RNA", "PROBLEM", 27, 36], ["viral replication", "PROBLEM", 67, 84], ["SARS", "OBSERVATION", 22, 26], ["may suggest the potential for", "UNCERTAINTY", 37, 66], ["viral replication", "OBSERVATION", 67, 84]]], ["The incubation time for SARS-CoV-2 also remains unclear to provide guidance to patients and clinics, especially when fertility services are to resume.Diagnostic testing relevant to understanding testing fertility patients and reproductive tissuesDue to the limitations in the accuracy of the diagnostic methods, every man with infertility and having a semen test and all women should be treated as potentially positive and infective even in case of negative results.", [["tissues", "ANATOMY", 239, 246], ["SARS", "DISEASE", 24, 28], ["infertility", "DISEASE", 327, 338], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 213, 221], ["reproductive tissues", "TISSUE", 226, 246], ["man", "ORGANISM", 318, 321], ["women", "ORGANISM", 371, 376], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 213, 221], ["man", "SPECIES", 318, 321], ["women", "SPECIES", 371, 376], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["Diagnostic testing", "TEST", 150, 168], ["reproductive tissues", "PROBLEM", 226, 246], ["infertility", "PROBLEM", 327, 338], ["a semen test", "TEST", 350, 362], ["infective", "PROBLEM", 423, 432]]], ["SARS-CoV-2 has brought unique challenges to the global reproductive healthcare community finding newer ways to risk manage patients (Anifandis etal 2020)Future outlookUnravelling the mechanism of SARS-CoV-2 entry into semen and the testes would help us assess the early impact on male reproductive function.", [["semen", "ANATOMY", 218, 223], ["testes", "ANATOMY", 232, 238], ["SARS", "DISEASE", 0, 4], ["patients", "ORGANISM", 123, 131], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 196, 206], ["semen", "ORGANISM_SUBSTANCE", 218, 223], ["testes", "ORGAN", 232, 238], ["patients", "SPECIES", 123, 131], ["SARS", "TEST", 196, 200], ["CoV", "TEST", 201, 204], ["SARS", "OBSERVATION", 196, 200], ["testes", "ANATOMY", 232, 238]]], ["Equally, the impact of SARS-CoV-2 related stress and fever manifesting in depressed semen quality can not be underestimated and also possible intergenerational effects (Chan et al., 2020) .", [["semen", "ANATOMY", 84, 89], ["SARS", "DISEASE", 23, 27], ["fever", "DISEASE", 53, 58], ["depressed", "DISEASE", 74, 83], ["SARS-CoV-2", "ORGANISM", 23, 33], ["semen", "ORGANISM_SUBSTANCE", 84, 89], ["SARS", "PROBLEM", 23, 27], ["stress", "PROBLEM", 42, 48], ["fever", "PROBLEM", 53, 58], ["depressed semen quality", "PROBLEM", 74, 97], ["SARS", "OBSERVATION", 23, 27]]], ["The limited and poorly reported small studies in seminal plasma and the testes lack adequate controls to establish evidence-based guidelines for the public nor are they able to produce guidance on sexual practices or reproduction, given the lack of social distancing appears a major risk.", [["seminal plasma", "ANATOMY", 49, 63], ["testes", "ANATOMY", 72, 78], ["seminal plasma", "ORGANISM_SUBSTANCE", 49, 63], ["testes", "ORGAN", 72, 78], ["seminal plasma", "TEST", 49, 63], ["sexual practices", "TREATMENT", 197, 213], ["seminal plasma", "ANATOMY", 49, 63], ["testes", "ANATOMY", 72, 78]]], ["The main weaknesses of reports relate to poorly validated diagnostic procedures, lack of controls, mildly infected males tested several weeks later along with the fact that vital respiratory tissue most likely to harbour the viral RNA has never been reported alongside as well as the lack of control analyses.ConclusionThe proof of SARS-CoV-2 shedding into semen or in the testes is still not established and there is a lack of good quality evidence.", [["respiratory tissue", "ANATOMY", 179, 197], ["semen", "ANATOMY", 357, 362], ["testes", "ANATOMY", 373, 379], ["tissue", "TISSUE", 191, 197], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 332, 342], ["semen", "ORGANISM_SUBSTANCE", 357, 362], ["testes", "ORGAN", 373, 379], ["viral RNA", "RNA", 225, 234], ["diagnostic procedures", "TEST", 58, 79], ["lack of controls", "PROBLEM", 81, 97], ["mildly infected males", "PROBLEM", 99, 120], ["vital respiratory tissue", "PROBLEM", 173, 197], ["the viral RNA", "PROBLEM", 221, 234], ["SARS", "TEST", 332, 336], ["CoV", "TEST", 337, 340], ["main", "OBSERVATION_MODIFIER", 4, 8], ["mildly", "OBSERVATION_MODIFIER", 99, 105], ["infected", "OBSERVATION", 106, 114], ["respiratory tissue", "OBSERVATION", 179, 197], ["viral RNA", "OBSERVATION", 225, 234], ["testes", "ANATOMY", 373, 379]]], ["The findings are consistent with all reports so far.", [["consistent with", "UNCERTAINTY", 17, 32]]], ["Therefore, no firm conclusions can be drawn on sexual transmission of SARS-CoV-2 but it makes sense to use barrier protection to minimise STD generally.", [["SARS", "DISEASE", 70, 74], ["STD", "DISEASE", 138, 141], ["SARS-CoV-2", "ORGANISM", 70, 80], ["barrier", "TISSUE", 107, 114], ["SARS-CoV", "SPECIES", 70, 78], ["firm conclusions", "PROBLEM", 14, 30], ["SARS", "PROBLEM", 70, 74], ["barrier protection", "TREATMENT", 107, 125], ["no", "UNCERTAINTY", 11, 13], ["firm", "OBSERVATION", 14, 18]]], ["The degree of SARS-CoV-2 detection uncertainty seems to have evaded public scrutiny, while media reporting from mainly non-peer reviewed reports is unacceptable.", [["SARS", "DISEASE", 14, 18], ["SARS", "PROBLEM", 14, 18], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["SARS", "OBSERVATION", 14, 18]]], ["Further studies are required at all levels to help improve the quality of evidence to understand the effects of SARS-CoV-2 on male fertility and the health of the testes.", [["testes", "ANATOMY", 163, 169], ["SARS", "DISEASE", 112, 116], ["SARS-CoV-2", "ORGANISM", 112, 122], ["testes", "ORGAN", 163, 169], ["Further studies", "TEST", 0, 15], ["testes", "ANATOMY", 163, 169]]]], "PMC7419580": [["IntroductionViruses causing respiratory tract infections have been the cause of high morbidities and mortality rates worldwide, often in a seasonal manner for decades (1).", [["respiratory tract", "ANATOMY", 28, 45], ["IntroductionViruses", "DISEASE", 0, 19], ["respiratory tract infections", "DISEASE", 28, 56], ["tract", "ORGANISM_SUBDIVISION", 40, 45], ["IntroductionViruses", "TREATMENT", 0, 19], ["respiratory tract infections", "PROBLEM", 28, 56], ["high morbidities", "PROBLEM", 80, 96], ["respiratory tract", "ANATOMY", 28, 45], ["high", "OBSERVATION_MODIFIER", 80, 84], ["morbidities", "OBSERVATION", 85, 96]]], ["In the last 20 years, the world has experienced six major outbreaks of infectious agents (SARS-CoV: 2002-2004; H1N1 Influenza: 2009\u20132010; MERS-CoV: 2012\u20132020; Ebola virus: 2013\u20132016; Zika virus: 2015\u20132016; SARS-CoV-2: 2019-present), infection with four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2) result in respiratory tract infections.", [["respiratory tract", "ANATOMY", 321, 338], ["SARS", "DISEASE", 90, 94], ["Influenza", "DISEASE", 116, 125], ["Ebola virus", "DISEASE", 159, 170], ["infection", "DISEASE", 233, 242], ["SARS-CoV", "DISEASE", 263, 271], ["Influenza", "DISEASE", 278, 287], ["respiratory tract infections", "DISEASE", 321, 349], ["SARS-CoV", "ORGANISM", 90, 98], ["MERS-CoV", "ORGANISM", 138, 146], ["Ebola virus", "ORGANISM", 159, 170], ["Zika virus", "ORGANISM", 183, 193], ["SARS-CoV", "ORGANISM", 206, 214], ["SARS-CoV", "ORGANISM", 263, 271], ["H1N1 Influenza", "ORGANISM", 273, 287], ["MERS-CoV", "ORGANISM", 289, 297], ["SARS-CoV-2", "ORGANISM", 299, 309], ["respiratory tract", "ORGANISM_SUBDIVISION", 321, 338], ["H1N1 Influenza", "SPECIES", 111, 125], ["Ebola virus", "SPECIES", 159, 170], ["H1N1 Influenza", "SPECIES", 273, 287], ["SARS-CoV: 2002-2004; H1N1 Influenza: 2009\u20132010; MERS-CoV: 2012\u20132020; Ebola virus: 2013\u20132016; Zika virus: 2015\u20132016; SARS-CoV", "SPECIES", 90, 214], ["SARS-CoV", "SPECIES", 263, 271], ["MERS-CoV", "SPECIES", 289, 297], ["SARS-CoV", "SPECIES", 299, 307], ["Ebola virus", "TEST", 159, 170], ["Zika virus", "TEST", 183, 193], ["SARS", "TEST", 206, 210], ["CoV", "TEST", 211, 214], ["infection", "PROBLEM", 233, 242], ["SARS", "TEST", 263, 267], ["CoV", "TEST", 268, 271], ["H1N1", "PROBLEM", 273, 277], ["Influenza", "PROBLEM", 278, 287], ["MERS", "TEST", 289, 293], ["CoV", "TEST", 294, 297], ["SARS", "PROBLEM", 299, 303], ["CoV", "TEST", 304, 307], ["respiratory tract infections", "PROBLEM", 321, 349], ["infection", "OBSERVATION", 233, 242], ["respiratory tract", "ANATOMY", 321, 338]]], ["During the emergency of a viral disease, attention is initially focussed on clinical management of the primary infection, but it is imperative to consider secondary bacterial infections that develop in patients during or following initial infection.", [["viral disease", "DISEASE", 26, 39], ["primary infection", "DISEASE", 103, 120], ["bacterial infections", "DISEASE", 165, 185], ["infection", "DISEASE", 239, 248], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["a viral disease", "PROBLEM", 24, 39], ["clinical management", "TREATMENT", 76, 95], ["the primary infection", "PROBLEM", 99, 120], ["secondary bacterial infections", "PROBLEM", 155, 185], ["initial infection", "PROBLEM", 231, 248], ["viral disease", "OBSERVATION", 26, 39], ["primary", "OBSERVATION_MODIFIER", 103, 110], ["infection", "OBSERVATION", 111, 120], ["bacterial", "OBSERVATION_MODIFIER", 165, 174], ["infections", "OBSERVATION", 175, 185], ["infection", "OBSERVATION", 239, 248]]], ["In addition, co-infections - the simultaneous infection with a second pathogen of viral or bacterial origin- can also occur and ultimately result in the same outcome: The patient suffers from complications caused by two different pathogens (2, 3).", [["infection", "DISEASE", 46, 55], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178], ["co-infections", "PROBLEM", 13, 26], ["the simultaneous infection", "PROBLEM", 29, 55], ["viral or bacterial origin", "PROBLEM", 82, 107], ["complications", "PROBLEM", 192, 205], ["two different pathogens", "PROBLEM", 216, 239], ["co-infections", "OBSERVATION", 13, 26], ["infection", "OBSERVATION", 46, 55], ["viral", "OBSERVATION", 82, 87], ["bacterial origin", "OBSERVATION", 91, 107], ["complications", "OBSERVATION", 192, 205], ["different", "OBSERVATION_MODIFIER", 220, 229], ["pathogens", "OBSERVATION", 230, 239]]], ["One major complication of viral infections, especially pulmonary viruses, is colonization of the viral affected organs by bacteria which is associated with high morbidity and mortality rates (Figure 1A), following a weakened immune response and/or opportunistic and accessible routes of entry for bacterial pathogen(s) (4).", [["pulmonary", "ANATOMY", 55, 64], ["organs", "ANATOMY", 112, 118], ["viral infections", "DISEASE", 26, 42], ["pulmonary viruses", "DISEASE", 55, 72], ["pulmonary", "ORGAN", 55, 64], ["organs", "ORGAN", 112, 118], ["viral infections", "PROBLEM", 26, 42], ["pulmonary viruses", "PROBLEM", 55, 72], ["the viral affected organs", "PROBLEM", 93, 118], ["bacteria", "PROBLEM", 122, 130], ["high morbidity", "PROBLEM", 156, 170], ["mortality rates", "TEST", 175, 190], ["a weakened immune response", "PROBLEM", 214, 240], ["bacterial pathogen", "PROBLEM", 297, 315], ["major", "OBSERVATION_MODIFIER", 4, 9], ["complication", "OBSERVATION", 10, 22], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infections", "OBSERVATION", 32, 42], ["pulmonary", "ANATOMY", 55, 64], ["viruses", "OBSERVATION", 65, 72], ["colonization", "OBSERVATION_MODIFIER", 77, 89], ["viral", "OBSERVATION", 97, 102], ["high", "OBSERVATION_MODIFIER", 156, 160], ["morbidity", "OBSERVATION", 161, 170]]], ["While secondary bacterial infections or superinfections are largely a consequence of immune susceptibility caused by the primary viral infection, co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously.", [["bacterial infections", "DISEASE", 16, 36], ["superinfections", "DISEASE", 40, 55], ["primary viral infection", "DISEASE", 121, 144], ["co-infections", "DISEASE", 146, 159], ["infections", "DISEASE", 173, 183], ["yeast", "SPECIES", 201, 206], ["yeast", "SPECIES", 201, 206], ["secondary bacterial infections", "PROBLEM", 6, 36], ["superinfections", "PROBLEM", 40, 55], ["immune susceptibility", "PROBLEM", 85, 106], ["the primary viral infection", "PROBLEM", 117, 144], ["co-infections", "PROBLEM", 146, 159], ["multiple infections (viral/bacterial/yeast", "PROBLEM", 164, 206], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 26, 36], ["superinfections", "OBSERVATION", 40, 55], ["immune susceptibility", "OBSERVATION", 85, 106], ["primary", "OBSERVATION_MODIFIER", 121, 128], ["viral", "OBSERVATION_MODIFIER", 129, 134], ["infection", "OBSERVATION", 135, 144], ["multiple", "OBSERVATION_MODIFIER", 164, 172], ["infections", "OBSERVATION", 173, 183]]], ["Co-infections, secondary infections or \u201csuperinfections\u201d are common during viral pandemics.", [["Co-infections", "DISEASE", 0, 13], ["infections", "DISEASE", 25, 35], ["superinfections", "DISEASE", 40, 55], ["viral pandemics", "DISEASE", 75, 90], ["Co-infections", "PROBLEM", 0, 13], ["secondary infections", "PROBLEM", 15, 35], ["\u201csuperinfections", "PROBLEM", 39, 55], ["viral pandemics", "PROBLEM", 75, 90], ["secondary", "OBSERVATION_MODIFIER", 15, 24], ["infections", "OBSERVATION", 25, 35], ["superinfections", "OBSERVATION", 40, 55]]], ["The 1918 Spanish Flu pandemic saw around 50 million deaths ascribed to bacterial co-infections and during the 2009 H1N1 Influenza pandemic up to 34% of all deaths were a result of bacterial co-infections (5).", [["Flu", "CHEMICAL", 17, 20], ["deaths", "DISEASE", 52, 58], ["bacterial co-infections", "DISEASE", 71, 94], ["Influenza", "DISEASE", 120, 129], ["deaths", "DISEASE", 156, 162], ["bacterial co-infections", "DISEASE", 180, 203], ["H1N1 Influenza pandemic", "SPECIES", 115, 138], ["bacterial co-infections", "PROBLEM", 71, 94], ["H1N1 Influenza pandemic", "PROBLEM", 115, 138], ["all deaths", "PROBLEM", 152, 162], ["bacterial co-infections", "PROBLEM", 180, 203], ["bacterial co-infections", "OBSERVATION", 71, 94], ["bacterial co-infections", "OBSERVATION", 180, 203]]], ["These complications are often neglected in the clinical record (Figure 1B) (6, 7).IntroductionWhile the precise mechanism for susceptibility to secondary infections is poorly understood, it is likely that virus-mediated immunosuppression of the host innate immune enables opportunistic bacteria to colonize the host as it was shown for Streptococcus (8).", [["infections", "DISEASE", 154, 164], ["These complications", "PROBLEM", 0, 19], ["secondary infections", "PROBLEM", 144, 164], ["virus-mediated immunosuppression", "TREATMENT", 205, 237], ["opportunistic bacteria", "PROBLEM", 272, 294], ["Streptococcus", "PROBLEM", 336, 349], ["complications", "OBSERVATION", 6, 19], ["infections", "OBSERVATION", 154, 164]]], ["Most studies on host-pathogen interactions focus on a single-pathogen, one-host model although mammalian hosts are simultaneously exposed to multiple (opportunistic) pathogens (9).", [["opportunistic) pathogens", "DISEASE", 151, 175], ["mammalian hosts", "ORGANISM", 95, 110], ["Most studies", "TEST", 0, 12], ["mammalian hosts", "TREATMENT", 95, 110]]], ["The immune response to one pathogen may alter the immunity to other infectious agent(s), resulting in increased prevalence of viral-induced secondary bacterial infections (10).", [["bacterial infections", "DISEASE", 150, 170], ["viral-induced secondary bacterial infections", "PROBLEM", 126, 170], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["viral", "OBSERVATION", 126, 131], ["secondary", "OBSERVATION_MODIFIER", 140, 149], ["bacterial", "OBSERVATION_MODIFIER", 150, 159], ["infections", "OBSERVATION", 160, 170]]], ["Mammalian cells are more susceptible to bacterial attachment and colonization when infected by a virus (11, 12); infection with respiratory syncytial virus (RSV), rhinovirus and influenza virus (all of which damage the mucosal layer), lead to bacterial adherence of Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae, and biofilm formation on the linings of the airways (13).IntroductionCommon bacteria isolated during secondary infections include Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H. influenzae, Klebsiella pneumoniae and members of the Proteus, Enterobacter and Citrobacter spp.", [["cells", "ANATOMY", 10, 15], ["mucosal layer", "ANATOMY", 219, 232], ["biofilm", "ANATOMY", 348, 355], ["airways", "ANATOMY", 388, 395], ["infection", "DISEASE", 113, 122], ["respiratory syncytial virus", "DISEASE", 128, 155], ["influenza virus", "DISEASE", 178, 193], ["Streptococcus pneumoniae", "DISEASE", 266, 290], ["Haemophilus influenzae", "DISEASE", 320, 342], ["infections", "DISEASE", 455, 465], ["Staphylococcus aureus", "DISEASE", 474, 495], ["Neisseria meningitides", "DISEASE", 512, 534], ["Mammalian cells", "CELL", 0, 15], ["respiratory syncytial virus", "ORGANISM", 128, 155], ["RSV", "ORGANISM", 157, 160], ["rhinovirus", "ORGANISM", 163, 173], ["influenza virus", "ORGANISM", 178, 193], ["mucosal layer", "TISSUE", 219, 232], ["Streptococcus pneumoniae", "ORGANISM", 266, 290], ["Pseudomonas aeruginosa", "ORGANISM", 292, 314], ["Haemophilus influenzae", "ORGANISM", 320, 342], ["airways", "MULTI-TISSUE_STRUCTURE", 388, 395], ["Staphylococcus aureus", "ORGANISM", 474, 495], ["S. pneumoniae", "ORGANISM", 497, 510], ["Neisseria meningitides", "ORGANISM", 512, 534], ["H. influenzae", "ORGANISM", 536, 549], ["Klebsiella pneumoniae", "ORGANISM", 551, 572], ["Citrobacter spp", "ORGANISM", 618, 633], ["Mammalian cells", "CELL_TYPE", 0, 15], ["respiratory syncytial virus", "SPECIES", 128, 155], ["rhinovirus and influenza virus", "SPECIES", 163, 193], ["Streptococcus pneumoniae", "SPECIES", 266, 290], ["Pseudomonas aeruginosa", "SPECIES", 292, 314], ["Haemophilus influenzae", "SPECIES", 320, 342], ["Staphylococcus aureus", "SPECIES", 474, 495], ["S. pneumoniae", "SPECIES", 497, 510], ["Neisseria meningitides", "SPECIES", 512, 534], ["H. influenzae", "SPECIES", 536, 549], ["Klebsiella pneumoniae", "SPECIES", 551, 572], ["respiratory syncytial virus", "SPECIES", 128, 155], ["RSV", "SPECIES", 157, 160], ["Streptococcus pneumoniae", "SPECIES", 266, 290], ["Pseudomonas aeruginosa", "SPECIES", 292, 314], ["Haemophilus influenzae", "SPECIES", 320, 342], ["Staphylococcus aureus", "SPECIES", 474, 495], ["S. pneumoniae", "SPECIES", 497, 510], ["Neisseria meningitides", "SPECIES", 512, 534], ["H. influenzae", "SPECIES", 536, 549], ["Klebsiella pneumoniae", "SPECIES", 551, 572], ["Mammalian cells", "PROBLEM", 0, 15], ["bacterial attachment", "PROBLEM", 40, 60], ["colonization", "PROBLEM", 65, 77], ["a virus", "PROBLEM", 95, 102], ["infection", "PROBLEM", 113, 122], ["respiratory syncytial virus (RSV)", "PROBLEM", 128, 161], ["rhinovirus", "PROBLEM", 163, 173], ["influenza virus", "PROBLEM", 178, 193], ["Streptococcus pneumoniae", "PROBLEM", 266, 290], ["Pseudomonas aeruginosa", "PROBLEM", 292, 314], ["Haemophilus influenzae", "PROBLEM", 320, 342], ["biofilm formation", "PROBLEM", 348, 365], ["IntroductionCommon bacteria", "PROBLEM", 401, 428], ["secondary infections", "PROBLEM", 445, 465], ["Staphylococcus aureus", "PROBLEM", 474, 495], ["S. pneumoniae", "PROBLEM", 497, 510], ["Neisseria meningitides", "PROBLEM", 512, 534], ["H. influenzae", "PROBLEM", 536, 549], ["Klebsiella pneumoniae", "PROBLEM", 551, 572], ["the Proteus", "PROBLEM", 588, 599], ["Enterobacter", "PROBLEM", 601, 613], ["Citrobacter spp", "PROBLEM", 618, 633], ["bacterial attachment", "OBSERVATION_MODIFIER", 40, 60], ["respiratory", "ANATOMY", 128, 139], ["syncytial virus", "OBSERVATION", 140, 155], ["influenza virus", "OBSERVATION", 178, 193], ["mucosal layer", "ANATOMY", 219, 232], ["Streptococcus pneumoniae", "OBSERVATION", 266, 290], ["Haemophilus influenzae", "OBSERVATION", 320, 342], ["biofilm formation", "OBSERVATION", 348, 365], ["linings", "ANATOMY_MODIFIER", 373, 380], ["airways", "ANATOMY", 388, 395], ["Staphylococcus aureus", "OBSERVATION", 474, 495], ["pneumoniae", "OBSERVATION", 500, 510], ["Klebsiella pneumoniae", "OBSERVATION", 551, 572], ["Proteus", "ANATOMY", 592, 599], ["Citrobacter spp", "OBSERVATION", 618, 633]]], ["During active viral infections, the route of infection, proximity of infection as well as virulence factors varies between bacterial strains resulting in different outcomes.", [["viral infections", "DISEASE", 14, 30], ["infection", "DISEASE", 45, 54], ["infection", "DISEASE", 69, 78], ["virulence factors", "PROTEIN", 90, 107], ["active viral infections", "PROBLEM", 7, 30], ["infection", "PROBLEM", 45, 54], ["infection", "PROBLEM", 69, 78], ["virulence factors", "PROBLEM", 90, 107], ["bacterial strains", "PROBLEM", 123, 140], ["active", "OBSERVATION_MODIFIER", 7, 13], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["infection", "OBSERVATION", 45, 54], ["infection", "OBSERVATION", 69, 78], ["bacterial strains", "OBSERVATION", 123, 140]]], ["Effective treatment of both the viral and the secondary bacterial infection(s) is of critical importance.", [["bacterial infection", "DISEASE", 56, 75], ["Effective treatment", "TREATMENT", 0, 19], ["the viral", "PROBLEM", 28, 37], ["the secondary bacterial infection", "PROBLEM", 42, 75], ["viral", "OBSERVATION", 32, 37], ["secondary", "OBSERVATION_MODIFIER", 46, 55], ["bacterial", "OBSERVATION_MODIFIER", 56, 65], ["infection", "OBSERVATION", 66, 75]]], ["Antiviral treatments deployed initially do not treat secondary bacterial infections (15).", [["bacterial infections", "DISEASE", 63, 83], ["Antiviral treatments", "TREATMENT", 0, 20], ["bacterial infections", "PROBLEM", 63, 83]]], ["The preferred treatment for bacterial infections is generally broad-spectrum antibiotics, but this can result in undesirable side effects that have a negative impact on the normal microflora of the host (16\u201318).", [["bacterial infections", "DISEASE", 28, 48], ["bacterial infections", "PROBLEM", 28, 48], ["broad-spectrum antibiotics", "TREATMENT", 62, 88], ["undesirable side effects", "PROBLEM", 113, 137], ["bacterial", "OBSERVATION_MODIFIER", 28, 37], ["infections", "OBSERVATION", 38, 48]]], ["Susceptible individuals within a population can be protected from risk of some common bacterial pathogens that are also capable to cause secondary infections, for example pneumonia, if vaccines are available; furthermore, the immune system is often capable of fighting bacterial infections alone, while during a virus-bacterial infection, the complex immune responses might be inapt to eliminate bacterial-induced disease complications (19).", [["immune system", "ANATOMY", 226, 239], ["infections", "DISEASE", 147, 157], ["pneumonia", "DISEASE", 171, 180], ["bacterial infections", "DISEASE", 269, 289], ["infection", "DISEASE", 328, 337], ["Susceptible individuals", "PROBLEM", 0, 23], ["some common bacterial pathogens", "PROBLEM", 74, 105], ["secondary infections", "PROBLEM", 137, 157], ["pneumonia", "PROBLEM", 171, 180], ["vaccines", "TREATMENT", 185, 193], ["fighting bacterial infections", "PROBLEM", 260, 289], ["a virus", "PROBLEM", 310, 317], ["bacterial infection", "PROBLEM", 318, 337], ["bacterial-induced disease complications", "PROBLEM", 396, 435], ["common", "OBSERVATION_MODIFIER", 79, 85], ["bacterial", "OBSERVATION_MODIFIER", 86, 95], ["pathogens", "OBSERVATION", 96, 105], ["secondary", "OBSERVATION_MODIFIER", 137, 146], ["infections", "OBSERVATION", 147, 157], ["pneumonia", "OBSERVATION", 171, 180], ["infections", "OBSERVATION", 279, 289], ["bacterial", "OBSERVATION_MODIFIER", 318, 327], ["infection", "OBSERVATION", 328, 337]]], ["To reduce severe disease progression or lethal outcomes, alternative ways to alleviate complications due to secondary bacterial infections and to eliminate bacterial pathogens while preserving host immunity might be necessary.IntroductionSecondary infections can also be acquired from the patient's environment i.e., hospital-acquired or nosocomial infections.", [["bacterial infections", "DISEASE", 118, 138], ["Secondary infections", "DISEASE", 238, 258], ["nosocomial infections", "DISEASE", 338, 359], ["patient", "ORGANISM", 289, 296], ["patient", "SPECIES", 289, 296], ["severe disease progression", "PROBLEM", 10, 36], ["lethal outcomes", "PROBLEM", 40, 55], ["alleviate complications", "PROBLEM", 77, 100], ["secondary bacterial infections", "PROBLEM", 108, 138], ["bacterial pathogens", "PROBLEM", 156, 175], ["Secondary infections", "PROBLEM", 238, 258], ["nosocomial infections", "PROBLEM", 338, 359], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["disease", "OBSERVATION", 17, 24], ["bacterial", "OBSERVATION_MODIFIER", 118, 127], ["infections", "OBSERVATION", 128, 138], ["infections", "OBSERVATION", 248, 258], ["nosocomial", "OBSERVATION_MODIFIER", 338, 348], ["infections", "OBSERVATION", 349, 359]]], ["Nosocomial pathogens are often resistant to a wide range of antibiotics; a result of increased use of antibiotics and decades of over- and misuse resulting in selection for multi-drug resistant pathogens (MDR pathogens) (20).", [["Nosocomial pathogens", "PROBLEM", 0, 20], ["a wide range of antibiotics", "TREATMENT", 44, 71], ["antibiotics", "TREATMENT", 102, 113], ["multi-drug resistant pathogens (MDR pathogens", "PROBLEM", 173, 218], ["increased", "OBSERVATION_MODIFIER", 85, 94]]], ["MDR is a global problem with >50,000 people per year infected, of which in ~25% of the cases no effective antibiotic is available (21) as many major pharmaceutical stakeholders have discontinued their search for new chemical antimicrobials (22).", [["MDR", "DISEASE", 0, 3], ["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["MDR", "PROBLEM", 0, 3], ["a global problem", "PROBLEM", 7, 23], ["effective antibiotic", "TREATMENT", 96, 116], ["new chemical antimicrobials", "TREATMENT", 212, 239], ["global", "OBSERVATION_MODIFIER", 9, 15]]], ["Antibiotic resistant organisms include Methicillin-resistant S. aureus (MRSA), Drug-resistant Streptococcus, Vancomycin-resistant Enterococci (VRE), drug-resistant Mycobacterium, Carbapenem-resistant Enterobacteriaceae (CRE), Colistin-resistant Klebsiella, Carbapenem-resistant Pseudomonas aeruginosa, and Carbapenem-resistant Acinetobacter baumannii (20).", [["Methicillin", "CHEMICAL", 39, 50], ["S. aureus", "DISEASE", 61, 70], ["MRSA", "DISEASE", 72, 76], ["Vancomycin", "CHEMICAL", 109, 119], ["Enterococci", "CHEMICAL", 130, 141], ["VRE", "CHEMICAL", 143, 146], ["Mycobacterium", "CHEMICAL", 164, 177], ["Carbapenem", "CHEMICAL", 179, 189], ["Colistin", "CHEMICAL", 226, 234], ["Klebsiella", "CHEMICAL", 245, 255], ["Carbapenem", "CHEMICAL", 257, 267], ["Pseudomonas aeruginosa", "DISEASE", 278, 300], ["Carbapenem", "CHEMICAL", 306, 316], ["Methicillin", "CHEMICAL", 39, 50], ["Vancomycin", "CHEMICAL", 109, 119], ["Methicillin-resistant S. aureus", "ORGANISM", 39, 70], ["MRSA", "CANCER", 72, 76], ["Drug-resistant Streptococcus", "ORGANISM", 79, 107], ["Vancomycin-resistant Enterococci", "SIMPLE_CHEMICAL", 109, 141], ["Carbapenem-resistant Enterobacteriaceae", "SIMPLE_CHEMICAL", 179, 218], ["Colistin", "SIMPLE_CHEMICAL", 226, 234], ["Carbapenem-resistant", "ORGANISM", 257, 277], ["Pseudomonas aeruginosa", "ORGANISM", 278, 300], ["Carbapenem-resistant Acinetobacter baumannii", "ORGANISM", 306, 350], ["S. aureus", "SPECIES", 61, 70], ["MRSA", "SPECIES", 72, 76], ["Pseudomonas aeruginosa", "SPECIES", 278, 300], ["Acinetobacter baumannii", "SPECIES", 327, 350], ["S. aureus", "SPECIES", 61, 70], ["MRSA", "SPECIES", 72, 76], ["Pseudomonas aeruginosa", "SPECIES", 278, 300], ["Acinetobacter baumannii", "SPECIES", 327, 350], ["Antibiotic resistant organisms", "PROBLEM", 0, 30], ["Methicillin-resistant S. aureus", "PROBLEM", 39, 70], ["MRSA", "PROBLEM", 72, 76], ["Drug-resistant Streptococcus", "PROBLEM", 79, 107], ["Vancomycin", "TEST", 109, 119], ["resistant Enterococci", "PROBLEM", 120, 141], ["VRE", "PROBLEM", 143, 146], ["drug", "TEST", 149, 153], ["resistant Mycobacterium", "PROBLEM", 154, 177], ["Carbapenem", "TEST", 179, 189], ["resistant Enterobacteriaceae (CRE", "PROBLEM", 190, 223], ["Colistin", "TEST", 226, 234], ["resistant Klebsiella", "PROBLEM", 235, 255], ["Carbapenem", "TEST", 257, 267], ["resistant Pseudomonas aeruginosa", "PROBLEM", 268, 300], ["Carbapenem", "TREATMENT", 306, 316], ["resistant Acinetobacter baumannii", "PROBLEM", 317, 350], ["aureus", "OBSERVATION", 64, 70], ["MRSA", "OBSERVATION", 72, 76], ["Drug-resistant Streptococcus", "OBSERVATION", 79, 107], ["resistant Mycobacterium", "OBSERVATION", 154, 177], ["Acinetobacter baumannii", "OBSERVATION", 327, 350]]], ["If a patient with a viral infection is unfortunate to become infected by MDR bacteria, no standard treatment is currently available.", [["viral infection", "DISEASE", 20, 35], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["a viral infection", "PROBLEM", 18, 35], ["MDR bacteria", "PROBLEM", 73, 85], ["standard treatment", "TREATMENT", 90, 108], ["viral", "OBSERVATION_MODIFIER", 20, 25], ["infection", "OBSERVATION", 26, 35]]], ["In one COVID-19 cohort study, described in more detail below; almost 50% (10 of 21) patients developed secondary bacterial infections in the lung caused by Klebsiella pneumoniae, Staphylococcus, Acinetobacter baumannii, and E. coli, ultimately leading to their death, despite receiving prophylactic antibiotic therapy (23).IntroductionThis evaluation of all the COVID-19 reports available that reference secondary infections showed that most clinicians prescribed meropenem and linezolid to children with a rate of prophylactic treatment between 19.4 and 100.0% (24).", [["lung", "ANATOMY", 141, 145], ["bacterial infections", "DISEASE", 113, 133], ["Klebsiella pneumoniae", "DISEASE", 156, 177], ["death", "DISEASE", 261, 266], ["secondary infections", "DISEASE", 404, 424], ["meropenem", "CHEMICAL", 464, 473], ["linezolid", "CHEMICAL", 478, 487], ["meropenem", "CHEMICAL", 464, 473], ["linezolid", "CHEMICAL", 478, 487], ["patients", "ORGANISM", 84, 92], ["lung", "ORGAN", 141, 145], ["Klebsiella pneumoniae", "ORGANISM", 156, 177], ["Staphylococcus,", "ORGANISM", 179, 194], ["Acinetobacter baumannii", "ORGANISM", 195, 218], ["E. coli", "ORGANISM", 224, 231], ["meropenem", "SIMPLE_CHEMICAL", 464, 473], ["linezolid", "SIMPLE_CHEMICAL", 478, 487], ["children", "ORGANISM", 491, 499], ["patients", "SPECIES", 84, 92], ["Klebsiella pneumoniae", "SPECIES", 156, 177], ["Staphylococcus", "SPECIES", 179, 193], ["Acinetobacter baumannii", "SPECIES", 195, 218], ["E. coli", "SPECIES", 224, 231], ["children", "SPECIES", 491, 499], ["Klebsiella pneumoniae", "SPECIES", 156, 177], ["Acinetobacter baumannii", "SPECIES", 195, 218], ["E. coli", "SPECIES", 224, 231], ["cohort study", "TEST", 16, 28], ["secondary bacterial infections in the lung", "PROBLEM", 103, 145], ["Klebsiella pneumoniae", "PROBLEM", 156, 177], ["Staphylococcus", "PROBLEM", 179, 193], ["Acinetobacter baumannii", "PROBLEM", 195, 218], ["E. coli", "PROBLEM", 224, 231], ["their death", "PROBLEM", 255, 266], ["prophylactic antibiotic therapy", "TREATMENT", 286, 317], ["This evaluation", "TEST", 335, 350], ["all the COVID", "TEST", 354, 367], ["secondary infections", "PROBLEM", 404, 424], ["meropenem", "TREATMENT", 464, 473], ["linezolid", "TREATMENT", 478, 487], ["prophylactic treatment", "TREATMENT", 515, 537], ["secondary", "OBSERVATION_MODIFIER", 103, 112], ["bacterial", "OBSERVATION_MODIFIER", 113, 122], ["infections", "OBSERVATION", 123, 133], ["lung", "ANATOMY", 141, 145], ["Klebsiella pneumoniae", "OBSERVATION", 156, 177], ["Staphylococcus", "OBSERVATION_MODIFIER", 179, 193], ["Acinetobacter baumannii", "OBSERVATION", 195, 218], ["E. coli", "OBSERVATION", 224, 231]]], ["In adults mainly quinolones, cephalosporins and macrolides were used for treatment with rates of prophylaxis between 13.2 and 100.0%.", [["quinolones", "CHEMICAL", 17, 27], ["cephalosporins", "CHEMICAL", 29, 43], ["macrolides", "CHEMICAL", 48, 58], ["quinolones", "CHEMICAL", 17, 27], ["cephalosporins", "CHEMICAL", 29, 43], ["macrolides", "CHEMICAL", 48, 58], ["quinolones", "SIMPLE_CHEMICAL", 17, 27], ["cephalosporins", "SIMPLE_CHEMICAL", 29, 43], ["macrolides", "SIMPLE_CHEMICAL", 48, 58], ["quinolones", "TREATMENT", 17, 27], ["cephalosporins", "TREATMENT", 29, 43], ["macrolides", "TREATMENT", 48, 58], ["treatment", "TREATMENT", 73, 82], ["prophylaxis", "TREATMENT", 97, 108]]], ["In most cases, etiological evidence was not used for therapeutic use of antibiotics.IntroductionIn this study, we have assimilated the most recent clinical data on bacterial secondary infections associated with pneumonias, caused by pulmonary viruses, including for SARS-CoV-2.", [["pulmonary", "ANATOMY", 233, 242], ["bacterial secondary infections", "DISEASE", 164, 194], ["pneumonias", "DISEASE", 211, 221], ["pulmonary viruses", "DISEASE", 233, 250], ["pulmonary", "ORGAN", 233, 242], ["CoV-2", "ORGANISM", 271, 276], ["SARS-CoV", "SPECIES", 266, 274], ["antibiotics", "TREATMENT", 72, 83], ["this study", "TEST", 99, 109], ["bacterial secondary infections", "PROBLEM", 164, 194], ["pneumonias", "PROBLEM", 211, 221], ["pulmonary viruses", "PROBLEM", 233, 250], ["SARS", "PROBLEM", 266, 270], ["CoV", "TEST", 271, 274], ["infections", "OBSERVATION", 184, 194], ["pneumonias", "OBSERVATION", 211, 221], ["pulmonary", "ANATOMY", 233, 242], ["viruses", "OBSERVATION", 243, 250]]], ["We outline treatments used or prophylactic measures employed for secondary bacterial infections.", [["bacterial infections", "DISEASE", 75, 95], ["outline treatments", "TREATMENT", 3, 21], ["prophylactic measures", "TREATMENT", 30, 51], ["secondary bacterial infections", "PROBLEM", 65, 95], ["bacterial", "OBSERVATION_MODIFIER", 75, 84], ["infections", "OBSERVATION", 85, 95]]], ["This review focuses on secondary bacterial infections that occur in the respiratory tissue of patients suffering from a viral infection, as most lung infections by secondary bacterial pathogens remain localized in the respiratory tract, while a small percentage leads to infections that spread systematically.COVID-19 Related Secondary Bacterial Infections and TreatmentSARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus, belonging to the family Coronaviridae.", [["respiratory tissue", "ANATOMY", 72, 90], ["lung", "ANATOMY", 145, 149], ["respiratory tract", "ANATOMY", 218, 235], ["bacterial infections", "DISEASE", 33, 53], ["viral infection", "DISEASE", 120, 135], ["lung infections", "DISEASE", 145, 160], ["infections", "DISEASE", 271, 281], ["Bacterial Infections", "DISEASE", 336, 356], ["respiratory tissue", "TISSUE", 72, 90], ["patients", "ORGANISM", 94, 102], ["lung", "ORGAN", 145, 149], ["respiratory tract", "ORGANISM_SUBDIVISION", 218, 235], ["TreatmentSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 361, 380], ["patients", "SPECIES", 94, 102], ["secondary bacterial infections", "PROBLEM", 23, 53], ["a viral infection", "PROBLEM", 118, 135], ["most lung infections", "PROBLEM", 140, 160], ["secondary bacterial pathogens", "PROBLEM", 164, 193], ["a small percentage leads to infections", "PROBLEM", 243, 281], ["COVID", "TEST", 309, 314], ["Secondary Bacterial Infections", "PROBLEM", 326, 356], ["TreatmentSARS-CoV", "TEST", 361, 378], ["single-stranded RNA virus", "PROBLEM", 414, 439], ["bacterial", "OBSERVATION_MODIFIER", 33, 42], ["infections", "OBSERVATION", 43, 53], ["respiratory tissue", "ANATOMY", 72, 90], ["viral", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135], ["lung", "ANATOMY", 145, 149], ["infections", "OBSERVATION", 150, 160], ["bacterial pathogens", "OBSERVATION", 174, 193], ["respiratory tract", "ANATOMY", 218, 235], ["small", "OBSERVATION_MODIFIER", 245, 250], ["infections", "OBSERVATION", 271, 281], ["Secondary", "OBSERVATION_MODIFIER", 326, 335], ["Bacterial", "OBSERVATION_MODIFIER", 336, 345], ["Infections", "OBSERVATION", 346, 356]]], ["The virus emerged in 2019 and is responsible for respiratory illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory tract infections and causes severe lung damage in most fatal cases.", [["respiratory tract", "ANATOMY", 123, 140], ["lung", "ANATOMY", 170, 174], ["respiratory illnesses Coronavirus Disease", "DISEASE", 49, 90], ["COVID-19", "CHEMICAL", 97, 105], ["respiratory tract infections", "DISEASE", 123, 151], ["lung damage", "DISEASE", 170, 181], ["tract", "ORGANISM_SUBDIVISION", 135, 140], ["lung", "ORGAN", 170, 174], ["The virus", "PROBLEM", 0, 9], ["respiratory illnesses Coronavirus Disease", "PROBLEM", 49, 90], ["COVID", "TEST", 97, 102], ["respiratory tract infections", "PROBLEM", 123, 151], ["severe lung damage in most fatal cases", "PROBLEM", 163, 201], ["virus", "OBSERVATION", 4, 9], ["responsible for", "UNCERTAINTY", 33, 48], ["respiratory tract", "ANATOMY", 123, 140], ["infections", "OBSERVATION", 141, 151], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["lung", "ANATOMY", 170, 174], ["damage", "OBSERVATION", 175, 181]]], ["SARS-CoV-2 has overwhelmed health systems, with numbers of those infected with COVID-19 requiring hospitalization and critical care.COVID-19 Related Secondary Bacterial Infections and TreatmentEarly stages of SARS-CoV-2 infection typically include symptoms of mild fever and shortness of breath (25).", [["SARS", "DISEASE", 0, 4], ["Bacterial Infections", "DISEASE", 159, 179], ["SARS-CoV-2 infection", "DISEASE", 209, 229], ["fever", "DISEASE", 265, 270], ["shortness of breath", "DISEASE", 275, 294], ["SARS-CoV-2", "ORGANISM", 209, 219], ["CoV-2", "SPECIES", 214, 219], ["SARS-CoV-2", "SPECIES", 209, 219], ["overwhelmed health systems", "PROBLEM", 15, 41], ["COVID", "TEST", 79, 84], ["hospitalization", "TREATMENT", 98, 113], ["critical care", "TREATMENT", 118, 131], ["COVID", "TEST", 132, 137], ["Secondary Bacterial Infections", "PROBLEM", 149, 179], ["TreatmentEarly stages", "PROBLEM", 184, 205], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["2 infection", "PROBLEM", 218, 229], ["symptoms", "PROBLEM", 248, 256], ["mild fever", "PROBLEM", 260, 270], ["shortness of breath", "PROBLEM", 275, 294], ["infected", "OBSERVATION", 65, 73], ["Secondary", "OBSERVATION_MODIFIER", 149, 158], ["Bacterial", "OBSERVATION_MODIFIER", 159, 168], ["Infections", "OBSERVATION", 169, 179], ["mild", "OBSERVATION_MODIFIER", 260, 264], ["fever", "OBSERVATION", 265, 270]]], ["As the virus replicates in the respiratory tract, the symptoms worsen and once the virus reaches and begins infecting the alveoli, the host responds by generating inflammatory factors in alveolar tissues that may result in pneumonia.", [["respiratory tract", "ANATOMY", 31, 48], ["alveoli", "ANATOMY", 122, 129], ["alveolar tissues", "ANATOMY", 187, 203], ["pneumonia", "DISEASE", 223, 232], ["respiratory tract", "ORGANISM_SUBDIVISION", 31, 48], ["alveoli", "MULTI-TISSUE_STRUCTURE", 122, 129], ["alveolar tissues", "TISSUE", 187, 203], ["inflammatory factors", "PROTEIN", 163, 183], ["the virus", "PROBLEM", 3, 12], ["the symptoms", "PROBLEM", 50, 62], ["the virus", "PROBLEM", 79, 88], ["inflammatory factors in alveolar tissues", "PROBLEM", 163, 203], ["pneumonia", "PROBLEM", 223, 232], ["virus", "OBSERVATION", 7, 12], ["respiratory tract", "ANATOMY", 31, 48], ["alveoli", "ANATOMY", 122, 129], ["inflammatory", "OBSERVATION_MODIFIER", 163, 175], ["alveolar tissues", "OBSERVATION", 187, 203], ["may result in", "UNCERTAINTY", 209, 222], ["pneumonia", "OBSERVATION", 223, 232]]], ["In almost all severe cases, SARS-CoV-2 infection results in pneumonia and the inflamed fluid-filled alveolar tissue now is an ideal habitat for bacterial growth for pathogens including P. aeruginosa and S. aureus.", [["fluid", "ANATOMY", 87, 92], ["alveolar tissue", "ANATOMY", 100, 115], ["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["pneumonia", "DISEASE", 60, 69], ["SARS-CoV-2", "ORGANISM", 28, 38], ["alveolar tissue", "TISSUE", 100, 115], ["P. aeruginosa", "ORGANISM", 185, 198], ["S. aureus", "ORGANISM", 203, 212], ["P. aeruginosa", "SPECIES", 185, 198], ["S. aureus", "SPECIES", 203, 212], ["SARS-CoV-2", "SPECIES", 28, 38], ["P. aeruginosa", "SPECIES", 185, 198], ["S. aureus", "SPECIES", 203, 212], ["SARS", "PROBLEM", 28, 32], ["CoV-2 infection", "PROBLEM", 33, 48], ["pneumonia", "PROBLEM", 60, 69], ["the inflamed fluid-filled alveolar tissue", "PROBLEM", 74, 115], ["bacterial growth", "PROBLEM", 144, 160], ["pathogens", "PROBLEM", 165, 174], ["P. aeruginosa", "PROBLEM", 185, 198], ["S. aureus", "PROBLEM", 203, 212], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["pneumonia", "OBSERVATION", 60, 69], ["inflamed", "OBSERVATION_MODIFIER", 78, 86], ["fluid", "OBSERVATION", 87, 92], ["filled", "OBSERVATION_MODIFIER", 93, 99], ["alveolar tissue", "OBSERVATION", 100, 115], ["aureus", "OBSERVATION", 206, 212]]], ["The causative agent resulting in a severe disease progression may be bacteria, virus or fungi (26).COVID-19 Related Secondary Bacterial Infections and TreatmentThe presence of secondary bacterial infections in those infected with SARS-CoV-2 complicates treatment (26, 27).", [["Bacterial Infections", "DISEASE", 126, 146], ["bacterial infections", "DISEASE", 186, 206], ["SARS", "DISEASE", 230, 234], ["SARS-CoV-2", "ORGANISM", 230, 240], ["SARS-CoV", "SPECIES", 230, 238], ["a severe disease progression", "PROBLEM", 33, 61], ["bacteria", "PROBLEM", 69, 77], ["virus", "PROBLEM", 79, 84], ["fungi", "PROBLEM", 88, 93], ["COVID", "TEST", 99, 104], ["Secondary Bacterial Infections", "PROBLEM", 116, 146], ["Treatment", "TREATMENT", 151, 160], ["secondary bacterial infections", "PROBLEM", 176, 206], ["SARS", "PROBLEM", 230, 234], ["treatment", "TREATMENT", 253, 262], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["disease", "OBSERVATION", 42, 49], ["may be", "UNCERTAINTY", 62, 68], ["bacteria", "OBSERVATION_MODIFIER", 69, 77], ["19 Related", "OBSERVATION_MODIFIER", 105, 115], ["Secondary Bacterial Infections", "OBSERVATION", 116, 146], ["secondary", "OBSERVATION_MODIFIER", 176, 185], ["bacterial", "OBSERVATION_MODIFIER", 186, 195], ["infections", "OBSERVATION", 196, 206], ["infected", "OBSERVATION_MODIFIER", 216, 224]]], ["An overview of all COVID-19 case studies, available as Supplementary Information, where we have analyzed 15 case studies reporting SARS-CoV-2 infection (Supplemental Data Sheet 1).", [["SARS-CoV-2 infection", "DISEASE", 131, 151], ["SARS-CoV", "SPECIES", 131, 139], ["SARS", "PROBLEM", 131, 135], ["infection", "PROBLEM", 142, 151]]], ["In particular for data obtained from clinical observations in China, COVID-19 patients are most commonly treated with antibiotics (azithromycin, moxifloxacin, ceftriaxone, vancomycin, cefepime) to reduce the risk of nosocomial infections, a prophylactic strategy.", [["azithromycin", "CHEMICAL", 131, 143], ["moxifloxacin", "CHEMICAL", 145, 157], ["ceftriaxone", "CHEMICAL", 159, 170], ["vancomycin", "CHEMICAL", 172, 182], ["cefepime", "CHEMICAL", 184, 192], ["infections", "DISEASE", 227, 237], ["azithromycin", "CHEMICAL", 131, 143], ["moxifloxacin", "CHEMICAL", 145, 157], ["ceftriaxone", "CHEMICAL", 159, 170], ["vancomycin", "CHEMICAL", 172, 182], ["cefepime", "CHEMICAL", 184, 192], ["patients", "ORGANISM", 78, 86], ["azithromycin", "SIMPLE_CHEMICAL", 131, 143], ["moxifloxacin", "SIMPLE_CHEMICAL", 145, 157], ["ceftriaxone", "SIMPLE_CHEMICAL", 159, 170], ["vancomycin", "SIMPLE_CHEMICAL", 172, 182], ["cefepime", "SIMPLE_CHEMICAL", 184, 192], ["patients", "SPECIES", 78, 86], ["antibiotics", "TREATMENT", 118, 129], ["azithromycin", "TREATMENT", 131, 143], ["moxifloxacin", "TREATMENT", 145, 157], ["ceftriaxone", "TREATMENT", 159, 170], ["vancomycin", "TREATMENT", 172, 182], ["cefepime", "TREATMENT", 184, 192], ["nosocomial infections", "PROBLEM", 216, 237], ["a prophylactic strategy", "TREATMENT", 239, 262], ["nosocomial infections", "OBSERVATION", 216, 237]]], ["Should a bacterial infection occur despite the prophylactic use of antibiotics, caused by bacteria that are resistant to one or more drugs, different combinations of the same drugs are being used for the treatment, as a therapeutic strategy.", [["bacterial infection", "DISEASE", 9, 28], ["a bacterial infection", "PROBLEM", 7, 28], ["antibiotics", "TREATMENT", 67, 78], ["bacteria", "PROBLEM", 90, 98], ["drugs", "TREATMENT", 133, 138], ["the same drugs", "TREATMENT", 166, 180], ["the treatment", "TREATMENT", 200, 213], ["a therapeutic strategy", "TREATMENT", 218, 240], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["infection", "OBSERVATION", 19, 28]]], ["Both strategies, the prophylactic and the therapeutic use of antibiotics, deploy the same types and dosage of drugs: however the prophylactic use of antibiotics is not recommended by most health institutions and governments around the globe, due to the observed increase in antibiotic resistance rates, which correlate with the overuse (and misuse) of antibiotics (28, 29).", [["the prophylactic", "TREATMENT", 17, 33], ["antibiotics", "TREATMENT", 61, 72], ["drugs", "TREATMENT", 110, 115], ["antibiotics", "TREATMENT", 149, 160], ["antibiotic resistance rates", "TREATMENT", 274, 301], ["antibiotics", "TREATMENT", 352, 363], ["globe", "ANATOMY", 235, 240], ["increase", "OBSERVATION_MODIFIER", 262, 270], ["antibiotic resistance", "OBSERVATION", 274, 295]]], ["However, the risk of superinfection with MDR bacteria poses additional challenges for the treatment of severely sick COVID-19 patients in intensive care units (ICU).Case Reports of Antibacterial Therapy in COVID-19 PatientsFifteen clinical reports, for which data for secondary infections were available, mainly from hospitals in China, were examined to provide information of the occurrence, treatment of or prophylactic measures for bacterial secondary infections during the course of COVID-19 infections (Supplementary File).", [["superinfection", "DISEASE", 21, 35], ["COVID", "DISEASE", 117, 122], ["infections", "DISEASE", 278, 288], ["bacterial secondary infections", "DISEASE", 435, 465], ["infections", "DISEASE", 496, 506], ["patients", "ORGANISM", 126, 134], ["Patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 126, 134], ["Patients", "SPECIES", 215, 223], ["superinfection", "PROBLEM", 21, 35], ["MDR bacteria", "PROBLEM", 41, 53], ["severely sick COVID", "PROBLEM", 103, 122], ["Antibacterial Therapy", "TREATMENT", 181, 202], ["secondary infections", "PROBLEM", 268, 288], ["treatment", "TREATMENT", 393, 402], ["prophylactic measures", "TREATMENT", 409, 430], ["bacterial secondary infections", "PROBLEM", 435, 465], ["COVID", "TREATMENT", 487, 492], ["superinfection", "OBSERVATION", 21, 35], ["Antibacterial Therapy", "OBSERVATION", 181, 202]]], ["A total of 3,133 COVID-19 patient cases were detailed in the 15 reports (25\u201339).", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33]]], ["Prophylactic antibiotic therapy was given to 1,901 of the 2,983 patients (63.7%).", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["Prophylactic antibiotic therapy", "TREATMENT", 0, 31]]], ["We excluded one study (patient n = 150), as they did not report details on the antibiotic therapy (31) and 5/14 studies did not report the type of antibiotics used.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["one study", "TEST", 12, 21], ["the antibiotic therapy", "TREATMENT", 75, 97], ["5/14 studies", "TEST", 107, 119], ["antibiotics", "TREATMENT", 147, 158]]], ["The most commonly used antibiotics were moxifloxacin (n = 452, 39.2%) and azithromycin (n = 294, 30.7%).", [["moxifloxacin", "CHEMICAL", 40, 52], ["azithromycin", "CHEMICAL", 74, 86], ["moxifloxacin", "CHEMICAL", 40, 52], ["azithromycin", "CHEMICAL", 74, 86], ["moxifloxacin", "SIMPLE_CHEMICAL", 40, 52], ["azithromycin", "SIMPLE_CHEMICAL", 74, 86], ["antibiotics", "TREATMENT", 23, 34], ["moxifloxacin", "TREATMENT", 40, 52], ["azithromycin", "TREATMENT", 74, 86]]], ["Others include ceftriaxone, vancomycin, cefepime, cephalosporins, quinolones, carbapenems, tigecycline, doxycycline, and cefoperazone.", [["ceftriaxone", "CHEMICAL", 15, 26], ["vancomycin", "CHEMICAL", 28, 38], ["cefepime", "CHEMICAL", 40, 48], ["cephalosporins", "CHEMICAL", 50, 64], ["quinolones", "CHEMICAL", 66, 76], ["carbapenems", "CHEMICAL", 78, 89], ["tigecycline", "CHEMICAL", 91, 102], ["doxycycline", "CHEMICAL", 104, 115], ["cefoperazone", "CHEMICAL", 121, 133], ["ceftriaxone", "CHEMICAL", 15, 26], ["vancomycin", "CHEMICAL", 28, 38], ["cefepime", "CHEMICAL", 40, 48], ["cephalosporins", "CHEMICAL", 50, 64], ["quinolones", "CHEMICAL", 66, 76], ["carbapenems", "CHEMICAL", 78, 89], ["tigecycline", "CHEMICAL", 91, 102], ["doxycycline", "CHEMICAL", 104, 115], ["cefoperazone", "CHEMICAL", 121, 133], ["ceftriaxone", "SIMPLE_CHEMICAL", 15, 26], ["vancomycin", "SIMPLE_CHEMICAL", 28, 38], ["cefepime", "SIMPLE_CHEMICAL", 40, 48], ["cephalosporins", "SIMPLE_CHEMICAL", 50, 64], ["quinolones", "SIMPLE_CHEMICAL", 66, 76], ["carbapenems", "SIMPLE_CHEMICAL", 78, 89], ["tigecycline", "SIMPLE_CHEMICAL", 91, 102], ["doxycycline", "SIMPLE_CHEMICAL", 104, 115], ["cefoperazone", "SIMPLE_CHEMICAL", 121, 133], ["ceftriaxone", "TREATMENT", 15, 26], ["vancomycin", "TREATMENT", 28, 38], ["cefepime", "TREATMENT", 40, 48], ["cephalosporins", "TREATMENT", 50, 64], ["quinolones", "TREATMENT", 66, 76], ["carbapenems", "TREATMENT", 78, 89], ["tigecycline", "TREATMENT", 91, 102], ["doxycycline", "TREATMENT", 104, 115], ["cefoperazone", "TREATMENT", 121, 133]]], ["In total, 10 studies reported secondary bacterial infections, with 273 of the 997 patients (27.3%) being infected.", [["bacterial infections", "DISEASE", 40, 60], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["10 studies", "TEST", 10, 20], ["secondary bacterial infections", "PROBLEM", 30, 60], ["infected", "PROBLEM", 105, 113], ["bacterial infections", "OBSERVATION", 40, 60], ["infected", "OBSERVATION", 105, 113]]], ["Again, we excluded 5 studies (patients n = 2,136), which did not report any information on any clinical complications other than caused by the SARS-CoV-2 virus (28, 30, 34, 35, 37).", [["SARS", "DISEASE", 143, 147], ["patients", "ORGANISM", 30, 38], ["SARS-CoV-2 virus", "ORGANISM", 143, 159], ["patients", "SPECIES", 30, 38], ["CoV-2 virus", "SPECIES", 148, 159], ["SARS-CoV-2 virus", "SPECIES", 143, 159], ["5 studies", "TEST", 19, 28], ["any clinical complications", "PROBLEM", 91, 117], ["the SARS-CoV-2 virus", "PROBLEM", 139, 159]]], ["The most common bacterial infections were caused by the Gram-positive pathogen Staphylococcus aureus or by strains of the Gram-negative bacterium Klebsiella pneumoniae.", [["bacterial infections", "DISEASE", 16, 36], ["Staphylococcus aureus", "DISEASE", 79, 100], ["Gram-positive pathogen", "ORGANISM", 56, 78], ["Staphylococcus aureus", "ORGANISM", 79, 100], ["Gram-negative bacterium", "ORGANISM", 122, 145], ["Klebsiella pneumoniae", "ORGANISM", 146, 167], ["Staphylococcus aureus", "SPECIES", 79, 100], ["Klebsiella pneumoniae", "SPECIES", 146, 167], ["Staphylococcus aureus", "SPECIES", 79, 100], ["Klebsiella pneumoniae", "SPECIES", 146, 167], ["The most common bacterial infections", "PROBLEM", 0, 36], ["the Gram-positive pathogen Staphylococcus aureus", "PROBLEM", 52, 100], ["the Gram-negative bacterium Klebsiella pneumoniae", "PROBLEM", 118, 167], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["infections", "OBSERVATION", 26, 36], ["positive", "OBSERVATION_MODIFIER", 61, 69], ["pathogen Staphylococcus aureus", "OBSERVATION", 70, 100], ["negative bacterium", "OBSERVATION", 127, 145], ["Klebsiella pneumoniae", "OBSERVATION", 146, 167]]], ["Five studies reported infections that were confirmed by tests in a microbiology laboratory, which identified MRSA, MSSA, Serratia, Acinetobacter, Pseudomonas, E. coli, H. influenza, and E. cloacae (patients n = 16) (25, 26, 29, 36, 38).", [["infections", "DISEASE", 22, 32], ["MSSA", "CHEMICAL", 115, 119], ["H. influenza", "DISEASE", 168, 180], ["Pseudomonas", "ORGANISM", 146, 157], ["E. coli", "ORGANISM", 159, 166], ["H. influenza", "ORGANISM", 168, 180], ["E. cloacae", "ORGANISM", 186, 196], ["patients", "ORGANISM", 198, 206], ["MRSA", "SPECIES", 109, 113], ["E. coli", "SPECIES", 159, 166], ["H. influenza", "SPECIES", 168, 180], ["E. cloacae", "SPECIES", 186, 196], ["patients", "SPECIES", 198, 206], ["MRSA", "SPECIES", 109, 113], ["E. coli", "SPECIES", 159, 166], ["H. influenza", "SPECIES", 168, 180], ["E. cloacae", "SPECIES", 186, 196], ["Five studies", "TEST", 0, 12], ["infections", "PROBLEM", 22, 32], ["MRSA", "PROBLEM", 109, 113], ["MSSA", "PROBLEM", 115, 119], ["Serratia", "PROBLEM", 121, 129], ["Acinetobacter", "PROBLEM", 131, 144], ["Pseudomonas", "PROBLEM", 146, 157], ["E. coli", "PROBLEM", 159, 166], ["H. influenza", "PROBLEM", 168, 180], ["E. cloacae", "PROBLEM", 186, 196], ["infections", "OBSERVATION", 22, 32], ["MRSA", "OBSERVATION", 109, 113], ["MSSA", "OBSERVATION", 115, 119], ["E. coli", "OBSERVATION", 159, 166]]], ["Three studies reported therapeutic antibiotic treatment in 92 of 146 patients (63%), which were administered as secondary bacterial infections were observed (29, 35, 39).", [["bacterial infections", "DISEASE", 122, 142], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Three studies", "TEST", 0, 13], ["therapeutic antibiotic treatment", "TREATMENT", 23, 55], ["secondary bacterial infections", "PROBLEM", 112, 142], ["bacterial", "OBSERVATION_MODIFIER", 122, 131], ["infections", "OBSERVATION", 132, 142]]], ["Four studies reported complications with fatal outcome due to bacterial infections that included 41 of 268 patients (15.2%) (26, 27, 33, 39).", [["bacterial infections", "DISEASE", 62, 82], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["Four studies", "TEST", 0, 12], ["fatal outcome", "PROBLEM", 41, 54], ["bacterial infections", "PROBLEM", 62, 82], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["infections", "OBSERVATION", 72, 82]]], ["An overview of the studies can be found in Supplementary Figure 1, which also provides the information on percentages of antibiotic use and types of antibiotic compounds, among others.Case Reports of Antibacterial Therapy in COVID-19 PatientsThese clinical reports provide insights into the complications and challenges faced in treating SARS-CoV-2 infected patients.", [["SARS-CoV-2 infected", "DISEASE", 338, 357], ["Patients", "ORGANISM", 234, 242], ["SARS-CoV-2", "ORGANISM", 338, 348], ["patients", "ORGANISM", 358, 366], ["Patients", "SPECIES", 234, 242], ["patients", "SPECIES", 358, 366], ["the studies", "TEST", 15, 26], ["antibiotic use", "TREATMENT", 121, 135], ["antibiotic compounds", "TREATMENT", 149, 169], ["Antibacterial Therapy", "TREATMENT", 200, 221], ["the complications", "PROBLEM", 287, 304], ["SARS", "PROBLEM", 338, 342], ["Antibacterial Therapy", "OBSERVATION", 200, 221]]], ["Patients with pneumonia caused by other respiratory viruses or SARS-CoV-2 pneumonia patients were often prophylactically treated with broad-spectrum antibiotics, in an attempt to reduce the risk of bacterial superinfections.", [["pneumonia", "DISEASE", 14, 23], ["respiratory viruses", "DISEASE", 40, 59], ["SARS", "DISEASE", 63, 67], ["pneumonia", "DISEASE", 74, 83], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 63, 73], ["patients", "ORGANISM", 84, 92], ["Patients", "SPECIES", 0, 8], ["CoV-2 pneumonia", "SPECIES", 68, 83], ["patients", "SPECIES", 84, 92], ["pneumonia", "PROBLEM", 14, 23], ["other respiratory viruses", "PROBLEM", 34, 59], ["SARS", "PROBLEM", 63, 67], ["CoV-2 pneumonia", "PROBLEM", 68, 83], ["broad-spectrum antibiotics", "TREATMENT", 134, 160], ["bacterial superinfections", "PROBLEM", 198, 223], ["pneumonia", "OBSERVATION", 14, 23], ["respiratory", "ANATOMY", 40, 51], ["viruses", "OBSERVATION", 52, 59], ["pneumonia", "OBSERVATION", 74, 83], ["bacterial superinfections", "OBSERVATION", 198, 223]]], ["Complications were observed in patients that were not treated with antibiotics.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Complications", "PROBLEM", 0, 13], ["antibiotics", "TREATMENT", 67, 78]]], ["Antibiotic-resistant infections, in particular, nosocomial - hospital-acquired - infections were common for more than one third of ICU patients, posing a threat to disease progression, often resulting in the death of the affected individual (26, 40).SARS-related Secondary Bacterial Infections and TreatmentSevere Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report in Guangdong Province, China in November 2002.", [["infections", "DISEASE", 21, 31], ["nosocomial - hospital-acquired - infections", "DISEASE", 48, 91], ["death", "DISEASE", 208, 213], ["SARS", "DISEASE", 250, 254], ["Bacterial Infections", "DISEASE", 273, 293], ["Acute Respiratory Syndrome-related Coronavirus", "DISEASE", 314, 360], ["SARS", "DISEASE", 362, 366], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["Antibiotic", "TREATMENT", 0, 10], ["resistant infections", "PROBLEM", 11, 31], ["infections", "PROBLEM", 81, 91], ["disease progression", "PROBLEM", 164, 183], ["SARS", "PROBLEM", 250, 254], ["Secondary Bacterial Infections", "PROBLEM", 263, 293], ["Acute Respiratory Syndrome", "PROBLEM", 314, 340], ["Coronavirus", "PROBLEM", 349, 360], ["resistant", "OBSERVATION_MODIFIER", 11, 20], ["infections", "OBSERVATION", 21, 31], ["infections", "OBSERVATION", 81, 91], ["disease", "OBSERVATION", 164, 171], ["Secondary", "OBSERVATION_MODIFIER", 263, 272], ["Bacterial Infections", "OBSERVATION", 273, 293], ["Acute", "OBSERVATION_MODIFIER", 314, 319], ["Respiratory Syndrome", "OBSERVATION", 320, 340], ["Coronavirus", "OBSERVATION_MODIFIER", 349, 360]]], ["At its initial outbreak (until August 2003), 8,096 probable cases were reported with an ~10% fatality rate (41).", [["fatality rate", "TEST", 93, 106]]], ["The case studies showed the occurrence of bacterial co-infections in the large number of patients.", [["bacterial co-infections", "DISEASE", 42, 65], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["The case studies", "TEST", 0, 16], ["bacterial co-infections", "PROBLEM", 42, 65], ["bacterial", "OBSERVATION_MODIFIER", 42, 51], ["co-infections", "OBSERVATION", 52, 65], ["large", "OBSERVATION_MODIFIER", 73, 78], ["number", "OBSERVATION_MODIFIER", 79, 85]]], ["These include infections by MRSA, Klebsiella spp., P. aeruginosa and Streptococcus (43).", [["infections", "DISEASE", 14, 24], ["MRSA", "DISEASE", 28, 32], ["Klebsiella spp., P. aeruginosa and Streptococcus", "DISEASE", 34, 82], ["Klebsiella spp.", "ORGANISM", 34, 49], ["P. aeruginosa", "ORGANISM", 51, 64], ["Streptococcus", "ORGANISM", 69, 82], ["MRSA", "SPECIES", 28, 32], ["Klebsiella spp.", "SPECIES", 34, 49], ["P. aeruginosa", "SPECIES", 51, 64], ["MRSA", "SPECIES", 28, 32], ["Klebsiella spp.", "SPECIES", 34, 49], ["P. aeruginosa", "SPECIES", 51, 64], ["infections", "PROBLEM", 14, 24], ["MRSA", "PROBLEM", 28, 32], ["Klebsiella spp.", "PROBLEM", 34, 49], ["P. aeruginosa", "PROBLEM", 51, 64], ["Streptococcus", "PROBLEM", 69, 82], ["infections", "OBSERVATION", 14, 24], ["MRSA", "OBSERVATION", 28, 32]]], ["The large multinucleated cells observed in the lungs of the SARS patients may be due to the underlining bacterial infections (43).", [["multinucleated cells", "ANATOMY", 10, 30], ["lungs", "ANATOMY", 47, 52], ["SARS", "DISEASE", 60, 64], ["bacterial infections", "DISEASE", 104, 124], ["multinucleated cells", "CELL", 10, 30], ["lungs", "ORGAN", 47, 52], ["patients", "ORGANISM", 65, 73], ["multinucleated cells", "CELL_TYPE", 10, 30], ["patients", "SPECIES", 65, 73], ["The large multinucleated cells", "PROBLEM", 0, 30], ["the underlining bacterial infections", "PROBLEM", 88, 124], ["large", "OBSERVATION_MODIFIER", 4, 9], ["multinucleated cells", "OBSERVATION", 10, 30], ["lungs", "ANATOMY", 47, 52], ["may be due to", "UNCERTAINTY", 74, 87], ["bacterial", "OBSERVATION_MODIFIER", 104, 113], ["infections", "OBSERVATION", 114, 124]]], ["The use of broad-spectrum antibiotics to cover the secondary bacterial infections is one of the supportive cares during SARS outbreak (44) (Supplementary File).", [["bacterial infections", "DISEASE", 61, 81], ["SARS", "DISEASE", 120, 124], ["broad-spectrum antibiotics", "TREATMENT", 11, 37], ["the secondary bacterial infections", "PROBLEM", 47, 81], ["secondary", "OBSERVATION_MODIFIER", 51, 60], ["bacterial infections", "OBSERVATION", 61, 81]]], ["The case studies (n = 7) reported the disease progression of a total of 534 SARS-CoV patients (45\u201351) (Supplementary File).", [["SARS", "DISEASE", 76, 80], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 76, 84], ["The case studies", "TEST", 0, 16], ["the disease progression", "PROBLEM", 34, 57]]], ["Details about prophylactic antibiotic therapy was reported in five studies (patients n = 385) and 100% patients were treated with prophylactic antibiotic therapy (48, 50\u201353).", [["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 103, 111], ["prophylactic antibiotic therapy", "TREATMENT", 14, 45], ["prophylactic antibiotic therapy", "TREATMENT", 130, 161]]], ["The antibiotics used for prophylactic treatment were levofloxacin, clarithromycin, amoxicillin-clavulanic acid, piperacillin-tazobactum, maxipime, azithromycin, amoxicillin-clavulanate, cefoperazone/sulbactam, quinolone plus azithromycin, levofloxacin, moxifloxacin, and ceftriaxone plus azithromycin, and most commonly azithromycin (n = 206, 74.6%).", [["levofloxacin", "CHEMICAL", 53, 65], ["clarithromycin", "CHEMICAL", 67, 81], ["amoxicillin-clavulanic acid", "CHEMICAL", 83, 110], ["piperacillin-tazobactum", "CHEMICAL", 112, 135], ["maxipime", "CHEMICAL", 137, 145], ["azithromycin", "CHEMICAL", 147, 159], ["amoxicillin-clavulanate", "CHEMICAL", 161, 184], ["cefoperazone", "CHEMICAL", 186, 198], ["sulbactam", "CHEMICAL", 199, 208], ["quinolone", "CHEMICAL", 210, 219], ["azithromycin", "CHEMICAL", 225, 237], ["levofloxacin", "CHEMICAL", 239, 251], ["moxifloxacin", "CHEMICAL", 253, 265], ["ceftriaxone", "CHEMICAL", 271, 282], ["azithromycin", "CHEMICAL", 288, 300], ["azithromycin", "CHEMICAL", 320, 332], ["levofloxacin", "CHEMICAL", 53, 65], ["clarithromycin", "CHEMICAL", 67, 81], ["amoxicillin-clavulanic acid", "CHEMICAL", 83, 110], ["piperacillin", "CHEMICAL", 112, 124], ["maxipime", "CHEMICAL", 137, 145], ["azithromycin", "CHEMICAL", 147, 159], ["amoxicillin-clavulanate", "CHEMICAL", 161, 184], ["cefoperazone", "CHEMICAL", 186, 198], ["sulbactam", "CHEMICAL", 199, 208], ["quinolone", "CHEMICAL", 210, 219], ["azithromycin", "CHEMICAL", 225, 237], ["levofloxacin", "CHEMICAL", 239, 251], ["moxifloxacin", "CHEMICAL", 253, 265], ["ceftriaxone", "CHEMICAL", 271, 282], ["azithromycin", "CHEMICAL", 288, 300], ["azithromycin", "CHEMICAL", 320, 332], ["levofloxacin", "SIMPLE_CHEMICAL", 53, 65], ["clarithromycin", "SIMPLE_CHEMICAL", 67, 81], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 83, 110], ["piperacillin-tazobactum", "SIMPLE_CHEMICAL", 112, 135], ["maxipime", "SIMPLE_CHEMICAL", 137, 145], ["azithromycin", "SIMPLE_CHEMICAL", 147, 159], ["amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 161, 184], ["cefoperazone", "SIMPLE_CHEMICAL", 186, 198], ["sulbactam", "SIMPLE_CHEMICAL", 199, 208], ["quinolone", "SIMPLE_CHEMICAL", 210, 219], ["azithromycin", "SIMPLE_CHEMICAL", 225, 237], ["levofloxacin", "SIMPLE_CHEMICAL", 239, 251], ["moxifloxacin", "SIMPLE_CHEMICAL", 253, 265], ["ceftriaxone", "SIMPLE_CHEMICAL", 271, 282], ["azithromycin", "SIMPLE_CHEMICAL", 288, 300], ["azithromycin", "SIMPLE_CHEMICAL", 320, 332], ["The antibiotics", "TREATMENT", 0, 15], ["prophylactic treatment", "TREATMENT", 25, 47], ["levofloxacin", "TREATMENT", 53, 65], ["clarithromycin", "TREATMENT", 67, 81], ["amoxicillin", "TREATMENT", 83, 94], ["clavulanic acid", "TREATMENT", 95, 110], ["piperacillin", "TREATMENT", 112, 124], ["tazobactum", "TREATMENT", 125, 135], ["maxipime", "TREATMENT", 137, 145], ["azithromycin", "TREATMENT", 147, 159], ["amoxicillin", "TREATMENT", 161, 172], ["clavulanate", "TREATMENT", 173, 184], ["cefoperazone", "TREATMENT", 186, 198], ["sulbactam", "TREATMENT", 199, 208], ["quinolone", "TREATMENT", 210, 219], ["azithromycin", "TREATMENT", 225, 237], ["levofloxacin", "TREATMENT", 239, 251], ["moxifloxacin", "TREATMENT", 253, 265], ["ceftriaxone", "TREATMENT", 271, 282], ["azithromycin", "TREATMENT", 288, 300], ["azithromycin", "TREATMENT", 320, 332]]], ["Of the four studies that reported secondary bacterial infections, 35 of 306 patients (11.4%) became infected.", [["bacterial infections", "DISEASE", 44, 64], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["the four studies", "TEST", 3, 19], ["secondary bacterial infections", "PROBLEM", 34, 64], ["infected", "PROBLEM", 100, 108], ["secondary", "OBSERVATION_MODIFIER", 34, 43], ["bacterial infections", "OBSERVATION", 44, 64], ["infected", "OBSERVATION", 100, 108]]], ["The pathogens that caused the infections included P. aeruginosa, MRSA, S. pneumoniae, K. pneumoniae, Enterococci, Acinetobacter baumannii, Enterobacter, H. influenza, S. maltophilia, and Serratia (45, 47, 49, 51).", [["infections", "DISEASE", 30, 40], ["P. aeruginosa, MRSA, S. pneumoniae", "DISEASE", 50, 84], ["Enterobacter", "CHEMICAL", 139, 151], ["H. influenza, S. maltophilia", "DISEASE", 153, 181], ["P. aeruginosa", "ORGANISM", 50, 63], ["S. pneumoniae", "ORGANISM", 71, 84], ["K. pneumoniae", "ORGANISM", 86, 99], ["Enterococci", "ORGANISM", 101, 112], ["Acinetobacter baumannii", "ORGANISM", 114, 137], ["Enterobacter", "ORGANISM", 139, 151], ["H. influenza", "ORGANISM", 153, 165], ["S. maltophilia", "ORGANISM", 167, 181], ["P. aeruginosa", "SPECIES", 50, 63], ["MRSA", "SPECIES", 65, 69], ["S. pneumoniae", "SPECIES", 71, 84], ["K. pneumoniae", "SPECIES", 86, 99], ["Acinetobacter baumannii", "SPECIES", 114, 137], ["H. influenza", "SPECIES", 153, 165], ["S. maltophilia", "SPECIES", 167, 181], ["P. aeruginosa", "SPECIES", 50, 63], ["MRSA", "SPECIES", 65, 69], ["S. pneumoniae", "SPECIES", 71, 84], ["K. pneumoniae", "SPECIES", 86, 99], ["Acinetobacter baumannii", "SPECIES", 114, 137], ["H. influenza", "SPECIES", 153, 165], ["S. maltophilia", "SPECIES", 167, 181], ["The pathogens", "PROBLEM", 0, 13], ["the infections", "PROBLEM", 26, 40], ["P. aeruginosa", "PROBLEM", 50, 63], ["MRSA", "PROBLEM", 65, 69], ["S. pneumoniae", "PROBLEM", 71, 84], ["pneumoniae", "PROBLEM", 89, 99], ["Enterococci", "PROBLEM", 101, 112], ["Acinetobacter baumannii", "PROBLEM", 114, 137], ["Enterobacter", "PROBLEM", 139, 151], ["H. influenza", "PROBLEM", 153, 165], ["S. maltophilia", "PROBLEM", 167, 181], ["Serratia", "PROBLEM", 187, 195], ["infections", "OBSERVATION", 30, 40], ["pneumoniae", "OBSERVATION", 74, 84], ["Acinetobacter baumannii", "OBSERVATION", 114, 137], ["maltophilia", "OBSERVATION", 170, 181], ["Serratia", "OBSERVATION_MODIFIER", 187, 195]]], ["Despite the deployment of prophylactic antibiotics, the use of therapeutic antibiotics was reported in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and ceftriaxone plus azithromycin (47, 49, 51).", [["amoxicillin-clavulanate", "CHEMICAL", 132, 155], ["clarithromycin", "CHEMICAL", 157, 171], ["azithromycin", "CHEMICAL", 173, 185], ["levofloxacin", "CHEMICAL", 187, 199], ["moxifloxacin", "CHEMICAL", 201, 213], ["ceftriaxone", "CHEMICAL", 218, 229], ["azithromycin", "CHEMICAL", 235, 247], ["amoxicillin-clavulanate", "CHEMICAL", 132, 155], ["clarithromycin", "CHEMICAL", 157, 171], ["azithromycin", "CHEMICAL", 173, 185], ["levofloxacin", "CHEMICAL", 187, 199], ["moxifloxacin", "CHEMICAL", 201, 213], ["ceftriaxone", "CHEMICAL", 218, 229], ["azithromycin", "CHEMICAL", 235, 247], ["amoxicillin-clavulanate", "SIMPLE_CHEMICAL", 132, 155], ["clarithromycin", "SIMPLE_CHEMICAL", 157, 171], ["azithromycin", "SIMPLE_CHEMICAL", 173, 185], ["levofloxacin", "SIMPLE_CHEMICAL", 187, 199], ["moxifloxacin", "SIMPLE_CHEMICAL", 201, 213], ["ceftriaxone", "SIMPLE_CHEMICAL", 218, 229], ["azithromycin", "SIMPLE_CHEMICAL", 235, 247], ["prophylactic antibiotics", "TREATMENT", 26, 50], ["therapeutic antibiotics", "TREATMENT", 63, 86], ["amoxicillin", "TREATMENT", 132, 143], ["clavulanate", "TREATMENT", 144, 155], ["clarithromycin", "TREATMENT", 157, 171], ["azithromycin", "TREATMENT", 173, 185], ["levofloxacin", "TREATMENT", 187, 199], ["moxifloxacin", "TREATMENT", 201, 213], ["ceftriaxone", "TREATMENT", 218, 229], ["azithromycin", "TREATMENT", 235, 247]]], ["In total, 12 patients out of 23 (52%, described in two studies who provided the respective information) had complications due to secondary bacterial infections (47, 51).SARS-related Secondary Bacterial Infections and TreatmentDuring the 2002 outbreak, most SARS patients were treated with broad-spectrum antibiotics as a prophylactic therapy.", [["bacterial infections", "DISEASE", 139, 159], ["SARS", "DISEASE", 169, 173], ["Bacterial Infections", "DISEASE", 192, 212], ["SARS", "DISEASE", 257, 261], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 262, 270], ["complications", "PROBLEM", 108, 121], ["secondary bacterial infections", "PROBLEM", 129, 159], ["SARS", "PROBLEM", 169, 173], ["Secondary Bacterial Infections", "PROBLEM", 182, 212], ["TreatmentDuring", "TREATMENT", 217, 232], ["broad-spectrum antibiotics", "TREATMENT", 289, 315], ["a prophylactic therapy", "TREATMENT", 319, 341], ["bacterial", "OBSERVATION_MODIFIER", 139, 148], ["infections", "OBSERVATION", 149, 159], ["Secondary", "OBSERVATION_MODIFIER", 182, 191], ["Bacterial Infections", "OBSERVATION", 192, 212]]], ["Contributing factors on antibiotic resistance had not been fully established by the early 2000's; however the use of antibiotics as a precaution in many viral infections and their potential overuse may have contributed to the current antibiotic crisis.MERS-related Secondary Bacterial Infections and TreatmentThe first cases of the Middle East respiratory syndrome (MERS) CoV epidemic occurred in June 2012 in Saudi Arabia with later outbreaks observed in 2015 and 2018.", [["viral infections", "DISEASE", 153, 169], ["Bacterial Infections", "DISEASE", 275, 295], ["Middle East respiratory syndrome (MERS) CoV epidemic", "DISEASE", 332, 384], ["Middle East respiratory syndrome (MERS) CoV", "SPECIES", 332, 375], ["antibiotic resistance", "TREATMENT", 24, 45], ["antibiotics", "TREATMENT", 117, 128], ["a precaution", "TREATMENT", 132, 144], ["many viral infections", "PROBLEM", 148, 169], ["the current antibiotic crisis", "PROBLEM", 222, 251], ["Secondary Bacterial Infections", "PROBLEM", 265, 295], ["Treatment", "TREATMENT", 300, 309], ["the Middle East respiratory syndrome", "PROBLEM", 328, 364], ["antibiotic resistance", "OBSERVATION", 24, 45], ["antibiotic crisis", "OBSERVATION", 234, 251], ["Secondary", "OBSERVATION_MODIFIER", 265, 274], ["Bacterial Infections", "OBSERVATION", 275, 295], ["Middle", "ANATOMY_MODIFIER", 332, 338], ["respiratory syndrome", "OBSERVATION", 344, 364]]], ["To date around 2,519 cases have been reported from more than 20 countries with a high fatality rate 34.3% (n = 866), the highest among all coronavirus diseases (52).", [["coronavirus diseases", "DISEASE", 139, 159], ["a high fatality rate", "TEST", 79, 99], ["all coronavirus diseases", "PROBLEM", 135, 159], ["coronavirus diseases", "OBSERVATION", 139, 159]]], ["The infection often starts as a mild viral respiratory illness but can rapidly progress to a fatal viral pneumonia mostly complicated by ARDS (acute respiratory distress syndrome) and ARF (acute renal failure) (53).", [["respiratory", "ANATOMY", 43, 54], ["renal", "ANATOMY", 195, 200], ["infection", "DISEASE", 4, 13], ["viral respiratory illness", "DISEASE", 37, 62], ["pneumonia", "DISEASE", 105, 114], ["ARDS", "DISEASE", 137, 141], ["acute respiratory distress syndrome", "DISEASE", 143, 178], ["ARF", "DISEASE", 184, 187], ["acute renal failure", "DISEASE", 189, 208], ["renal", "ORGAN", 195, 200], ["The infection", "PROBLEM", 0, 13], ["a mild viral respiratory illness", "PROBLEM", 30, 62], ["a fatal viral pneumonia", "PROBLEM", 91, 114], ["ARDS", "PROBLEM", 137, 141], ["acute respiratory distress syndrome", "PROBLEM", 143, 178], ["ARF", "PROBLEM", 184, 187], ["acute renal failure", "PROBLEM", 189, 208], ["infection", "OBSERVATION", 4, 13], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["viral", "OBSERVATION_MODIFIER", 37, 42], ["respiratory illness", "OBSERVATION", 43, 62], ["fatal", "OBSERVATION_MODIFIER", 93, 98], ["viral", "OBSERVATION_MODIFIER", 99, 104], ["pneumonia", "OBSERVATION", 105, 114], ["ARDS", "OBSERVATION", 137, 141], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["respiratory distress", "OBSERVATION", 149, 169], ["ARF", "OBSERVATION", 184, 187], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["renal", "ANATOMY", 195, 200], ["failure", "OBSERVATION", 201, 208]]], ["Due to the high mortality rate of MERS infections, the impact of the occurrence of bacterial infections remains unclear as death occurs due to hypoxemia and bilateral interstitial infiltrates in most cases, or ARDS.", [["interstitial infiltrates", "ANATOMY", 167, 191], ["infections", "DISEASE", 39, 49], ["bacterial infections", "DISEASE", 83, 103], ["death", "DISEASE", 123, 128], ["hypoxemia", "DISEASE", 143, 152], ["ARDS", "DISEASE", 210, 214], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 167, 191], ["MERS infections", "PROBLEM", 34, 49], ["bacterial infections", "PROBLEM", 83, 103], ["death", "PROBLEM", 123, 128], ["hypoxemia", "PROBLEM", 143, 152], ["bilateral interstitial infiltrates", "PROBLEM", 157, 191], ["ARDS", "PROBLEM", 210, 214], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103], ["hypoxemia", "OBSERVATION", 143, 152], ["bilateral", "ANATOMY_MODIFIER", 157, 166], ["interstitial", "ANATOMY_MODIFIER", 167, 179], ["infiltrates", "OBSERVATION", 180, 191], ["ARDS", "OBSERVATION", 210, 214]]], ["Nosocomial bacterial pneumonia is however common among MERS patients with ventilator support.", [["bacterial pneumonia", "DISEASE", 11, 30], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["Nosocomial bacterial pneumonia", "PROBLEM", 0, 30], ["ventilator support", "TREATMENT", 74, 92], ["bacterial", "OBSERVATION_MODIFIER", 11, 20], ["pneumonia", "OBSERVATION", 21, 30], ["ventilator support", "OBSERVATION", 74, 92]]], ["Therefore, antibiotic therapy was commonly deployed with secondary bacterial infections rarely occurring under this treatment regime (53\u201355).", [["bacterial infections", "DISEASE", 67, 87], ["antibiotic therapy", "TREATMENT", 11, 29], ["secondary bacterial infections", "PROBLEM", 57, 87], ["this treatment regime", "TREATMENT", 111, 132], ["bacterial infections", "OBSERVATION", 67, 87]]], ["Here, we review MERS-related case studies, outlining antibiotic therapies and bacterial infections.", [["bacterial infections", "DISEASE", 78, 98], ["case studies", "TEST", 29, 41], ["outlining antibiotic therapies", "TREATMENT", 43, 73], ["bacterial infections", "PROBLEM", 78, 98], ["bacterial", "OBSERVATION_MODIFIER", 78, 87], ["infections", "OBSERVATION", 88, 98]]], ["A total of 138 MERS-CoV infected patients were reported (55\u201359) (Supplementary File).", [["MERS-CoV infected", "DISEASE", 15, 32], ["MERS-CoV", "ORGANISM", 15, 23], ["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["MERS-CoV", "SPECIES", 15, 23], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The use of prophylactic antibiotic therapy was reported in 4 out of 5 studies.", [["prophylactic antibiotic therapy", "TREATMENT", 11, 42]]], ["Sixty eight patients were treated with the antibiotics piperacillin-tazobactam, azithromycin, ceftriaxone and trimethoprim- sulfamethoxazole, levofloxacin, imipenem and other broad-spectrum antibiotics (55, 56, 58, 59).", [["piperacillin-tazobactam", "CHEMICAL", 55, 78], ["azithromycin", "CHEMICAL", 80, 92], ["ceftriaxone", "CHEMICAL", 94, 105], ["trimethoprim- sulfamethoxazole", "CHEMICAL", 110, 140], ["levofloxacin", "CHEMICAL", 142, 154], ["imipenem", "CHEMICAL", 156, 164], ["piperacillin", "CHEMICAL", 55, 67], ["tazobactam", "CHEMICAL", 68, 78], ["azithromycin", "CHEMICAL", 80, 92], ["ceftriaxone", "CHEMICAL", 94, 105], ["trimethoprim- sulfamethoxazole", "CHEMICAL", 110, 140], ["levofloxacin", "CHEMICAL", 142, 154], ["imipenem", "CHEMICAL", 156, 164], ["patients", "ORGANISM", 12, 20], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 55, 78], ["azithromycin", "SIMPLE_CHEMICAL", 80, 92], ["ceftriaxone", "SIMPLE_CHEMICAL", 94, 105], ["trimethoprim- sulfamethoxazole", "SIMPLE_CHEMICAL", 110, 140], ["levofloxacin", "SIMPLE_CHEMICAL", 142, 154], ["imipenem", "SIMPLE_CHEMICAL", 156, 164], ["patients", "SPECIES", 12, 20], ["the antibiotics piperacillin", "TREATMENT", 39, 67], ["tazobactam", "TREATMENT", 68, 78], ["azithromycin", "TREATMENT", 80, 92], ["ceftriaxone", "TREATMENT", 94, 105], ["trimethoprim", "TREATMENT", 110, 122], ["sulfamethoxazole", "TREATMENT", 124, 140], ["levofloxacin", "TREATMENT", 142, 154], ["imipenem", "TREATMENT", 156, 164], ["other broad-spectrum antibiotics", "TREATMENT", 169, 201]]], ["The development of secondary bacterial infection was reported in two studies, with 32 of 82 patients experiencing complications due to bacterial pathogens (55, 57).", [["bacterial infection", "DISEASE", 29, 48], ["bacterial pathogens", "DISEASE", 135, 154], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["secondary bacterial infection", "PROBLEM", 19, 48], ["complications", "PROBLEM", 114, 127], ["bacterial pathogens", "PROBLEM", 135, 154], ["secondary", "OBSERVATION_MODIFIER", 19, 28], ["bacterial", "OBSERVATION_MODIFIER", 29, 38], ["infection", "OBSERVATION", 39, 48]]], ["The most common bacteria were MRSA, while others included carbapenem-resistant Acinetobacter baumannii, VRE and S. pneumoniae.", [["MRSA", "DISEASE", 30, 34], ["carbapenem", "CHEMICAL", 58, 68], ["Acinetobacter baumannii, VRE and S. pneumoniae", "DISEASE", 79, 125], ["carbapenem", "CHEMICAL", 58, 68], ["carbapenem-resistant", "ORGANISM", 58, 78], ["Acinetobacter baumannii", "ORGANISM", 79, 102], ["VRE", "CANCER", 104, 107], ["S. pneumoniae", "ORGANISM", 112, 125], ["MRSA", "SPECIES", 30, 34], ["Acinetobacter baumannii", "SPECIES", 79, 102], ["S. pneumoniae", "SPECIES", 112, 125], ["MRSA", "SPECIES", 30, 34], ["Acinetobacter baumannii", "SPECIES", 79, 102], ["S. pneumoniae", "SPECIES", 112, 125], ["The most common bacteria", "PROBLEM", 0, 24], ["MRSA", "PROBLEM", 30, 34], ["carbapenem", "PROBLEM", 58, 68], ["resistant Acinetobacter baumannii", "PROBLEM", 69, 102], ["VRE", "PROBLEM", 104, 107], ["S. pneumoniae", "PROBLEM", 112, 125], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["MRSA", "OBSERVATION", 30, 34], ["Acinetobacter baumannii", "OBSERVATION", 79, 102], ["pneumoniae", "OBSERVATION", 115, 125]]], ["No detailed report was provided about treatment antibiotics and one study reported (patients n = 15) complications due to bacterial infections in intensive care units (55).Influenza Viruses and Secondary Bacterial InfectionsInfluenza viruses are known to cause seasonal flu every year and of the four influenza types, type A and B are known to cause seasonal epidemics (60).", [["bacterial infections", "DISEASE", 122, 142], ["Influenza Viruses", "DISEASE", 172, 189], ["Bacterial Infections", "DISEASE", 204, 224], ["Influenza viruses", "DISEASE", 224, 241], ["influenza", "DISEASE", 301, 310], ["patients", "ORGANISM", 84, 92], ["Influenza Viruses", "ORGANISM", 172, 189], ["Secondary Bacterial InfectionsInfluenza viruses", "ORGANISM", 194, 241], ["B", "GENE_OR_GENE_PRODUCT", 329, 330], ["patients", "SPECIES", 84, 92], ["Influenza", "SPECIES", 172, 181], ["Bacterial InfectionsInfluenza viruses", "SPECIES", 204, 241], ["treatment antibiotics", "TREATMENT", 38, 59], ["one study", "TEST", 64, 73], ["complications", "PROBLEM", 101, 114], ["bacterial infections", "PROBLEM", 122, 142], ["Influenza Viruses", "PROBLEM", 172, 189], ["Secondary Bacterial InfectionsInfluenza viruses", "PROBLEM", 194, 241], ["seasonal flu", "PROBLEM", 261, 273], ["the four influenza types", "PROBLEM", 292, 316], ["seasonal epidemics", "PROBLEM", 350, 368], ["bacterial", "OBSERVATION_MODIFIER", 122, 131], ["infections", "OBSERVATION", 132, 142], ["Viruses", "OBSERVATION", 182, 189], ["Bacterial", "OBSERVATION_MODIFIER", 204, 213], ["Infections", "OBSERVATION", 214, 224]]], ["The influenza A (H1N1) outbreak in 2009 had even developed into a global pandemic while causing seasonal flu epidemics each year.", [["influenza A (H1N1) outbreak", "DISEASE", 4, 31], ["flu epidemics", "DISEASE", 105, 118], ["influenza A (H1N1", "ORGANISM", 4, 21], ["influenza A (H1N1", "SPECIES", 4, 21], ["The influenza A (H1N1) outbreak", "PROBLEM", 0, 31], ["a global pandemic", "PROBLEM", 64, 81], ["seasonal flu epidemics", "PROBLEM", 96, 118], ["influenza", "OBSERVATION", 4, 13]]], ["In spite of the availability of vaccines, the global death during the flu season was estimated to be between 0.25 and 0.5 million people according to the WHO (61).", [["death", "DISEASE", 53, 58], ["flu", "DISEASE", 70, 73], ["people", "SPECIES", 130, 136], ["vaccines", "TREATMENT", 32, 40], ["the global death", "PROBLEM", 42, 58], ["the flu season", "TEST", 66, 80]]], ["Secondary bacterial infections are one of the leading causes for influenza associated deaths (62).", [["Secondary bacterial infections", "DISEASE", 0, 30], ["influenza", "DISEASE", 65, 74], ["deaths", "DISEASE", 86, 92], ["Secondary bacterial infections", "PROBLEM", 0, 30], ["influenza associated deaths", "PROBLEM", 65, 92], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30]]], ["According to the Center for Disease Control and Prevention (CDC), during the 2009 H1N1 influenza pandemic between 29 and 55% of mortalities were due to secondary bacterial infections (63).", [["influenza", "DISEASE", 87, 96], ["bacterial infections", "DISEASE", 162, 182], ["H1N1 influenza pandemic", "SPECIES", 82, 105], ["Disease Control", "TREATMENT", 28, 43], ["H1N1 influenza pandemic", "PROBLEM", 82, 105], ["secondary bacterial infections", "PROBLEM", 152, 182], ["bacterial", "OBSERVATION_MODIFIER", 162, 171], ["infections", "OBSERVATION", 172, 182]]], ["The lethal synergism between influenza virus and Pneumococcus strains accounts for the majority of diseases as well as mortality during influenza epidemics (64).", [["influenza virus", "DISEASE", 29, 44], ["influenza", "DISEASE", 136, 145], ["influenza virus", "ORGANISM", 29, 44], ["Pneumococcus strains", "ORGANISM", 49, 69], ["influenza virus", "SPECIES", 29, 44], ["influenza virus", "SPECIES", 29, 44], ["The lethal synergism", "PROBLEM", 0, 20], ["influenza virus", "PROBLEM", 29, 44], ["Pneumococcus strains", "PROBLEM", 49, 69], ["diseases", "PROBLEM", 99, 107], ["influenza epidemics", "PROBLEM", 136, 155], ["influenza virus", "OBSERVATION", 29, 44], ["diseases", "OBSERVATION", 99, 107]]], ["Here, we summarize case studies that are related to influenza viruses and secondary bacterial infections (Supplementary File).", [["influenza viruses", "DISEASE", 52, 69], ["bacterial infections", "DISEASE", 84, 104], ["case studies", "TEST", 19, 31], ["influenza viruses", "PROBLEM", 52, 69], ["secondary bacterial infections", "PROBLEM", 74, 104], ["bacterial", "OBSERVATION_MODIFIER", 84, 93], ["infections", "OBSERVATION", 94, 104]]], ["Details on treatment and disease progression of a total of 910 patients that were infected with influenza were reported in eight case studies (65\u201372).", [["influenza", "DISEASE", 96, 105], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["treatment", "TREATMENT", 11, 20], ["influenza", "PROBLEM", 96, 105]]], ["Five studies reported the deployment of prophylactic antibiotic therapy in 718 of 743 patients (96.6%) (65\u201367, 71, 72).", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["Five studies", "TEST", 0, 12], ["prophylactic antibiotic therapy", "TREATMENT", 40, 71]]], ["The most commonly used antibiotics were vancomycin (n = 317, 46.2%) and imipenem/meropenem (n = 243, 54.7%).", [["vancomycin", "CHEMICAL", 40, 50], ["imipenem", "CHEMICAL", 72, 80], ["meropenem", "CHEMICAL", 81, 90], ["vancomycin", "CHEMICAL", 40, 50], ["imipenem", "CHEMICAL", 72, 80], ["meropenem", "CHEMICAL", 81, 90], ["vancomycin", "SIMPLE_CHEMICAL", 40, 50], ["imipenem", "SIMPLE_CHEMICAL", 72, 80], ["meropenem", "SIMPLE_CHEMICAL", 81, 90], ["antibiotics", "TREATMENT", 23, 34], ["vancomycin", "TREATMENT", 40, 50], ["imipenem", "TREATMENT", 72, 80], ["meropenem", "TREATMENT", 81, 90]]], ["Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime, vancomycin plus meropenem, clarithromycin, levofloxacin and dicloxacillin.", [["azithromycin", "CHEMICAL", 12, 24], ["ceftriaxone", "CHEMICAL", 26, 37], ["cephalosporin", "CHEMICAL", 39, 52], ["piperacillin-tazobactam", "CHEMICAL", 54, 77], ["linezolid", "CHEMICAL", 79, 88], ["vancomycin", "CHEMICAL", 90, 100], ["cefepime", "CHEMICAL", 106, 114], ["vancomycin", "CHEMICAL", 116, 126], ["meropenem", "CHEMICAL", 132, 141], ["clarithromycin", "CHEMICAL", 143, 157], ["levofloxacin", "CHEMICAL", 159, 171], ["dicloxacillin", "CHEMICAL", 176, 189], ["azithromycin", "CHEMICAL", 12, 24], ["ceftriaxone", "CHEMICAL", 26, 37], ["cephalosporin", "CHEMICAL", 39, 52], ["piperacillin-tazobactam", "CHEMICAL", 54, 77], ["linezolid", "CHEMICAL", 79, 88], ["vancomycin", "CHEMICAL", 90, 100], ["cefepime", "CHEMICAL", 106, 114], ["vancomycin", "CHEMICAL", 116, 126], ["meropenem", "CHEMICAL", 132, 141], ["clarithromycin", "CHEMICAL", 143, 157], ["levofloxacin", "CHEMICAL", 159, 171], ["dicloxacillin", "CHEMICAL", 176, 189], ["azithromycin", "SIMPLE_CHEMICAL", 12, 24], ["ceftriaxone", "SIMPLE_CHEMICAL", 26, 37], ["cephalosporin", "SIMPLE_CHEMICAL", 39, 52], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 54, 77], ["linezolid", "SIMPLE_CHEMICAL", 79, 88], ["vancomycin", "SIMPLE_CHEMICAL", 90, 100], ["cefepime", "SIMPLE_CHEMICAL", 106, 114], ["vancomycin", "SIMPLE_CHEMICAL", 116, 126], ["meropenem", "SIMPLE_CHEMICAL", 132, 141], ["clarithromycin", "SIMPLE_CHEMICAL", 143, 157], ["levofloxacin", "SIMPLE_CHEMICAL", 159, 171], ["dicloxacillin", "SIMPLE_CHEMICAL", 176, 189], ["azithromycin", "TREATMENT", 12, 24], ["ceftriaxone", "TREATMENT", 26, 37], ["cephalosporin", "TREATMENT", 39, 52], ["piperacillin", "TREATMENT", 54, 66], ["tazobactam", "TREATMENT", 67, 77], ["linezolid", "TREATMENT", 79, 88], ["vancomycin", "TREATMENT", 90, 100], ["cefepime", "TREATMENT", 106, 114], ["vancomycin", "TREATMENT", 116, 126], ["meropenem", "TREATMENT", 132, 141], ["clarithromycin", "TREATMENT", 143, 157], ["levofloxacin", "TREATMENT", 159, 171], ["dicloxacillin", "TREATMENT", 176, 189]]], ["In total, 223 patients of 910 (24.5%) developed secondary bacterial infections.", [["bacterial infections", "DISEASE", 58, 78], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["secondary bacterial infections", "PROBLEM", 48, 78], ["secondary", "OBSERVATION_MODIFIER", 48, 57], ["bacterial infections", "OBSERVATION", 58, 78]]], ["The infective agents were S. pneumoniae, MRSA, P. aeruginosa, S. viridians, S. hominis, Enterococci, H. influenza, S. pyogenes, S. mitis, S. agalactiae, Acinetobacter baumannii, E. coli, Chlamydophila pneumoniae, and Moraxella catarrhalis.", [["H. influenza", "DISEASE", 101, 113], ["Chlamydophila pneumoniae", "DISEASE", 187, 211], ["S. pneumoniae", "ORGANISM", 26, 39], ["MRSA", "ORGANISM", 41, 45], ["P. aeruginosa", "ORGANISM", 47, 60], ["S. viridians", "ORGANISM", 62, 74], ["S. hominis", "ORGANISM", 76, 86], ["Enterococci", "ORGANISM", 88, 99], ["H. influenza", "ORGANISM", 101, 113], ["S. pyogenes", "ORGANISM", 115, 126], ["S. mitis", "ORGANISM", 128, 136], ["S. agalactiae", "ORGANISM", 138, 151], ["Acinetobacter baumannii", "ORGANISM", 153, 176], ["E. coli", "ORGANISM", 178, 185], ["Chlamydophila pneumoniae", "ORGANISM", 187, 211], ["Moraxella catarrhalis", "ORGANISM", 217, 238], ["S. pneumoniae", "SPECIES", 26, 39], ["MRSA", "SPECIES", 41, 45], ["P. aeruginosa", "SPECIES", 47, 60], ["S. viridians", "SPECIES", 62, 74], ["S. hominis", "SPECIES", 76, 86], ["H. influenza", "SPECIES", 101, 113], ["S. pyogenes", "SPECIES", 115, 126], ["S. mitis", "SPECIES", 128, 136], ["S. agalactiae", "SPECIES", 138, 151], ["Acinetobacter baumannii", "SPECIES", 153, 176], ["E. coli", "SPECIES", 178, 185], ["Chlamydophila pneumoniae", "SPECIES", 187, 211], ["Moraxella catarrhalis", "SPECIES", 217, 238], ["S. pneumoniae", "SPECIES", 26, 39], ["MRSA", "SPECIES", 41, 45], ["P. aeruginosa", "SPECIES", 47, 60], ["S. viridians", "SPECIES", 62, 74], ["S. hominis", "SPECIES", 76, 86], ["H. influenza", "SPECIES", 101, 113], ["S. pyogenes", "SPECIES", 115, 126], ["S. mitis", "SPECIES", 128, 136], ["S. agalactiae", "SPECIES", 138, 151], ["Acinetobacter baumannii", "SPECIES", 153, 176], ["E. coli", "SPECIES", 178, 185], ["Chlamydophila pneumoniae", "SPECIES", 187, 211], ["Moraxella catarrhalis", "SPECIES", 217, 238], ["The infective agents", "TREATMENT", 0, 20], ["S. pneumoniae", "PROBLEM", 26, 39], ["MRSA", "PROBLEM", 41, 45], ["P. aeruginosa", "PROBLEM", 47, 60], ["S. viridians", "PROBLEM", 62, 74], ["S. hominis", "PROBLEM", 76, 86], ["Enterococci", "PROBLEM", 88, 99], ["H. influenza", "PROBLEM", 101, 113], ["S. pyogenes", "PROBLEM", 115, 126], ["S. mitis", "PROBLEM", 128, 136], ["S. agalactiae", "PROBLEM", 138, 151], ["Acinetobacter baumannii", "PROBLEM", 153, 176], ["E. coli", "PROBLEM", 178, 185], ["Chlamydophila pneumoniae", "PROBLEM", 187, 211], ["Moraxella catarrhalis", "PROBLEM", 217, 238], ["infective", "OBSERVATION_MODIFIER", 4, 13], ["Enterococci", "OBSERVATION", 88, 99], ["Acinetobacter baumannii", "OBSERVATION", 153, 176], ["E. coli", "OBSERVATION", 178, 185], ["Chlamydophila pneumoniae", "OBSERVATION", 187, 211], ["Moraxella catarrhalis", "OBSERVATION", 217, 238]]], ["To treat the infections, one of the studies reported the use of azithromycin, vancomycin, ceftriaxone and cephalosporin (65).", [["infections", "DISEASE", 13, 23], ["azithromycin", "CHEMICAL", 64, 76], ["vancomycin", "CHEMICAL", 78, 88], ["ceftriaxone", "CHEMICAL", 90, 101], ["cephalosporin", "CHEMICAL", 106, 119], ["azithromycin", "CHEMICAL", 64, 76], ["vancomycin", "CHEMICAL", 78, 88], ["ceftriaxone", "CHEMICAL", 90, 101], ["cephalosporin", "CHEMICAL", 106, 119], ["azithromycin", "SIMPLE_CHEMICAL", 64, 76], ["vancomycin", "SIMPLE_CHEMICAL", 78, 88], ["ceftriaxone", "SIMPLE_CHEMICAL", 90, 101], ["cephalosporin", "SIMPLE_CHEMICAL", 106, 119], ["the infections", "PROBLEM", 9, 23], ["the studies", "TEST", 32, 43], ["azithromycin", "TREATMENT", 64, 76], ["vancomycin", "TREATMENT", 78, 88], ["ceftriaxone", "TREATMENT", 90, 101], ["cephalosporin", "TREATMENT", 106, 119], ["infections", "OBSERVATION", 13, 23]]], ["In general, all eight case studies reported the treatment complications due to secondary bacterial infections.DiscussionThe lack of detailed clinical data regarding secondary bacterial infections following COVID-19, SARS, MERS and influenza is surprising.", [["bacterial infections", "DISEASE", 89, 109], ["bacterial infections", "DISEASE", 175, 195], ["COVID-19", "CHEMICAL", 206, 214], ["SARS", "DISEASE", 216, 220], ["MERS", "DISEASE", 222, 226], ["influenza", "DISEASE", 231, 240], ["the treatment complications", "PROBLEM", 44, 71], ["secondary bacterial infections", "PROBLEM", 79, 109], ["secondary bacterial infections", "PROBLEM", 165, 195], ["COVID", "TEST", 206, 211], ["SARS", "PROBLEM", 216, 220], ["MERS", "PROBLEM", 222, 226], ["influenza", "PROBLEM", 231, 240], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["infections", "OBSERVATION", 99, 109], ["bacterial", "OBSERVATION_MODIFIER", 175, 184], ["infections", "OBSERVATION", 185, 195]]], ["In addition, precise numbers of clinical cases of COVID-19 or other respiratory virus infections with antibiotic-resistant secondary bacterial infections are not available.", [["COVID-19", "CHEMICAL", 50, 58], ["respiratory virus infections", "DISEASE", 68, 96], ["bacterial infections", "DISEASE", 133, 153], ["COVID-19", "ORGANISM", 50, 58], ["respiratory virus", "ORGANISM", 68, 85], ["COVID", "TEST", 50, 55], ["other respiratory virus infections", "PROBLEM", 62, 96], ["antibiotic", "TREATMENT", 102, 112], ["resistant secondary bacterial infections", "PROBLEM", 113, 153], ["respiratory virus", "ANATOMY", 68, 85], ["bacterial infections", "OBSERVATION", 133, 153]]], ["As globally mortality rates from antibiotic-resistant bacterial infections are increasing, providing such data of secondary infection is important, almost critical.DiscussionClinical reports are a valuable source for biomedical scientists for the advancement of treatment; however, in many cases crucial data such as medical compounds, their dosage, and duration of the therapy, is often not reported, similar to details on patient data or the species of e.g., a pathogenic bacterium.", [["bacterial infections", "DISEASE", 54, 74], ["infection", "DISEASE", 124, 133], ["patient", "ORGANISM", 424, 431], ["patient", "SPECIES", 424, 431], ["globally mortality rates", "PROBLEM", 3, 27], ["antibiotic", "TREATMENT", 33, 43], ["resistant bacterial infections", "PROBLEM", 44, 74], ["secondary infection", "PROBLEM", 114, 133], ["treatment", "TREATMENT", 262, 271], ["the therapy", "TREATMENT", 366, 377], ["a pathogenic bacterium", "PROBLEM", 461, 483], ["resistant", "OBSERVATION_MODIFIER", 44, 53], ["bacterial", "OBSERVATION_MODIFIER", 54, 63], ["infections", "OBSERVATION", 64, 74], ["infection", "OBSERVATION", 124, 133]]], ["Such data are essential for the study of secondary infections in human patients; the scientific community and ultimately the patient will benefit when clinicians and non-clinical disease experts work close together.", [["infections", "DISEASE", 51, 61], ["human", "ORGANISM", 65, 70], ["patients", "ORGANISM", 71, 79], ["patient", "ORGANISM", 125, 132], ["human", "SPECIES", 65, 70], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 125, 132], ["human", "SPECIES", 65, 70], ["the study", "TEST", 28, 37], ["secondary infections", "PROBLEM", 41, 61]]], ["The information from such collaborative studies can provide a guideline for treatment.", [["collaborative studies", "TEST", 26, 47], ["treatment", "TREATMENT", 76, 85]]], ["At the same time, the lack of knowledge and studies that should be done in the future is evident.", [["studies", "TEST", 44, 51]]], ["Reviewing the available information, it becomes clear that secondary bacterial infections play a critical role in the morbidity and mortality rates of patients initially falling ill with pulmonary viral diseases.", [["pulmonary", "ANATOMY", 187, 196], ["bacterial infections", "DISEASE", 69, 89], ["pulmonary viral diseases", "DISEASE", 187, 211], ["patients", "ORGANISM", 151, 159], ["pulmonary", "ORGAN", 187, 196], ["patients", "SPECIES", 151, 159], ["secondary bacterial infections", "PROBLEM", 59, 89], ["pulmonary viral diseases", "PROBLEM", 187, 211], ["secondary", "OBSERVATION_MODIFIER", 59, 68], ["bacterial", "OBSERVATION_MODIFIER", 69, 78], ["infections", "OBSERVATION", 79, 89], ["pulmonary", "ANATOMY", 187, 196], ["viral diseases", "OBSERVATION", 197, 211]]], ["Similar to epidemics caused by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant bacterial infections are a significant threat to the well-being of hospitalized COVID-19 patients.", [["influenza viruses", "DISEASE", 31, 48], ["SARS-CoV-2 pandemic", "DISEASE", 69, 88], ["bacterial infections", "DISEASE", 111, 131], ["influenza viruses", "ORGANISM", 31, 48], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["epidemics", "PROBLEM", 11, 20], ["influenza viruses", "PROBLEM", 31, 48], ["CoV", "TEST", 74, 77], ["pandemic", "PROBLEM", 80, 88], ["antibiotic", "TREATMENT", 90, 100], ["resistant bacterial infections", "PROBLEM", 101, 131], ["influenza viruses", "OBSERVATION", 31, 48], ["bacterial infections", "OBSERVATION", 111, 131]]], ["Nosocomial infections including ventilator-associated infections are often unavoidable and especially so during a pandemic.", [["infections", "DISEASE", 11, 21], ["ventilator-associated infections", "DISEASE", 32, 64], ["Nosocomial infections", "PROBLEM", 0, 21], ["ventilator-associated infections", "PROBLEM", 32, 64], ["a pandemic", "PROBLEM", 112, 122], ["infections", "OBSERVATION", 11, 21], ["infections", "OBSERVATION", 54, 64]]], ["The use of broad-spectrum antibiotics is often a routine preventative measure and until alternative treatments and to this date unavailable preventive measures are in place at hospitals, secondary infections will remain unavoidable due to the nature of nosocomial and opportunistic pathogens in combination with the rise of multidrug resistance.DiscussionCOVID-19 is likely to reappear in populations until a vaccine is deployed, globally.", [["infections", "DISEASE", 197, 207], ["nosocomial and opportunistic pathogens", "DISEASE", 253, 291], ["broad-spectrum antibiotics", "TREATMENT", 11, 37], ["a routine preventative measure", "TREATMENT", 47, 77], ["alternative treatments", "TREATMENT", 88, 110], ["preventive measures", "TREATMENT", 140, 159], ["secondary infections", "PROBLEM", 187, 207], ["nosocomial", "PROBLEM", 253, 263], ["opportunistic pathogens", "PROBLEM", 268, 291], ["multidrug resistance", "PROBLEM", 324, 344], ["a vaccine", "TREATMENT", 407, 416], ["nosocomial", "OBSERVATION", 253, 263], ["multidrug resistance", "OBSERVATION", 324, 344]]], ["To prepare for recurrent waves of COVID-19 disease and the inevitable next new pandemic, new antibiotics or alternative treatments targeted against secondary bacterial infections are needed.", [["bacterial infections", "DISEASE", 158, 178], ["recurrent waves of COVID-19 disease", "PROBLEM", 15, 50], ["new antibiotics", "TREATMENT", 89, 104], ["alternative treatments", "TREATMENT", 108, 130], ["secondary bacterial infections", "PROBLEM", 148, 178], ["bacterial", "OBSERVATION_MODIFIER", 158, 167], ["infections", "OBSERVATION", 168, 178]]], ["Alternative therapies such as Antimicrobial Peptides or Phage Therapy are being explored and show promise.", [["Alternative therapies", "TREATMENT", 0, 21], ["Antimicrobial Peptides", "TREATMENT", 30, 52], ["Phage Therapy", "TREATMENT", 56, 69]]], ["Most antimicrobial peptides perturb the structure of the bacterial cell envelope while not affecting the eukaryotic cell membrane; eventually creating a leaky lipid bilayer and the collapse of the proton-motif-force, ultimately resulting in bacterial cell death (73\u201376).", [["cell", "ANATOMY", 67, 71], ["cell membrane", "ANATOMY", 116, 129], ["lipid bilayer", "ANATOMY", 159, 172], ["cell", "ANATOMY", 251, 255], ["death", "DISEASE", 256, 261], ["cell membrane", "CELLULAR_COMPONENT", 116, 129], ["lipid bilayer", "CELLULAR_COMPONENT", 159, 172], ["cell", "CELL", 251, 255], ["Most antimicrobial peptides", "TREATMENT", 0, 27], ["the bacterial cell envelope", "PROBLEM", 53, 80], ["a leaky lipid bilayer", "PROBLEM", 151, 172], ["bacterial cell death", "PROBLEM", 241, 261], ["bacterial cell envelope", "OBSERVATION", 57, 80], ["eukaryotic cell membrane", "OBSERVATION", 105, 129], ["leaky lipid bilayer", "OBSERVATION", 153, 172], ["collapse", "OBSERVATION", 181, 189], ["bacterial cell death", "OBSERVATION", 241, 261]]], ["Phage therapy makes use of bacterial viruses (or bacteriophages) that specifically infect bacterial pathogens for viral replication, which leads to the lysis of the host when phage progeny is being released (77\u201383).", [["bacterial viruses", "ORGANISM", 27, 44], ["Phage therapy", "TREATMENT", 0, 13], ["bacterial viruses", "PROBLEM", 27, 44], ["bacteriophages", "PROBLEM", 49, 63], ["bacterial pathogens", "PROBLEM", 90, 109], ["viral replication", "PROBLEM", 114, 131], ["the lysis of the host", "TREATMENT", 148, 169], ["bacterial viruses", "OBSERVATION", 27, 44]]], ["Anti-virulence compounds are substances that do not kill or arrest the growth of a bacterial pathogen, but rather target pathogen-intrinsic components important for the infection process.", [["infection", "DISEASE", 169, 178], ["Anti-virulence compounds", "TREATMENT", 0, 24], ["a bacterial pathogen", "PROBLEM", 81, 101], ["intrinsic components", "PROBLEM", 130, 150], ["the infection process", "PROBLEM", 165, 186], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["pathogen", "OBSERVATION", 93, 101], ["infection", "OBSERVATION", 169, 178]]], ["These include bacterial components such as exo- and endotoxins, i.e., actively secreted toxins (e.g., hemolysins) or cell-inherent structures that are toxic to the patient, such as LPS, and other factors which facilitate adhesion, invasion or colonization, but also the escape of the host's immune system.", [["cell", "ANATOMY", 117, 121], ["structures", "ANATOMY", 131, 141], ["LPS", "CHEMICAL", 181, 184], ["hemolysins", "GENE_OR_GENE_PRODUCT", 102, 112], ["cell", "CELL", 117, 121], ["patient", "ORGANISM", 164, 171], ["LPS", "SIMPLE_CHEMICAL", 181, 184], ["immune system", "ANATOMICAL_SYSTEM", 291, 304], ["patient", "SPECIES", 164, 171], ["bacterial components", "PROBLEM", 14, 34], ["exo", "TEST", 43, 46], ["endotoxins", "PROBLEM", 52, 62], ["actively secreted toxins", "PROBLEM", 70, 94], ["hemolysins", "PROBLEM", 102, 112], ["cell-inherent structures", "PROBLEM", 117, 141], ["LPS", "PROBLEM", 181, 184], ["other factors", "PROBLEM", 190, 203], ["adhesion", "PROBLEM", 221, 229], ["invasion", "PROBLEM", 231, 239], ["colonization", "PROBLEM", 243, 255], ["bacterial components", "OBSERVATION", 14, 34]]], ["Anti-virulence compounds have been demonstrated to prevent or reduce the severity of symptoms of acute infections (84, 85).DiscussionPulmonary coronaviruses will likely be a clinical challenge for many years to come.", [["infections", "DISEASE", 103, 113], ["DiscussionPulmonary coronaviruses", "DISEASE", 123, 156], ["Anti-virulence compounds", "TREATMENT", 0, 24], ["symptoms", "PROBLEM", 85, 93], ["acute infections", "PROBLEM", 97, 113], ["DiscussionPulmonary coronaviruses", "PROBLEM", 123, 156], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["infections", "OBSERVATION", 103, 113]]], ["Viral pandemics from coronaviruses and emerging pathogens are inevitable in a globalized world with interconnected societies, travel and commerce.", [["Viral pandemics", "DISEASE", 0, 15], ["coronaviruses", "DISEASE", 21, 34], ["coronaviruses", "ORGANISM", 21, 34], ["Viral pandemics", "PROBLEM", 0, 15], ["coronaviruses", "PROBLEM", 21, 34], ["emerging pathogens", "PROBLEM", 39, 57], ["pandemics", "OBSERVATION", 6, 15]]], ["We should be well-prepared for the next pandemic, exploring and establishing new avenues to treat bacterial pathogens commonly observed in secondary infections to avert a healthcare crisis due to antibiotic-resistance.Author ContributionsPM and SL: initial idea.", [["bacterial pathogens", "DISEASE", 98, 117], ["infections", "DISEASE", 149, 159], ["bacterial pathogens", "PROBLEM", 98, 117], ["secondary infections", "PROBLEM", 139, 159], ["a healthcare crisis", "PROBLEM", 169, 188], ["antibiotic-resistance", "TREATMENT", 196, 217]]], ["BL and SL: figures.", [["SL", "ANATOMY", 7, 9], ["figures", "OBSERVATION", 11, 18]]]], "PMC7349011": []}